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SYNOPSIS
This thesis describes studies of the requirements, applications 
and benefits of external quality assessment (EQA) of clinical 
chemistry laboratories.
The involvement of EQA in assessing the analytical quality of 
results from clinical chemistry laboratories is well-established. 
This thesis addresses the contribution of EQA in improving 
clinical chemistry practice and therefore patient care rather 
than as a method of 'policing' laboratory performance which is 
the objective of many national EQA schemes. The use of EQA in the 
assessment of interlaboratory agreement, of analytical methods, 
of individual laboratory performance, and of quality control and 
calibration materials is discussed.
Surveys are examined as a means to assess the prevailing standard 
of performance and determine priorities for further EQA to 
improve performance. The contribution of scoring systems to 
scheme success by making the information more intelligible to 
participants is described. The importance of reliable target 
values is shown, and the reproducibility and accuracy of 
consensus values in such schemes have been studied. EQA data are 
shown to be invaluable in providing information on the relative 
performance of analytical procedures, and on factors such as 
analyte concentration and laboratory workload which affect 
performance. The stepwise interpretation of the Variance Index 
scoring system, and the use of graphical presentations in 
assisting the assessment of laboratory performance are described. 
Finally, the use of EQA data in the study of the suitability of 
quality control materials is examined, with particular reference 
to their commutability, their use in calibration, and the effects 
of manufacturing procedures upon their properties.
This thesis illustrates the importance of EQA to clinical 
chemistry practice and to patient care.
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Chapter 1:
INTRODUCTION
1.1 Quality assurance in clinical chemistry
The primary role of any clinical laboratory is to assist in the 
diagnosis, monitoring and prevention of disease and the 
monitoring of therapy, through provision of quantitative or 
qualitative data on specimens from patients or subjects. These 
data can only be of optimal assistance if they are completely 
reliable, both within and among laboratories. Unreliable 
laboratory reports may lead to inaccurate diagnoses or 
inappropriate treatment, and increase suffering and healthcare 
costs thereby or by necessitating repeated tests.
All measurements, including clinical chemical analyses, are 
subject to variance: 'variance' here denotes discord and 
discrepancy in the results of measuring the same quantity on the 
same material (Whitehead, 1977) rather than its statistical usage 
as the square of the standard deviation (SD). This variance was 
largely overlooked in the early development of clinical 
chemistry. Clinical chemists only became aware of the importance 
of quality assurance in their professional activity when external 
quality assessment (EQA) surveys, such as those of Belk and 
Sunderman (1947) in the USA and later of Wootton and King (1953) 
in the UK, revealed large variations in the the results obtained 
on the same specimen in different laboratories.
The terms quality assurance, internal quality control (IQC) and 
external quality assessment (EQA) are used here as defined by the 
World Health Organization (WHO; WHO, 1981) and the European 
Committee for Clinical Laboratory Standards (ECCLS; Leblanc et 
al, 1985a):
1.1.1 Quality assurance
All measures taken to increase within-laboratory reproducibility 
and bet ween-laboratory comparability, and to ensure the 
usefulness of laboratory investigations generally.
1.1.2 Internal quality control
The set of procedures undertaken by the staff of a laboratory for 
the continual evaluation of the reliability of the work of the 
laboratory and its emergent results, in order to decide whether 
they are reliable enough to be released.
1.1.3 External quality assessment
A system of retrospectively and objectively comparing results 
from different laboratories by means of an external agency.
1.2 Terminology in quality assurance
The terminology used in quality assurance, both within 
laboratories and in the published literature, was confused until 
1981.
Originally "quality control" was the main term used to denote the 
general field of quality assurance, and this was qualified to 
designate the aspects of analytical QC as internal quality 
control and external quality control. This usage was confirmed by 
the recommendations of the IFCC Expert Panel on Quality Control 
(Buttner et al, 1979a), developed during the 1970s.
"Internal quality control" was widely and almost universally 
used, but terms such as "preventive measures" (Whitehead, 1977) 
and "good laboratory practice" were evolved to cover much of 
quality assurance. In the field of EQA a much greater diversity 
in nomenclature had arisen, with "external quality control" being
used only occasionally. Thus, there were "roundrobins", 
"interlaboratory surveys", "proficiency testing surveys", 
"quality assurance programs" and "clinical laboratory improvement 
programs"; many systems, eg the National Quality Control Scheme 
in the UK (Whitehead et al, 1973), were simply designated as 
"quality control schemes".
Confusion over the objectives of the various aspects of quality 
assurance was almost inevitable in such a situation, with IQC and 
external QC being considered to be as interchangeable as this 
nomenclature implied. The WHO Working Group considered that a 
change in terminology was essential, both to emphasise the 
complementary nature of IQC and EQA and to bring out the 
objectives of EQA besides the 'control' of individual laboratory 
performance.
The terms "quality assurance", "internal quality control" and 
"external quality assessment" were therefore selected, as best 
conveying the intent and content of these aspects of activity 
(WHO, 1981). This terminology, defined above, has also been 
endorsed by ECCLS (Leblanc et al, 1985a) and the International 
Committee for Standardization in Haematology (Lewis, 1984).
1.3 Early external quality assessment surveys
The earliest published EQA surveys of clinical chemical analyses 
were conducted in the USA by Belk and Sunderman (1947), with the 
primary objective of checking accuracy. These surveys, involving 
59 pathologists' laboratories in Pennsylvania, used aqueous 
solutions of salts, glucose or urea, serum (for protein assays) 
and preserved whole blood (for haemoglobin assay). Essentially 
arbitrary limits of acceptability were set, of ±10% for most 
analytes but based on the authors' opinion of satisfactory
laboratory practice. Belk and Sunderman expressed surprise at the 
scatter and consequent unreliability of the results obtained. For 
example, calcium results ranged from 3 to 13 and from 7 to 15 
mg/dL (0.75 - 3.25 and 1.75 - 3.75 mmol/L) for solutions prepared 
to contain 6.6 and 12.6 mg/dL (1.65 and 3.15 mmol/L) 
respectively, and more than 60% of participants failed to obtain 
'acceptable' results for at least half of the specimens. There 
seemed, however, to be no evidence of an overall bias relative to 
weighed-in values.
In further enquiries, most of the participating pathologists 
attributed the unreliability of results to the inadequate numbers 
and poor training of their technical staff. Some also blamed poor 
equipment and lack of space, and lack of understanding between 
the pathologist and his staff; the authors felt this latter 
reflected poor communication between hospital wards and the 
laboratory as a whole.
Other groups in the USA also carried out local (statewide) 
surveys around this time (Snavely and Golden, 1949 and 1951). 
The spread of results was broadly similar to that shown by Belk 
and Sunderman, with about one third of results being classified 
as unsatisfactory. These authors attributed much of the poor 
performance to inadequate staffing, training and supervision, 
but also commented on the deficiencies of pre-calibrated 
instruments (Snavely and Golden, 1949) and advocated the trial 
of standardised methods in further surveys (Snavely and Golden,
1951). Surveys were also undertaken in other laboratory 
disciplines, with similar findings (Marsters, 1949; Hardy,
1952); there was over 10 years' experience of EQA in syphilis 
serology testing (Gumming et al, 1935). Again these authors
stressed the need for improvement through provision of advice 
and assistance and through standardisation of procedures, with 
EQA providing an educational stimulus for improvement.
A few years later, the first survey in the UK was undertaken by 
Wootton and King (1953). These workers had derived reference 
intervals (then termed "normal ranges") for common laboratory 
investigations, and wished to determine their applicability to 
assays carried out in other laboratories. The initial study 
involved determination by 21 laboratories of 6 analytes in a 
specimen of preserved whole blood. The wide scatter of results 
(eg from 45% to 170% of the mean for urea) prompted a further 
survey of 9 assays among 36 laboratories, this time using an 
aqueous solution of pure inorganic and simple organic compounds 
at known concentrations. Though there was no evidence of 
consistent bias from the weighed-in value in most cases (apart 
from an average overestimation of creatinine by about 40%), a 
considerable part of the variability persisted. The authors 
asserted that the use of different analytical methods did not 
explain the observed lack of agreement.
Wootton and King emphasised the need to investigate further the 
causes of the between-laboratory variance revealed by their 
survey, and proposed the institution of a system of regular 
checks on a national scale.
1.4 External quality assessment through occasional surveys
Through the years following the initial surveys described above a 
number of workers pursued the study of between-laboratory 
variability in results. Many of these reported the results of 
'one-off local or national EQA surveys (eg Tonks and Alien,
1955; Holtz, 1959; Tonks, 1963; Desmond, 1964; Gowenlock, 1969), 
and in one case an international survey (Wootton, 1956). Other 
publications reviewed the results of regular but essentially 
local EQA schemes (eg Shuey and Cebel, 1949; Campbell, 1962; 
Merritt et al, 1965; Evans et al, 1966).
These largely confirmed the findings of the earlier surveys. 
Shuey and Cebel (1949), reporting several years' experience in 
surveys of military laboratories, postulated that the efficacy of 
EQA was directly related to the survey frequency and to the 
number of specimens included. Interestingly, Merritt et al (1965) 
reported only insignificant overall improvement in laboratories 
provided with additional advice and assistance.
The 1954 international survey, sponsored by IFCC, showed that 
the unsatisfactory between-laboratory agreement was not confined 
to individual countries, and demonstrated for the first time that 
laboratories could compare two solutions more accurately than 
determine the absolute concentration of an analyte (Wootton,
1956). Overall, there appeared to be a need for more satisfactory 
analytical methods and procedures for their control (eg Wootton,
1957).
The EQA surveys conducted during the 1950s and early 1960s were 
limited in scope. The facilities available to their organisers 
were also limited. Thus the specimens may have been less than 
ideal, the surveys often covered a few analytes only, and the 
intervals between the survey itself and the appearance of reports 
for participants and/or publication in the scientific literature 
were prolonged. Surveys other than those mentioned above were 
also carried out, but the results were not published.
1.5 The development: of internal quality control
Publication and disussion of the findings of the initial EQA 
surveys led to a growing awareness of the importance of quality 
assurance in clinical laboratory medicine. In particular the 
possibilities of developing IQC procedures based on the 
successful applications of quality control (QC) in manufacturing 
industry (eg Shewhart, 1931) were explored by authors such as 
Levey and Jennings (1950). Such procedures had already been 
implemented in analytical chemistry laboratories (Wernimont, 
1946; Mitchell, 1947).
One problem, however, is that while industrial QC employs 
measured characteristics of the manufactured item itself to 
monitor the production process chemical analyses yield only an 
analytical result, which should differ for each specimen. Thus 
most IQC procedures in clinical chemistry use the reference 
sample technique, whereby a control specimen (or specimens) is 
analysed periodically among the clinical specimens (eg 
Archibald, 1950; Levey and Jennings, 1950; Henry and Segalove, 
1952; Benenson et al, 1955; Henry, 1959). Clinical and control 
specimens are assumed to be affected identically by the 
analytical procedure, though this may not be true in all cases 
if commercial QC materials are used. In the earlier literature 
there is confusion between the use of "standards" for 
calibration of the assay and/or for its control; Archibald 
(1950) was the first to advocate the inclusion of a pooled serum 
specimen with every set of determinations, to be carried through 
all steps of the analysis (including calculation), for control 
purposes.
In addition to the reference sample approach, other workers
advocated the use in IQC of the results on clinical specimens, 
through the calculation of 'daily means' (Waid and Hoffmann, 
1955; Hoffmann et al, 1961; Whitehead and Morris, 1969). This 
approach yields information on performance which is not subject 
to errors due to the 'artificial' nature of some QCMs. It does, 
however, require additional calculations and is prone to 
influences from variation in the population from which the 
specimens originate, necessitating extra precautions to avoid 
erroneous conclusions (eg Dixon and Northam, 1970).
IQC procedures have been continually improved over subsequent 
years, and increasingly sophisticated systems have been devised 
(eg Whitby et al, 1967; Whitehead, 1976 and 1977; Grannis and 
Caragher, 1977; Stamm, 1981; Buttner et al, 1983a), some endorsed 
by international organisations such as WHO and IFCC. Westgard and 
his colleagues have made a notable contribution in validating 
statistically the effectiveness of IQC systems (eg Westgard et 
al, 1979; Westgard and Groth, 1981), and the so-called 'Westgard 
rules' (Westgard et al, 1981) have been widely accepted. More 
recently, Westgard and Groth (1983) have proposed models based on 
the predictive value approach previously used to assess and 
optimise the interpretation of diagnostic procedures (Galen and 
Gambino, 1975). Fraser (1983) has also advocated use of 
analytical goals based on biological variability in place of 
statistical considerations (eg +2 SD) in setting control limits.
In parallel with the development of IQC programmes came the 
realisation of the importance of quality assurance, covering all 
activities from test selection, through specimen collection and 
transportation, laboratory analysis and report generation, to 
report interpretation. Many aspects of quality assurance
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represent 'good laboratory practice', and were previously termed 
'preventive measures' by Whitehead (1977). There have also been 
improvements in education and awareness of the need for quality 
in laboratory investigation (Buttner et al, 1980b).
IQC is now applied almost universally in the developed world as 
an integral part of laboratory practice. These procedures are a 
major cost in both time and materials (Tydeman et al, 1982), but 
this is accepted as essential to the production of reliable 
laboratory results; as in industry, the price of poor quality is 
greater than that of good quality (Price, 1984).
1.6 External quality assessment
However sophisticated a laboratory's IQC programme may be, it was 
apparent by the 1960s that EQA was essential to attain and 
maintain comparability of results among laboratories. The reasons 
for this were later categorised (WHO, 1981; Buttner et al, 
1983b).
1.6.1 The need for external quality assessment
These groups pointed out that comparability of results among 
laboratories (transferability with respect to geography) is 
essential to ensure uniformity of interpretation with regard to:
- common reference intervals
- mobility of medical staff between healthcare facilities 
(eg hospitals)
- movement of patients between healthcare facilities
- analyses provided by different laboratories at different 
stages of investigation or treatment
- clinical or epidemiological multicentre studies
- application of legal provisions (eg Health and Safety
Commission, 1980)
The emphasis of IQC is on control of batch-to-batch imprecision, 
and its basic question is whether the batch is sufficiently 
similar to preceding batches to permit release of results from 
the laboratory. Such control is normally prospective relative to 
reporting procedures, and unsatisfactory batches of results can 
therefore be identified and eliminated. The primary objective of 
EQA, however, is the assessment of accuracy. This is more usually 
expressed as bias relative to a designated or target value, since 
the true value for many analytes in biological specimens is 
unknown and the designated value ("correct value"; Whitehead, 
1977) must be used as an approximation to this (WHO, 1981).
Since its outcome cannot influence release of results, EQA is 
essentially a retrospective activity and is complementary to IQC. 
These factors prompted the change in terminology (see section 1.2 
above; WHO, 1981), since the previous use of "external quality 
control" had misled some into thinking that IQC and EQA were 
interchangeable. The term "external quality assessment" also 
emphasises the aspects (assessment of interlaboratory agreement, 
of analytical methods, and of quality control materials) of EQA 
other than 'control' of individual laboratories' performance, 
which are discussed in section 1.9 below and which form the 
subject of this thesis.
1.6.2 Interlaboratory surveys
EQA may be considered to include procedures such as specimen 
exchange (eg Whitehead, 1977), but usually takes the form of 
interlaboratory surveys. In essence, an interlaboratory survey 
(WHO, 1981; Buttner et al, 1983b) includes the following stages:
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- distribution of a specimen or specimens from the organising 
laboratory to participant laboratories
- assay of the specimen(s) by participants according to the 
instructions provided
- return of results to the organising centre
- data processing, usually using computer facilities, of 
these results to yield information on interlaboratory 
agreement and other aspects of performance
- distribution to participants of a report based on the
processed data, which may include interpretive comments 
(general, and/or specific to individual laboratories 
such as those returning discrepant results)
EQA surveys may be proficiency surveys conducted for the purpose 
of licensing the participant laboratories, ie determining whether 
their results are sufficiently reliable to provide satisfactory 
patient care, or be primarily educational in intent.
1.7 The development of external quality assessment schemes
During the 1960s the potential benefits of established EQASs on a 
national scale became increasingly apparent, echoing the original 
conclusions of King and Wootton (1953). Thus, in his Presidential 
address to the Association of Clinical Pathologists Jordan (1965) 
emphasised the need for EQA in addition to IQC and hoped the 
Association would support the establishment of national EQASs for 
the UK, which need not be restricted to clinical chemistry.
This changing attitude, towards acceptance by many clinical 
chemists that participation in EQA was not only desirable but 
essential for improving the reliability of laboratory 
investigations, was important since it ensured an enthusiastic 
initial group of participating laboratories. At the same time
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developments in electronic data processing in laboratories 
enabled not only the easier and more efficient use of IQC 
procedures, but also the rapid processing of the large numbers of 
results regularly required to operate a national EQAS (NEQAS).
Following this professional pressure, several proposed national 
schemes secured funding, primarily from governmental sources. In 
the UK, National Quality Control Schemes (Whitehead and 
Woodford, 1981) covering firstly clinical chemistry and later 
haematology were initiated by groups in Birmingham (Whitehead et 
al, 1973) and London (Lewis and Burgess, 1969; Ward and Lewis, 
1975), to be joined by a commercial scheme operated by Wellcome 
Diagnostics (then Wellcome Reagents Ltd). Activities were also 
started in other countries, including Canada (Ley and Ezer, 
1974) the German Federal Republic (GFR; Bundesarztekammer, 1971; 
Stamm, 1975) and the USA (Gilbert, 1975a; Grannis and Caragher, 
1977). In some cases the development of EQASs was stimulated by 
legislation, such as the Calibration Law in GFR and the Clinical 
Laboratories Improvement Act in the USA, whereas in others 
professional societies provided the main impetus.
These schemes evolved over the succeeding years, and the scope of 
EQA was broadened through the introduction of NEQASs covering 
more specialised aspects of clinical chemistry such as 
radioimmunoassays (RIAs) for hormones (eg Hunter and McKenzie, 
1979; Rohle and Breuer, 1978; Groom, 1985a) and other clinical 
laboratory disciplines (see Whitehead and Woodford, 1981). Other 
countries, such as Belgium (de Leenheer et al, 1983), France, and 
Holland (Jansen et al, 1977), also initiated NEQASs.
A different EQA design, with interlaboratory comparison of
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results from IQC procedures using the same material, was proposed 
by Limonard (1979) and implemented in Holland (Jansen and Jansen, 
1980). This was based on the principles of 'regional quality 
control' administered by the College of American Pathologists 
(CAP; Lawson et al, 1980) and the commercial schemes operated by 
companies such as American Hospital Supply, and its deficiencies 
have been discussed by Tonks (1982).
By the mid-1980s, NEQASs had been established in most countries 
of the developed world and many in the developing world. There 
was common ground in many aspects of scheme design (WHO, 1981), 
but differences in details have persisted. In particular the 
derivation of designated values from assays by reference 
laboratories (eg Hansert and Stamm, 1980) or from consensus 
values (eg Gilbert, 1976; Grannis, 1976) has continued to 
generate considerable dispute. This and the other main factors 
are discussed in detail in Chapters 3 to 6.
1.8 Evolution of the UKEQAS for General Clinical Chemistry
This scheme was instituted in 1969 as the National Quality 
Control Scheme, supported by Department of Health and Social 
Security (DHSS) research and development funds. The main 
objectives (Whitehead et al, 1973) were:
- frequent distributions (every 14 days) of reliable 
specimens, prepared from human serum
- rapid return of results by participants
- rapid processing of these results, to make a report 
available within 10 days of specimen receipt
- results presentation to enable participants to assess 
their performance
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- voluntary and confidential participation, open to all 
UK clinical laboratories
- assessment of any improvements in precision or accuracy, 
and of any effects of workload or analytical procedures
This design appeared to be well-accepted by the participants, 
which grew in numbers to about 350 from the initial 200 
laboratories. By 1971 each analyte had been surveyed up to 21 
times but there was no evidence of improving overall performance 
during this period. To provide a greater stimulus for 
improvement, a system for scoring performance, the Variance Index 
(VI), was then introduced and thereafter between-laboratory 
agreement was seen to improve (Whitehead et al, 1973). The 
authors postulated that a scoring system assisted in both 
assessing and monitoring changes in participants' performance; 
the VI system was later modified to increase its utility 
(Whitehead, 1977; Bullock and Wilde, 1985).
Modifications, some described in Whitehead (1977) and many of 
which are discussed in this thesis, were made to the basic 
scheme design in succeeding years. In particular the scope was 
broadened by occasional surveys (eg Bold and Browning, 1975; 
McSweeney et al, 1979) and by the introduction of sub-schemes for 
more specialised assays, the first of which was the UKEQAS for 
Lead in Blood (Bullock et al, 1986c). The current situation has 
recently been reviewed briefly (Bullock, 1985; DHSS, 1986b).
1.9 Potential applications of data from external quality 
assessment
Most clinical chemists think of EQA purely in terms of monitoring 
the performance of individual laboratories. Though many EQASs are 
established primarily with this objective, the true purposes of
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EQA are much wider, as emphasised by use of the term external 
quality assessment (WHO, 1981).
Any EQA survey or scheme will yield information about the degree 
of agreement among results from the various participating 
laboratories. This interlaboratory concordance, often referred to 
as 'the state of the art', can be useful in comparisons with 
medical requirements and judging whether improvements are 
required. One means for such improvement is EQA, and the 
information can be used to determine priorities for EQAS 
establishment (WHO, 1981).
This assessment of the state of the art can be extended to 
individual analytical procedures. Thus the performance 
characteristics of method principles and instrumentation can be 
assessed (WHO, 1981; Jansen et al, 1981).
The main objective of most EQASs is the assessment of the 
performance of individual participant laboratories. A number of 
determinants of performance can be examined, covering aspects 
such as turnround time for assays in addition to analytical 
characteristics such as accuracy and precision (WHO, 1981). The 
aim is not only to stimulate and monitor improvements in 
performance, but also to identify those laboratories experiencing 
problems and in particular need of assistance (eg Browning, 
1984; Walker, 1985).
Finally, interlaboratory agreement in EQA is intimately related 
to the behaviour of the materials distributed. Thus EQA data 
provide a means for study of the properties and quality of QC 
materials (eg Jansen, 1980). A related aspect is the ability to 
assess the effects of calibration practices (eg Jansen and
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Jansen, 1983).
1.10 Consideration of the requirements, applications and benefits 
of external quality assessment
As an important element of quality assurance, external quality 
assessment is a determinant of the quality of patient care. The 
fundamental aspects of EQAS design do not seem, however, to be 
based on clear logical principles. Though their role in 
monitoring laboratory performance is obvious, the potential roles 
of EQA schemes in the assessment of interlaboratory agreement, 
in the assessment of analytical methods, in the assessment of 
individual laboratory performance and in the assessment of 
quality control materials, appear not to have been widely 
appreciated.
In this thesis these applications of external quality assessment 
schemes and their benefits are examined in turn, with 
consideration of the basic requirements of scheme design. This 
thesis is concerned with the following question: What has 
external quality assessment to contribute to the scientific 
development of clinical chemistry and to patient care, besides 
the 'policing 1 of laboratory performance?
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ASSESSMENT OF INTERLABORATORY AGREEMENT
Chapter 2:
EXTERNAL QUALITY ASSESSMENT SURVEYS IN ASSESSING THE STATE 
OF THE ART
2.1 Introduction
From the very earliest surveys EQA has been used to assess the 
state of the art (Gumming et al, 1935; Belk and Sunderman, 1947; 
Wootton and King, 1953). The survey organisers, concerned for the 
quality of patient care decisions based on the results of 
laboratory investigations, sought information on the degree of 
interlaboratory agreement and within-laboratory precision, and 
EQA was the tool best suited to this objective.
Reasons (more than one of which may motivate surveys in many 
cases) for desiring such information include:
- curiosity about the situation
- determining the factors contributing to good or poor 
performance
- monitoring the effects on interlaboratory agreeement of 
other activities (eg the introduction of recommended 
methods)
- assessment of the need for continued survey and for 
establishment of an EQA scheme
Consider for example an assay for which a number of analytical 
methods are available and which has only recently come into 
widespread use as a 'routine' analysis. Though the methods 
performed well in their originators' laboratories they are known 
not to be robust and to be difficult to control; current 
performance under routine conditions may therefore be less
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satisfactory with regard to both precision and accuracy. The 
calibration materials are believed to be unstable, and since 
serum-based secondary calibrants are needed differences in the 
values assigned by various manufacturers are suspected, thus 
compounding the problems.
What then should be done about the situation? An EQAS could be 
initiated, but it is conceivable that the problems suspected 
on scientific grounds may be groundless: the EQAS would then be 
superfluous, and resources be wasted thereby. Alternatively, the 
situation may prove to be grossly unsatisfactory and a major 
initiative to provide better methods or improved means for their 
control be required: continued frequent and regular survey would 
again be inappropriate. Finally the specimens chosen for 
distribution may be unstable or otherwise unsuitable, requiring 
identification or development of more appropriate alternative 
materials.
The inevitable conclusion is that it is unwise to initiate an 
EQAS without first obtaining information on the current state of 
the art and on the design criteria for a scheme which is likely 
to succeed in its objectives (discussed in Chapter 3 below). The 
logical course of action would therefore be to carry out a pilot 
survey, or a short series of surveys, to assess the former.
The information generated will then be of prime assistance in 
determining the appropriate further action(s), if any. Thus, if 
the situation is deemed satisfactory then action may be 
unnecessary (or at least not urgent), and if it is less so then 
an EQAS to stimulate improvement may be indicated. If it is 
totally unsatisfactory then immediate actions by way of method 
selection and recommendation or by implementation of effective
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IQC procedures will be required.
Numerous such situations exist within clinical chemistry. The 
continually-widening test repertoire has provided a major 
challenge to EQAS organisers in selecting which analytes require 
regular schemes, and even in allocating priorities for 
exploratory survey since resources are limited. Clinical 
relevance, within-laboratory performance data and evidence from 
limited EQA activities all lend some assistance in this latter, 
which should then yield the quantitative information on which 
rational policy decisions may be based.
Extra-laboratory investigations, the quality of which is of great 
clinical importance to the provision of reliable patient care, 
provide a good example of the application of EQA surveys. These 
therefore form the basis of the consideration below, other 
aspects then being discussed in relation to laboratory 
determinations.
Before embarking on any consideration of the application of EQA, 
however, the question of whether patient care in fact benefits 
from improved within- and between-laboratory agreement must first 
be addressed.
2.2 The relationship of patient care to reliability of laboratory 
results
The aim of quality assurance is to increase the reliability of 
results leaving the laboratory, but is this relevant to patient 
care? This question may be addressed using the the concepts of 
the sensitivity, specificity and predictive value of laboratory 
tests developed by Galen and Gambino (1975), and the 
determination of analytical goals in terms of their relationship
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to biological variation pioneered by Harris and his co-workers 
(Subcommittee on Analytical Goals, 1979; Harris, 1979; reviewed 
by Eraser, 1983).
2.2.1 Sensitivity, specificity and efficiency
Consider the application of a laboratory test to differentiate 
between populations of 'normal' and a 'diseased' individuals 
(Figure 2.1). As with many investigations there is incomplete 
separation of the two groups. The test thus gives false positive 
and false negative results, due to failings in its specificity 
and sensitivity respectively, and its predictive value and 
efficiency are consequently suboptimal.
What then is the effect of analytical variance on these 
characteristics? The variation in each group is composed of both 
analytical and biological variation, so any change in analytical 
performance will be reflected in the overall spread of results. 
For example, Figure 2.2 shows the consequences of doubling and 
halving the analytical variation (here assumed initially to be 
equal to the inherent biological variance; Figure 2.1) on the 
incidence of misclassification as false positives and false 
negatives.
It is clear from such simulations that the clinical 
discrimination of the test is related directly to analytical 
performance. The position of the cut-off can be varied to 
optimise sensitivity, specificity, predictive value or efficiency 
according to the application (Galen and Gambino, 1975), but for 
any given position improvements in analytical performance will 
improve all these characteristics contributing to the reliability 
of healthcare.
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Figure 2.1 Hypothetical distributions of results from populations 
of normal and diseased individuals, assuming equal 
contributions from biological and analytical variability 
(SD). Arrow denotes position of cut-off; FP and FN are false 
positive and false negative results
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Figure 2.2 Effect on distributions of results from populations of 
normal and diseased individuals of doubling (A) and halving 
(B) the analytical variability. For explanation see Figure 
2.1
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These conclusions will not, however, apply to situations where 
there is complete separation of the groups unless deterioration 
in performance leads to the appearance of overlap, but such 
'ideal' tests are extremely uncommon. Analogous arguments apply 
to the other applications of laboratory investigations, ie 
discrimination between several 'diseased' populations, comparison 
of results with externally-derived reference values, and the 
assessment of changes within a patient (Grasbeck et al, 1979).
2.2.2 Analytical goals
Given the assumption that laboratory investigations 
do benefit patient care, one would expect both intuitively and 
from the analysis above that the better the analytical quality 
the better would be patient care. As discussed by Harris (1979) 
and Fraser (1983), however, analysis takes place against a 
background of biological variation in analyte concentrations, 
both within and between individuals. Thus a goal for analytical 
variation may be elaborated, improvement beyond which will not 
yield significant improvement in the variance of measured 
results. Conventionally (since serial monitoring of patients is 
the most demanding application), intra-individual variation is 
considered and the goal for analytical variance is taken as one 
quarter of the biological variance (Subcommittee on Analytical
Goals, 1979):
2
2 (SDbiological^_ (^analytical) < —————~~~
cvbiological ie cvanalytical < ————~ —— ~~~
Such goals may then be compared with the state of the art to 
determine whether improvement is necessary (eg Fraser, 1986).
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Data from EQA surveys or schemes should be integral to such 
comparisons, which have almost without exception revealed a need 
for improvement beyond the current state of the art to attain 
these goals. For example, a study of the information available on 
glucose assay demonstrated generally suboptimal performance, 
though some of the techniques in use were capable of surpassing 
the goal of 2.2% CV (Fraser, 1986). Similar comparisons for a 
wider range of analytes, such as those summarised in Table 2.1 
(Fraser CG, personal communication), confirm that this is still 
generally true, despite the tremendous improvements in 
performance since the introduction of QA into clinical chemistry.
This approach can assist in the appraisal of EQA survey data, but 
it must be remembered that these goals are not objective despite 
their derivation in terms of biological variance. Thus the 
selection of the fraction of one quarter is essentially 
arbitrary, dependent upon a judgement that below this level 
analytical variation no longer makes a significant contribution 
to total variance. If there are changes in the application of 
laboratory investigations, then these goals must be revised.
At present, however, such goals are generally not met and 
consequently there is a need for improvement of the reliability 
of most assays. Through surveys and schemes, EQA provides the 
means both to assess and to stimulate improvements in the quality 
of laboratories' analytical results and hence the reliability of 
patient care.
2.3 The quality of extra-laboratory assays in clinical chemistry
Extra-laboratory or 'decentralised' assays (those carried out 
outwith conventional laboratories by non-laboratory staff, such
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Table 2.1 Comparison of analytical goals for commonly-determined 
analytes in serum with median within-laboratory imprecision 
from the Wellcome QC Programme in 1971 and 1986 (Eraser CG, 
personal communication; Stevens and Hjelm, 1986) Data 
expressed as SD at mid-point of adult reference interval, in 
mmol/L unless specified
Analytical goal Median imprecision
1971 1986
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron (umol/L)
Urate
Creatinine (umol/L)
Bilirubin (umol/L)
Total protein (g/L)
Cholesterol
Magnesium
0.6
0.11
0.8
0.30
0.14
0.02
0.04
2.4
0.010
2.2
1.1
1.0
0.16
0.01
.
.
2.0
0.14
1.9
0.71
0.50
0.09
0.11
3.0
0.030
15.4
6.5
2.2
0.39
0-07
1.4
0.07
1.6
0.25
0.15
0.06
0.04
1.6
0.014
6.5
2.3
1.4
0.12
0.06
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as medical and nursing staff) are becoming increasingly important 
in patient care. Though other factors are also involved, the 
primary justification for such assays is to enable better 
clinical management through the availability of test results with 
greater speed and/or convenience than the laboratory could 
provide (Watson, 1980; Marks, 1983; Belsey et al, 1986). The 
scale of this activity in the UK in 1982 was revealed by a 
questionnaire (Browning et al, 1984), indicating that extra- 
laboratory assays were carried out in at least 40% of hospitals; 
there was collaboration with the clinical chemistry laboratory in 
only half of these. Such assays are likely to increase, with 
further devolution into community health centres and patients' 
homes.
Quality assurance in this situation is at least as important as 
within laboratories (Whitehead and Garvey, 1985), but there has 
been concern over the quality of such assays. Though some had 
endeavoured to assess quality within hospitals (eg Andrews et al, 
1983; Drucker et al, 1983; Smith, 1983) or in the community (eg 
Petranyi et al, 1984; Burrin et al, 1985), no information was 
available on the situation nationally in the UK. A programme of 
surveys to investigate the national situation and provide the 
basis for rational action was therefore undertaken by the Wolfson 
Research Laboratories (WRL; Browning and Bullock, 1987).
2.3.1 Exploratory survey - Survey 1
It was decided that these surveys should be conducted initially 
through hospital laboratories. Contact with laboratories was 
readily available, laboratory expertise would be necessary 
to ensure satisfactory reconstitution of lyophilised materials, 
and distribution from a centralised hospital site would permit
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economy of specimen usage. The disadvantage of incomplete 
national coverage was a secondary consideration at this stage. 
Sodium, potassium, glucose and bilirubin, the most widely- 
determined serum analytes, were selected for survey. This survey 
(Appendix 1.5.3) therefore comprised distribution of a specimen 
of lyophilised bovine serum to the 210 laboratories responding to 
the 1982 questionnaire (Browning et al, 1984). Recipients were 
asked to reconstitute the specimen and provide aliquots for assay 
to extra-laboratory sites.
The results returned were then assessed by comparison with those 
obtained on distribution of the same serum though the UKEQAS for 
General Clinical Chemistry. This (Table 2.2) demonstrated firstly 
much greater variability of the extra-laboratory sodium and 
potassium results, with performance apparently about 50% worse 
than that for laboratory assays. There were few results, however, 
and further study on a larger scale would be required to confirm 
this conclusion.
The variance of extra-laboratory glucose assays appeared 
substantially worse. When assessed by CV and by average VIS, it 
was at least double that among laboratories, and the range of 
results obtained appeared clinically significant. The small 
number of results in each group made more detailed assessment 
according to the manufacturer and model of reflectance meter less 
reliable, but no major differences in performance were apparent. 
A national survey of glucose assay thus appeared essential.
The results also confirmed the unsuitability of bovine serum for 
spectrophotometric bilirubin assays, due to the presence of 
interfering chromophores. Survey of bilirubin was therefore 
discontinued, to be combined with assessment of paediatric
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Table 2.2 Comparison of the results from the first WRL survey of 
extra-laboratory assays, October 1985, with UKEQAS 
distribution of the same lyophilised serum. All data 
recalculated after exclusion of results more than 2SD from 
the untrimmed mean; VISs calculated relative to the method 
mean.
n Mean CV Range Average VIS
Sodium (mmol/L)
Extra-lab
UKEQAS
34 152.4 2.0%
429 150.7 1.1%
147 - 164 88
144 - 156 57
Potassium (mmol/L)
Extra-lab 45
UKEQAS 438
7.26 3.4%
7.23 1.9%
2.0 - 7.8 91
6.7 - 8.8 55
Glucose (mmo1/L)
Extra-lab 152
UKEQAS 434
19.03 12.3% 
17.15 3.4%
5.6 - 23.0 183
14.9 - 20.4 40
Bilirubin (umol/L)
Extra-lab* 33 123.3 17.2%
UKEQAS 380 92.9 7.3%
67 - 320 
30 - 154
80
37
*Diazo
*Spectro
4 86.8 21.3% 
27 128.2 12.7%
67 - 110 
81 - 320 89
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bilirubin assays within laboratories (see section 2.4.3 below).
2.3.2 First national survey - Survey 2
Survey 2 was designed to assess the applicability of these 
findings on a national scale. Specimens were therefore sent to 
all UKEQAS participants; the other aspects were as in Survey 1 
(Appendix 1.5.3).
The variance of sodium and potassium assays (Table 2.3) was 
confirmed as being 1.5 times that seen in the UKEQAS for 
laboratory assays. Though this is a cause for concern, the ranges 
of results obtained did not appear likely to cause major errors 
in the clinical management of patients. Thus these analytes could 
no longer be considered as priorities for survey.
A similar relationship held for glucose using 'laboratory' 
instruments such as glucose oxidase (GOD)/oxygen electrode 
procedures (Table 2.3). When glucose assays using reagent 
'sticks' and reflectance meters were considered, however, the 
situation was again much worse, the average scores being about 
four times those obtained by UKEQAS laboratories on the same 
specimen. The ranges of results returned also confirmed a 
potential for gross errors in clinical management if diagnoses or 
therapy were based on these results. This is emphasised by the 
distributions of extra-laboratory and UKEQAS results shown in 
Figure 2.3.
Glucose assay under extra-laboratory conditions thus appeared to 
be in need of greatest improvement and of further survey. The two 
initial surveys were susceptible to several criticisms:
- the specimens were of bovine rather than human origin
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Table 2.3 Comparison of the results from the second WRL survey of 
extra-laboratory assays, April 1986, with UKEQAS 
distribution of the same lyophilised serum. All data 
recalculated after exclusion of results more than 2SD from 
the untrimmed mean; VISs calculated relative to the method 
mean.
n Mean CV Range Average VIS
Sodium (mmol/L)
Extra-lab
UKEQAS
69 152.8 1.6%
412 151.3 1.2%
146 - 166 85
141 - 165 62
Potassium (mmol/L)
Extra-lab 71
UKEQAS 422
6.17 3.0%
6.15 1.9%
4.7 - 7.2 91
4.5 - 7.8 57
Glucose (mmol/L)
Extra-lab* 492
UKEQAS 418
13.6 14.6%
13.4 3.6%
1.5 - 22.0 150
6.2 - 16.1 41
*GOD 31 12.7 6.6% 9.4 - 14.6 70
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Figure 2.3 Comparison of glucose results in the second WRL survey 
of extra-laboratory assays, April 1986, with those from 
UKEQAS distribution of the same serum
201 Ectra-lab
50 -. UKEQAS
of
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Glucose (mnol/L)
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- the lyophilised specimens were reconstituted in and 
distributed from laboratories, casting doubt on specimen 
stability
- the specimens were of serum rather than whole blood, for 
which the procedures are designed
- performance was assessed at a single level only, of 
uncertain clinical relevance
- the coverage was unlikely to be complete, due to 
distribution through laboratories and to self-selection of 
sites returning results
Though the last potential objection must be accepted in any such 
survey, it proved possible to resolve all others apart from the 
first for glucose assay by using a newly-available material in 
Survey 3.
2.3.3 Second national survey - Survey 3
Survey 3 (Appendix 1.5.3) therefore used two liquid blood-based 
specimens ("Sugar-Chex") at clinically high and low levels. Other 
aspects were as before, though no UKEQAS results were available 
for comparison. Studies by the suppliers confirmed this material 
to be stable, have negligible vial-to-vial variability and show 
minimal effect of mixing efficiency (some participants reported 
difficulty in resuspending settled erythrocytes).
The results of this survey (Table 2.4) confirmed for glucose the 
findings of the earlier surveys. The ranges of results for the 
two specimens were clinically significant (Figure 2.4), 
interpretation of the extreme results of 2.1 and 22.2 mmol/L 
obtained for specimen 2 being obviously different.
Glucose results obtained by visual reading of reagent sticks had
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Table 2.4 Results from the third WRL survey of extra-laboratory
assays, November 1986. All data recalculated after exclusion 
of results more than 2SD from the untrimmed mean; VISs 
calculated relative to the method mean.
n Mean CV Range Average VIS
Glucose (mmol/L) - results from quantitative assay
Specimen 1 623 3.84 22.4% 1.1-10.3 196
Specimen 2 592 15.74 11.5% 2.1-22.2 128
Glucose (mmol/L) - results by visual reading
Specimen 1 192 4.68 22.1% 1-17 157
Specimen 2 162 16.40 8.2% 5-44 111
n Average VIS 
Overall 646 162
GOD 'automated' 24 88
BCL meter 350 136
Ames meter 178 192
Hypocount meter 64 216
Other meter 30 237
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Figure 2.4 Distributions of glucose results in the third WRL 
survey of extra-laboratory assays, November 1986
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been reported by some participants in Survey 2. These were, as 
expected, even more variable than those from reflectance meters: 
the trimmed CV for 170 results was 26.7%, with a range of 2.2-44 
mmol/L. In Survey 3 such results were also requested, and 192 
were received. The performance (trimmed CVs 2.1 and 8.2%, average 
VISs 157 and 111), however, appeared similar to that using 
reflectance meters though the ranges of results (1-17 and 5-44 
mmol/L) were greater.
2.3.4 Conclusions from the surveys
These surveys demonstrate clearly that the standard of 
performance of extra-laboratory assays in the UK in 1986 was not 
fully satisfactory. Variability appeared to be 50% greater than 
that of laboratory assays for sodium and potassium and for 
glucose using laboratory instruments, presumably reflecting the 
lesser experience of the operators and their lower awareness of 
quality assurance. The variability was about three times greater 
for glucose using reflectance meters, with potentially adverse 
clinical consequences of diagnoses or therapy based on such 
results. The information on visually-read glucose assays was not 
fully consistent, though variability appeared to be greater than 
for assays using meters.
How reliable are these conclusions? Survey 1 was intended as a 
feasibility study only, and the primary outcome was to indicate 
that the design could be applied on a larger scale. It also 
suggested that problems did exist with extra-laboratory assays, 
and that bovine serum was not useful for survey of bilirubin 
assays.
Survey 2 confirmed the existence of greater variance in extra- 
laboratory assays than that seen in the UKEQAS for laboratory
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determinations. The variability for glucose was by far the 
greatest, indicating this analyte as the priority for further 
survey, whereas that for sodium and potassium was of doubtful 
clinical significance.
As described above (section 2.3.2), the design used in Surveys 1 
and 2 was susceptible to several criticisms. Most were obviated 
by the amended design chosen for Survey 3, of glucose alone. Thus 
two specimens were used, at levels with clinically significance; 
they were stable and did not need laboratory reconstitution. The 
specimens were also blood-based, so their performance should have 
more closely reflected that obtained for clinical specimens as 
well appearing more realistic to the operators. The species of 
origin was again bovine, but differences in behaviour between 
materials including bovine and human erythrocytes are most 
unlikely to be sufficiently great to influence the conclusions 
drawn from Survey 3.
The final point cannot be answered at this time, since there is 
no centralised source of information on sites where extra- 
laboratory equipment is used. Indeed, many laboratories are 
unaware of the situation within their own hospital. The surveys 
may thus not have been fully representative of the situation 
throughout the UK: the coverage was almost certainly incomplete, 
and the participants all had some contact with laboratories. The 
information available indicates that collaboration with 
laboratory staff can improve performance (Smith, 1983; Whitehead 
and Garvey, 1985), so it is unlikely that these surveys 
overestimated the true variability.
The data on visual glucose readings from Survey 3 illustrate an
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important point. The agreement, apparently better than that using 
meters, may be explained by the high proportion of results at a 
single value (64% and 70% of 4.5 and 17.0 mmol/L respectively), 
grossly distorting the distribution from Gaussian and making 
unreliable any judgements from parametric estimators of 
dispersion such as the CVs. The average VISs were also distorted, 
due primarily to the effect on the method mean (the average 
scores increased to 262 and 151 if the reflectance meter means 
were used as designated values).
Thus the conclusions from these surveys appear to be valid in 
indicating that the performance of at least glucose assays 
requires urgent improvement if extra-laboratory assays are to 
benefit patient care.
What steps should be taken to bring about such improvement? One 
obvious and often-repeated suggestion is to establish an NEQAS to 
cover these assays. There are practical problems in implementing 
such a scheme, relating mainly to ascertainment of participant 
sites, to selection of suitable and stable specimens, and not 
least to the sheer scale of the undertaking. Moreover, experience 
suggests this would be unlikely to stimulate great improvement in 
the absence of adequate internal quality control procedures and 
of quality assurance in general. The laboratory is the obvious 
source for the necessary expertise, and collaboration with extra- 
laboratory sites appears essential in the interests of safe and 
effective patient care. This will constitute a major challenge 
for clinical chemists over the coming years, and continuing EQA 
surveys offer the most convenient means to monitor the situation.
2.4 Laboratory examples
Other examples drawn from laboratory assays demonstrate
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additional aspects of the application of EQA surveys in assessing 
the need for institution of an EQAS.
2.4.1 Salicylate and paracetamol
Assays of salicylate and paracetamol in serum are of great 
clinical importance in the diagnosis and treatment of suspected 
overdose, and accurate and precise determinations are essential 
for reliable patient care. Many of the methods in use, however, 
were considered to be imprecise or non-specific, as suggested by 
the two local EQASs in the UK (Epton, 1979; Wiener, 1980), 
requests for participation in which were increasingly coming from 
outside the respective Regions. Thus there appeared to be both a 
demand for regular EQA of these determinations and evidence that 
this was necessary, and UKEQAS surveys were therefore initiated 
in 1983, building on the experience of the Regional schemes.
The first survey used three specimens of lyophilised human serum 
to which pure drugs had been added (Appendix 1.2.6). To avoid 
potential complications due to salicylate interference in some 
paracetamol assays each specimen contained only one drug (Wiener, 
1980). The results (Table 2.5) showed unsatisfactory agreement. 
Many participants had, however, complained that the specimens 
were turbid and that 1 mL of serum was insufficient for assay.
Further surveys were thus necessary to confirm the conclusions. 
These specimens were liquid to reduce the turbidity, based on 
sterile equine serum (since no matrix effects due to species were 
expected) to which pure drugs were added, and provided in larger 
volume. Gentamicin was used as an antibacterial agent since azide 
causes spectral interference in the Trinder procedure for 
salicylate assay (Davies KW, personal communication). The results
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Table 2.5 Interlaboratory agreement in the first three UKEQAS
surveys of salicylate and paracetamol assay, November 1983 
August 1984
n Mean CV Recovery
(mg/L) (%) (%)
Salicylate
Survey 1 272 
Survey 2 271
Survey 3 268
Paracetamol
Survey 1
Survey 2 
Survey 3
379.3
350.3
489.0
556.3
11.1
7.2
7.1
6.7
—
101.5
101.2
101.1
256
259
259
118
161
133
176
61
.7
.4
.9
.5
.5
16.
10.
10.
8.
22.
1
5
6
3
6
-
-
98.5
98.1
102.5
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(Table 2.5) confirmed the need for improvement, and a UKEQAS was 
therefore established. This continued with a similar design 
(Appendix 1.2.6), though specimens later contained both drugs and 
a further change to single-specimen distributions was made. Data 
from the scheme on method performance are given in Chapter 8 and 
on performance improvements in Chapter 9.
2.4.2 Specific proteins in serum
Measurement of proteins became more widespread during the 1970s, 
with increased use of nephelometric and turbidimetric assays and 
less reliance on radial immunodiffusion (RID) procedures. This 
expansion, coupled with intermethod differences in values 
obtained for calibrants and the improved between-laboratory 
agreement with regular EQA documented in the USA (eg Taylor and 
Fulford, 1981) suggested that an NEQAS for the UK could be 
beneficial. Surveys were therefore undertaken, starting in 1980.
Immunoglobulins G, A and M (IgG, IgA and IgM) were selected for 
the initial surveys (Appendix 1.2.5) primarily to validate the 
specimens (comprising liquid human serum), since wide variations 
were not expected. The results, however, showed considerable 
variation (Table 2.6), much of which appeared to be related to 
the calibration materials used (Chambers et al, 1984). Further 
surveys were therefore undertaken, with a method grouping 
including classification according to calibrant.
In the initial stages distributions comprised multiple specimens, 
including pairs related by dilution which enabled assessment of 
intralaboratory precision (Chambers et al, 1984). Additional 
studies (see section 13.2; Chambers et al, 1987) examined the 
potential improvement which might be gained from use of a common 
calibration material. Later distributions were reduced to a
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Table 2.6 Average interlaboratory agreement for immunoglobulins 
for the four specimens in the first UKEQAS survey of 
specific protein assays, September 1980. All data 
recalculated after exclusion of results more than 2SD from 
the untrimmed mean.
n
IgG
Average CV (%)
IgA IgM
Electroimmunoassay 4
AIP 12
Turbidimetry 20
Nephelometry
(Hyland calibrant) 19
Nephelometry
(other calibrant) 9
RID
(Hyland calibrant) 5
RID
(other calibrant) 118
31.9
7.6
11.4
12.7
12.7
10.5
13.6
14.7
8.7
17.4
23.0
14.2
17.6
16.0
36.4
14.9
17.4
12.5
8.4
32.5
15.5
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single specimen as the UKEQAS became established and Variance 
Index (VI) scoring was introduced; an increasing number of 
proteins were incorporated during the scheme's evolution.
2.4.3 Serum bilirubin in paediatrics
The assay of bilirubin is critical in the clinical management of 
neonatal jaundice, with therapy based primarily on the assay 
results (Mollison and Cutbush, 1954; Isherwood and Fletcher, 
1985). The results of overseas surveys (Schreiner and Click, 
1982; Watkinson et al, 1982; Blijenberg et al, 1984), supported 
by anecdotal evidence from Regional surveys within the UK, 
indicated between-laboratory and between-method differences. 
Surveys to ascertain the national state of the art in the UK 
therefore appeared essential, and were instituted in 1984.
The survey used a commercial lyophilised human-based QCM, since 
use of pooled clinical specimens on a national scale was 
infeasible; such QCMs are used widely for IQC with no apparent 
problems. All UK laboratories received the specimen, and only 
results obtained within laboratories were processed. These (Table 
2.7) showed that there was variability among laboratories, and 
confirmed the existence of accuracy differences between 
diazotisation and direct spectrophotometric methods.
Comparability was thus not fully satisfactory, and further 
surveys to investigate this in more detail and to stimulate 
improvement would be justified. The situation was, however, not 
as poor as had been anticipated and this activity was therefore 
allocated a lower priority. An additional factor delaying 
further surveys was the need (DHSS, 1986a) to ensure that the 
human-based materials to be distributed were negative for
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Table 2.7 Iirterlaboratory agreement in the first UKEQAS survey of 
paediatric bilirubin assay, April 1984
n Mean CV
(umol/L) (%)
Overall 315 376.7 8.3
Diazotisation methods:
Caffeine/benzoate 62 387.7 6.0 
Diphylline 9 374.7 5.8 
Other accelerator 26 392.7 8.3 
Dichlorophenyldiazo salt 20 385.2 7.1
Spectrophotometric methods:
Bilirubinometer - direct 86 359.0 7.9 
Bilirubinometer - diluted 17 377.8 8.1 
Dilution & spectrophotometry 78 379.2 8.4
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antibody to human immunodeficiency virus (HIV) at the individual 
donation stage. These surveys would also attempt to assess the 
quality of extra-laboratory assays (section 2.3.1 above).
2.4.4 Urinary total protein
Urinary protein assays are important in the diagnosis and 
monitoring of renal disease, and form part of the medical 
examination of apparently healthy subjects for insurance 
purposes. Thus reliability is essential, especially at low 
protein concentrations. Published data from the USA and Australia 
(Glenn, 1980; Shephard et al, 1983) and from UK Regional surveys 
(Legg and Hurrell, 1984) indicated that between-laboratory 
agreement was poor, and a national survey in the UK was therefore 
undertaken in 1985. The same published data suggested that the 
situation for other common urinary assays (glucose, electrolytes, 
urea and creatinine) was relatively satisfactory, so total 
protein only was surveyed.
The initial survey (Appendix 1.5.2) confirmed that variance was 
high (Table 2.8), indicating the need for further activity. 
Institution of a full EQAS was felt, however, not to be 
essential, and a series of surveys was planned. These confirmed 
that the most widely-used method, turbidimetry with 
sulphosalicylic acid (SSA), appeared to give inferior 
performance, and that several laboratories continued to use the 
unsatisfactory direct biuret procedure. The surveys included more 
than one specimen and enabled study of the effects of using a 
common calibration material, discussed fully in Chapter 13. These 
studies (see section 13.4) suggested, however, that problems with 
the materials distributed might have contributed to the 
variability seen, and caution should therefore be exercised in
44
Table 2.8 Inter laboratory agreement in the first UKEQAS survey of 
urinary total protein assay, April 1985
Specimen
Overall n 326 320 335
Mean (g/L) 5.14 6.67 0.27
CV 38.9% 22.8% 57.1%
Turbidimetry - SSA 7.52 6.84 0.22
41.7% 29.7% 53.6%
Turbidimetry - SSA/Na2S04 4.36 6.22 0.23
27.6% 21.5% 32.2%
Turbidimetry - TCA 4.24 7.37 0-29
19.7% 18.9% 30.6%
Precipitation & dye binding 4.59 6.23 0.27
16.6% 21.3% 21.0%
Precipitation & biuret 4.56 6.86 0.29
19.1% 16.5% 42.6%
Direct biuret 4.55 7.45 0-81
17.0% 10.1% 71.9%
Direct Coomassie blue 4.80 6.17 0.33
16.0% 19.7% 91.7%
Benzethonium chloride 4.29 6.52 0.28
23.8% 12.7% 15.7%
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interpreting the survey results.
Another important performance characteristic studied through 
these surveys was the detection limit. Two specimens without 
detectable protein content were distributed, one of urea and 
sodium and potassium chlorides in distilled water and the other a 
normal urine. For both specimens many laboratories reported a 
finite protein content (Table 2.9); only a few represented 
transposition errors or results reported in mg/L. When results 
(both quantitative results and those reported as below the 
detection limit) were analysed according to participants' 
detection limit (Table 2.9), an appreciable number were shown to 
be inappropriate when considered in relation to the generally- 
accepted reference interval of 0.15 g/24h, roughly equivalent to 
0.1 g/L.
2.4.5 Diagnosis of phenylketonuria
Phenylketonuria (PKU; Knox, 1972) is an inherited metabolic 
disease, the effects of which on mental development can be 
minimised by early diagnosis and dietary restriction. The UK 
incidence makes screening of the newborn population cost- 
effective, and such a programme has operated since the 1960s 
(Medical Research Council, 1981). A variety of method principles 
are in use for the assay of phenylalanine in blood specimens, 
and there was evidence that cases had been missed due to 
analytical as well as administrative errors (eg Smith, 1985; 
Holtzman et al, 1986). Such failures undermine the efficacy of 
the screening programme, and UKEQAS surveys were undertaken at 
the request of the DHSS/Medical Research Council Steering 
Committee for the PKU Register.
One survey was of the screening procedures (using dried blood
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Table 2.9 Quantitative results and detection limits reported for 
specimens 8 (urea and salts in distilled water) and 9 
(normal human urine) in UKEQAS urinary total protein surveys 
3 and 4, June and November 1986. Means recalculated after 
exclusion of results more than 2SD from the untrimmed mean.
Specimen 
8 9
Quantitative results:
n 99 145 
Mean (g/L) 0.092 0.083
Range (g/L) 0.002 - 12.23 0.01-2.96 
Results >0.1 g/L 22 23
Detection limits:
0.5 2
0.3 - 3 
0.2 5 6 
0.1 58 63
0-05 27 33
0.02 - 4
0.01 8 4
0.005 - 2
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Table 2.10 Interlaboratory agreement in UKEQAS surveys of
phenylketonuria screening and quantitative phenylalanine 
assay, June and November 1978. All data recalculated after 
exclusion of results more than 2SD from the untrimmed mean.
n Mean CV
(umol/L) (%)
PKU screening:
Overall 18 256 31.1
Guthrie 9 225 36.3
Fluorimetry 5 291 24.2
Chromatography 4 283 26.7
Phenylalanine assay:
Overall, excluding Guthrie 44 483 11.2
Guthrie 8 289 31.5
Fluorimetry 24 488 12.6
Aminoacid analyser 4 497 4.7
Other method 9 495 16.9
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spots or liquid whole blood specimens) and one of quantitative 
phenylalanine assay (using lyophilised bovine serum). The 
results (Table 2.10) showed the interlaboratory agreement of 
phenylalanine assay to be relatively satisfactory at about 11% 
CV, with even better agreement being obtained within the more 
reliable method groups. In contrast, the variability of blood 
phenylalanine results by the screening procedures was very poor 
at around 20-30% CV.
Priority for further EQA activity clearly lay with the screening 
procedures, since it would be of little benefit to improve 
slightly further the reliability of diagnostic and monitoring 
assays if the initial screening process was unreliable. Further 
surveys of screening assays then evolved into a UKEQAS, as 
described in Chapter 7, though the emphasis was placed on 
consideration of the action taken in response to screening of the 
specimen rather than the quantitative results obtained by these 
screening procedures.
2.5 Summary
In almost all cases patient care can be improved through 
improvement of the quality of analytical performance. The rare 
exceptions are when the test is so efficient that there is 
complete separation of the populations of interest, and when 
performance is already so good that analytical variance is 
negligible relative to biological variation.
EQA surveys provide an assessment of the state of the art for the 
analyte of interest, on a national or local basis and without 
necessarily committing the organisers to establishing a regular 
EQAS. This information is invaluable in determining the most
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appropriate further action, and in conjunction with the clinical 
importance of the assays in indicating the priorities for such 
action.
If the situation proves relatively satisfactory an EQAS may be 
unnecessary, but otherwise establishment of an EQAS would be 
indicated. A grossly unsatisfactory situation may require other 
measures, such as method standardisation or the introduction of 
adequate QA and IQC procedures, before an EQAS might be expected 
to improve agreement; continued surveys would, however, enable 
monitoring of overall performance.
Appropriately-designed surveys will also yield valuable 
information on individual aspects of assay performance, eg 
within-laboratory imprecision, assay detection limits and the 
efficacy of calibration procedures. Such studies can be 
incorporated into an EQAS.
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ASSESSMENT OF INTERLABORATORY AGREEMENT
Chapter 3:
FUNDAMENTAL REQUIREMENTS OF SCHEME AND SURVEY DESIGN
3.1 Introduction
The aim of an EQAS is to provide participants with a reliable and 
objective reflection of their laboratory's routine performance. 
Reports from the scheme will then indicate any need for 
improvement, and ideally identify where the deficiencies lie and 
provide assistance in remedying them. EQASs can only be 
successful in influencing clinical chemists' actions when the 
participants have confidence in the design and operation of the 
scheme.
Three major elements of scheme design are important in providing 
this confidence:
- organisation of the scheme
- validity of the specimens
- assessment of performance
There is no consensus on the ideal design, though a number of the 
issues involved were addressed by the WHO Working Group (WHO, 
1981) and guidelines were suggested. The many EQASs in operation 
embody different choices in design elements, and there has been 
no scientific study of many factors. Indeed no truly objective 
study of the value of EQA in improving laboratory performance is 
possible: all evidence on these points is circumstantial, and 
much is anecdotal.
3.2 Organisation of the scheme
This element of confidence relates not only to the structural 
design of the scheme, predominantly in terms of distribution
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schedules, but also to the administrative procedures.
3.2.1 Scheme administration
It is essential for participants to perceive the organising 
centre as efficient as well as scientifically competent. 
Procedures must be evolved to ensure that, for instance, results 
are processed promptly and accurately, reports are correctly 
addressed, and queries and complaints are dealt with courteously 
and within a reasonable time. Any errors arising within the 
organising centre must be acknowledged and rapidly corrected.
All these factors contribute to the scheme's public image and may 
be likened to the general sense of quality assurance, ie to 'good 
EQA practice 1 .
3.2.2 Frequency of distributions
A minimum amount of information, with a certain degree of 
confidence, is required before anyone will give credence to 
conclusions drawn from the data and act upon these conclusions. 
With a constant number of specimens in each distribution (see 
section 3.2.3 below), more frequent distribution will provide 
this minimum more quickly.
It is therefore widely held (eg Whitehead et al, 1973; WHO, 1981) 
that distributions must be frequent for an EQAS to be effective, 
as was suggested first by Shuey and Cebel (1949). The minimum 
amount of information required will vary among participants, due 
in part to their varying degrees of confidence, but the overall 
conclusion remains.
The information considered must, however, be current; no-one 
should take action now on the basis of performance data obtained
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in past years. The more frequent the distributions, the more 
recent is the period to which the information pertains. There is 
also greater confidence that the data reflect current 
performance, since the two factors are intimately and probably 
inextricably linked.
Consider, for instance, a clinical chemist receiving EQAS 
reports, the first of which shows a positive bias of 7%. No 
action would be taken on this single figure, which may be subject 
to many influences. The second report shows a bias of +4%; the 
clinical chemist is relieved, assuming this to reflect 
improvement. The third, however, shows a positive bias of 11%. 
The average bias of +7.3% (or the change in bias of 7%), taken in 
conjunction with IQC data, may then be considered significant and 
investigative or remedial action be taken. With a two-weekly 
distribution schedule only one month would have elapsed, whereas 
with six-monthly distributions it would take one year to reach 
this point; confidence in the data could also have been so eroded 
that no action might be taken even then.
Though this proposition has not been subjected to formal study, 
incidental findings in the UKEQAS for Urinary Pregnancy 
Oestrogens are relevant. The scheme design was changed in 1980, 
when organisation of this scheme was transferred to WRL (Bullock 
and Wilde, 1985; Appendix 1.2.4). There had been little evidence 
of improved interlaboratory agreement over the scheme's six-year 
previous operation with three-weekly distributions (Oakey, 1980). 
Following a change to two-weekly distribution of the same type of 
specimens, agreement improved dramatically as reflected by the 
average MRVIS and SDBIS for all participants (Figure 3.1). 
Though other aspects, discussed below, were also changed (reports
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Figure 3.1 Average performance (MRVIS and SDBIS) for all
UKEQAS for UrinarY Pregnancy Oestrogens,
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now gave a much more detailed analysis of participants' 
performance; the VI system with running scores updated each 
distribution replaced a scoring system applied only 9-monthly and 
based solely on within-laboratory reproducibility), it is likely 
that the increased frequency at least contributed to the 
improvement. Later this very success, with the continuing 
decrease in the number of laboratories carrying out the assay, 
led to redeployment of resources by reducing the distribution 
frequency to four-weekly.
Though frequent distributions are necessary to encourage action 
by participants, distributions may also be too frequent and lead 
some participants to feel that EQA on such a frequent basis can 
obviate, or at least reduce, the need for IQC. By ignoring the 
retrospective nature of EQA, and effectively removing the control 
over each analytical batch normally provided by IQC, this will 
lead to a loss of reliability and hence worse patient care. 
'Hybrid 1 IQC/EQA schemes, whether commercially or professionally 
organised, offer an extreme example of this potential confusion. 
These (eg Limonard, 1979; Jansen and Jansen, 1980; Lawson et al, 
1980) use the same material to provide both an IQC programme and 
a retrospective element of EQA; they also suffer from unconscious 
bias due to continual use of the same specimen, and are most 
appropriately classed as an IQC procedure.
In addition, it can be argued that EQA would be more cost- 
effective if an interval is left between distributions to allow 
participants time to take any remedial action necessary; this is 
a feature of, for example, Whitehead's 'intensive' scheme design, 
discussed in section 3.2.3 below.
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3.2.3 Number of specimens in each distribution
Use of a single specimen is the most widely-used and most 
economical approach. Distributions can be more frequent at the 
same specimen cost; scheme administration, in terms of specimen 
despatch, data processing and report despatch, is also 
simplified. There is no possibility of the EQAS specimens (or 
their results) being transposed, making the performance 
assessment slightly more reliable.
The apparent disadvantages (see below) of using a single specimen 
can effectively be removed by cumulation of data over a period. 
For example, the relationship between a laboratory's performance 
and analyte level can be examined by plotting their results 
against the designated (target) values for a number of 
distributions (Whitehead, 1977; Lever et al, 1981; Bullock and 
Wilde, 1985).
Figure 3.2 shows such cumulations for two participants in the 
Middle East EQAS (MEEQAS); from this the laboratories' positive 
bias for phosphate and imprecision for calcium are clear. One 
potential disadvantage is that performance may have changed over 
the period covered, and it is therefore essential that the 
temporal relationship is also examined; the issues are discussed 
in more detail in Chapter 10.
Distribution of a pair of specimens (eg, Stamm, 1975; Jansen et 
al, 1977) enables a rudimentary assessment of bias and 
imprecision at each distribution. This has some advantage in 
using more data to yield a more reliable estimate of 
participants' performance, important in making judgements in 
licensing schemes such as that in GFR (Bundesarztekammer, 1971). 
The Dutch scheme (Jansen et al, 1977), however, discards much of
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Figure 3.2 Graphs for phosphate and calcium of laboratory result 
against designated value for two participants in the Middle 
East EQAS.
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this by scoring performance solely on the worse of the two 
results for each analyte.
Any assessment of bias and imprecision based on two points is, 
however, inherently unreliable. It cannot for instance 
distinguish between imprecision and a linear relationship removed 
from or with slope dissimilar to that of the line of identity 
(Lever et al, 1981). Recovery studies, with distribution of 
spiked and unspiked specimens, can also be undertaken, which is 
useful in validating consensus means as well as in assessing 
individual participants' performance (Hunter and McKenzie, 1979).
Paired specimens may also be applied in 'ratio reporting' for 
interlaboratory assessment of analytes for which many numerically 
discordant methods are in use. A historical example is assay of 
enzyme activities, eg acid phosphatase (Rosalki, 1972), enabling 
the performance of different methods to be assessed. This 
approach, however, is based on intralaboratory imprecision only 
since any contribution from biases among laboratories is 
eliminated in taking the ratio. The procedure thus reduces to an 
interlaboratory assessment of a performance characteristic better 
dealt with through IQC. A more reliable estimate of 
intralaboratory precision may, if necessary, be derived from 
distribution of replicates or a pair of specimens related by 
dilution (eg Chambers et al, 1984) since these should be 
commutable.
A more useful application is in studies of calibration (eg Jansen 
and Jansen, 1983; Bullock and Wilde, 1985; Bullock et al, 1986b), 
discussed fully in Chapter 13. In essence the distribution of two 
specimens for assay together enables assessment of the
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performance that would be obtained if all participants used a 
common calibration material. Such use is only occasional, and 
would not be a regular element of scheme design.
Simultaneous distribution of a set of specimens increases the 
rate at which performance data can be accumulated (Hunter and 
McKenzie, 1979; Groom, 1985b), with the specimens treated as 
independent distributions. These sets may include recovery and 
calibration studies, as described above for paired specimens.
If the specimens within a set are related in a known manner, 
however, more reliable judgements become feasible (Caragher and 
Grannis, 1978). Such linearly-related specimens have been used in 
CAP surveys (Grannis and Miller, 1976; Caragher and Grannis, 
1978), and on a regular basis by some regional schemes (eg Davies 
KW, personal communication). Regression analysis and graphical 
presentation of the results describe participants' assay 
performance in terms of bias, imprecision or nonlinearity, though 
interpretations differ (Grannis, 1979; Lever and Munster, 1979).
To provide such information at least 5 or 6 specimens are needed, 
prepared specially with analyte concentrations spread evenly over 
the range studied. The costs of materials and the more complex 
data processing are thus high. Obtaining such detailed 
information on performance distribution after distribution is 
hard to justify, and it is inappropriate to use this scheme 
design exclusively. Such a scheme would be extremely expensive, 
and may yield more information than can really be used 
effectively; frequent presentation of detailed information can 
lead to familiarity and blindness to its import.
In the 'intensive' scheme design, originated by Whitehead
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(Whitehead TP, personal communication), participants receive a 
set of three specimens for assay in the same analytical batch. 
Reports give not only results and VI scores (discussed in section 
3.4.2 and Chapters 4 and 9) but also a graph for each analyte 
relating their results to the designated (target) values for the 
specimens, with interpretive comments on their performance. 
Participants also receive a further vial of each specimen to 
check the efficacy of their remedial action before they receive 
the next distribution. With three specimens, the graphical 
presentation offers a reasonable chance of identifying the 
underlying deficiencies in participants' performance, as 
discussed further in Chapter 10. Provision of the second set of 
specimens in each distribution is expensive, however, and it may 
be argued that use of 6 specimens together might be more cost- 
effective, though Whitehead's premise is that the effectiveness 
of participants' actions can be improved by giving them increased 
confidence that they have succeeded.
Though this design is much more expensive than a conventional 
single-specimen system, distributions are less frequent (to allow 
time for corrective action and verification) and such schemes are 
not intended to be permanent. Rather, they should be short-term 
undertakings to bring the participants' results roughly into 
consensus so that a more conventional EQAS design may then be 
used for subsequent monitoring and 'fine tuning' of performance. 
Thus Figure 3.3 gives examples of acceptable initial performance 
showing some improvement, of initially unsatisfactory results 
which improved, and of unsatisfactory results showing no 
improvement. The first and second groups could benefit from 
transfer to a conventional scheme, whereas it is unlikely that 
the third would be stimulated to improve more than by the
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Figure 3.3 Changes in average VIS for participants in an 
'intensive 1 EQAS. Patterns of (A) acceptable initial 
performance showing some improvement,
(B) initially unsatisfactory performance which improved,
(C) unsatisfactory performance with no improvement
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intensive scheme design. Depending on circumstances, this last 
group may then be classified as either not deserving attention or 
requiring considerable further guidance.
It must be remembered that the number of specimens in a 
distribution is linked with the distribution frequency, since the 
same rate of data accumulation can be attained by distributing 
many specimens infrequently or single specimens frequently. This 
choice is dictated largely by considerations of cost and 
organisation: if specimens are expensive and distribution costs 
are low the single-specimen design is favoured. Single-specimen 
distributions also reduce data processing requirements, and may 
facilitate faster return of reports to participants.
3.2.4 Period between assay and receipt of report
Participants' confidence can be increased by rapid return to them 
of EQAS reports, in much the same way as for distribution 
frequency (section 3.2.2). Clinical chemists are more likely to 
take note of a report referring to assays carried out the 
preceding week than to those a month or two before. It is also 
more likely that an explanation can be found for any aberrant 
results, since some laboratory records and analysts' 
recollections are of limited span.
The period between specimen assay and receipt of report by a 
participant is limited by communication between the participants 
and the organising centre, by the time required for data 
processing and report printing, and by the necessity to allow 
sufficient time for participants to assay the specimen and return 
results. An ideal situation, provided that designated values were 
available in advance, could be electronic communication of
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results to the organising centre with provision of a report on 
performance by similar electronic means immediately after. Such a 
system, though becoming technically feasible, would further 
increase the risk of confusion between IQC and EQA and may be 
undesirable on these grounds. It would, however, be excellent for 
the 'external' control of individual users of extra-laboratory 
equipment.
At present postal communication is the usual means for 
transmission of results and reports. This, with the use by many 
schemes of consensus values as designated values, dictates a 
longer timescale than that envisaged above. Electronic data 
processing is essential to provide rapid turnround as well as to 
store and manage the resultant data.
The frequency with which assays are carried out in participants' 
laboratories is also relevant. If batches are infrequent, a 
longer period between specimen despatch and the deadline for 
receipt of results must be allowed. This then entails a 
correspondingly greater delay between assay and receipt of 
reports by those participants analysing specimens soon after 
receipt. The effects of infrequent assay batches on performance 
are discussed in Chapter 11.
3.3 Validity of the specimens
Effective EQA demands that the specimens distributed are reliable 
and have properties such that they reflect faithfully the 
behaviour of clinical specimens - "fidelity", as defined by Fasce 
et al (1973).
Clinical chemistry is concerned primarily with determinations on 
specimens from human patients and subjects. To be most effective,
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therefore, quality assurance procedures should ideally use serum 
from these patients or subjects as the QCM. Such QCMs are indeed 
used in IQC in the daily mean, in analysis of 'carryover' 
specimens from the previous batch, and in the use of pooled sera. 
These benefit from the ready availability of material at 
clinically relevant concentrations, as do specimen exchange 
procedures. Some attempts have been made (eg Becktel et al, 1973; 
Leclercq, 1975) to conduct EQA through comparison of daily means 
or reference intervals, but the authors concluded that such 
procedures were impractical and insensitive for EQA though of 
undoubted use in IQC.
There are problems, however, associated with the instability, 
infectivity (DHSS, 1986a) and restricted availability of 
authentic clinical material, particularly for widespread EQA. 
Commercial products, especially those stabilised by freeze-drying 
or other means, are convenient and relatively free from such 
problems.
In EQA (other categories of QCM use are discussed in Chapters 12 
to 14), the QCM must be stable, and the precision for the QCM 
should be identical to that for clinical specimens. If the 
designated value against which a participant's result is assessed 
is derived using an identical analytical procedure there is no 
further requirement on QCM properties (though an animal-based QCM 
would not be ideal for assessing, for example, albumin assay). 
If, however, the designated value is for all methods, or for a 
group of methods, the QCM's reponse to differing analytical 
procedures within the grouping used should be the same as the 
response of clinical specimens. This requirement is for 
"commutability", defined originally by Fasce et al (1973) in the
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context of enzyme activity assays but for which a more general 
definition is the consistency of the relationship between results 
obtained by different analytical methods for the QCM and for 
freshly-drawn sera from patients (Bullock et al, 1980b; Broughton 
et al, 1981).
Commutability is of vital importance in EQA if information on 
laboratory and method performance is to be reliable. The QCMs 
distributed must therefore be commutable or the scheme design be 
such as to render negligible the effects of any lack of 
commutability, eg by use of method means as designated values. If 
not, participants will not have confidence in the information 
generated by the EQAS and the scheme will fail in its objectives.
The main choices are with respect to origin and presentation of 
the specimens, lying between human and animal sources and between 
liquid and lyophilised materials.
3.3.1 Species of origin
As mentioned above, a human base might be thought essential for 
EQA specimens and some schemes have therefore used human-based 
materials exclusively. Indeed one of the original objectives of 
the UKEQAS (Whitehead et al, 1973) was to distribute liquid 
pooled clinical specimens, to avoid any criticism that a 
participant's poor results could be due to the animal basis or 
lyophilised nature of the specimens.
Such specimens are cheap and relatively simple to prepare (Bowers 
et al, 1975; Kenny and Eaton, 1981), provided sufficient base 
serum is available following routine analysis of specimens from 
patients or through blood transfusion services (from donors whose 
blood is unsuitable for therapeutic purposes). The resulting
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material, however, needs to be sterilised (usually by filtration) 
and liquid specimens have frequently proved to have limited 
stability in the EQAS situation. Furthermore the problems of 
potential infectivity of human-based materials (eg Compton et al, 
1979) must be faced, not only with regard to hepatitis viruses 
but also to human immunodeficiency virus (HIV) and other as yet 
unknown agents. Recent UK guidelines (Advisory Committee on 
Dangerous Pathogens, 1986; DHSS, 1986a) on testing for antibody 
to HIV at the individual donation stage virtually preclude the 
general use of clinical specimens, unless heating (see Chapter 
15) or chemical treatments can be applied to inactivate the 
virus.
In the case of proteins, such as albumin or peptide hormones, 
with species-related differences in structure, human serum is 
essential for reliable judgements of performance through EQA, 
though within a laboratory animal-based materials may suffice for 
calibration and precision control in IQC. Such differences are 
likely to be much less marked in total protein assay, where the 
analyte is already a heterogeneous mixture. For steroid and 
thyroid hormone assays, though the hormones do not differ in 
structure both their relative concentrations and the structures 
of their binding proteins do. Interspecies differences in 
behaviour can then be expected, both from these factors and from 
the additional effects of the different protein milieu on some 
(eg double antibody) procedures for separation of bound and free 
antigen.
For some analytes, eg enzyme activity assays, the (kinetic) 
properties of the added isoenzyme are more important than its 
species of origin in determining the specimen's properties (Moss
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et al, 1985). For example alkaline phosphatase (ALP) from bovine 
liver is preferable to that from human placenta since placental 
ALP differs greatly in behaviour from the liver and bone 
isoenzymes which commonly comprise the activity in clinical 
specimens. For other analytes the stabilisers, buffers and other 
additives encountered in commercial products, or even the process 
of lyophilisation itself, may have a greater effect on the 
material's properties than does the origin of the base serum. 
Empirical studies of the effect of base serum on properties, as 
described and discussed in Chapter 14, may thus be the only way 
to resolve the question of suitability of animal-based materials.
Table 3.1 summarises the main factors influencing this choice, 
which has also been considered by others (eg Kenny and Eaton, 
1981; Fraser and Peake, 1980). As a general rule, animal-based 
materials should not be used exclusively, but a human base is not 
essential for all analytes. Since manufacturing procedures can 
influence QCM properties, it is prudent to minimise the impact of 
matrix effects by using specimens from a wide variety of sources.
3.3.2 Specimen presentation
The primary choice is between lyophilised and liquid specimens, 
which may in turn contain a preservative.
Lyophilised materials are undoubtedly more stable (Lawson et al, 
1982), though earlier data from some within-laboratory studies 
reviewed by Fraser and Peake (1980) showed only small differences 
in the between-day precision obtained, some in favour of liquid 
specimens. The outcome of such studies reflects a balance between 
the amount of thermal and other stress applied (greater in 
interlaboratory surveys than within individual laboratories), the 
analyte stability, the vial-to-vial inhomogeneity (including
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Table 3.1 Considerations in the selection of QC materials based 
on human or animal serum
Human Animal
Availability
Infectivity
Limited
Hepatitis 
HIV
Effectively unlimited
Brucellosis
Cost
Problems
Suitability 
Properties
Expensive
Moral -
therapeutic use
Universal
Cheap
Religious -
in some societies
Not for immunoassays, etc
Often related more closely to additives
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filling imprecision for lyophilised materials) and the analytical 
imprecision.
Most commercial lyophilised materials available in the 1960s and 
early 1970s were not fully satisfactory. There were problems both 
with imprecise vial filling and with regard to their properties 
since experience in optimising the procedures to cause as little 
disturbance as possible was then extremely limited. Many were 
also based on animal rather than human serum, and clinical 
chemists were then unsure whether there were significant 
differences in behaviour from that of clinical specimens (see 
section 3.3.1 above). Because use of such specimens might cause 
participants to blame discrepant results on the material 
distributed rather than their own laboratory's perfomance, EQAS 
organisers tended to favour a liquid presentation to engender 
confidence in the scheme.
As the numbers of participants increased, however, the 
difficulties of providing specimens sufficient in quality and 
quantity led many schemes to reconsider their initial decision. 
With improvements in filling and freeze drying procedures, the 
balance changed and now almost all EQASs in developed countries 
distribute commercial or commissioned lyophilised serum specimens 
with no apparent lack of confidence by participants.
In the tropical climate of many developing countries the need for 
specimen stability is even greater, but adequate lyophilisation 
technology is rarely available or economic to operate. Here there 
has therefore been a considerable problem which now appears to be 
potentially soluble through the use of ethylene glycol or similar 
chemical preservatives (Maurukas, 1975). These materials are
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stable (Hartmann et al, 1981), convenient to use and have been 
advocated by some (eg Pope et al, 1979) for linearity evaluation. 
A particular advantage of ethylene glycol is that it not only 
prevents microbiological growth and minimises freezing damage to 
serum constituents by enabling storage at -20°C in the liquid 
state, but also appears to 'sterilise' so that even infected 
pooled serum may be used successfully. The preparations are more 
viscous than serum, however, with a large dependence on 
temperature; storage conditions and thermal equilibration before 
use are therefore important in obtaining correct results, and 
some authors (eg Pope et al, 1979) have reported unusual 
intermethod biases, for example due to differences in dialyser 
design between AAI and AAII/SMA systems. Such effects can create 
problems in EQA due to non-commutability with clinical specimens. 
Recent endorsement by WHO (Browning et al, 1986) should 
nevertheless lead to more widespread use for both IQC and EQA in 
developing countries as a stable low-cost alternative to liquid 
or lyophilised materials.
Their greater stability makes lyophilised materials more popular, 
whereas liquid materials are cheaper to prepare and may be more 
convenient. Specimens incorporating ethylene glycol are becoming 
more popular, but can present difficulties in determination of 
designated values due to their lack of commutability (disussed 
further in Chapters 12 to 14). Table 3.2 reviews the relative 
advantages of these presentations, each of which may have 
application in EQA with the choice being dependent upon 
circumstances.
3.4 Assessment of performance
The experience of most scheme organisers is that the participants
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Table 3.2 Considerations in the selection of lyophilised or 
liquid QC materials
Lyophilised Liquid
Frozen* Ethylene glycol
Stability Excellent Limited Good
Convenience Limited Good Excellent
Preparation Reconstitution Thawing None
Vial-to-vial
variability
Dependent upon Excellent
manufacture
Mixing required
Clarity Turbid Good Good
Physical properties Little changed Unchanged High viscosity
Cost High Low Intermediate
*with or without preservative, eg azide, antibiotics
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most in need of taking note of and acting on EQAS reports are 
those with the least time, inclination and ability to do so. 
Performance assessment is therefore of paramount importance for 
EQASs to gain the confidence of participants and to stimulate 
improvement.
Elements of importance in producing a reliable assessment of 
performance include:
- clear and concise report presentation
- scoring system for performance assessment
- valid target values
3.4.1 Report presentation
Reports must be clear, consistent and intelligible, and above all 
be capable of ready interpretation.
The ideal report might thus be an individually-produced text 
report commenting on the current set of results, their relation 
to the designated values, to the results from other participants 
and to the laboratory's past results, with an exposition of where 
problems lie and suggestions for their resolution. Such a report 
would, however, entail considerable effort and investigation, 
particularly since the organiser would not be fully aware of all 
the relevant factors peculiar to the individual laboratory. 
Multiplied by the number of participants and the frequency of 
distributions (eg 520 x 22 = 11440 reports/year in the UKEQAS for 
General Clinical Chemistry) such a task becomes completely 
impracticable.
What then can be done to provide the basis of this information? 
The format of the report can be simplified in a number of ways. 
Preprinting and highlighting (by boxing or shading sections, or
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printing in a different typeface or colour) makes the text easier 
to read and important sections easier to identify. Redundant or 
unhelpful information, or information of very limited interest 
such as the mean of untrimmed results, should be eliminated from 
the report; though the mean, the SD and the CV are determined by 
any two of the values it is in practice advisable to give all 
three since SDs are more meaningful to some clinical chemists 
whereas others prefer CVs.
The designated values must be given, and their derivation should 
be clear; a preprinted explanation, perhaps on the reverse of the 
report, can be useful here. The participant's results must also 
be shown, so that their correct attribution may be verified and 
they may be compared with the designated values.
The results from other participants should be indicated, in 
tabular, statistical or histogram form. Statistical evaluations 
are the most common and most widely comprehended, and should 
include some classification according to analytical procedure. 
These data are useful in method and instrument selection, as 
discussed in Chapter 8.
An assessment of performance in terms of a scoring system is also 
helpful, as outlined below and discussed in Chapter 4 and 9. 
Again, this information should be given in a clear and simple 
manner. Reports should facilitate a logical progression through a 
hierarchy of information in examining firstly whether analytical 
problems exist and secondly their nature, as outlined in Chapter 
9. Some participants, however, demand more and more information 
in reports, and overenthusiastic scheme organisers may also be 
tempted to incorporate far too much, often in an indigestible 
form.
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Presentation of any information in graphic form can improve 
comprehension, and this aspect is discussed in Chapter 10.
3.4.2 Scoring system for performance assessment
In any form of communication, data reduction is a major aid to 
the recipient's comprehension of the content. Many EQAS 
organisers have felt the need to use some form of scoring system 
as a means of data reduction and of stimulating improvements 
(WHO, 1981). The requirements, applications and benefits are 
discussed fully in Chapters 4 and 9.
3.4.3 Source of target values
Two main types of procedure have been used to derive designated 
(target) values for use in both EQA and IQC, involving the use of 
either reference laboratories or consensus values.
Reference laboratories have been used mostly in EQASs with 
laboratory licensing as their primary objective, eg in GFR 
(Hansert and Stamm, 1980) and the USA (Boone, 1984). In essence, 
one or more reference laboratories are selected by some means and 
the material is then analysed repeatedly over a period, by 
routine or reference procedures, and a designated value derived 
from the results obtained. Problems may arise at any of these 
stages.
Firstly, how should reference laboratories be selected? Possible 
criteria include the laboratories' performance, determined from 
EQA or other data, their reputation or the possession of 
particular facilities or expertise. In GFR, a reference 
laboratory is defined as one of which the director is well- 
qualified; obviously, though the laboratory may therefore have
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better than average performance, there is no guarantee of this. 
Selection based on performance appears better on intuitive 
grounds, but the initial standard may not be maintained. Some 
system of continual reassessment is therefore advisable, and a 
good procedure for this is through the scheme itself. An example 
is the use of a reference laboratory group within the scheme, 
with selection criteria based on continuous demonstration of 
baseline security and quantitative recovery of added analyte, in 
the early years of the UKEQAS for Human Growth Hormone prior to a 
change to consensus values after their validation (Hunter and 
McKenzie, 1979). Where reference or definitive methods are 
required, the choice of reference laboratories may be dictated by 
their possession of the necessary equipment (eg for mass 
spectrometry) or willingness to undertake such work. An 
additional problem is whether the identity of reference 
laboratories should be known, either to participants or to the 
laboratories themselves.
The second problem lies in the analytical technique(s) used, 
which may be either routine or reference procedures. If the 
laboratory's routine method is used, eg in their normal 
participation in the scheme (Hunter and McKenzie, 1979), no 
complications arise but if a technique must be established 
specifically for this purpose its IQC can present great 
difficulties. If reference methods are employed then their 
validity and comparability among centres cannot be taken for 
granted (Eldjam and Broughton, 1985) and must be established (eg 
Gaskell et al, 1984). Furthermore, if the method used differs 
from those used by the participants the specimen distributed must 
be commutable with clinical specimens, as discussed in section 
3.3 above and Chapters 12 and 14. This is the main drawback of
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the "new concept" proposed by Stamm (1982), whereby reference 
methods are used to provide a single designated value for each 
analyte against which all participants' results are assessed. 
Extensive theoretical justifications of the system and studies of 
the individual methods (eg Siekmann and Breuer, 1982; Kulpmann et 
al, 1985) have been offered, but there is a lack of evidence that 
the intermethod relationships for the EQA specimens mirror those 
for clinical specimens.
Finally, the combination of the results to derive a designated 
value leads to controversy. The results obtained comprise several 
dependent sets, and though each set may be normally distributed 
the overall data are unlikely to be. The initial approach in GFR 
of using the mean as designated value and the SD to derive limits 
of acceptability (Stamm, 1975; Hansert and Stamm, 1980) was 
therefore not statistically valid, and later studies developed 
procedures using non-parametric statistics (Passing, 1981a and 
1981b; Passing et al, 1981). Even these were not universally 
accepted in GFR, and Haug et al (1978) argued strongly that the 
disagreements observed between the reference laboratories made 
the whole procedure suspect and that consensus values should 
therefore be more reliable. Indeed, reanalysis of the data 
presented by Stamm (1975) yields designated values for total 
protein which vary by 3% (from 61.0 to 62.8 g/L) if results from 
only four of the five reference laboratories are considered.
Overall, the main advantage of using reference laboratory assays 
lies where the material is such that a true definitive or 
reference method will yield valid results. Their use can also be 
helpful where the procedure must to be rigorously defined for 
possible explanation in a court of law, as in the case of
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'licensing' schemes, or for assigning values to reference 
materials (Merchandise and Colinet, 1983). Interestingly, the 
licensing scheme organised by CDC in the USA used a combination 
of criteria derived from consensus and reference laboratories in 
determining the acceptability of participants' performance, but 
CDC recently determined that examination of performance data from 
the CAP programme (using consensus values) now obviates the need 
to organise their own scheme.
Consensus values (the mean of results for all participants or 
for those using a particular method) have been used as designated 
values in many schemes (eg Whitehead et al, 1973; Jansen et al, 
1977; de Leenheer et al, 1983) over a long period. Consensus 
values are convenient for scheme operation. They are inexpensive, 
requiring no more than calculation, and are available when 
required. In some circumstances having to wait until all results 
are available before assessments can be made may be a 
disadvantage, but is quite satisfactory in most EQASs.
Though consensus values were used initially purely on the grounds 
of their convenience and for lack of any viable alternative, as 
experience was gained they were found to be reproducible, both 
within a scheme (eg Gilbert, 1976) and between countries (eg 
Whitehead and Woodford, 1981). There was also increasing 
confidence that consensus values were indeed close to the true 
analyte concentrations in specimens of liquid human serum, though 
there is no theoretical reason why consensus values should be 
accurate. Thus Whitehead and Woodford (1981) commented on the 
close agreement for calcium among the UKEQAS consensus values for 
methods employing different analytical principles and with 
definitive values determined by the US National Bureau of
77
Standards (NBS), with similar findings for other analytes. Good 
agreement of CAP survey consensus values with NBS definitive 
methods was also documented in the USA for calcium (Gilbert, 
1975b) and for other analytes (Grannis, 1976). Further studies on 
the validity of consensus values, primarily those from UKEQASs, 
are presented and discussed in Chapter 5 below.
A potential problem with consensus values is the possibility that 
they may 'drift 1 . Consider the consequences of a supplier of 
calibration materials assigning an incorrect value to these 
materials. Users will then have biased results, and if these 
materials are widely used there will be some effect on EQAS 
consensus values. Other laboratories will then note from the 
scheme that their performance is biased and may therefore adjust 
their procedures to be in consensus again. The bias generated by 
a single manufacturer could thus be incorporated into the scheme 
and affect the goal of all participants; results obtained 
throughout the country would then be inaccurate. There is so far 
no evidence, however, of such a drift from truth occurring, as 
discussed further in Chapter 5.
Consensus values have been used predominantly by EQASs which are 
primarily 'educational' in intent, such as those in Belgium, 
Holland, the UK and the CAP programme in the USA; they are also 
used in most commercial schemes. This choice has been dictated 
largely by their convenience and negligible cost, in the absence 
of any evidence to contraindicate their use. Participants now 
have confidence in the assessment of their performance against 
consensus values.
78
3.5 Summary
The primary consideration in EQAS design is to ensure the 
confidence of participants in the scheme's assessment of their 
performance, and thus increase the likelihood of their taking 
action on these conclusions.
The following elements and factors in interlaboratory survey 
design are important in engendering this confidence:
- scheme organisation
- reliable administration
- frequent distributions
- rapid return of reports on each distribution
- specimens that are stable and have properties resembling 
closely those of clinical specimens
- performance assessment
- reports that are informative, yet readily comprehended
- a scoring system for performance assessment
- reliable designated values, of described derivation
Though many schemes have broad similarities in design, there are 
individual differences. These lie mainly in the numbers of 
specimens constituting a distribution, in the scoring system 
used, and in the derivation of designated values from reference 
laboratories or from consensus values. Scoring systems are 
discussed further in Chapters 4 and 9, the validity of consensus 
values in Chapter 5, and the properties of QC materials in 
Chapters 12 to 14.
79
ASSESSMENT OF INTERLABORATORY AGREEMENT
Chapter 4:
SCORING SYSTEMS IN EXTERNAL QUALITY ASSESSMENT
4.1 Introduction - the need for scoring systems
The objective of any EQA scheme is to stimulate interlaboratory 
concordance of numerical results. Thus, as outlined in Chapter 3, 
participants require a clear demonstration of whether their 
results are in consensus, ie whether or not corrective actions 
are needed. Many participants experience difficulty in comparing 
their results with the 'target' data provided by the scheme, 
whether it be in the form of designated values, histograms, 
statistical parameters classified according to method, etc. In 
addition, experience indicates that it is usually just those 
laboratories which have least time, inclination, and ability to 
devote to this task which have most need to. Some form of data 
reduction is therefore essential if participants are to derive 
maximum benefit from the scheme; this most usually takes the form 
of a scoring system.
4.2 Classification of scoring systems
Scheme organisers have devised a plethora of scoring systems. 
There are several basic types, however:
- 'pass/fail' systems
- semi-quantitative systems
- quantitative systems
4.2.1 Pass/fail systems
Such systems comprise assessment of each result against some 
criterion of acceptability. This criterion may be derived as a 
multiple of the observed SD or of the SD obtained by reference
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laboratories (Bundesarztekammer, 1971; Stamm, 1975), or from an 
estimate of clinical requirements in the form of analytical goals 
(Bowyer et al, 1981) or medical need (Stamm, 1982).
4.2.2 Semi-quantitative systems
In these systems results are classified on a semi-quantitative 
scale, eg the allocation of 'points' according to how close the 
result approaches the designated value (DV). This gradation may 
be in terms of observed SDs in the initial definition of Variance 
Index (VI; Whitehead et al, 1973) or of an arbitrary scale of 
clinical needs (eg Jansen et al, 1977).
Later such systems were applied to other and less quantitative 
laboratory investigations. Examples here are the system adopted 
by the UKEQAS for Microbiology, which classifies participants' 
returns as fully correct, partly correct, wrong and badly wrong 
on a scale of +2 to -1 (Leblanc et al, 1985c; section 7.1.4), and 
the similar system adopted initially in the UKEQAS for PKU 
Screening, described in section 7.2.3.
4.2.3 Quantitative systems
In the final type of procedure results are scored on a continuous 
scale. The main applications are SD differences (SDDs or 'Z 
scores': eg Merritt et al, 1965; Ley and Ezer, 1974; Wellcome 
Diagnostics, 1984), the Variance Index system (Whitehead, 1977) 
and systems based on cumulated estimates of bias and precision or 
consistency of bias (Bacon et al, 1983; Groom, 1985d; Bullock and 
Wilde, 1985). In some of these applications logarithmic 
transformation or other statistical manoeuvres are applied to the 
results before and/or after scoring (Healy, 1979).
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4.2.4 f Hybrid' systems
Several schemes, eg that operated in the USA by CDC (Boone, 
1984), use a combination of these procedures.
4.3 Scoring as a stimulus to improvement
Scoring systems are a potent means of data reduction, to assist 
participants in assessing their performance relative either to 
other laboratories or to a defined or arbitrary standard. This 
objective applies to the individual laboratory situation, and is 
therefore discussed in detail in Chapter 9 below.
4.4 Scoring in assessment of the state of the art
Scoring systems also simplify the assessment of overall 
concordance, though the primary objective of most is to stimulate 
improvements in the performance of individual participant 
laboratories.
For example, interlaboratory CVs provide a measure of the 
dispersion of results, but they can be influenced unduly by the 
proportion of results lying in the 'tails' of the distribution. 
If the distribution is not in fact Gaussian then the CV is not an 
accurate reflection of dispersion and non-parametric statistics 
should be considered instead (Passing, 1981b; Rohle et al 1986). 
Average scores provide a measure derived from all results and 
which is therefore effectively distribution-free. This measure is 
also convenient to obtain and use, and likely to be more robust, 
ie less variable. An additional advantage is that an average 
score based on use of the method mean as designated value will 
compensate for any intermethod differences.
Figure 4.1 illustrates this advantage in terms of variability, 
using data for urea from the UKEQAS for General Clinical
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Figure 4.1 Relationship of interlaboratory agreement
(recalculated CV and average VIS) with analyte concentration 
(mmol/L) for urea in UKEQAS for General Clinical Chemistry, 
1980-1982
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Chemistry. The relationship between interlaboratory agreement and 
concentration (discussed in detail in Chapter 6 below) is 
demonstrated more clearly by the average VISs than by the CVs.
Scores also simplify the assessment of methods and other factors 
affecting performance (discussed in Chapters 8 and 11) through 
their cumulation of information over time. The resultant estimate 
is more representative in that it includes contributions not only 
from variations over time but also from differences due to 
analyte concentration and the material distributed. Such an 
application is demonstrated in section 8.3.2 below (Table 8.2) 
for calcium in the UKEQAS for General Clinical Chemistry.
4.5 Assessment of progress - comparisons over time
A well-designed scoring system should delineate changes in the 
performance of an individual laboratory. The main requirement for 
this, as discussed in sections 4.6 and 9.3 below, is that the 
score should be independent of other participants' performance. 
Such scoring systems then also enable assessment of trends in 
interlaboratory agreement, and provide one means to judge the 
overall success of the scheme in stimulating improvement.
Such application can be demonstrated for many schemes, as shown 
in Figures 4.2, 4.3 and 3.1 for the UKEQASs for General Clinical 
Chemistry (OMRVIS), Lead in Blood and Urinary Pregnancy 
Oestrogens (both MRVIS). In all cases the average scores show an 
improvement in interlaboratory agreement following the 
introduction of VI scoring into participants' reports, confirming 
the stimulus to performance improvement afforded by scoring. In 
some cases little improvement had been noted over several years 
of operation prior to the introduction of scoring (Whitehead et 
al, 1973; Oakey, 1980).
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Figure 4.2 Improvement in interlaboratory agreement (average
OMRVIS) in UKEQAS for General Clinical Chemistry, 1972-1986.
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Figure 4.3 Improvement in inter laboratory agreement (average 
MRVIS) in UKEQAS for Lead in Blood, 1979-1985
Average MRVIS
100
80
60.
40J
1979 1980 1981 1982 1983 1984 1985
Year
86
Though in some cases other elements of scheme design were changed 
at the same time (distribution frequency and report format for 
urinary pregnancy oestrogens; report format for blood lead), and 
associations between design changes and performance are purely 
circumstantial, demonstration of the same apparent effect in 
three schemes is strong evidence of the effectiveness of scoring 
as a stimulus to improvement.
Scoring systems such as the VI system can also assist in 
differentiation among the factors contributing to variance. 
Figure 3.1 illustrates that in the UKEQAS for Urinary Pregnancy 
Oestrogens there was improvement in within-laboratory consistency 
of bias (represented by SDBIS, and equivalent in this case to 
imprecision) as well as in interlaboratory agreement (represented 
by MRVIS).
4.6 Comparisons over geography
Average scores provide a convenient and reliable assessment of 
performance in different groups of laboratories. These may be 
groups within a scheme or be the participants in different 
schemes. For example Table 4.1 demonstrates the relative 
performance of occupational monitoring, clinical, and 
environmental monitoring laboratories in the case of blood lead 
assay, where the latter group seemed to have superior performance 
(Bullock et al, 1986c)
If participants in different schemes are to be compared, the 
scoring system must again be one which is independent of the 
performance of other participants. Otherwise the comparison is 
meaningless, since for example the average SDD in any scheme will 
be approximately the same and does not reflect the standard of
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Table 4.1 Relative performance of participants in the UKEQAS for 
Lead in Blood, classified according to principal 
component(s) of workload and laboratory type. *"Other" 
includes governmental, university nonclinical, and 
commercial laboratories
n
MRVIS
Average SD
Source of workload:
Occupational
Clinical
Environmental
49
26
14
62
68
45
36
36
18
Type of laboratory:
Health service
Industrial
Other*
42
20
27
64
72
52
37
36
28
All participants 89 62 35
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performance within the scheme. The Variance Index system is such 
a system, and Table 4.2 shows the average OMRVISs in a number of 
national and regional schemes administered from WRL in 1984/1985. 
The calculation of the OMRVIS in the UKEQAS differs slightly from 
that in the other schemes (see Appendix II.2), but scores should 
be comparable as the majority of the materials distributed were 
identical. These figures confirm that the interlaboratory 
variance seen in the International EQAS was 2-2.5 times that in 
the UKEQAS for General Clinical Chemistry, a conclusion which 
could also but less conveniently be drawn from the average CVs.
4.7 Appraisal of scoring systems
Having reviewed the uses of scoring, how well do the various 
systems which have been devised fulfil these objectives?
4.7.1 Assessment of imprecision
Though bias is the prime concern of EQA, with imprecision 
assessed primarily through IQC procedures, it may be advantageous 
to assess both aspects of performance since laboratories may not 
have (or may not take sufficient note of) an effective IQC 
programme to assist in interpretation of EQA data. In addition, 
IQC data is by definition internal to the participant laboratory 
and it would otherwise be impossible in an EQAS to interpret 
reliably an assessment of bias without also having some 
indication of within-laboratory precision as an estimate of 
confidence in the bias assessment.
Some EQA schemes include a formal assessment of imprecision, 
through the replicate analysis of specimens. This may be 
by 'open 1 replicate analysis of each individual specimen, which 
is obviously open to manipulation by participants, as in the
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Table 4.2 Average running scores (OMRVIS) in EQASs administered 
from Wolfson Research Laboratories, 1985. OMRVIS (Appendix 
II) derived from 30 VISs (40 VISs in UKEQAS); data for China 
EQAS obtained in 1982
Average OMRVIS
UKEQAS 55
China EQAS 154
International EQAS 122
Middle East EQAS 92
Thailand EQAS 105
Colombia intensive EQAS 200
Mexico intensive EQAS 124
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'hybrid' IQC/EQA schemes (Limonard, 1979; Jansen and Jansen, 
1980; Lawson et al, 1980). The alternative is repeated 
distribution of the same specimen as part of the scheme design, 
to afford an estimate of within-laboratory precision (eg Oakey, 
1980, Bacon et al, 1983; Wellcome Diagnostics, 1984; Groom, 
1985d). Some of these schemes (Oakey, 1980; Wellcome Diagnostics, 
1984) use this estimate as their only or primary assessment of 
laboratory performance. This is merely a duplication of what the 
laboratory's IQC program should be providing and is hence a waste 
of resources; if the semi-blind EQA replicate data conflict with 
the IQC estimate then the more favourable figure will tend to be 
believed.
4.7.2 SD differences
More complex algorithms, such as the standard deviation 
difference (SDD) or 'Z score' (eg Merritt et al, 1965; Wellcome 
Diagnostics, 1984), may be employed as indicators of laboratory 
performance. The SDD is calculated by dividing the observed SD 
into the difference of the participant's result from the mean. 
This statistic, however, can only be used to compare performance 
of laboratories with others in the same scheme at the same time. 
SDDs can not be compared over time since the performance of the 
other laboratories (and hence the observed SD) may change, nor in 
different schemes since the observed SD will almost certainly 
differ. The average SDD in any scheme at any time will always 
have a similar value, and changes will only represent a change in 
the shape of the frequency distribution of results.
4.7.3 The Variance Index (VI) system
Consideration of these factors led to the devising and 
subsequent refinement of the Variance Index (VI) scoring system
91
(Whitehead et al, 1973 and 1975; Whitehead, 1977; Bullock and 
Wilde, 1985). The formal definitions are given in Appendix II.2.
Variance Indices offer a convenient system for comparing 
assessments of performance over time and over geography. 
Cumulation over analytes and over time yields an Overall Mean 
Running VIS (OMRVIS) as an empirically-useful assessment of 
overall performance. Its application in comparisons of the state 
of the art is demonstrated in sections 4.5 and 4.6 above, and its 
utility in the assessment of individual laboratory performance is 
discussed in Chapter 9.
The VIS is a mixed index, responsive to failures both of accuracy 
and of precision, but the MRBIS and SDBIS (Bullock and Wilde, 
1985) afford a means of separating the effects of these aspects 
of performance. Their interpretation is discussed in detail in 
Chapter 9. They thus correspond closely in intent to the BIAS and 
VAR estimators used in UKEQASs for hormone assay (Groom, 1985a).
4.7.4 BIAS and VAR
These parameters (Bacon et al, 1983; Groom, 1985b) provide an 
assessment of bias and its variability, both in percentage terms. 
Interpretation is similar to that of the MRBIS and SDBIS, but 
there are several differences.
Firstly, the scores are not in a 'common currency'. Thus the 
scores for analytes cannot be combined to give an estimate of 
overall performance. Interpretation must also be individual for 
each analyte, whereas in the VI system similar performance 
relative to the state of the art yields similar scores. Clinical 
relevance may be more readily discerned from the percentage error 
presentation, but VISs can be transformed simply into such terms
92
(eg a BIS of -85 for calcium indicates a negative bias of 3.4%).
Secondly the derivation of BIAS and VAR includes an outlier 
elimination procedure. Any discrepant individual biases are 
classified separately as 'blunders' and therefore not lost 
entirely from consideration, but do not contribute to the 
performance assessment used most commonly in these schemes. In 
the VI system the effects of grossly discrepant individual 
results are mitigated by truncation of the VIS at a maximum of 
400, but such scores do still contribute.
4.8 Selection of Chosen Coefficients of Variation (CCVs)
The CCVs (Table 4.3) were originally determined as the best 
average CVs obtained in the UKEQAS for General Clinical Chemistry 
during 1972 (Whitehead et al, 1973). This gave a balance 
according to the state of the art existing then, and combination 
of scores for the various analytes would be valid. Such a 
derivation is independent of the clinical requirements, however, 
and the relative merits of assessment with respect to the state 
of the art and to medical needs are discussed in section 9.6.
For other analytes in this scheme the CCVs were determined from 
an assessment of the interlaboratory agreement obtained over a 
period of at least a year and the average OMRVIS at the time. 
This procedure was employed for the relatively 'mature' assays 
lithium, magnesium and osmolality. For enzyme activity assays, 
however, the interlaboratory agreement was unsatisfactory and 
short-term improvement was sought, so the 'calibrated' CVs for 
reliable method groups were considered (Bullock et al, 1986b).
A similar procedure using 'calibrated' data was adopted for 
immunoglobulin assays (Chambers et al, 1987). For single-analyte
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Table 4.3 Chosen Coefficients of Variation (CCVs) and average 
Variance Index Scores (VISs) for all participants during 
1986 in the UKEQAS for General Clinical Chemistry
CCV Average VIS
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
Osmolality
AST
ALT
LD
CK
ALP
Amylase
1.6
2.9
2.2
5.7
7.7
4.0
7.8
15.0
7.7
8.9
19.2
3.9
7.5
7.6
11.0
10.0
2.9
12.5
17.3
13.2
18.5
15.5
11.5
61
55
77
55
44
64
54
46
64
45
37
66
53
48
34
55
46
59
52
58
62
57
80
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schemes no combination of scores for different analytes is 
required and the choice is consequently less critical. CCVs were 
therefore selected to give approximately similar average scores; 
those for salicylate and paracetamol were continued from one of 
the Regional schemes which preceded the UKEQAS (Epton, 1979).
Inspection of the CCVs (Table 4.3) suggests that there would be 
more scope for improvement in the analytes such as iron, 
bilirubin and creatinine which showed worst agreement initially 
than in for example sodium. Has the balance among the CCVs been 
maintained, and do they then still give VISs in a common 
currency?
Table 4.3 also gives the average scores from 1986 in the UK, 
which show a considerable range (34-80). Considering only those 
analytes (sodium to cholesterol) for which CCVs were established 
in 1972 the range is reduced (37-77) but still appreciable. 
Indeed the scores for iron, bilirubin and creatinine are among 
the lowest, and that for sodium one of the highest, but the 
relation with CCV is not simple. For example glucose gives the 
second lowest score and chloride the highest. Its clinical 
importance has presumably stimulated the progress for glucose, 
whereas the decreasing interest and workload for chloride has led 
to a relative deterioration in performance. The lack of major 
improvement for calcium despite its critical clinical application 
is disappointing.
Should the CCVs therefore be reallocated to bring them back into 
alignment? This would certainly provide a fairer assessment of 
performance, in line with the current relative state of the art 
in the UK. The system is also applied to other schemes, however, 
and as might be anticipated the balance differs somewhat from
95
Table 4.4 Ratio of average VISs obtained in International EQAS 
and Middle East EQAS to those for distribution of the same 
material in the UKEQAS for General Clinical Chemistry, 1986.
UKEQAS distribution 305 (heat-treated human serum)
International EQAS Middle East EQAS
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
2.12
1.88
1.87
2.32
2.69
2.36
2.01
2.06
1.84
2.21
2.35
1.64
2.22
1.84
1.59
2.23
1.83
1.91
1.69
1.69
1.76
1.53
1.04
2.02
1.43
1.62
1.68
2.01
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scheme to scheme (Table 4.4). Should the advantages of between- 
scheme comparison and immediate availability of a performance 
assesment then be sacrificed to give a slightly more even balance 
within each individual scheme?
The main argument against readjusting the balance by changing 
CCVs, however, is the consequent loss of continuity. Thus 15 
years' performance data from the UKEQAS for General Clinical 
Chemistry are on file, and comparability with these past data 
would be forfeited through a change in CCVs. Minor changes, such 
as that caused by the inclusion of VISs below 50 in 1979, have 
been assimilated, however, and a readjustment for all schemes 
merits consideration.
4.9 Summary
Scoring systems make a major contribution to the effectiveness of 
EQA in performance assessment. This applies not only to the 
assessment of performance for individual participants (detailed 
in Chapter 9), but also to the assessment of:
- the state of the art
- the effects of analytical procedure
- progress over time
- relative performance in different schemes and countries
Many systems have been devised, and all have disadvantages.
Simple 'pass/fail' systems are useful in the licensing situation, 
but have no fine discrimination of performance standards. They 
also pose the problem of determining the criterion of 
acceptability. Semi-quantitative systems also have limited 
discrimination, and are applicable primarily to non-quantitative 
assays, as discussed in Chapter 7.
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Among quantitative (continuously discriminating) systems, SDD 
scores suffer from lack of a consistent baseline; each 
laboratory's scores are also dependent upon other participants' 
performance. They cannot then be used for assessment of progress, 
nor for comparison of performance among schemes.
The BIAS/VAR system gives good distinction between bias and other 
factors contributing to errors, but is not scaled to give scores 
in a 'common currency' for all analytes. More importantly, there 
is no single estimator of total error, and performance estimates 
for different analytes cannot be combined.
The Variance Index system appears to overcome most of these 
problems, yielding an estimator of total error (VIS). VISs can be 
cumulated over time to give performance indicators for individual 
analytes (MRVIS) and also over analytes for overall performance 
(OMRVIS) which are robust and readily interpretable in terms of 
the state of the art. Similar calculations will also yield 
estimators of bias (MRBIS) and consistency of bias (SDBIS) for 
each analyte. The hierarchical interpretation of these indices is 
discussed in Chapter 9.
A potential problem in the VI system arises if the relative state 
of the art changes, ie there is a shift in performance for some 
analytes. Examination of data from the UK confirms there has been 
some movement, and a readjustment of Chosen Coefficients of 
Variation to restore the common currency must be considered 
despite the practical difficulties entailed.
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ASSESSMENT OF INTERLABORATORY AGREEMENT
Chapter 5:
THE VALIDITY OF CONSENSUS VALUES
5.1 Introduction
A consensus value is the mean, usually following some form of 
trimming procedure to remove 'outliers' and thus increase its 
reliability, of results returned by participants in an EQAS. 
Dependent upon circumstances the overall mean (ie including 
results from all participants) or the mean of results from 
participants using an individual method, or group of methods, 
may be used. The main purposes of calculating consensus values 
are to obtain:
- a target value (designated value) for assessment of
participants' performance, as discussed in Section 3.4 and 
Chapter 4
- an assigned value for the material
- a value for comparison with some externally-derived 
designated value in the assessment of overall accuracy.
Their variability (expressed in SD or CV terms) may also be used, 
in deriving confidence intervals for the assigned values, in the 
assessment of the state of the art (see Chapters 2 and 6), in the 
assessment of individual participants' performance in terms of 
'SD differences' ('Z scores', as discussed in Chapter 4), or in 
identifying some results as statistical outliers (Healy and 
Whitehead, 1980; Bacon et al, 1983; Groom, 1985b). In this case 
the procedure used for elimination can be important, and 
truncation (Buttner et al, 1983b), proportional censoring 
(Healy, 1979) and non-parametric procedures (Passing et al, 
1981) each have their advocates. In most other situations,
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however, the exact procedure adopted is largely irrelevant since 
the purpose of outlier elimination is to give a more robust 
estimate of the analyte concentration by removal of grossly 
discrepant results.
Consensus values were used in EQASs originally because they 
were convenient to obtain and use. The first objective of such 
schemes was also to attain numerical concordance of results 
within a country rather than strive for absolute accuracy, which 
was then probably not accessible within the constraints of the 
reference system at the time. Though there is no scientific 
reason why consensus values should be accurate, as experience 
with the developing EQASs increased it became apparent that these 
values had additional properties (eg Whitehead et al, 1973; 
Gilbert, 1976; Grannis, 1976; Whitehead, 1977).
Thus, there appeared to be consistent agreement among the means 
for methods with completely different analytical principles, eg 
atomic absorption photometric, titrimetric and dye-binding 
colorimetric procedures for serum calcium assay. Furthermore such 
method means also seemed to agree with values obtained by the 
newly-developing reference and definitive methods. Consensus 
values also appeared to be reproducible on repeated distribution 
of the same specimen, provided stability could be assured.
These studies, however, were conducted using pooled liquid human 
sera, ie the specimens distributed resembled very closely the 
specimens of fresh human serum to which the methods were applied 
and for which they had been optimised. As EQASs developed and the 
numbers of participants increased it became impractical to use 
such specimens. Improvements in manufacturing technique at this
100
time (around 1970-1975), yielding lyophilised products which no 
longer suffered from such deficiencies as high vial-to-vial 
variability due to imprecise filling, therefore made such 
materials increasingly attractive as an alternative source of 
specimens. Most of these materials, however, were still based on 
animal rather than human serum, and the full range of their 
properties and the effects of manufacturing procedures were 
unknown. Such factors are best studied empirically, as described 
in Chapters 14 and 15.
It was then possible that the good agreement obtained for liquid 
human sera would no longer be obtained with these materials. It 
was then necessary for EQASs to use method-related consensus 
values for the assessment of performance. Otherwise, if the 
material proved not to be commutable (see sections 3.3, 12.1 and 
13.5.2), participants could be penalised for deficiencies in the 
specimen distributed rather than in their analytical performance 
on clinical specimens: this could rapidly lead to erosion of 
.confidence in a scheme's validity. In addition, EQAS results 
could no longer provide a reliable comparison with reference or 
definitive methods since the materials distributed might not be 
commutable with fresh human serum. In this situation it would be 
impossible to relate the analytical performance attained in 
countries with NEQASs relying on consensus values for assessment 
of participants. Drifts away from accuracy might then occur, 
with no means for their detection, and international concordance 
be lost through the continuing introduction of more national or 
regional schemes.
International comparisons were thus essential to assess whether 
such drift, the potential for which appears to be inherent in the
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use of consensus values, was in fact occurring. Such comparisons 
were initially conducted on an ad hoc basis. Usually the schemes 
involved were well-established, with one or both using consensus 
values for assessment. Comparisons arose incidentally, when both 
schemes distributed the same material, or deliberately, with one 
scheme providing material to the other or the manufacturer 
providing it to both. In other cases schemes used only materials 
distributed previously through another, longer-established 
scheme, often using consensus values from the latter as 
designated values.
Though such studies largely indicated that consensus values were 
indeed reproducible among as well as within schemes, more 
systematic study of interrelationships between NEQASs was needed. 
The Wolfson Research Laboratories (WRL) therefore instituted the 
WRL International Intercomparison Scheme (WHS) in 1984 as a 
feasibility study for such a system, involving as many 
established schemes as practicable.
5.2 Reproducibility of consensus values
Before any comparison of consensus values between EQASs, their 
reproducibility within schemes must first be assessed. Some 
scheme designs include repeated distribution of specimens (eg for 
assessment of reproducibility of participants' results; Oakey, 
1980) and facilitate such studies, but in others a second 
distribution of the same material is only occasional.
5.2.1 Studies using UKEQASs
The UKEQAS for General Clinical Chemistry (Appendix 1.2.1) is of 
the latter type, though the scheme organisers have endeavoured 
to carry out such repeats about 6 months after the material's 
first distribution. Experience with 13 paired distributions in a
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7-year period (Appendix III.1.1) is summarised in Table 5.1; the 
presentation in terms of percentage differences is necessitated 
by the wide range of analyte concentrations. From these data it 
is clear that the consensus values for 'mature 1 assays with 
largely satisfactory interlaboratory agreement obtained in a 
scheme with many participants are highly reproducible. The 
differences for glucose, bilirubin and enzymes represent 
decreases, and may therefore in part reflect material 
instability; the variability for iron is unexplained.
Is this also true for other cases? The UKEQAS for Lead in Blood 
(Appendix 1.2.3) offers an example of a smaller scheme with a 
less mature assay. Here assessment (Bullock et al, 1986c) showed 
a CV of 1.2% for consensus values on 11 pairs of duplicate 
specimens distributed sequentially with lead concentrations in 
the range 1.56-3.73 umol/L, based on 47-91 results (average 68).
The UKEQAS for Urinary Pregnancy Oestrogens (Appendix 1.2.4) is 
also a small scheme, and its design (Oakey, 1980; Bullock and 
Wilde, 1985) incorporates replicate distribution of a set of 
linearly-related specimens over one to two years. Table 5.2 
summarises experience with a set of specimens for the Lever, 
Brombacher and RIA method groups (an overall mean is 
inappropriate here, since assays have differing specificities, as 
demonstrated by the regression slopes and discussed in section 
13.3). Here again the consensus values are highly reproducible, 
bearing in mind the relatively low numbers of results 
contributing; the average VISs are less reproducible, since 
interlaboratory agreement was improving during this period 
(Figure 3.1).
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Table 5.1 Reproducibility of consensus values in the UKEQAS for 
General Clinical Chemistry, 1981-1987. Percentage 
differences between overall means (SCE 37°C for AST and ALP) 
for 13 distributions
n
Percentage difference
Average SD
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
Osmolality
AST
ALP
13
11
7
13
13
13
11
9
13
13
9
13
7
11
10
7
3
1
2
0.12
0.09
0.17
0.21
1.44
0.21
0.28
1.03
0.70
0.54
1.80
0.17
0.32
0.47
0.39
0.43
0.11
1.95
1.98
0.08
0.10
0.14
0.15
1.55
0.20
0.27
0.88
0.83
0.42
1.25
0.12
0.20
0.49
0.29
0.29
0.10
—
_
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Table 5.2 Reproducibility of consensus values in the UKEQAS for 
Urinary Pregnancy Oestrogens, 1980-1981 (24 distributions),
n=48 laboratories for Lever method group, 47 for 
Brombacher/Hainsworth & Hall, 14 for RIA (total 123 
participants)
Average VIS Mean oestrogen (umol/2L)
Lever Brombacher RIA
92.5 36.2 36.6 28.5
80.1 36.1 36.3 27-0
71.2 35.6 37.1 28.6
72.7 34.5 35.5 27.3
71.5 46.7 47.9 38.1
70-6 46.8 47.4 35.2
76.4 44.9 47.4 37.9
64.5 44.6 47.2 34.8
64.4 61.0 65.0 49.4
68.9 61.4 65.4 49.4
70.5 62.8 63.5 49.6
63.7 60.9 65.1 46.8
74.5 81.1 86.5 66.2
58.2 82.6 85.3 68.9
68.3 82.2 86.8 69.6
56.1 82.9 85.0 62.2
59.2 113.2 118.5 92.4
52.2 116.2 116.0 87.5
57.4 112.8 117.9 89.0
57.5 114.0 118.8 90.6
63.5 140.2 146.6 108.4
60.9 140.7 143.8 107.6
67.4 139.8 145.1 107.4
55.6 140.2 145.4 108.4
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5.2.2 Studies in the International and Middle East EQASs
Experience from organising EQASs in developing countries 
indicates that the interlaboratory agreement is substantially 
worse than that seen in UKEQASs, with SDs and CVs typically 
double the UK values (eg Table 4.4). The additional variance 
makes consensus values less robust, leading to preference for 
UKEQAS data as designated values for such schemes. Is this then 
reflected in the reproducibility of their consensus values?
Table 5.3 summarises the percentage differences observed in the 
International EQAS (Appendix 1.3.1) and the Middle East EQAS 
(Appendix 1.3.2), for comparison with the corresponding data 
from the UKEQAS for General Clinical Chemistry above (Table 
5.1). The pattern is similar to that in the UK scheme, and the 
consensus values in these schemes are also reproducible. The 
greater variability results from the worse interlaboratory 
agreement and consequently larger standard errors.
5.3 Ad hoc comparisons of consensus values
Some materials distributed in the UKEQAS for General Clinical 
Chemistry (Appendix 1.2.1) were also distributed either in other 
NEQASs or in commercial EQASs. The NEQASs for which data were 
available were those in the Netherlands (Jansen et al, 1977), 
Norway and South Africa (Georges, 1985). The commercial schemes 
were organised by Merz+Dade, Ortho Diagnostics (both 'hybrid' 
IQC/EQA schemes, discussed in section 3.2) and Wellcome 
Diagnostics. The overall consensus means were compared, since 
the balance between use of different method principles between 
the schemes appeared small.
5.3.1 National EQASs
These comparisons (Appendix III.1.2) are summarised in Tables
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Table 5.3 Reproducibility of consensus values in the
International EQAS (11 distributions) and Middle East EQAS 
(8 distributions), 1985-1987. Percentage difference between 
overall means
IEQAS
Average SD
MEEQAS
Average SD
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
0.4
0.8
0.6
1.4
1.2
1.2
1.6
5.2
1.4
2.5
1.9
1.1
2.1
1.7
0.
0.
0.
0.
1.
1.
1.
4.
1.
2.
1.
1.
-
1.
2
6
3
8
1
4
2
5
0
0
6
1
2
0.
0.
0.
1.
1.
0.
1.
2.
1.
1.
1.
1.
0.
2.
5
5
4
0
1
9
7
8
2
2
9
1
3
3
0.3
0.5
0.3
0.8
0.6
0.4
1.3
2.1
1.0
0.9
1.5
0.6
-
1.6
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5.4 and 5.5, and demonstrate excellent agreement in most cases. 
Similar agreement was obtained for a further three materials 
distributed in the UK and Holland during 1982 and 1983. The 
isolated instances where values diverged, eg creatinine and South 
Africa in Table 5.5, could not readily be explained; an 
independent comparison in South Africa showed good agreement with 
values obtained on prior distribution in the Wellcome Diagnostics 
scheme (Georges, 1985).
5.3.2 Commercial EQASs
Tables 5.6 and 5.7 give similar summary data from these 
comparisons (Appendix III.1.2). Again there is good agreement, 
with no consistent differences. This might be expected since some 
of the participants in the commercial schemes are UK 
laboratories, though only for the Wellcome programme (with about 
25% of participants in the UK) is this likely to have been an 
appreciable factor. The tendency for slightly higher urate values 
in the UKEQAS may have been due to greater use of chemical 
procedures.
5.4 Comparisons with reference and definitive methods
Comparisons with values assigned to materials using definitive or 
reference methods serve two main purposes:
- validation of the accuracy of consensus values
- assessment of any 'drift' in consensus values
For the first the properties of the specimens considered must be 
very close to those of clinical specimens; liquid specimens of 
human serum are necessary for this. In the second application, 
however, it is only necessary that the composition of the 
specimens is consistent over time, and materials from the same 
manufacturer should suffice.
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Table 5.4 Comparison of consensus values in the UKEQAS for
General Clinical Chemistry with those in the Netherlands 
EQAS for Armtrol bovine serum, lots 488 and 489, 1980.
Units as in Table 5.5
	Lot 488 Lot 489 
	UK Holland UK Holland
Sodium 150.3 150.9 141.4 141.9
Potassium 4.95 4.95 4.38 4.40
Chloride 110.2 110.9 101.1 101.1
Glucose 9.30 10.86 5.02 5.57
Calcium 2.79 2.71 2.44 2.39
Phosphate 1.98 2.03 1.64 1.67
Iron 39.8 39.8 32.2 32.2
Urate 0.569 0.556 0.297 0.296
Creatinine 247 240 119 114
Bilirubin 138 135 23.6 22.5
Total protein 75.0 75.2 70.8 71.1
Cholesterol 4.89 5.08 4.79 4.99
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Table 5.5 Comparison of consensus values in the UKEQAS for 
General Clinical Chemistry with those in the Norwegian 
(Seronorm, lot 158) and South African (UKEQAS human serum, 
lot L4/80) EQASs. All results in mmol/L unless specified
UK Norway UK S Africa
Sodium 137.5 137.1 141.0 140.9
Potassium 4.56 4.56 4.97 4.95
Chloride 107.7 107.1 105.2 105.8
Urea 8.6 8.6 4.59 4.76
Glucose 5.00 5.01 5.38 5.51
Calcium 2.71 2.73 2.23 2.28
Phosphate 1.06 1.07 1.32 1.34
Iron (umol/L) 29.7 29.7
Urate 0.464 0.463 0.266 0.266
Creatinine(umol/L) 145 147 87 100
Bilirubin (umol/L) 22.4 21.9
Total protein (g/L) 64.5 63.9 65.4 66.7
Albumin (g/L) - - 40.7 39.6
Cholesterol 2.29 2.26 4.45 4.36
Magnesium 0.88 0.87
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Table 5.6 Comparison of consensus values in the UKEQAS for
General Clinical Chemistry with those in the Merz+Dade QAP, 
1984 (Levels I and II) and 1986 (Level II). Units as in 
Table 5.5; enzyme data (U/L) for SCE optimised 37°C, except 
amylase (Phadebas 37°C)
Level I
UK QAP
Level II
UK QAP
Level II
UK QAP
Sodium
Potassium
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Magnesium
Osmolality
ALT
CK
ALP
Amylase
140
5
6
4
1
1
36
0
138
25
67
42
6
1
-
—
-
—
.0
.96
.62
.72
.93
.57
.2
.299
.2
.4
.7
.15
.68
140
5
6
4
1
1
34
0
138
25
67
43
6
1
-
—
-
-
.0
.95
.63
.68
.94
.56
.3
.294
.2
.6
.1
.03
.71
122
3
17
11
2
2
16
0
505
87
53
36
2
0
—
-
-
—
.0
.80
.85
.10
.81
.56
.0
.561
.4
.8
.5
.57
.70
122.
3.
17.
11.
2.
2.
16.
0.
491
86.
54.
36.
2.
0.
-
-
—
-
_
0
80
55
05
80
57
2
543
3
2
6
60
73
111.
6.
18.
13.
3.
-
40.
0.
512
60.
46.
28.
2.
1.
264
132
585
481
1106
5
76
23
21
13
5
112.
6.
18.
13.
3.
-
40.
506 0.
8
0
4
37
88
507
59.
46.
28.
2.
2.
265
133
577
461
1115
4
78
00
14
12
4
486
5
4
5
36
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Table 5.7 Comparison of consensus values in the UKEQAS for 
General Clinical Chemistry with those in the Ortho QC 
Program (1979-1980) and the Wellcome Group QA Programme 
(1985). Units as in Table 5.5
Level I
UK Ortho
Level II
UK Ortho UK Wellcome
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
Osmolality
139.6 139.6
4.2 4.21
102.4 102.0
5.5
4.3
5.42
4.53
2.33 2.35
1.12 1.23
20.3 20.2
0.273 0.271
85
8.1
4.0
89
8.5
60.6 61.4
37.7 37.4
3.98
152.8 152.5
7.25 7.26
118.6 118.1
19.17 18.61
17.46 17.45
3.27 3.27
2.38 2.49
49.1 47.5
0.591 0.563
809 796
103.0 96.3
54.8 55.8
33.9 33.1
3.86 3.67
150.3 150.3
4.48 4.48
109.7 110.0
9.26 9.23
9.46
2.08
9.57
2.09
1.71 1.70
34.5 33.8
0.298 0.298
212 212
39.4 39.8
75.7 75.5
3.97 3.96
0-90 0.90
1.13 1.13
313 313
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5.4.1 Definitive methods
Several constituents of a tentative reference material prepared 
at CDC for WHO were analysed by definitive methods at the US 
National Bureau of Standards (NBS), and the assessment of the 
material also included UKEQAS distribution in 1977 (Appendix 
III.1.3). The values obtained are summarised in Table 5.8. Close 
agreement is demonstrated between NBS definitive method values 
and the consensus values for reliable method principles, 
supporting their validity for these simple constituents.
The reliable comparative data (ie those obtained using liquid 
human sera) for the UKEQAS for General Clinical Chemistry are now 
historical, since lyophilised materials have been distributed 
since the mid-1970s. A more recent comparison with definitive 
methods was, however, undertaken on a specimen of lyophilised 
equine serum (Appendix 111.1.3) as part of a study of value 
assignment procedures (Eldjarn and Broughton, 1985). The results, 
summarised in Table 5.9, showed generally good agreement but 
anomalies were noted for sodium and cholesterol. The authors 
suggested that the data should be interpreted with caution, since 
the definitive method assays were carried out in one laboratory 
only and without external validation. More detailed examination 
showed a range of transferred values for sodium of 134.6 - 138.5 
mmol/L (Eldjarn and Broughton, 1985), and the cholesterol 
concentration is low with the absolute deviation being only 0.14 
mmol/L.
Studies on other analytes have revealed great discrepancies 
between definitive method values and EQAS consensus values, and 
steroid hormone assays (Siekmann and Breuer, 1982; Gaskell et al,
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Table 5.8 Comparison of consensus values in the UKEQAS for
General Clinical Chemistry with NBS definitive method values 
for WHO Experimental Reference Serum, lot 4976, 1977. Units 
as in Table 5.5
Definitive
Overall
UKEQAS
Method-related
Sodium 142.2 142.2 142.4 AutoAnalyzer flame
142.3 IL flame
141.9 Corning-EEL flame
Potassium 4.79 4.83 4.85 AutoAnalyzer flame
4.82 IL flame
4.81 Corning-EEL flame
Chloride 100.2 99.5 99.7 AutoAnalyzer
99.4 Coulometry
99.1 Titrimetry
Urea 5.76 5.96 5.82 AutoAnalyzer DAM 
6.43 Manual urease
Glucose 5.40 5.58 5.56 AutoAnalyzer GOD
5.45 Manual GOD
5.30 Beckman
5.50 o-Toluidine
5.93 AutoAnalyzer reduction
Calcium 2.27 2.27 2.29 AutoAnalyzer CPC
2.25 Atomic absorption
2.26 Vickers 300 CPC
2.24 MTB
2.23 EDTA titration
Urate 0.273 0.290 0.294 AutoAnalyzer chemical
0.283 Manual chemical
0.277 Manual uricase
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Table 5.9 Comparison of consensus values in the UKEQAS for
General Clinical Chemistry obtained on Seronorm, lot 158, 
with definitive method values and with values transferred 
from NBS SRM909. Units as in Table 5.5; transferred values 
defined by Broughton and Eldjarn (1985)
UKEQAS Definitive Transferred
Sodium 137.5 135.8
Potassium 4.56 4.50
Chloride 107.7 108.0 108.5
Glucose 5.00 4.96 4.93
Calcium 2.71 2.76 2.74
Urate 0.464 - 0.462
Cholesterol 2.29 2.15 2.15
Magnesium 0.88 0.86 0.88
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1984; Groom, 1985b) provide an excellent example of this 
situation. Here the underlying problem is one of method non- 
specificity, so that the mean of results obtained using 
relatively unsatisfactory methods cannot be expected to approach 
the true analyte concentration in specimens, as estimated by 
reference or definitive method values. Provision of such 
information in reports, rather than its application in scoring of 
performance, can stimulate method improvements and a consequent 
drift in consensus values towards this reference point, ie 
towards 'truth'.
5.4.2 DGKC reference methods
Materials for use in GFR have values assigned by the Central 
Reference Institution of the DGKC; such values are also used for 
performance assessment in the NEQAS in GFR (Bundesartztekammer, 
1971; Stamm, 1975). Values are obes are also used for 
performance assessment in the NEQAS in FRG (Bundesartztekammer, 
1971; Stamm, 1975). Values are obtained using approved reference 
methods, and in combination with a single type of QCM provide a 
stable baseline for assessment of any drift in consensus values.
Batches of Roche Diagnostica Control Sera N and P have been 
distributed regularly through the UKEQAS in addition to having 
values assigned by DGKC. Table 5.10 summarises the comparison of 
these results over 10 years (Appendix III.1.3). Minor deviations 
are shown, eg for iron, bilirubin and total protein, reflecting 
differences in the method principles used in combination with 
possible deficiencies in the QCMs. The relationships show no 
consistent trends or changes, apart from iron and creatinine (for 
which the reference method principle was changed) in 1986.
5.5 Systematic comparisons between schemes
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Table 5.10 Comparison of consensus values in the UKEQAS for 
General Clinical Chemistry with reference method values 
assigned by the DGKC to Roche Control Sera N and P, 1977 - 
1986. Average difference UKEQAS - DGKC (* denotes difference 
for one batch only); units as in Table 5.5
n (bstdnes)
1977 1978 1979 I960 19BL 1982 1983 1984 1905 1986 
4222044355
Soctiun
Chloride
Ucea
Calcnin
Iron
Lfcate
-0.2
O.OL
0.1
0.12
-O06
0
-0.03
3.0
0.035
-1.5
3.7
-0.8
-0.14
-1.0
-0.11
O12
0.08
-O.16
1.7
0.029
6.0
4.4
1.8
-0.02
-1.0
-0.25
Q07
0.2L
-O.15
2.1
O.OL6
5.0
3.2
1.4
-O.05
2.25
0.19
O30
0.08
-0.04
5.0
0.003
-O.I
2.1Rili-nhrin
Total jxotein -0.5 0.5 -0.6 1.7
pKl MT nil 0.12 -0.10 0.20 0.24
LLthiun
-0.7
0.
0.8
-0.3
0.16
0.1 0 0.8 0.5
-O.CB 0
0.2 0.8
0.02 -0.30 -0.05
0 1.1
0
5.5 5.7 6.0
1.1
-0.34 -O.47 -0.02 O.OL -0.31
000019015029046
0.01 0.04 0.08
-0.07 0.01 O.QL
3.6 -2.6
0.014 0.007 0.019 0.003
1.3
4.0
1.2 4.1 37
2.9 3.3
0.02 -0.02
-0.07 -0.08* -0.05 -0.06
0.02* -0.10 -0.( -0.04
0.9
0.8 -1.6 -1.3 -3.0 0.7
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In these cases the schemes distributed specimens which had 
previously been distributed in the UKEQAS for General Clinical 
Chemistry (Appendix 1.2.1), and consensus values could thus be 
compared for all distributions (Appendix III.1.4). In such 
situations, with participants striving to attain the UKEQAS 
consensus values used for performance assessment, good agreement 
might be anticipated but would not be automatic in view of the 
wide spread of results (see section 5.2.2 above).
5.5.1 International EQAS
Comparison based on 20 distributions yielded good agreement, 
summarised in Table 5.11. The lower values for glucose and 
bilirubin suggest possible deterioration in transit or during 
handling within participant laboratories. The variability in 
relationships appears to reflect the greater variability of 
consensus values in the IEQAS (Table 5.3).
5.5.2 Middle East EQAS
Table 5.12 summarises the good agreement also seen for most 
analytes in the 20 distributions studied (Bacchus et al, 1987). 
Here features similar to those described above for the IEQAS were 
also seen. Slight differences were seen for phosphate, iron, 
bilirubin and enzymic cholesterol, though there were no 
significant relationships with analyte concentration.
5.6 The WRL International Intercomparison Scheme (WHS)
This scheme was established in 1984 with the aim of obtaining a 
more objective assessment of whether biases did exist between 
established national EQASs, and of the magnitude of any such 
biases. The principle of the scheme was to use a small number of 
participants from each country to reflect the accuracy base of
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Table 5.11 Comparison of consensus values in the International 
EQAS with those in the UKEQAS for General Clinical 
Chemistry, 1985 - 1987. n=20 distributions unless specified
Average
Ratio IEQAS/UKEQAS (%)
SD Range
Sodium
Potassium
Chloride (n=18) 
Urea (n=16)
Glucose
Calcium (n=19) 
Phosphate (n=19 ) 
Iron (n=19) 
Urate (n=16) 
Creatinine 
Bilirubin 
Total protein 
Albumin (n=5) 
Cholesterol 
AST (n=6) 
ALP (n=2)
99.4
99.0
100.2
99.2
95.8
98.7
98.8
98.3
99.2
98.5
95.5
101.0
99.4
102.4
104.8
103.1
0.5
0.9
1.1
4.0
2.8
2.0
2.5
5.6
2.4
3.4
3.8
1.3
2.1
2.1
5.9
«
98.8-100.2
97.3-100.0
98.7-103.1
89.2-104.1
88.9-102.4
95.5-103.9
94.2-102.7
92.1-108.9
96.3-105.2
93.4-105.8
89.3-108.2
98.8-102.8
96.9-101.4
99.2-107.8
97.6-114.4
98.1;108.0
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Table 5.12 Comparison of consensus values in the Middle East EQAS 
with those in the UKEQAS for General Clinical Chemistry, 
September 1983 - May 1985. n=20 distributions unless 
specified
Sodium
Flame photometric 
Indirect ISE
Potassium (n = 19) 
Flame photometric 
Indirect ISE
Chloride (n = 18)
Colorimetric
Electrometric
Urea
Diacetylmonoxime( n=19
Urease (n=18)
Glucose
Enzymic 
Reduction (n=15)
Calcium
Dye binding
Phosphate
Colorimetric
Iron (n = 18) 
Dye binding
Urate
Colorimetric 
Uricase
Creatinine
Jaffe (non-kinetic)
Bilirubin (n = 17) 
Diazotisation
Total Protein
Biuret
Albumin
BCG (n = 5) 
BCP (n = 3)
Cholesterol
Enzymic (n=18) 
Chemical (n=17)
Average
99.4
100.1
99.1
99.6
101.1
100.3
97.9
98.3
97.9
93.4
99.7
103.5
95.6
98.3
99.6
99.4
96.6
99.3
101.5
106.7
96.8
99.5
Ratio MEEQAS/UKEQAS (%)
SD Range
1.0 
0.4
0.7 
0.8
0.6 
1.0
3.5 
1.1
1.8 
4.8
0.8 
1.9 
3.3
3.8 
1.7
2.9 
4.4 
2.3 
1.3
97.1-102.1 
99.2-100.5
97.3-100.3 
97.5-101.0
100.2-102.3 
98.4-102.4
1.6 
5.7
93.8-110.2 
96.5-100.4
95.4-101.9 
78.6-101.2
98.1-100.9 
99.3-108.1 
88.9-99.9
86.6-101.5 
97.0-101.8
94.9-107.1 
84.9-102.6 
93.1-104.3
100.3-103.5 
103.6-110.7
93.6- 99.0 
90.8-110.1
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Figure 5.1 Schematic design for WRL International
Intercomparison Scheme (WHS), with several repesentative 
laboratories from each national EQAS participating. See
section 5.6.1 for explanation
WRL International Intercomparison 
Scheme for Clinical Chemistry
National EQAS
International 
Intercomparison Scheme
National EQAS
tional EQAS
ational EQAS
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their national scheme (Figure 5.1).
5.6.1 Principles and establishment
These laboratories would be selected on the basis of regular 
participation in their NEQAS (to ensure complete returns in the 
WHS), and of consistent performance. Thus, they should be among 
the 'best' participants in their national scheme over a period of 
years, and ideally with small bias; to facilitate communication 
these would normally include the scheme organiser's laboratory. 
Depending on scheme size, between 3 and 5 laboratories per scheme 
was felt to be appropriate for the initial stages of the WHS, 
which would in effect be a feasibility study (Figure 5.1). Of 
course, with such a small number of laboratories they could not 
be assumed to be fully representative of their national EQAS for 
all analytes. It would therefore be necessary to obtain data 
regarding biases relative to their own scheme to draw reliable 
conclusions.
A monthly distribution frequency was chosen. To minimise postal 
delays sufficient materials for a six-month cycle were despatched 
together, as in the IEQAS and MEEQAS. Participants would be 
requested to report the mean of replicate assays, preferably from 
separate analytical batches, to reduce the effects of within- 
laboratory imprecision.
The design depended on the cooperation of national EQAS 
organisers in selecting suitable laboratories from their scheme, 
in redistributing specimens to them, and in subsequently 
providing performance data on these laboratories. Initially 33 
scheme organisers were contacted, of which 28 agreed to 
participate from the inception of the WHS. A further two 
participated later; most of these represented situations where
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responsibility for scheme organisation had been transferred, 
though no response was obtained from the three others. 
Participation in the scheme was anonymous, and each country was 
therefore identified only by a country code; countries are listed 
geographically in Table 5.13.
5.6.2 Experience with scheme operation
The return rate from almost all laboratories was satisfactory. 
Any results received after the deadline for the main computer run 
were assessed and the files updated before results for the 
following distribution were processed.
The reports to participants showed the overall and recalulated 
(after truncation at ±3 SD) statistics for all laboratories, and 
the percentage deviations from the recalculated mean for the 
laboratories in their own country. The individual results 
returned were not given, in an attempt to reduce the tendency for 
the participants to 'adjust' their methods to agree with the 
international consensus obtained through the WHS. The purpose of 
this scheme thus differed fundamentally fom that of most EQASs.
Following pages showed the average percentage deviation for each 
analyte for the laboratories in each country, and the cumulative 
average percentage deviation for each analyte for each country 
(Appendix 1.4). This latter figure was the average of all the 
individual percentage deviations obtained by laboratories from 
that country over the four most recent distributions; ie with 
three laboratories the maximum number of contributory percentage 
deviations would be 12.
The criteria for assessment were similar to those used for VIS 
calculation in the UKEQAS. Thus, no percentage deviations were
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Table 5.13 Countries with NEQASs participating in the WRL 
International Intercomparison Scheme
Africa and Middle East
Saudi Arabia 
South Africa
Americas
Canada
United States of America (CDC)
United States of America (CAP)
United States of America (New York State)
Asia
Burma
China (Peoples Republic)
India (Chandigarh)
India (Vellore)
Indonesia
Japan
South Korea
Thailand
Australasia
Australia 
New Zealand
Eastern Europe
Bulgaria
Czechoslovakia (Czech SSR)
Czechoslovakia (Slovak SSR)
Germany (Democratic Republic)
Poland
Union of Soviet Socialist Republics
Western Europe
Belgium
Denmark
France
Germany (Federal Republic)
Netherlands
Spain
Switzerland
United Kingdom
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calculated for very high or very low analyte concentrations, nor 
where the specimen would not necessarily yield a reliable 
assessment, eg for albumin on specimens of non-human origin or 
for urea on specimens containing Tris buffer, a urease inhibitor 
causing low results in some urease-based procedures. In the 
initial stages of scheme operation no account was taken of the 
methods used by individual participants. Provision was, however, 
made for its subsequent inclusion, and details of the methods and 
instrumentation used were obtained from participants.
Though facilities were offered for laboratories to return results 
in either SI or 'conventional' (mg/dL) unit sets, with reports in 
SI units, some participants initially returned grossly discrepant 
results. This was particularly marked for magnesium and calcium, 
due possibly to the use of mEq/L by some laboratories. The return 
rate was also initially disappointing. For these reasons the 
results of the first two distributions were omitted from data 
analyses.
5.6.3 Comparison of results
Thus distributions 101-112, being the first reliable year's data 
(September 1984 to August 1985), formed the basis of assessment. 
Table 5.14 gives the average percentage deviations for each 
country and analyte over these distributions. These were derived 
by taking the mean of the cumulative average percentage 
deviations at distributions 104, 108 and 112; each figure would 
be derived from 36 individual determinations for a country with 
three participants returning results reliably. As shown for 
calcium and countries 20 and 76 in Figure 5.2, these average 
percentage deviations were stable in most cases.
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Table 5.14 Cumulative average percentage deviation from WHS
consensus in Trials 101-112. Asterisks indicate data from 
countries using predominantly chemical procedures (for urea, 
glucose, urate and cholesterol)
Country Na K Cl Urea fflim Ca ftm H» Drate Great Bin IP Alb ChaL LI ME
20
21
22
23
24
25
26
27
28
50
51
52
53
54
55
70
71
72
73
74
75
76
77
78
79
80
81
120
121
160
161
162
163
0.2
0
0.57
-0.37
0.73
0.73
-0.1
-0.8
0.07
-0.37
-0.3
-0.77
0.17
0.47
0.43
0.57
0.5
-3-1
0.27
0
-2.77
-0.23
0.1
0.33
-0.66
-0.03
0.4
0.8
0.4
0.37
0.8
0.53
-0.85
1-5
0.8
-0.7
0.27
0.6
-0.07
-0.1
0.033
0.23
-0.1
-0.53
-1-13
-2.4
-3-47
0
0.4
1.43
0.17
0.47
-1.13
-0.33
1.47
-0.2
1.05
-0.9
-0.2
-1.4
-1.63
-2.87
-0.13
-0.6
-0-5
0.87
0.4
-0.17
-1-53
0.5
0.13
-2-7
0.83
-0.13
0.5
0.97
2.07
-3.1
2.83
0.23
-0.13
0.6
0-3
0.1
0.05
0.25
0.57
0-93*
-0.27
-3.37
-6.0
0.23*
1.23*
-0.7
1.03
-3-13
-2.77*
-1.4
4.93
0.5
1.6*
0.3*
2.03*
-6.83*
1.27*
0.8*
1-33
2.67
0*
2.03*.
1.3
1.33
1.1*
3.55*
-2.45
0*
2.22
-1.14
-0.7
-0.77
0.73
1.93
-0.9
-2.83
-2.73
-2.87
2.13*
-4.47
1.1
1.53*
1.07
4.83*
-2.47*
-3.27*
0.43
2.1
-8.6
-1.3
2.2
-1.2
-0.8
3.7
2.5
0.55
-1.4
0.09
-1.34
0
0.05
-0.5
0.97
-0.8
0.27
-0.07
0.47
-2.37
7.73
-0.53
-2.53
-2.87
0.73
-0.1
-1.5
-1.77
1.37
0.7
0.8
1.33
0.57
-0.03
0.75
0.45
-0.97
-1.88
-0.57
-2.0
1.0
-1.03
-0.97
-0.1
1.37
2.57
1-13
3-4
7.63
3.53
1.8
-0.7
1.87
-0.5
2.73
1.2
-0.3
3-9
-2.6
-2.23
0.63
-3-97
2.6
1.45
0.15
-2-33.
2.0
0.6
0.4
3.53
0
-5.6
-4.65
-0.9
5.1
8.27
-2.33
5.13
10.73
21.63
14.5
-7.63
1.87
6.87
-4.17
-1.4
9-0
-0.9
0-37
2.15
-0.75
-2.67
4.17*
-3-23
0.43
-6.77
-5.67
-5.33
2.1
1.67
-2.5
1-13
-2.9*
-1.2*
-1.2*
2.0*
7-27*
4.6*
2.u.
0.9*
0.87*
0.8*
-7.23
0.77
2.7*
1.2
3.6
5-93*
3.55*
1.15
-4.2
1.2
-3-5
-2.73
-3-73
-3-93
-2.2
-2.5
-0.83
-2.17
-3.6
0.87
14.1
0.77
-4.8
-0.3
4.63
1-93
4.0
-2.63
1.03
2.63
-0.17
12.73
0.2
9-43
-1.0
2.25
-0.43
1.07
0.17
-5-83
-2.53
-5.17
0.67
4.6
-5-93
0-3
-3-13
1.07
2.1
2.37
-1.4
3.73
15-3
-2.07
-8.77
-0.8
0.9
-0.87
4.67
-0.53
3.1
3-07
7.8
-4.65
0.15
-0.1
-0.17
-1.97
1.0
5-87
0.13
-1.6
-2.9
0.3
-1-93
1.0
1.77
0.5
2.0
-2.6
0.23
-2.07
3-87
-0.53
1.0
0.38
-1.47
0.37
0.7
-2.13
-1.87
2.1
0.9
0.55
-0.63
-1.23
-3-97
12.87
-3-7
1.53
5-03
-6.7
2.3
2.5
-0.50
1.07
6.7
-0.9
-0.57
3.37
1.17
4.83
0.47
4.57
0.77
-4.97
1.03
-H.23
-4.2
-5-83
1.83
-1.05
0.5
-1.67
-2.83
-3.03
-2.0
-3.0
-1-73
-3-27
-5.5
-2.37
7.9*
3.37*
4.03*
5.63
4.97*
12.87*
12.29*
8.1*
3.13*
2.97*
7-47
1.63
-6.0
0.83*
-3.53
-8.6
0.17
-3.57
1-3
-8.7
2.33
0.23
0.6
-0.03
-3.37
-2.4
-3.6
-5.87
-2.5
-1.03
-5.63
4.1
-2.5
2.86
2.73
2.7
0.2
0.3
-10.4
3.07
0.7
-0.85
-2.73
-1.67
-1.27
2.77
-0.7
8.2
-1.83
3.8
-3-43
4.13
-5.57
11.47
0.93
5-1
-45.il
34.37
25.67
9.27
-7.1
-2.53
2.33
-6.4
-4.03
-19.8
2.1
0.9
-8.13
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Figure 5.2 Stability of cumulative average percentage deviations 
for calcium in WHS
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The data show good agreement among many countries for most 
analytes. Agreement appears excellent for electrolytes in 
particular, as shown by the average deviations (irrespective of 
sign) in Table 5.15. Method differences may have contributed to 
the residual differences for some analytes. For example, 
countries using predominantly chemical (indicated by asterisks 
in Table 5.14) or enzymic procedures for urea, glucose, urate 
and cholesterol assay could be expected to differ in bias. 
Little difference was shown for urea (+0.4% and -0.3%) and 
glucose (+0.6% and -0.5%), but urate (+2.1% and -1.5%) and 
cholesterol (+6.0% and -2.6%) showed the anticipated marked 
effects.
In general, considering only countries 20-28 and 79-163 gives the 
closest concordance. These represent Western Europe, North 
America, the Middle East, Japan, South Africa and Australasia, 
and their comparability thus appears better than that among 
schemes in Asia (70-78) and Eastern Europe (50-55). Within each 
of these groups, however, there are exceptions. These may be 
generalised (eg countries 50 and 81) or with respect to 
individual analytes only (eg bilirubin and albumin in country 
23; cholesterol and magnesium in country 163), but inspection 
failed to suggest any reason for these.
Because the laboratories participating in the WHS may not be 
fully representative of their national EQAS, the scheme 
organisers were each asked in August 1985 to provide data from 
their own scheme. The data requested were the average percentage 
deviations (for the 3-5 laboratories representing their scheme in 
the WHS) over the same period (September 1984 to August 1985) 
relative to their national scheme. These would be relative to
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Table 5.15 Overall average cumulative average percentage
deviation from WHS consensus in Trials 101-112, with 
corresponding data and average percentage deviation of 
national EQAS from WHS consensus (Table 5.18) only for 
countries providing information on national performance
All countries Countries giving information
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
n
29
29
29
29
29
28
29
26
29
28
29
29
29
28
23
26
WHS
0.56
0.76
0.91
1.90
2.15
1.13
1.93
4.74
3.02
3.22
3.20
1.47
3.11
4.67
2.64
8.17
n
11
11
11
13
14
13
10
7
14
12
13
14
10
13
6
8
WHS
0.4
0.8
0.9
2.2
2.0
0.7
1.8
1.7
3.3
2.4
2.5
1.6
1.9
3.7
1.4
3.0
NEQAS 
v WHS
0.9
1.4
1.4
3.7
3.3
1.4
2.4
4.8
4.1
3.7
4.8
2.3
3.3
5.3
3.3
5.1
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designated values from reference laboratories, or to overall or 
method-related consensus values. These figures are given in Table 
5.16. Unfortunately, responses were received initially from only 
very few organisers, and further requests were therefore sent. 
These emphasised that confidentiality agreements would not be 
broken by reporting average data for several laboratories, and 
clarified the situation where some of the WHS participants were 
also reference laboratories for the national scheme. The response 
was still disappointing, with to date only 14 returns from the 29 
schemes for which WHS data were available.
These data on the bias relationship between WHS participants and 
their national scheme can then be combined with the data from the 
WHS to yield an assessment of the bias between each national 
EQAS and the international (WHS) consensus:
National scheme relative to WHS =
Average % deviation from WHS - Average % deviation from NEQAS
This is exemplified for the UKEQAS in Table 5.17. Here for 
analytes such as sodium and potassium the two deviations cancel, 
giving better agreement between UKEQAS and WHS consensus values, 
whereas for others such as chloride the resultant deviation 
becomes worse. The positive biases for urea and urate may be due 
to the then predominant use in the UK of chemical rather than 
enzymic procedures, with the reverse effect contributing to the 
apparent negative bias for cholesterol.
The resultant values for all schemes providing data on national 
scheme performance are given in Table 5.18. Unfortunately, the 
apparent divergence of many NEQASs from the WHS consensus was 
greater than that of their group of 'representative' laboratories
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Table 5.16 Percentage deviations of WHS participants from their 
national EQAS
Country Ma K d Urea Gliic Ca Phoe 5te Urate Great R1H Tf Alb Cboi Li (*fe
20 0.21 0.39 0.19 -0-73 0.51 -0.66 -0.48 -1.37 0.11 -0.6l 1.63 -0-53 1.01 -1.6 2.18 -0.26
21
22
23
24 -2.5 -2.5 -0.02 -0.02 -0.73 2.05 3-6 6.2 -11.6 2.0 -0.3 3.8 -4.5 -9.8 -0.75 2.5
25 0.56 0.05 -0.37 0.16 -1.8 1.09 -0.33 2.83 -2.72 0.88 0.11 -0.43 -4.16 0.78 3.17
26 1.13 l.« -1-22 -7.2 -0.5 -1.35 -5.85 2.28 -1.5 4.9 -0.3 1.1 0.7 -1.05 6.5
27
28
50 -1-39 -2-32 -2.12 -5-74 -6.7 4.26 -4.35 9-2 10.5 8.26 -8.31 -5-83 3-27 6.46 7.78 -10.7 
51-
52 -0.72 -0.42 -0.62 1.67 0.45 -0.1 1.22 -2.04 1.42 0.89 0.5 -4.23
53
54
55
70
71 4.43 3.61 1.1 8.03 -1.76 2.73 -5-25
72
73 0.78 0.2 1.57 -2.51 -5.25 0.58 2.12 3-2 5-64 -6.54 -0.7 3.01 7-39
74
75
76 -2.3 -1.6 0.6 -1.9 12.7 -1-5 0.9 4.6 0.5 -0.8 0.1 6.0 4.1
77 7.6 5.1 0.95 -0-73 0.25 2.9 -0-53 9-1
78
79 0.8 -1.0 1.3 2.35 -1-25 0 -1.5 2.25 1-45 -1-4 7-2 1.15 2.9 -0.25 -3.85 2-3
80
81
120 -0.25 -1.46 0.15 2.66 -2.44 2.13 -4.47 -0.49 2.05 -6.38 0.45 4.42 0.64 -2.42
121
160
161 -0.8 2.15 -H.75 7-33 -2.61 1.3 4.06 0.04 5-52 -15-57 4.33 2.8 -2.52 -4.2 -0.29
162
163 -0-3 -1-6 3-6 7-3 -0-3
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Table 5.17 Comparison of performance in the UKEQAS for General 
Clinical Chemistry and the WHS. *the 5 UK participants in 
the WHS; see section 5.6.3 for explanation
Percentage deviation
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
UK V WHS
+0.2
+0.4
-0.2
+0.9
+ 2.2
+0.1
-1.9
+2.0
+4.2
+1.2
+ 1.1
-0.2
-1.2
-2.8
+2.3
-1.7
UK v UKEQAS
+0.2
+0.4
+0.2
-0.7
+0.5
-0.7
-0.5
-1.4
+0.1
-0.6
+ 1.6
-0.5
+ 1.0
-1.6
+2.2
-0.3
UKEQAS v
0.0
0.0
-0.4
+ 1.7
+ 1.7
+0.8
-1.4
+3.4
+4.1
+ 1.8
-0.6
+0.4
-2.2
-1.2
+0.2
-1.4
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Table 5.18 Percentage deviation of national EQAS from WHS 
consensus. Derived from cumulative average percentage 
deviations in WHS (Table 5.14) and information from 
national EQASs (Table 5.16); see section 5.6.3 for 
explanation
Gantry
20
21
22
23
21
25
26
27
28 .
50
51
52
53
51
55
70
71
72
73
71
75
76
77
78
79
80
81
120
121
160
161
162
163
Na K Cl Urea (Tlir Ca Ftos Be Urate Great Rill ip Alb Cbol Ii Mg 
-0.01 -0.02 -0.39 1.66 1.71 0.75 -1.1 3.37 1.06 1.81 -0.56 0.36 -2.21 -1.23 0.15 -1-11
2.13 1.65 -2.85 -5-98 -0.01 -2.0 -2.6 -5.8 1.83 -5.75 -2.23 2.07 0.8 6.8 0.72 -3.2
0.17 1.15 0.21 -0.23 2.53 -1-59 -0.7 0.7 -1.95 -4.81 -5-28 0.56 5-69 -2-51 5-03
-0.1 -0.6 0.62 5-97 ' 2.13 2.32 1.82 -2.28 -3.83 -7.1 0.97 -2.7 -3-97 -1.35 -8-33
1.16 2.92 2.52 2.61 3-97 -1-33 6.92 -10.1 -13.0 -10.13 8.61 3-9 -0.77 l.H -10.28 11.83
0.12 0.32 -0.91 -3.07 1.68 -2.27 2.18 -0.86 -0.53 0.18 1.27 8.26
-2.1 1.22
-0.28 -2.6 -1.07 -1-32 2.78 0.15 -2.62
-4.93 -13-7 0.12
2.3 2.0 -3-7 3-23 -10.6 -0.27 -1.2
3.5 7.27 0.31 -1.56 13-35
-0.8 -1.01 1.17 1.57 1-82 -1.26
-6.5 0.78 -3-77 -0-91 -15-1
-3-8 -3-13 1-7 0.28 -5-23 -2.17
-1.03 1.17 -1.07 -2.35 -0.05 0.7 -1.1 -6.12 -0.68 1.03 -2-53 -0.78 -1.87 1.08 1.05 -1.83
-0.11 1.13 0-15 -1.33 1-61 -1.56 0.5
1.6 -1.1 5-0 -9-78 3-11 -0.85
-1.1 0.63
1.09 -1.85 9.15 -2-32 -10.25 -0.17 -1.61
-1.81 1.11 -3-27 15-72 -3-78 -2.3 3.35 1.19
-7-8 -7-93 -8.1
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participating in the WHS, demonstrated in the average 
deviations in Table 5.15. One effect which may have contributed 
to this would be a misunderstanding on the part of some NEQAS 
organisers; thus they may have provided data with incorrect sign 
(ie the bias of the scheme relative to the group of laboratories 
participating in the WHS), or data for their own laboratory 
alone.
An alternative contributory effect could have been that the 
laboratories selected were not in fact representive of their 
national scheme. This might reflect a failure in the initial 
choice (organisers may have selected the most technologically 
advanced and outward-looking laboratories, whose performance 
could reflect this) or, more importantly, an unwanted 'success' 
of the scheme if participants used it to approach more closely 
the international consensus at the expense of agreement in their 
NEQAS.
5.6.4 Appraisal of the scheme
The study showed that such a scheme design is practicable. NEQAS 
participants could be selected by their national organiser, and 
returned results reliably for the specimens distributed. Some 
organisers expressed doubts regarding the validity of the design, 
and several were only willing to cooperate for a limited period.
Is the use of the WHS consensus value as reference point valid? 
Firstly, this was intended only as a stable yardstick to which 
countries' performance could be related, rather than being 
claimed to be accurate and reflect the true value. Experience 
(see section 5.2 above) had indicated consensus values to be 
highly reproducible within schemes, borne out by differences 
averaging <1% for repeated distributions (101/109 and 102/108) of
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the same material, so the stability condition should have been 
satisfied. Secondly the WHS incorporated NEQASs with very 
different approaches to determining target values (see section 
3.4.3), including the use of consensus values and of reference 
laboratory values; many scheme organisers would have satisfied 
themselves that their approach yielded accurate and reproducible 
targets. Such heterogeneity would be unlikely to lead to a biased 
consensus value from the WHS. Apart from cholesterol, which 
showed method-related effects, the close agreement demonstrated 
in Table 5.19 suggests that it should also be close to the true 
value. These data may be compared with average scores in the 
UKEQAS given in Table 4.3, confirming the initial impression 
that CVs were only one third higher than in the UKEQAS.
Inter-country agreement appeared from the WHS data (Table 5.14) 
to be quite good, particularly for the most mature assays and the 
more developed countries. The effects of analytical method seemed 
to be confined to urate and cholesterol assay, and it would be 
advisable to take the method used into account for at least these 
analytes in any more detailed further study. The more definitive 
procedure of also making allowance for biases of the WHS 
laboratories relative to other participants in their NEQAS 
(Tables 5.16 and 5.17) confirmed UKEQAS consensus values to be 
close to the international consensus.
The effects shown in Tables 5.15 and 5.17 indicate, however, two 
failings in the scheme. One appears to reflect the reluctance of 
NEQAS organisers to divulge performance data, which might 
conceivably be overcome with more intensive contact. The other is 
more serious (unless it simply represents poor initial selection 
of laboratories) in that participants may have misunderstood, or
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Table 5.19 Average VISs in the WHS for Trials 101-112, with 
ratio to those in UKEQAS for General Clinical Chemistry
(Table 4.3)
Average VIS Ratio to UKEQAS
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
86
78
95
84
56
78
69
59
84
72
48
88
76
95
47
82
1.40
1.41
1.23
1.52
1.27
1.22
1.27
1.29
1.31
1.59
1.29
1.33
1.44
1.98
1.37
1.50
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ignored, the WIIS's objective and used it successfully as a 
conventional EQAS.
This latter effect could be beneficial to patient care, since 
results on patients served by these laboratories would be in 
better agreement with the international consensus and thus more 
accurate, and such a change in bias could stimulate a more 
general movement in the country towards greater accuracy. On the 
other hand there would be worse interlaboratory agreement within 
the NEQAS, which is less desirable. These short-term effects 
seem, however, to be the cost of progress, and the long-term 
outcome would outweigh this temporary perturbation.
The objective of the WHS was assessment of the situation rather 
than correction of any between-country discrepancies, so this 
should be classed as a partial failure rather than a success of 
the scheme. Nevertheless it appears to indicate the remarkable 
power of EQA in influencing laboratories' practice, even where 
this was not intended.
5.7 Summary
Consensus values are highly reproducible on repeated distribution 
of the same material through an EQAS. Consensus values obtained 
in different schemes show close agreement, whether the schemes 
are dependent or independent.
Comparisons using liquid human sera show close agreement of 
consensus values with definitive methods for several analytes in 
the UKEQAS for General Clinical Chemistry. Study of values 
assigned using reference methods to a single manufacturer's 
materials confirm that consensus values in the UKEQAS for General 
Clinical Chemistry have not been subject to any 'drift' away from
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accuracy.
Feasibility studies in the WHS show that a small group of 
laboratories which perform well in their own national EQAS can be 
used to reflect the accuracy base of their scheme in 
international comparison. In most cases good agreement was found, 
though as expected greater variability was found for developing 
than for the most developed countries. UKEQAS consensus values 
were confirmed to be in good agreement with the international 
consensus.
Attempts to adjust this comparison according to these 
laboratories' bias in their NEQAS led to apparent divergences in 
some cases, however, due perhaps to difficulties of 
interpretation. Alternatively results from these laboratories may 
be more accurate than is general within their country, due in 
part to an (unwanted) influence of participation in the WHS on 
their performance.
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ASSESSMENT OF INTERLABORATORY AGREEMENT
Chapter 6:
THE EFFECTS OF ANALYTE LEVEL ON INTERLABORATORY AGREEMENT
6.1 Introduction
For a comprehensive assessment of performance, EQASs must 
distribute specimens with analyte concentrations covering the 
range encountered clinically. The scheme design must therefore 
take into account any effect of analyte level on interlaboratory 
agreement, or misleading information may be generated.
If interlaboratory agreement varies substantially with analyte 
level it may not be valid to combine performance estimates 
obtained at different levels, or such combination should be 
confined to concentration bands. A curvilinear relationship 
between CV and analyte level is normally seen in the 'precision 
profile 1 from IQC data (eg Jeffcoate, 1981; Ekins, 1983) and 
would be expected in EQA data. This has, however, never been 
fully demonstrated for the organic and inorganic constituents of 
serum, though Roehle and Voigt (1986) have recently published 
preliminary data for three analytes.
Such information has policy implications for organisers of 
schemes such as the UKEQAS, eg in the selection of analyte levels 
for survey and scoring. The question is indeed of particular 
importance for the UKEQAS for General Clinical Chemistry and its 
sub-schemes, since VI scoring (see Appendix II and Chapter 4) 
assumes that the interlaboratory CV is effectively independent of 
concentration over the range surveyed.
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6.2 Studies in the UKEQAS for General Clinical Chemistry 
6.2.1 Study design
This study was undertaken as the first stage of an investigation 
of the effects of species of origin and of manufacturing 
technique on interlaboratory agreement, as discussed in Chapter 
14. Prior inspection of data from the scheme had shown little 
fluctuation from distribution to distribution in the spread of 
results provided that materials distributed were of satisfactory 
quality. This reproducibility, due perhaps to the relatively 
large number of participants (about 400 results for each 
distribution), is discussed in Chapter 5.
A two-year period, covering 40 distributions, should have yielded 
a sufficiently large database for assessment without excessive 
complications from improvement in participants' performance. The 
study period was chosen such that the method classification used 
was unchanged throughout the period, though the CCVs for lithium 
and magnesium were not established until part way through.
A similar two-year period of data (but with a slightly different 
method classification) was also available to validate the 
conclusions. This was essential because previous work (eg Wilding 
et al, 1979) had demonstrated the importance of testing findings 
on an independent set of data.
The study design included examination of several indicators of 
performance (Table 6.1) in two years' data from the scheme. To 
characterise any relationships, graphical presentation against 
the truncated mean (Appendix I.I; the most reliable estimate of 
analyte level) of all performance indicators was chosen.
Appendix III.2.1 gives full details of the study. As described
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Table 6.1 Indicators of performance used in study of
relationships between analyte level and interlaboratory 
agreement
Indicators of overall performance:
overall CV
recalculated CV
average Variance Index Score (VIS)
Indicators of discrepant performance:
number of results excluded in the truncation 
number of VISs greater than 200 
number of VISs greater than 300 
number of VISs of 400
percentage of results excluded in the truncation 
percentage of VISs greater than 200 
percentage of VISs greater than 300 
percentage of VISs of 400
Indicators of method performance:
recalculated CV 
average VIS
difference of recalculated method mean from recalculated 
mean
percentage difference of recalculated method mean from 
recalculated mean
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therein, many of the indicators appeared unhelpful, as overall 
CVs on untrimmed data are more likely to be influenced by gross 
errors ('blunders') on the part of individual participants than 
by any underlying relationship with analyte level. Examination of 
the recalculated CV and the average VIS therefore constituted the 
main part of the study. Data classified according to method were 
examined for a more limited range of analytes, to confirm that 
the conclusions drawn also held for individual method groups.
6.2.2 Overall data
In all cases some variability in interlaboratory agreement, as 
reflected by recalculated CV or average VIS, was found. For some 
analytes, eg chloride and iron, no consistent relationship of the 
recalculated CV or average VIS with analyte level was 
discernible (Figure 6.1). For others such as urea and bilirubin, 
however, definite level-dependence lay beneath an apparently 
random variation in the indicators.
In these cases interlaboratory agreement deteriorated rapidly as 
levels approached and decreased through the reference interval 
(Figures 4.1 and 6.2). The patterns for glucose, creatinine and 
cholesterol were similar. Apart from cholesterol at levels below 
2.5 mmol/L, average VISs did not usually exceed 100, with the 
best average VISs attained being around 40. During this period 
the average VIS for all analytes was about 65.
Graphs from the validation period yielded conclusions virtually 
identical to those drawn from the initial evaluation of the 
first database studied, illustrated in Figure 6.3 for glucose. 
In some cases there were slight differences in the magnitude and 
variability of the relationship, due probably to a somewhat 
different selection of materials being distributed in the two
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Figure 6.1 Relationship with the recalculated mean of
recalculated CV for chloride and of average CV for iron in 
study period
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Figure 6.2 Relationship with recalculated CV and average VIS for 
bilirubin in study period
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Figure 6.3 Relationship with average VIS for glucose in study and 
validation periods
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periods. For lithium and magnesium, however, relationships 
emerged which had not been discernible initially, as these 
analytes were introduced into the scheme during the study 
period.
Examination of the indicators of discrepant performance (Table 
6.1) yielded relationships between the percentage of VISs >200 
and analyte level similar to those for recalculated CV and 
average VIS, though with lesser clarity. The variability 
increased and the clarity of the relationship decreased further 
as the percentages of VISs >300 and of VISs of 400 were examined, 
exemplified for creatinine in Figure 6.4. No relationship between 
the percentage of results excluded in the truncation and analyte 
level was apparent for any analyte.
Since the level-dependences observed are reflected in average 
VISs, and supported by the VIS indicators of discrepant 
performance, they cannot be due to the effects of intermethod 
differences or of little-used methods (no VISs are calculated if 
<15 results contribute to a method mean). Furthermore they were 
almost all confirmed by the data from the validation period and 
may therefore be considered real phenomena rather than artefacts.
The extent of the level-dependence seen for, eg, urea, 
creatinine, bilirubin and cholesterol also leads to difficulties 
in interpreting VISs (or indeed any system of assessment based on 
percentage deviations from the designated value) if the range of 
levels in the specimens distributed is not controlled. 
Interlaboratory agreement (ie laboratory performance) for some 
analytes is demonstrably worse at normal levels. This confirms 
the subjective impression that average performance appears to
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Figure 6.4 Relationship with percentages of VISs >200, >300 and 
400 and of numbers of results excluded for creatinine
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deteriorate if several materials with low or normal levels are 
distributed within a short time, and the UKEQAS policy of 
distributing a balance of materials at differing analyte levels 
(see Chapter 3) is thus supported.
The dependence seen was the 'classical' U-shaped precision 
profile relationship described from IQC data for analytes such as 
potassium and urea (Figure 4.1). The range of concentrations 
studied did not, however, extend for all analytes above the level 
of optimal agreement (eg Figures 6.2 and 6.3). These 
observations were of importance for UKEQAS operation, and 
prompted recommendations to the Steering Committee on External 
Quality Assssment for General Clinical Chemistry (SCEQCC) that 
some of the limits on the mean (outside which VISs are not 
calculated) were no longer appropriate. The lower limits for 
bilirubin and cholesterol were accordingly raised to 17 from 9 
umol/L and to 2.5 from 1.3 mmol/L respectively; the upper limit 
for glucose was also raised, to 30 from 22.2 mmol/L.
Exceptions to the general relationships were found for several 
materials. In some cases behaviour was exceptional for all 
analytes, in others for one or two analytes only. Almost all of 
these had been detected at the time of distribution, so that no 
VISs were calculated, and the availability of this well-studied 
database increases the reliability of assessment for future 
distributions.
6.2.3 Method-related data
As expected, the method-related data confirmed the existence of 
differences in specificity for some analytes, eg between chemical 
and enzymic procedures for glucose, urate and cholesterol, and 
differences in performance for others. Differences in the pattern
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of relationship with analyte level were also revealed. These 
appeared to be associated primarily with the degree of 
interlaboratory agreement, less clear-cut relationships being 
observed for those methods with higher CVs.
For example, examination of the recalculated CVs for creatinine 
(Figure 6.5) reveals that, though similar patterns exist for the 
AAII/SMA and Other (ie kinetic Jaffe) groups the variability 
within the kinetic group is almost twice that within the 
continuous flow group. Differing patterns for different methods 
were observed for some analytes. For instance with the two 
ostensibly similar glucose analyser groups (Figure 6.6) there was 
a smaller though less consistent bias for Beckman instruments.
The effects of automation in yielding improved interlaboratory 
agreement and average VISs were also shown. For example the 
AAII/SMA group for urea performed better than the Manual urease 
group, which also gave a correspondingly less clear relationship 
with analyte level (Figure 6.7).
6.3 Studies in other schemes
Similar studies may be undertaken for the analytes in other 
schemes. Many of these assays are less mature, with 
correspondingly greater interlaboratory variance.
6.3.1 UKEQAS for Salicylate and Paracetamol
Examination of performance for these analytes revealed definite 
relationships, similar to those described above for cholesterol 
and bilirubin. Figure 6.8 shows the relationship for salicylate, 
and Figure 8.3 the much more marked relationship for 
paracetamol; the latter is discussed in detail in section 8.4.1.
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Figure 6.5 Relationship with recalculated CV for creatinine by 
AAII/SMA and by Other
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Figure 6.6 Relationship with percentage difference from
recalculated mean for glucose by Beckman Glucose Analyzer 
and by YSI Glucose Analyzer
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Figure 6.7 Relationship with average VIS for urea by Manual 
urease and by AAII/SMA
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Figure 6.8 Relationship between interlaboratory agreement (CV;
average VIS) and mean salicylate concentration in UKEQAS for 
Salicylate & Paracetamol, 1985-1986
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These data underline the need for EQAS specimens to cover a range 
of concentrations so that trends in performance can be truly 
reflected. Fortunately, the degree of dependence for paracetamol 
is decreasing, as a greater proportion of participants adopt the 
enzymic procedures with their lesser concentration-dependence 
(Figures 8.2 and 8.3).
6.3.2 UKEQAS for Lead in Blood
Figure 6.9 demonstrates the relationship between interlaboratory 
agreement and lead concentration lying beneath the scatter in 
the early years (1973-1974) of this scheme's operation. With 
improvements in participants' performance during the following 
years, the level-dependence became less apparent: thus by 1978 
much of the effect had gone and the data for 1983 show no real 
indication of any dependence (Bullock et al, 1986c).
Does this pattern, here demonstrated in two schemes, reflect a 
true loss of concentration-dependence with improved agreement? 
This may be so, but it would appear more likely that improvements 
in participants' procedures are widening the 'trough 1 region of 
the relationship, ie that the region of optimal method 
performance has been increased.
6.3.3 UKEQAS Enzyme Surveys
For other assays, however, neither a striking relationship nor 
independence of concentration is seen. Figure 6.10 illustrates 
this for two enzyme activity assays, AST and CK. The points are 
widely scattered and no relationship is clearly discernible, 
though there is a suggestion of worse agreement at low CK 
activities.
Why is this? One possible explanation is that the interlaboratory
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Figure 6.9 Relationship between interlaboratory agreement (CV) 
and mean in UKEQAS for Lead in Blood in 1973-1974 (•), 
1978 (o) and 1983 (•)
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Figure 6.10 Relationship between interlaboratory agreement and 
mean activity for AST and CK in UKEQAS Enzyme Surveys and 
UKEQAS for General Clinical Chemistry, 1985-1986. Average 
VIS for all participants for AST; CV for SCE optimised NAC- 
activated procedures at 37°C for CK
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variance is too great, even within 'reliable' method groups 
(Bullock et al, 1986b) for an underlying relationship to be 
resolved at present, though future improvements in agreement may 
reveal one. Alternatively, there may simply be insufficient data 
to delineate such a relationship. A further possibility is that 
there are greater differences in the behaviour of the various 
materials distributed (as discussed in Chapter 13), and these 
differences are masking any relationship which exists.
It might be possible to investigate some of these aspects through 
examination of data from the 'calibration' studies (Chapter 13), 
which yield greater agreement, and from distributions using 
similar materials. Such examination, however, does not appear to 
clarify the situation: there are even fewer data points, and in 
the latter case investigation is hampered by the tendency of the 
groups of materials to have similar enzyme activities.
6.4 Summary
For many analytes EQAS data show a relationship between 
analytical performance and analyte concentration. In these cases 
interlaboratory agreement is best at intermediate concentrations, 
though in some the range of concentrations surveyed does not 
extend high enough to demonstrate deteriorating agreement.
The effects of such relationships on performance assessment must 
be minimised, eg by confining scoring to a band of concentrations 
(see Chapter 4).
The interrelationships between concentration-dependence and 
interlaboratory agreement are complex. Relationships are more 
readily discernible for methods with better performance, so 
improvement over time may lead to improved delineation of such
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relationships. In other cases, however, the degree of dependence 
may be reduced as assays become more mature and performance 
improves.
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ASSESSMENT OF INTERLABORATORY AGREEMENT
Chapter 7:
EXTERNAL QUALITY ASSESSMENT OF NON-QUANTITATIVE TESTS: 
AMINOACID INVESTIGATIONS
7.1 Introduction
Though the initial EQA surveys were conducted in the field of 
syphilis serology testing (Gumming et al, 1935), EQA has 
developed most readily and widely for the quantitative assays in 
clinical chemistry and haematology, as reviewed by WHO (1981), 
Whitehead and Woodford (1981) and ECCLS (Leblanc et al, 1985a; 
Lewis et al, 1986). Some progress has been made in microbiology 
(Leblanc et al, 1985b and 1985c) and immunology, but little 
beyond very localised systems, often almost exclusively for 
continuing education rather than quality asessment, in 
histopathology (Whitehead and Woodford, 1981).
Truly quantitative assays obviously present fewer problems for 
the design and operation of an EQAS. Thus, as discussed in 
Chapter 3, appropriate identical specimens can be produced in 
sufficient numbers for national survey, and the results can 
readily be evaluated by simple statistical techniques against a 
target derived by consensus or reference laboratory analyses. 
Scoring systems can also be devised, as demonstrated in Chapters 
4 and 9, to facilitate further assessment of the state of the art 
and of individual laboratory performance.
Quality assurance is required for semi-quantitative and 
qualitative as well as for quantitative investigations. For IQC 
this often takes the form of use of positive and/or negative 
controls in laboratory assays, though such QA procedures are
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rarely applied to urinary dipstick tests and even blood glucose 
test strips read visually or using reflectance meters (see 
section 2.2). Such procedures, however, are essentially 
'pass/fail' systems and do not readily lend themselves to any 
form of performance monitoring over time.
What then are the problems associated with EQA of such assays? 
There appear to be four main groups:
- provision of appropriate specimens
- realistic survey design
- criteria for performance evaluation
- design of a scoring system
7.1.1 Specimen provision
As in any EQA activity, the specimens distributed should have 
properties resembling closely those of clinical specimens. This 
may be more difficult for qualitative investigations involving 
the identification of a pattern than the relatively simple 
quantitation of an organic or inorganic component in serum. For 
example, inherited metabolic diseases cause secondary changes in 
metabolism which may be reflected in the composition of blood and 
urine. Thus though cystinuria is characterised by a high urinary 
excretion of cystine, addition of cystine to normal urine will 
not yield a specimen which mimics urine from a cystinuric patient 
since the other aminoacids sharing a tubular reabsorption 
mechanism with cystine (ornithine, arginine and lysine) will not 
also be present in increased amounts. In such instances, 
therefore, material from authentic clinical cases is highly 
desirable wherever this is at all feasible.
Similar considerations apply to 'specialised 1 specimen 
presentations. For example, in screening for PKU and neonatal
160
hypothyroidism it would be inappropriate to provide laboratories 
with serum since routine specimens are received as dried blood 
spots on filter paper or liquid whole blood in capillaries.
7.1.2 Survey design
A particular difficulty with many of these investigations is 
treating EQA specimens in exactly the same way as clinical 
specimens. This is relatively easy for quantitative assays, 
which are done routinely, often on an automated system, and 
reported similarly. Non-quantitative tests are generally done 
manually, and may require considerable human input in terms of 
interpretation. An EQA specimen will also lack the personal 
involvement and clinical urgency associated with the 
investigation of real cases, though the potential also exists for 
excessive care to be taken.
The circumstances of laboratories may also differ. Thus for 
example in urinary aminoacid investigation some participants may 
only be trying to determine whether the specimen is abnormal and 
should be referred to a specialist laboratory for further 
investigation, whereas the latter must endeavour to make a 
definitive diagnosis of the underlying disorder. The scheme 
design must accommodate this diversity, and in particular must 
not penalise laboratories for failing to make an identification 
which they would not be expected to make in their clinical role.
7.1.3 Performance criteria
Several attempts have been made to assess the quality of urinary 
dipstick tests, within and among hospitals (eg Simpson and 
Thompson, 1978; Shephard et al, 1982), which have revealed wide 
divergence in the results reported. The latter group adopted a
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tentative criterion for satisfactory performance in semi- 
quantitative tests of negative where the analyte was absent and 
of the correct value plus or minus one positive colour block at 
finite concentrations (Shephard et al, 1982; Eraser, 1983). For 
qualitative assays specimens should be identified correctly as 
positive or negative, but here there may be difficulties in 
determining the cut-off concentration and in assessing the 
significance of false positive and false negative results at 
levels close to this cut-off.
7.1.4 Scoring systems
This problem has so far only been thoroughly examined in 
microbiology, since EQA of this type of assay in clinical 
chemistry has been confined to occasional surveys. Here a system 
based on the "degree of correctness" of the participant's 
response has been used; this was evolved initially for bacterial 
isolation and identification surveys, but has since been 
modified for other microbiological applications (Leblanc et al, 
1985c). In essence the system reduces to the following 
classification of responses:
Fully correct +2
Partly correct +1
Wrong, or no return 0
Badly wrong -1
This system has been criticised in that it combines non-return 
with identification performance (though some laboratories fail 
to return only for 'difficult' specimens, justifying such 
combination in this scheme) and that gross errors can be 
compensated for by correct identification of other specimens. The 
latter may also be true of other scoring systems, and suggests
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that particular note should be taken of any scores of -1 in 
addition to an appraisal of average scores. Nevertheless, the 
system has provided a means of identifying participants with the 
best and worst performance, and can highlight the incidence of 
gross errors.
7.1.5 EQA of non-quantitative screening assays
What then is the most appropriate form of survey design for this 
type of assay? Investigations of aminoacid disorders provide an 
appropriate model within clinical chemistry. Here false negative 
results are detrimental to the individual subject concerned and 
must be avoided if the screening procedure is to be effective. 
False positives are also far from desirable since they have a 
cost in terms of increased work and anxiety even if further 
investigation confirms the subject as negative. Both factors must 
be borne in mind in devising an appropriate scheme.
The development of the UKEQAS for PKU Screening provides an 
example of many of the issues mentioned above, complemented by 
points arising from the initial UKEQAS surveys of urinary 
aminoacid investigations.
7.2 Development of the UKEQAS for Phenylketonuria (PKU) 
Screening
Following the demonstration through survey (section 2.4.5) of 
analytical problems in these screening assays, a scheme was 
established in the UK in 1980. Its design and subsequent 
development were determined through consideration of the above- 
mentioned elements.
7.2.1 Specimen provision
Blood from patients with PKU would be ideal, but the disease is
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rare and patients should be on dietary treatment until 
adulthood to reduce their blood phenylalanine (PheA) 
concentration. Use of such clinical specimens is therefore 
infeasible, and spiked blood must be used. The screening tests 
rely on assessment of PheA itself rather than the pattern of 
aminoacids in blood, so spiking with PheA alone would be 
satisfactory. Normal adult blood levels of around 60 umol/L give 
a useful baseline, providing 'negative' specimens which can be 
spiked with PheA to yield any concentration up to the 1500-2000 
umol/L seen at presentation of 'classical' PKU.
The need to spike the blood and allow equilibration necessitates 
use of an anticoagulant, whereas specimens for screening are 
collected directly onto cards or into capillaries. The blood 
will be somewhat more dilute, especially if citrate/phosphate/ 
dextrose/adenine (CPDA) rather than heparin is used. 
Unfortunately, however, only CPDA-anticoagulated blood could be 
obtained from the Blood Transfusion Service, and this material 
was therefore used; there was no indication that this would be 
unsuitable for any of the methods used. The blood used would, by 
special arrangement, be available the day following collection 
(after testing for HBgAg and, more recently, antibody to HIV) to 
avoid any problems in fluorimetric procedures due to a rise in 
blank absorbance with aging of the blood.
Various cards were in use in different Regions, including 
differing filter papers. Since spreading properties are paper- 
dependent, it was important to provide specimens on the same 
type of card normally received by each laboratory. Those 
participants not using HMR 101/6 cards (obtained centrally from 
DHSS) were therefore asked to provide a supply of their own
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cards. Laboratories receiving liquid blood specimens were 
similarly asked to provide tubes or capillaries.
The EQAS specimens thus resembled the specimens received for 
screening in all but the inclusion of CPDA anticoagulant. This 
might affect spreading properties, but many laboratories used 
materials based on outdated blood bank blood for calibration and 
IQC.
7.2.2 Scheme design
Each survey would comprise several specimens, covering a range 
of PheA concentrations. This should provide a more complete 
assessment performance at each survey rather than relying on 
cumulation of data over time; multiple specimen distributions 
also include a more realistic contribution from transposition and 
other specimen identification errors, which are of major 
importance in screening procedures. The specimen preparation 
procedure was relatively complex, and blood collection required 
special arrangements, so more comprehensive but less frequent 
surveys gave the most effective use of these resources. In later 
stages of the scheme two-monthly distributions were maintained, 
but distributions were less frequent in the earlier phases.
Since laboratories must process specimens rapidly to enable 
diagnosis and treatment of affected cases as early as possible, 
a fairly short period, usually around two weeks, was allowed for 
results return. Laboratories failing to return two consecutive 
surveys were approached to ascertain the reasons, and in one such 
case a postal processing delay which also affected clinical 
specimens was identified and rectified. As usual, reports were 
prepared for distribution as soon as feasible after the closing 
date.
165
The screening methods used were varied, including microbiological 
inhibition (Guthrie test), fluorimetric and chromatographic 
procedures. The latter were mostly qualitative procedures only, 
the others being at best semi-quantitative. Since numerical 
results were not reported routinely, and the primary outcome of 
screening relates to the action taken, the emphasis in the scheme 
was on clinical action. Thus participants were asked to 
categorise each specimen according to a range of potential 
actions (Table 7.1) derived from an initial questionnaire to 
these laboratories. PheA concentrations, as a single figure or 
range, were also requested where the participant's method would 
provide these, to assist in differentiation between analytical 
and interpretation errors if an incorrect action was recommended.
7.2.3 Performance assessment and scoring systems
With this type of investigation consensus values are not 
reliable, and an externally-derived target must be used. Weighed- 
in values could not be used since the endogenous PheA content of 
the blood was unknown, though estimates were available as an 
independent check. The true PheA concentrations were therefore 
estimated by aminoacid analyser in two laboratories which did not 
provide a PKU screening service. The mean PheA was included in 
the report, provided the two results agreed with each other and 
the intended content.
In the initial surveys this information was provided to 
participants in tabular form (Figure 7.1), allowing comparison 
of their own return with the 'reference laboratory' PheA and 
other participants' returns. Categorisation of returns in terms 
of false positives and missed cases was possible after two
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Table 7.1 Coded alternative laboratory actions which would
normally be taken following the first analysis of a specimen 
by the routine screening procedure, used in the UKEQAS for 
PKU Screening. A combination of two or more codes may be 
returned
Code Action
A No action beyond issuing a negative report
B Repeat analysis by the same screening procedure using
the same card 
C Confirm analysis by an alternative method using the
same card, in own or other laboratory 
D Request further specimen 2-3 weeks later 
E Request repeat specimen for analysis by the same
screening procedure 
F Request repeat specimen for confirmation by an
alternative method 
G Summon infant to hospital urgently, or ensure that
medical staff institute similar immediate investigation
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Figure 7.1 Example of report format in UKEQAS for PKU Screening: 
Summary of coded actions and PheA concentrations returned by 
participants. Action codes as in Table 7.1
EXTERNAL QUALITY ASSESSMENT OF PKU SCREENING 
SORVEI 20 - APRIL 1986
Lab
i-t-
Ref erenc s 19 1*
15
29
32 250
11
51 220
60 178
61
72
92 220
91 60-120 
98
201 300 
279 120-210
289
315 250 
«37
U92 <210
599 <210
906 210
922 180
926 <120
3*
191
220
230
210
220
60-120
280 
120-210
250
<210
210-700
220
195
<120
Phenylalanine (umol/1) Actlon(s) (Code)
Specimen 
6 2 1 5 1+ 3* 6 2 1 5
229 253 "96 669
A CA CA CA CF FG
A BD 3D BD BG BG
200 250 «50 810 3 B A 3 3CD GC
A A A AB GG CG
235 320 190 660 BC BC BC BCD BCEF BCG
211 211 127 531 A A BA BA BE BE
A A A CD CD F
A A BG A BG BG
235 250 515 760 A A 3D BD BE BFG
60-120 120 150 720 A A A A BE CG 
GCEF GCEF GCEF GCEF GC GC
31 1 316 187 673 BCE BCE 3CF. BCE BCE 3CE 
120-210 210-360 180-600 720-1200 A A A SE CFG CFG
A A A A BE BE
360 350 500 710 BE BE 3£ BE BEG BEG 
SE A A BE EFG EFG
<210 210-360 210-360 360-180 A A A BE BE BE
<210 210-700 700 >700 A F A ? F FG
270 310 530 710 D D D D c. G
210 280 500 600 A A A CF CF CF
<120 <120 210-360 360-180 A A A A BF FG
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surveys, and the apparent incidence (7% and 8% respectively, 
with 14% of participants failing to summon the infant urgently 
for specimens with a PheA level >1000 umol/L) gave cause for 
concern.
A more discriminating means of performance assessment therefore 
appeared necessary, since introduction of such scoring systems 
had led to improvement in quantitative assays (Chapters 4 and 
9). A system based on that for the microbiology UKEQAS (see 
section 7.1.4 above) was then devised. This was based on the 
identification of certain actions as inappropriate for the PheA 
concentration (stratified into bands), with weighting according 
to the severity of the error, as shown in Table 7.2. 
Participants received scores for each specimen distributed, with 
cumulation over four distributions.
This system was introduced at Survey 4, and a number of 
complaints were received. These related mostly to the 
weightings, which for example would give a score for classifying 
as worthy of further investigation two specimens with PheA 
levels approaching the upper limit of the reference interval (eg 
at around 200 umol/L) equal to that for missing a case with a 
level about 1500 umol/L. Participants using a cut-off of 200 or 
260 rather than 240 umol/L were also penalised unduly, and 
participants requested that the system be reconsidered.
A meeting with a representative selection of screening laboratory 
directors was therefore arranged to discuss the scheme. The 
differences in practice among screening centres, for reasons of 
geography and differences in the local paediatric services, were 
emphasised, but agreement was reached on the major objectives of 
screening:
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Table 7.2 First scoring system in UKEQAS for PKU Screening, used 
in Survey 4, November 1981. Action codes as in Table 7.1; 
score = -3 for non-return of results in a survey (6 
specimens). Criterion for unacceptable performance: a total 
score of -3 or worse in two or more of 4 consecutive surveys
Pheny1alanine
(umol/L)
Appropriate Inappropriate Highly
inappropri ate
<240
240 - 360 
361 - 480 
481 - 800 
>800
A (B, C) 
B - F 
E, F 
E, F (G) 
G with F
D - F
A, G
B - D, G
D A - C
A - F 
without G
Score for each 
specimen 0 -1 -2
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- identification of PKU cases with grossly elevated PheA 
levels, for urgent confirmation and treatment
- detection of PheA elevations as possible PKU cases, for 
further investigation
- identification of babies with normal PheA levels as 
normal, with no requirement for further action
A simplified scoring system was then devised, based upon these 
three categories. Participants would be asked to classify each 
specimen as one of:
- 'normal' (N), requiring no follow-up
- 'intermediate' (I), requiring follow-up
- 'high' (H), requiring urgent follow-up
The boundaries between these categories would be at 240 and 700 
umol/L, as determined by the DV from the reference laboratories. 
Participants classifying the specimen correctly would score zero, 
whereas any misclassification would score the difference between 
the DV and the furthest boundary crossed. For example, 
classification of a specimen with a DV of 220 umol/L as N would 
score zero, as I would score 20, and as H would score 480.
This system should yield scores related more closely to the 
severity of the error, so the examples cited above of two false 
positives and one missed case would give scores of 2 x 40 = 80 
and 1260 respectively. Because of imprecision around 240 umol/L 
some 'noise' would be expected and participants were unlikely to 
obtain zero scores, but laboratories making major errors should 
be readily identifiable. Example sections of participants' 
reports tabulating the scores for the survey and the cumulated 
scores over 4 surveys are shown in Figure 7.2. This system 
appeared to be accepted much better by participants, and there
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Figure 7.2 Example of report format in UKEQAS for PKU Screening. 
A: Summary of classifications by participants, with 
corresponding scores
B: Summary of total scores in and average scores for most 
recent surveys
EXTERNAL QUALITY ASSESSMENT OF PKU SCREENING 
SURVEY 20 - APRIL 1986
Lab
Reference
(PheA, umol/1)
15
29
32
44
51
60
61
72
92
94
98
1*
N
194
N
N
I
N
N
N
N
N
N
N
I
Classification
Specimen 
3 + 6 2 4 5
N N I I I
194 229 253 496 669
N N I I H
I I I H H
I N I I H
N N N I I
N N I I I
N N N I I
N N N N I
N I N I I
N I I I H
N N N I H
I I I H H
Score
Specimen 
I* 3* 6 2 4
+46 +11 +204
+46 +46
-13
-13
-13 -256
+11 -13
+ 11
-13
+46 +46 +11 +204
5
+31
+31
+31
+31
+ 31
+31
UK EQAS FOR PKU SCREENING - PERFORMANCE SCORES
Lab
15
29
32
44
51
60
61
72
92
94
98
Total
17
549
90
246
90
0
0
79
0
0
0
0
score
18
0
0
0
0
86
86
0
0
—
0
86
for Survey
19
114
114
114
114
0
0
17
114
0
70
114
20
31
292
123
13
0
13
269
24
42
44
338
Average score
174
124
121
54
22
25
91
35
14
29
135
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were no further complaints. Figure 7.2 also shows the effect on 
laboratory 29 f s scores of over-reaction, particularly for Survey 
20.
Examination of average scores for all participants proved less 
useful than in other schemes (section 4.5), however, due to 
volatility. This is attributable to their greater dependence 
upon the PheA concentrations surveyed (ie proximity to the 
classification boundaries) and the relatively small number 
(around 30) of participants. The system was nevertheless useful 
in practice and in assessing the effects on performance of 
factors such as method and workload, as described in sections 8.4 
and 11.2.2, provided scores were averaged over a sufficiently 
long period.
7.3 Establishment of UKEQAS Surveys of Urinary Aminoacid 
Investigations
Following demonstration in Regional schemes of poor quality in 
this investigation (Green A, Holton JB, Worthy E, 1985, personal 
communications), the UKEQAS Steering Committee was persuaded that 
a national assessment of performance was necessary. A programme 
of two exploratory surveys was therefore agreed for 1986, and the 
need to to continue survey was accepted following review of the 
results.
7.3.1 Specimen provision
The investigation comprises the production and interpretation of 
an aminoacid pattern, produced by separation in one or two 
dimensions by chromatographic and/or electrophoretic means; one- 
and two-dimensional thin layer chromatography (TLC) are used most 
commonly. Since most metabolic disorders, whether inherited or
173
acquired, lead to widespread alterations in the pattern rather 
than to discrete changes in the concentration of one or two 
aminoacids or metabolites it appeared essential to use specimens 
from authentic clinical cases. This should provide additional 
interest and motivation for participants, and permit refutation 
of any suggestions that the specimens were unsatisfactory for a 
laboratory's particular procedures.
Such materials are difficult to obtain, however, requiring 
considerable effort and cooperation from the scientific advisors 
for these surveys. Urine could most readily be obtained from 
cases with disorders which are relatively benign; with disorders 
which are treated urine would only be useful when obtained at 
time when control was poor, and such cases are often associated 
with lack of understanding and cooperation by the patient's 
family.
Specimens would almost certainly not be obtainable from disorders 
which present acutely and in very young children. To cover the 
full range of disorders likely to be encountered clinically, and 
in particular those which must be identified as a matter of great 
urgency, later surveys would have to use 'synthetic 1 specimens. 
Because some of the characteristic patterns are complex such 
specimens would first need to be tested through one of the 
Regional schemes.
Following assessment by questionnaire of laboratories' 
requirements, a 5 mL specimen volume was chosen. Though some 
participants claimed to need more, it was felt that this volume 
was more characteristic of that provided in many clinical cases; 
the total volume available was also limited, and slightly less 
was distributed on some occasions. No preservative was included
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in the first survey, but following reports from several 
participants of bacterial contamination merthiolate (100 mg/L) 
was added to all subsequent specimens.
7.3.2 Scheme design
Two specimens would be included in each survey, to give the 
maximum information yield that could be supported by the supply 
of urine from authentic cases. Errors in specimen identification 
might thus also be detected.
It is unrealistic to expect participants to carry out 
investigations such as these in the absence of clinical 
information, but decisions as to what is appropriate are 
difficult: many clinical details would be non-informative or 
suggest strongly the diagnosis. Where possible the details 
accompanying the initial specimen from the individual case 
concerned would be used, though directly leading comments (such 
as "brittle curly hair" from a case of argininosuccinic 
aciduria) would be omitted.
Though the clinical details might not indicate a need for urgent 
investigation (requiring results to be available on the same 
day), reports should be generated on all clinical specimens 
within 5 working days. A deadline for return of results of 16 
days from specimen despatch was therefore determined. Despite 
this, around 20% of participants failed to return results, and 
many had a turnround longer than 5 days (Table 7.3).
The format in which results were requested also presented 
difficulties. Some Regional schemes allowed free text returns, 
which were then evaluated in detail by the organiser, but this 
was not viable with 150 rather than 30 participants. Some
175
Table 7.3 Turnround times for UKEQAS Surveys 2 and 3 of Urinary 
Aminoacid Investigation, October 1986 and February 1987.
Interval between specimen receipt and results despatch 
(working days); 19 (18 for Survey 3) laboratories provided 
insufficient information
Turnround Survey 
(working days) 2
3 2
2 13 6
3 6 10
4 10 5
5 11 7
667
7 12 9
8 19 16
9 4 10
10 8 12
11 6 10
12 3 5 
3-1
14 1 1
15 1 1
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structuring of response was therefore essential, and participants 
were asked to classify each specimen as normal, as showing 
generalised aminoaciduria or as showing a specific increase in 
one or more aminoacids (or groups of aminoacids where the 
technique could not resolve these). There was also provision 
for results of auxiliary tests, such as pH, creatinine content 
and 'spot test' results, as shown in Figure 7.3. These could 
provide useful data on the variance of these investigations and 
their influence on the overall response given, eg participants 
who were apparently misled into identifying argininosuccinic acid 
as cystine following a false positive cyanide/nitroprusside 
test.
The report format was dictated by this design. A table of 
participants' responses (Figure 7.4) was supplemented by 
summaries of the spot test results (Figure 7.5) and comments from 
the scientific advisors. In addition to the overall standard of 
responses with regard to the aminoacid patterns, these comments 
addressed problems associated with the apparently poor turnround, 
the advisability of loading chromatograms relative to creatinine 
content and the susceptibility of spot tests to error.
7.3.3 Performance assessment
Each participant thus received information on the correct answer 
(in terms of the patient's diagnosis) and the variability of 
responses. How then should they assess their performance? Here 
the variations in laboratory circumstances must be considered. 
Some merely act as a 'filter' in deciding which specimens are 
abnormal and need referring to a specialised laboratory for 
further investigation, whereas the latter must make a definitive 
diagnosis.
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Figure 7.3 Format of results document in UKEQAS Surveys of 
Urinary Aminoacid Investigation
UK EQAS SURVEYS OP URINARY AMINQACID INVESTIGATION
SURVEY 2, October 1986 
1. Origin of specimen
Laboratory 
SPECIMEN 2A (^ label
Age: 3 years Sex: Male Source: Ward 
Clinical details: Developmental delay 
2. Dates
Specimen receipt: 
: :86
3- Qualitative response
Chromatographic analysis: 
: :86
Results despatch 
: :86
Please indicate below whether you found the specimen normal, or 
whether there was a generalised aminoaciduria or whether specific 
aminoacids were present in increased concentration:
Normal? Generalised? Specific increases?*
* please use conventional 3-letter abbreviations (eg Met for 
methionione); indicate clusters of aminoacids which migrate 
together in your procedure as follows, eg Lys/Orn/Arg
4. Spot test results
Please indicate below the results of any spot tests you carried 
out on this specimen.
PH JCreatinlne \t |mmol/L
Negative Trace Positive Strong positive
Albustix/Protein
Ferric chloride/Phenistix
Reducing substances
Acetest/Ketostix
2,4 DNP
Cyanide/nitroprusside
5- Comments
Please complete and return as soon as possible, and by Friday 31 
October 1986 to:
UK EQAS for General Clinical Chemistry, Clinical Chemistry 
Department, Queen Elizabeth Hospital, BIRMINGHAM B15 2TH
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Figure 7.4 Format of report in UKEQAS Surveys of Urinary
Aminoacid Investigation: Specimen description and summary of 
responses by participants
UK EQAS SURVEYS OF URINARY AMINOACID INVESTIGATION
SURVEY 2, OCTOBER 1986 SPECIMEN 2A (red label)
1. Origin of specimen
Age: 3 years Sex« Male Sourcet Ward
Clinical details: Developmental delay
The specimen was obtained from a patient with citrullinaemla. The 
chromatographlc pattern showed an Increased amount of cltrulline 
which was confirmed by quantitative analysis. The specimen had a 
pH of 6.0 and a creatinine of 11.4 mmol/L; it was negative by 
ferric chloride, Clinitest, Acetest and 2 ; 4 DNP, and showed a 
trace by cyanide/nitroprusside.
2. Reports from individual participants
Lab Method Normal Generalised Specific increase(s)
Cys
Cit
?Cit ?Lys/Arg
Arg/Cit/Gln
1
2
5
7
10
11
13
15
17
20
25
26
31
33
38
39
47
48
49
51
52
54
1A
3A
1B/5C
1A
IB
2A
7C
1B/2B
1B/2B
1A/5A
2A
1A
5C
IB
2A/5A
1A
1A/2A
3A
7A
1B/2B
1A
1A
57
58
59
61
62
64
66
67
68
72
IB
1A
1A/1B 
6B/8B 
2A/2B 
1B/2B
5C
1A/2A 
3A/8B 
1A/7A
Y 
Y
Y 
Y
Y 
Y
Y 
Y
Gin His/Cys
Gin 
Git 
Cit 
Horn
Cit 
Cit
Cys His/Lys/Orn/Arg 
?Cit/?HomoCys
Cit/Arg
Glu/Gln
Cit
Ser/Cit Ala
Cit
His/Cys/Arg
Asp/Gly/Glu
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Figure 7.5 Format of report in UKEQAS Surveys of Urinary
Aminoacid Investigation: Summary of spot test results
Specimen 2A
3 . Summary of pH, creatinlne and spot test results
i.
<5-75 3 X
6.0 69 XXXXXXXXXXXXXXXXXXXXXXX
• 6,5 27 XXXXXXXXX
7.0 8 XXX
ii. Creatlnine (mmol/L)
< 9=5 2 X
10.0 7 XX
11.0 41 XXXXXXXXXXXXXX
12.0 40 XXXXXXXXXXXXX
13.0 7 XX
>13.5 4 X
Hi. Spot tests Negative Trace Positive Strong positive
Albustix/Protein 41 28 1 
Ferric chloride/Phenistix 83 3
Reducing substances 96
Acetest/Ketostix 84 3
2,4 DNP 67
Cyanide/nitroprusside 48 23 11
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If a laboratory undertakes such investigations, however, it 
should be aware of the conditions which may be encountered (eg 
Holton, 1982) and their characteristic patterns, so diagnoses are 
neither missed nor delayed and the specialist laboratory receives 
helpful information with the referred specimen. Errors can have 
tragic consequences for patient care, particularly where acutely 
ill neonates are concerned.
Provision of a competent service thus requires expertise in 
interpretation, usually acquired by experience or through 
training in a specialised centre. Though aminoacid 
chromatography is often perceived as an occasional activity 
which provides interest but is of little consequence, if a 
laboratory receives requests only infrequently patient care may 
be best served by immediate referral. Indeed several 
laboratories suspended their service following the institution 
of the UKEQAS surveys, some because they recognised their 
staffing was insufficient to provide a satisfactory service and 
one due to serious errors in their responses to survey 
specimens.
For these reasons it is appropriate to use a single standard for 
judging performance, that of a competent general laboratory which 
should be capable not only of recognising promptly that an 
abnormality is present but also of making a tentative 
identification of the aminoacid(s) involved before referring for 
further investigation or confirmation. Specialist laboratories 
should obviously be capable of an accurate identification.
A simple statement that a specimen is "not normal" should not be 
regarded as satisfactory, and laboratories should be expected to
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know which aminoacid or group of aminoacids is present in 
abnormal amounts. Instances where a specimen from a patient with 
argininosuccinic aciduria was identified as "a case of gross 
homocystinuria", supported by quantitation of the homocystine 
and metabolites present, are plainly also unsatisfactory.
Laboratories should also be capable of recognising normal urines 
as not requiring further investigation, to avoid unnecessary 
anxiety for parents and clinicians and unnecessary use of 
laboratory resources. One of the first 6 specimens was normal, 
and disturbingly several participants failed to classify it thus: 
most indicated minor abnormalities only, but others reported more 
serious errors such as the presence of tyrosine, citrulline, or 
valine and methionine. In this survey three participants returned 
the same response (which was correct for one of the specimens) 
for both specimens, indicating failures in their specimen 
identification procedures, which are as important for these 
investigations as for quantitative assays.
7.3.4 Scoring systems
The judgements discussed above are still to a large degree 
subjective, and it might be expected that a scoring system could 
simplify such interpretation, as in other cases (see Chapter 9). 
Unfortunately, however, where individual laboratories vary in 
their capability and the detail provided in their responses 
devising a scoring system is fraught with difficulties; here the 
situation is much less well characterised than even that for PKU 
screening, discussed in section 7.2.3 above. Any system to 
assist interpretation by individual participants thus appears 
impractical.
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Table 7.4 Summary of tentative categorisation of participants 1 
responses in UKEQAS Surveys 1-3 of Urinary Aminoacid 
Investigation. See section 7.3.4 for explanation of 
categories
Lab Method Specimen
	112233 
	A B A B A B
11A + + _ + + _
23A + + _ + __
5 1B/5C + + + + + +
71A XX + - + -
10 IB + + + + + _
11 2A + __ + __
13 7C X X - + X X
15 1B/2B + + _ + + -
17 1B/2B + + - +
20 1A/5A + + X X X X
25 2A X X - + +
26 1A X X - + + -
31 5C +_ + + + -
33 IB ___ + + +
38 2A/5A + + + + + +
39 1A X X X X +
47 1A/2A //- + + +
48 3A + + - + + +
49 7A + + + + + -
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It may nevertheless be feasible to provide a categorisation 
which would be helpful for another application, that of 
identifying laboratories apparently experiencing problems and 
which may benefit from a more detailed appraisal and the 
provision of advice. Table 7.4 represents a preliminary attempt 
at such a classification, using the following symbols:
Correct +
Unclassifiable response
Wrong
No return X
Specimen not provided /
As can be seen, patterns begin to emerge from such a 
classification after only three surveys (6 specimens). For 
example, laboratories 5 and 38 appear to perform reliably, 
whereas 2, 11 and 33 made frequent incorrect responses and 13, 
20 and 39 failed to make regular returns.
It is premature to use such a system in reports to participants, 
since many of the classifications cannot be completely objective, 
but it promises to serve well in indicating to the scheme's 
advisors which laboratories' returns should receive particular 
attention. This will complete the service provided by these 
surveys, which initially provided only an assessment of the 
state of the art but have progressed to assessment of individual 
laboratories' performance and, in a limited way, of method 
performance.
7.4 Summary
The requirements for EQA of semi-quantitative and qualitative 
investigations differ from those for quantitative assays, 
discussed in Chapter 3. These differences centre on:
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- specimen provision
- scheme design
- performance assessment
- scoring systems
Provision of appropriate specimens can cause difficulties. 
Presentation must be in a form as close as possible to that of 
routine specimens and, where feasible, specimens from authentic 
clinical cases should be used.
Scheme design must also approach the routine clinical situation 
and avoid appearing to be an 'artificial' exercise.
Performance appraisal can be complicated by differences in 
laboratory circumstances and practices. The fundamental objective 
of carrying out the investigation, often a clinical action, must 
be identified and satisfying this treated as the minimum 
criterion for satisfactory performance. Some participants should 
be aiming higher than this, but patients are more at risk from a 
laboratory which fails in the basic objective.
Scoring systems can be devised for such investigations, but to 
ensure general applicability these must be simple and concentrate 
on the essentials. More detailed, but more subjective, 
appraisals may be valuable for use by scheme organisers in 
identifying participants in apparent need of assistance.
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ASSESSMENT OF ANALYTICAL METHODS
Chapter 8:
EXTERNAL QUALITY ASSESSMENT IN THE CHOICE OF ANALYTICAL 
PROCEDURES
8.1 Introduction
A clinical chemist who has to select an analytical procedure must 
consider many factors. The overall objective is a procedure which 
yields results of the greatest clinical usefulness in the 
diagnosis and management of patients. Such a procedure must 
ideally be accurate, precise, rapid and robust, yet be practical 
within the constraints of the laboratory circumstances. Such a 
combination of performance characteristics may well be 
unattainable in practice, given the lack of maturity of many 
analytical procedures, and a compromise may need to be sought. To 
arrive at such a compromise may, however, require more care than 
fulfilling the ideal.
The potential sources of information on the performance 
characteristics of candidate procedures include:
- information from reagent and instrument manufacturers
- the scientific literature
- evaluations carried out previously or conducted as part of 
the selection procedure
- information from colleagues using the procedure now or in
the past 
EQAS results
All are useful to some extent, but criticism may be directed at 
each.
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8.1.1 Reagent and instrument manufacturers
Suppliers of instruments and reagents are not in general 
philanthropic, their primary aim being to increase sales of their 
products. Thus the information they provide, though it may be 
accurate in that it could be defended in law, is suspect from the 
point of view of selectivity.
For example, where precision data are quoted their derivation 
(from optimal or routine conditions) is often unclear, and the 
concentrations at which they are obtained may have been selected 
to give the most favourable impression. In comparisons with the 
performance of alternative procedures data from inferior methods 
may be given. In method comparison studies, the method against 
which the supplier's procedure has been assessed may itself not 
have been fully validated, eg an enzymic urea assay claimed to 
give improved specificity might be demonstrated as having 
excellent correlation with a routine method based on 
diacetylmonoxime. The International Federation of Clinical 
Chemistry (IFCC) has provided guidelines for the presentation of 
claimed performance characteristics (Okuda, 1984; Rubin et al, 
1984) which have improved the situation slightly, but most 
manufacturers do not adhere to these.
8.1.2 Scientific literature
This should be more objective, since reports will have been 
refereed before publication. Authors intent on demonstrating the 
superiority of their procedure, however, may be equally selective 
in their choice of data for publication and will frequently 
choose the best performance from that obtained over a period. 
They may also not record the problems experienced, nor any 
deficiencies in the method. Even where objective data are
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reported, the performance may reflect in part the 'hands of the 
devoted' effect and not be reproducible in other laboratories. 
Reference and selected methods (eg those of the American 
Association for Clinical Chemistry) do undergo a rigorous 
refereeing procedure and transferability studies, but these are 
small in number and may not be widely applicable.
8.1.3 Evaluations
Properly constructed evaluations (eg Broughton et al, 1974; 
Btittner et al, 1979b; Logan et al, 1983) should yield reliable 
information about the performance characteristics of a procedure. 
Thus precision and accuracy, and any additional factors such as 
potential interferences in the analysis, can be addressed. The 
component (eg dispensing and photometric) subsystems, safety, 
reliability and servicing of instruments may also be investigated 
thoroughly. The accuracy of many clinical chemistry assays is 
difficult to assess in such evaluations if true recovery studies 
cannot be undertaken; accuracy is therefore frequently assessed 
as bias relative to some other procedure or relative to values 
assigned to QC materials through EQAS distribution or by 
manufacturers.
Thorough evaluations, however, are time-consuming and therefore 
not carried out on all procedures; their availability through the 
conventional scientific literature is also limited, and many 
prospective users may be unaware of their existence. Secondly, 
they are conducted over a relatively short period and since the 
procedure is not in true routine use even the 'routine conditions 
variance' (Whitehead, 1977) may not reflect accurately actual 
performance. These limitations in time and effort will apply 
particularly to evaluations undertaken by the individual
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laboratory, especially if several procedures are to be assessed. 
Furthermore, manufacturers often alter products after an 
evaluation and thus undermine the applicability of the 
conclusions.
8.1.4 Information from colleagues
Colleagues using the procedure should be able to give a good 
assessment of its true routine performance. This would include 
such aspects as precision, ease of control and acceptance by 
laboratory staff. The procedure's performance in EQASs will also 
be an important element of the information.
The comments of laboratories which were faced with a similar 
choice, and those of laboratories which have since abandoned the 
method in question, can be particularly valuable. Identification 
of such users may be difficult, however, and instrument or 
reagent suppliers may suggest satisfied rather than dissatisfied 
customers if experiences differ.
8.2 External quality assessment data in method selection
The results obtained in EQASs yield much information about the 
relative performance of analytical procedures, and should be used 
in method selection for a wide range of reasons.
Firstly and most importantly, EQAS data reflect in large part the 
routine performance of methods. Thus each participant laboratory 
is reporting results obtained from their routine procedure, ie 
the procedure which is used for release of results for patient 
care, which is subject to an internal QC program, and which is 
being carried out with none of the special precautions to which 
evaluation assays may be subject. Though some laboratories may 
apply special treatment to EQAS specimens, as exemplified in the
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studies of Rumley and Roberts (1982) and of Rowan et al (1984), 
such treatments have only a minor effect on the EQAS performance 
of an individual laboratory. The effects will be diluted when a 
group of laboratories is considered, and it is implausible that 
the application of such treatment would be concentrated within 
particular method groups, so this factor should not affect 
conclusions about the relative performance of methods. As a 
consequence of this, however, EQAS performance may give a 
slightly favourable picture of the routine performance obtained, 
though the effects of 'blunders' (eg transcription or 
transposition errors in the participating laboratory) due to the 
additional step in reporting EQAS results may cancel this out. 
EQAS data will only reflect performance of the assay when it is 
in control, since results from analytical batches shown to be out 
of control by the participant's IQC programme will not be 
reported, and EQAS performance will thus appear better. EQA 
cannot normally give any assessment of this aspect of method 
performance, ie the proportion of batches rejected, unless such 
information is specifically requested through the scheme.
The data on method performance from an EQAS are averaged over all 
laboratories employing the procedure. In practice, performance is 
not determined exclusively by the analytical method used, and 
some laboratories will attain superior results because of their 
closer attention to other aspects of quality assurance. These 
disparities will be reflected in EQAS performance and in most 
cases there will be a considerable range of achievement within 
each method grouping. Again it is unlikely that the better 
laboratories would disproportionately make a similar choice of 
method (unless there were indeed methods with compelling 
reasons in their favour), so this should also not invalidate the
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usefulness of EQAS data in method selection. Such diversity may 
in fact be an excellent indicator of method quality, in that a 
greater than average spread of attainment for a method probably 
indicates susceptibility to problems. For example, an analytical 
principle may be unsuited to particular equipment, it may be 
difficult to control and its performance therefore be related to 
IQC programme efficiency, or there may be variability in the 
quality of reagents from alternative suppliers. Each of these 
factors may make the method less robust and indicate a need for 
caution in selecting such a method.
The main information provided by EQAS data is on the degree of 
interlaboratory agreement. Variance in a scheme arises from 
within-laboratory imprecision (both short- and long-term) and 
between-laboratory differences in bias. Such differences in bias 
may be real, provided that the behaviour of the material 
distributed is identical to that for clinical specimens. In some 
cases, however, interactions between analytical methods and the 
specimen distributed may prevent judgement against other than a 
value assigned for each method group and no overall assessment of 
accuracy may be made; this problem is discussed in detail in 
Chapters 12 and 13.
The information obtainable thus depends upon scheme design. The 
most informative design would be one in which authentic clinical 
specimens were distributed repeatedly, to assess within- 
laboratory precision (or f more strictly, reproducibility of 
results over a long period), with studies using analyte-free 
matrix to assess baseline security and addition of pure analyte 
to assess recovery (eg Hunter and McKenzie, 1979). This is the 
ideal, however, and can rarely be attained in practice, except
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within relatively small schemes and where analyte-free matrix can 
be obtained. More limited scheme designs, where only agreement 
within a method group can be assessed reliably, should still 
yield sufficient information to enable comparison of methods on 
this basis alone. Such approaches can also be used to assess the 
effects of reagent kit (Hayes et al, 1985), instrument (Westwood 
et al, 1986) or modifying analytical procedures (Groom, 1985c).
Overall, therefore, EQAS results provide an important source 
of information on method performance and facilitate reliable 
choices of analytical procedures. In addition, EQAS performance 
is valuable in monitoring whether the correct choice of procedure 
has been made. The selection of a method for serum calcium assay, 
an assay with great clinical importance, provides a useful 
illustration of the use of EQAS data.
8.3 The selection of a method for serum calcium assay
Consider the situation of a clinical chemist in 1980 selecting a 
method for serum calcium assay (a decision most important for 
patient care, since the assay is critical for diagnosis and 
treatment and in general the state of the art falls short of 
analytical goals derived from biological variation). Information 
would have been available from the sources discussed above, but 
EQAS results would have formed the most readily accessible and 
comprehensive database for initial assessment.
8.3.1 Assessment of EQAS data
A wide variety of method principles for serum calcium assay were 
available at that time. These included atomic absorption 
photometry, titrimetry and dye-binding procedures employing a 
number of chromophores. Table 8.1 shows the information provided
192
Table 8.1 Average interlaboratory agreement for serum calcium
assay in UKEQAS for General Clinical Chemistry, January-June 
1980 (n = 10 distributions)
n Mean CV
(mmol/L) (%)
Overall 335 2.67 3.6
EDTA titration 19 2.62 4.0
Atomic absorption 50 2.65 3.8
AutoAnalyzer I 37 2.69 3.2
AAII or SMA system 123 2.67 2.9
Vickers M300/D300 20 2.69 2.4
Manual methylthymol blue 21 2.64 4.7
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by averaging the data from the UKEQAS for General Clinical 
Chemistry reported to participants for the first 6 months of 
1980. The classification used in 1980 was based on the method 
principle, except in the case of automated procedures which were 
divided on the basis of instrument type.
It is readily apparent from these data that the automated 
procedures (AAI, AAII/SMA and Vickers groups) show the best 
interlaboratory agreement, ie these methods appear overall to be 
the most reliable. Atomic absorption and EDTA titration are 
somewhat less reliable, though the titrimetric procedure is less 
widely used, and the methylthymol blue (MTB) method group is 
apparently the least satisfactory. In no case is there evidence 
of a large bias relative to other procedures, though the 
automated procedures do tend to give results higher than those by 
atomic absorption, the principle on which reference methods (eg 
Cali et al, 1973) have been based.
Within each group there are variations due to individual 
laboratory factors, to robustness of the procedure, and to the 
reliability of the instrumentation used. Thus the EDTA titration 
and MTB groups are essentially manual procedures, the atomic 
absorption group uses a single type of instrument, whereas the 
AutoAnalyzer and Vickers groups employ automated systems of 
varying degree of sophistication. In the situation of increasing 
workload an automated procedure would be advisable and the 
obvious choice would be an AutoAnalyzer II or SMA; AutoAnalyzer I 
and Vickers systems were by this time no longer in production.
The choice of a continuous flow system may, however, not have 
been in complete accord with the work pattern of the laboratory. 
An increasing dissatisfaction with the concept of 'profiling 1 and
194
movement towards discretionary testing had made discrete 
analysers a new and more popular choice for many laboratories, 
their greater versatility with regard to carrying out a range of 
different assays at different times on the same instrument being 
particularly attractive. In this case the choice would be one of 
method principle rather than of procedure. Improving 
instrumentation for atomic absorption assays and the possibility 
of also carrying out other cation assays on the same instrument 
could, however, have made this theoretically more accurate 
procedure the choice for some laboratories.
Which method principle should then be selected? Discrete 
analysers are limited to dye-binding assays, and here the choice 
essentially lies between o-cresolphthalein complexone (CPC) and 
MTB, though methods based on, for example, alizarin have also 
been proposed. The UKEQAS data favour CPC, as the predominant dye 
in continuous flow procedures, rather than MTB, which shows 
substantially worse interlaboratory agreement. This difference 
may at first sight be due solely to the degree of automation, but 
discrete analyser procedures using MTB were in fact also included 
within the group described as "Manual MTB".
This illustrates one problem of method assessment using EQAS 
data, as the method classification used may be designed primarily 
to avoid the consequences of matrix effects and not take account 
of all differences between methods which are of interest. Thus 
from the 1980 data there is no way of distinguishing between the 
performance of MTB assays performed manually, by means of a 
centrifugal analyser, or by means of any other type of discrete 
analyser.
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Therefore the EQAS data indicate that an automated procedure 
based on CPC should be best, with laboratory circumstances 
dictating whether continuous flow or a discrete analyser system 
should be used. The performance of discrete systems could not be 
forecast directly from the EQAS data since such methods lay 
outside the 1980 classification, and CPC on a continuous flow 
system would consequently be the 'safest' choice.
8.3.2 Appraisal of the conclusions
How accurate were these conclusions? This can also be determined 
through examination of EQAS data. Thus Table 8.2 shows the UKEQAS 
results from the corresponding period of 1986.
Now, with a larger number of participants than in 1980, CPC 
procedures as a whole appear in fact not to have the most 
reliable performance. The best interlaboratory agreement is now 
shared with continuous flow CPC by the automatic titrator and 
atomic absorption groups. There have been continuing advances in 
atomic absorption instrumentation over the last few years, and 
current equipment is more reliable than that available in 1980. 
The automatic titrator performance also demonstrates that EQA 
data cannot forecast future developments, and thus cannot yield 
information on novel instrumentation until it is in routine use; 
evaluation data should therefore be used in conjunction to 
alleviate this problem.
Table 8.2 raises a number of other issues about the use of 
EQAS data in studies of method performance. Firstly, as discussed 
in Chapter 4, the use of an appropriate scoring system will give 
an additional and more readily interpreted way of assessing 
cumulative data. Thus the MRVISs are akin to average CVs in 
yelding an overall assessment of interlaboratory comparability
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Table 8.2 Average interlaboratory agreement for serum calcium
assay in UKEQAS for General Clinical Chemistry, January-June 
1986 (n = 12 distributions), with average running scores at 
June 1986
n Mean CV MRVIS SDBIS
(mmol/L) (%)
Overall 412 2.82 3.2 61 65
Atomic absorption 
Manual/discrete CPC
Continuous flow CPC
Methylthymol blue 
Automatic titrator
26
188
140
25
27
2.78
2.82
2.83
2.77
2.75
2.7
3.3
2.3
3.9
2.4
56
68
48
81
51
57
76
49
84
54
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and general method reliability. This will pertain to reliability 
within the method group if a method-related figure is used as 
designated value. The SDBIS then yields information on each 
laboratory's consistency of bias (or, in many circumstances, 
within-laboratory repeatability). The MRBIS yields information on 
bias, provided that method is not taken into account in 
derivation of designated values though bias information can be 
obtained for subclassifications within a method group, eg for 
different manufacturers' instruments within an indirect ISE group 
for sodium and potassium. The average MRVIS and SDBIS figures 
confirm the overall impressions of relative performance discussed 
above, though they also suggest the possibility that laboratories 
in the manual/discrete analyser CPC group show slightly more 
inconsistency of bias.
The inhomogeneity of some method groups is apparent from Table 
8.3, which gives running scores for the MTB calcium method group 
from 1983. There is considerable diversity in performance, with 
some laboratories showing satisfactory and others grossly 
unsatisfactory performance. Examination of the scores for 
individual laboratories showed the primary problem to be one of 
inconsistency of bias; very few participants had a large and 
consistent bias. These data were circulated to participants in 
1984, with the recommendation that users of this method should 
re-assess their performance and consider a change of method if 
this was unsatisfactory. The MTB method has since decreased in 
use but it has not been eliminated completely. The same 
diversities in performance persist, as demonstrated in the graphs 
of laboratory result against method mean for two participant 
laboratories using this procedure shown in Figure 8.1.
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Table 8.3 Average and range of running scores for serum calcium 
assay by methyl thymol blue method group in UKEQAS for 
General Clinical Chemistry, 1983 and 1984
MRVIS MRBIS SDBIS
November 1983 (distribution 257; n = 33)
Average 74 -5 80
Range 26 - 198 -128 - +148 25 - 235
June 1984 (distribution 267; n = 36)
Average 80 -3 86
Range 35 - 198 -142 - +129 23 - 196
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Figure 8.1 Graphs of laboratory result against method mean for
calcium by methylthymol blue in UKEQAS for General Clinical 
Chemistry, 1986, for participants with (A) good performance, 
and (B) poor performance
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The EDTA titration method is no longer used by UK laboratories, 
which may be related to the demonstration by EQASs of its overall 
inferiority. Before its disappearance in 1983, however, the 
remaining group of very few laboratories using EDTA titrimetric 
procedures performed reliably. Thus the average CV for 2-3 
laboratories in late 1982 was 2.0%, which is good in comparison 
with the majority of average CVs in Tables 8.1 and 8.2. This 
confirms previous experience with methods which seem to require 
considerable effort to maintain: some participants can attain 
excellent performance with them, but the majority of laboratories 
attempting to apply them experience difficulties. The manual 
dithizone procedure for blood lead (Table 8.4) provides a further 
example of this situation. Overall, the dithizone method shows 
poor performance (as judged by MRVIS) relative to other methods, 
but of the five laboratories in the group one showed good 
performance. Studies through the scheme of reproducibility and 
recovery of added lead (Bullock et al, 1986c) confirmed these 
conclusions (Table 8.4).
The effect, which may be likened to the 'hands of the devoted' 
effect in new methods, suggests considerable caution in 
interpreting EQAS data obtained from a group of a few 
laboratories only. Besides the purely statistical considerations, 
the performance of these laboratories is thus much less likely to 
be representative of the method's routine performance than is 
performance information derived from a larger group of 
participants.
8.4 Assessment of factors other than inter laboratory agreement
As discussed above, some EQAS designs can also yield information 
on aspects of performance such as accuracy and turnround time,
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Table 8.4 Average MRVIS and recovery and repeatability studies in 
UKEQAS for Lead in Blood, 1980, with ranges for dithizone 
method group
n MRVIS Recovery of Within-lab 
added lead CV (%)
Overall 90 72 98.1 8.6
Delves cup 33
Electrothermal atomisation 33
Other atomic absorption
Dithizone 
(range)
14
62
65
63
93.8
102.6
103.2
8.1
7.5
8.1
90 79.6 20.3 
(50-163) (48-123) (12.1-35.9)
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which may be of particular importance in some assays.
8.4.1 Accuracy
Paracetamol and salicylate are added to drug-free equine serum to 
yield specimens for the UKEQAS for Salicylate and Paracetamol, 
and recovery may therefore be assessed.
Figure 8.2 shows the relationships between percentage recovery 
and added paracetamol for the enzymic and Glynn & Kendal method 
groups. The enzymic procedures show a much more quantitative 
recovery of paracetamol, with less concentration-dependence. 
There is also a clear relationship between interlaboratory 
agreement and analyte level (Figure 8.3) so simple examination of 
average CVs may not be sufficient to determine the relative 
merits of the various methods. Figure 8.3 therefore compares the 
relationships for the enzymic and the Glynn & Kendal method 
groups, from which the superiority of the enzymic procedures is 
readily apparent (Bullock, 1987).
These impressions are confirmed by the average MRVISs (December 
1986) of 41 for enzymic and 73 for Glynn & Kendal users; the 
average SDBISs, of 48 and 73 respectively, also indicate superior 
within-laboratory consistency for the enzymic methods. 
Demonstration of these facts by the scheme has been associated 
with a large swing towards the enzymic methods, used by 57% of 
participants by December 1986 but only 33% two years earlier. The 
evidence for any link between these two facts is purely 
circumstantial, and the reagent manufacturers have also promoted 
their products, but it is reasonable to assume that EQAS results 
have contributed towards this change in practice. Such a 
contribution may of course be mediated by the early introduction
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Figure 8.2 Relationship between percentage recovery and
paracetamol added for enzymic and Glynn & Kendal method 
groups in UKEQAS for Salicylate and Paracetamol, 1985-1986
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Figure 8.3 Relationship between inter laboratory agreement (CV)
and paracetamol added for enzymic and Glynn & Kendal method 
groups in UKEQAS for Salicylate and Paracetamol, 1985-1986
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of scoring of individual laboratories' performance (see Chapter 
9) as well as by the presentation of overall method-related data.
The design of the UKEQAS for PKU Screening also allows assessment 
of a number of aspects of method performance. Accuracy of overall 
interpretation can be quantitated here through the scoring system 
for participants' classification of each specimen as having a 
'normal', an 'intermediate' or a 'high' phenylalanine level 
(Chapter 7; Appendix 1.2.7). Since errors of classification are 
infrequent, and the scheme has few participants overall (and 
consequently even fewer in some method groups), performance must 
be cumulated over a long period to gain a reliable assessment. 
Figure 8.4 shows the average score per survey (6 specimens) over 
Surveys 6-19, with participants classified according to their 
method; these are broad groupings, with many variations 
introduced by individual laboratories. From this it is apparent 
that the performance of the four method groups is very similar, 
perhaps suggesting that each laboratory has now controlled most 
aspects of their own method. Indeed, the two laboratories having 
high average scores obtained the contributory scores early in 
their participation.
8.4.2 Turnround time
In addition to analytical performance, the UKEQAS for PKU 
Screening also endeavours to assess turnround time through 
requesting information on the dates of specimen receipt, specimen 
analysis and results despatch. Turnround is important in this 
assay because the response to treatment is better the earlier 
treatment is started (Williamson et al, 1981; Smith, 1985).
In some cases delays before receipt of specimens have been found 
to be due to delays within the recipient hospital's postal
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Figure 8.4 Relationship between analytical method and average 
score for Surveys 6-19 in UKEQAS for PKU Screening
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Figure 8.5 Relationship between analytical method and average
turnround time (delay between specimen receipt and analysis- 
working days) for Surveys 17-20 in UKEQAS for PKU Screening'
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Figure 8.6 Relationship between 1983 workload and average
turnround time (delay between specimen receipt and analysis; 
working days) for Surveys 17-20 in UKEQAS for PKU Screening
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arrangements, and investigations have led to elimination of this 
problem for clinical screening specimens as well as for EQA 
specimens. The most useful interval susceptible to study is that 
between specimen receipt and analysis. The relationship between 
method and average interval (in working days) between specimen 
receipt and analysis over Surveys 17-20 is shown in Figure 8.5. 
Here the Guthrie and Scriver groups seem to have a slightly 
faster turnround of specimens, with greater variability within 
the other groups. As Figure 8.6 demonstrates, however, this may 
be related in part to the relationship with annual workload for 
PKU screening.
Total turnround (specimen receipt to results despatch) has not 
been studied in detail since the nature of the scheme prevents 
participants from dealing with the results in their routine 
manner: specimens are grouped on a single request/results 
document whereas routine specimens are dealt with independently 
and turnround time is likely to be shorter for specimens having 
raised phenylalanine levels.
8.5 Summary
EQAS data provide an excellent medium for assessing the routine 
performance of analytical procedures in current use, though the 
estimate may be slightly more favourable than would be obtained 
in practice. Use of a scoring system can be a more convenient and 
sensitive means of performance assessment than average 
interlaboratory CVs. This also facilitates identification of 
heterogeneity of performance, indicating susceptibility to 
problems, within method groups.
Scheme designs may also enable aspects of performance other than
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interlaboratory agreement, such as accuracy and turnround time, 
to be assessed. For example, schemes incorporating known 
additions of pure analyte to analyte-free matrix provide a 
reliable assessment of method accuracy. The assessment of 
relative biases in schemes subject to matrix effects is, however, 
much less reliable.
Overall, the ability to assess method performance is limited by 
the degree of discrimination available in the classification 
used in the scheme, and new methods are not immediately 
susceptible to study.
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ASSESSMENT OF INDIVIDUAL LABORATORY PERFORMANCE
Chapter 9:
SCORING AS A STIMULUS TO IMPROVED LABORATORY PERFORMANCE
9.1 Introduction - the assessment of performance
Data reduction through use of a scoring system is invaluable in 
rendering the performance information from EQA easier to 
interpret in terms of the assessment of interlaboratory agreement 
over geography (ie among schemes) and time (ie within a scheme), 
as described in Chapter 4. The original intention behind the 
introduction of scoring systems, however, was to make EQAS 
information more comprehensible to participants (see section 
3.4.2).
Comparison of results with targets in the form of overall or 
method-related means or histograms is difficult. If a number of 
analytes (10 to 20 in many schemes covering general clinical 
chemistry) are involved the problem becomes more complex, even 
for a single specimen distribution only. The assessment 'by eye' 
of the data accumulated over several distributions is yet more 
difficult, and anything other than a gross change in performance 
is effectively impossible to detect.
A scoring system makes such assessment much simpler through the 
cumulation of information in more readily comprehensible form. 
This cumulation may refer to a single analyte only, with use of 
results covering a period, to permit appraisal of performance 
relative to other participants at that time or to the individual 
laboratory's past performance; for the latter, the score must be 
independent of other participants' performance, as discussed in 
section 4.7.2.
212
Appropriate scoring systems can also permit combination of data 
from more than one analyte, and so provide an overall assessment 
of the laboratory's overall performance. Again appraisal can be 
against others or against previous performance. Such measures of 
'performance at a glance' are extremely powerful distillations of 
EQAS information and are thus a useful managerial tool, providing 
the limitations discussed below are recognised.
The most primitive systems give information in qualitative form, 
eg the 'pass/fail' criteria applied by licensing schemes 
(Bundesarztekammer, 1971; Stamm, 1975), and thus give only the 
crudest reflection of performance. More sophisticated systems 
such as VI scoring yield quantitative information as a numeric 
score, retaining the potential for easy interpretation and being 
susceptible to graphical presentation (see Chapter 10). These 
have been of great assistance in enabling laboratories to 
recognise the existence of suboptimal performance and in 
stimulating them to improve towards this goal.
Most systems are based on an estimate of total error, but further 
refinement can also provide guidance on the type of contributory 
errors. Schemes usually rely on precision information gained 
separately through the laboratory's IQC programme to assist in 
interpretation (though some do assess imprecision through 
repeated distribution of the same specimens), and provide 
estimates of bias and its consistency. A bias may be inconsistent 
due to poor within- or between-assay precision, but the potential 
presence of other contributory factors such as nonlinearity or 
other concentration-dependent bias, short- or long-term accuracy 
changes and specimen/method interactions usually precludes such a 
simplistic interpretation.
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Application of a good scoring system can then provide a robust 
and reliable assessment of overall performance, indicating 
improvement or deterioration and identifying any need for 
improvement. It should then also assist in the resolution of 
any problems indicated through provision of more detailed 
information for the individual analytes concerned, since 
different approaches are required for problems arising from eg 
erroneous calibration and nonlinearity. To avoid unnecessary 
sifting through irrelevant information (and thus defeat the 
object of using a scoring system) the scoring system and report 
format should enable the participant to proceed in a stepwise 
manner through a hierarchy of increasingly detailed performance 
data, deciding at each stage whether it is necessary to proceed 
further.
Though detailed information must be provided by scoring systems, 
this sophistication may make it increasingly difficult to relate 
performance scores to patient care, especially where they are 
determined by consideration of the state of the art rather than 
clinical requirements. In such contexts there is also perhaps a 
need for a 'pass/fail' system in addition, to indicate in a very 
simple manner whether performance is good enough to satisfy 
medical decision criteria.
9.2 Hierarchical interpretation of scoring
The most helpful scoring system will fail in its objective if the 
scores are not presented in such a way as to simplify the 
interpretation. Each participant has only limited resources (in 
term of time, effort and ability) to devote to this 
interpretation, and experience suggests that those in most need
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of acting on EQA data devote or choose to devote the least.
A clinical chemist receiving a report needs to make decisions on 
a series of questions, which are usually self-terminating when a 
negative answer is given:
- do I have a major overall problem?
- which analytes are contributing most to this?
- are these problems significant?
- what is the source of the errors in each case?
A well-designed combination of scoring system and report format 
can assist considerably in this process, and thus contribute to 
patient care not only through stimulation of improvement where 
this is indicated but also through removing the need for 
unnecessary investigation.
The application of VI scoring (defined in Appendix II) in the 
UKEQAS for General Clinical Chemistry will be used as an example 
of such application. Consider then the report of which the 
primary and an example secondary pages are shown in Figures 9.1 
and 9.2 respectively.
9.2.1 The OMRVIS and assessment of overall performance
The first element to be considered is the laboratory's OMRVIS, 
which represents the average of the 40 most recent VISs. The 
value of 66 here will have been derived from roughly the last 3 
fortnightly distributions (6-8 weeks), since the laboratory is 
receiving scores for about 14 analytes.
The most direct comparison is with the mean OMRVIS for all 
participants (60), which shows the laboratory to be slightly 
worse than average. A more appropriate comparison is with the 
mean OMRVIS for participants in the same size group, ie with the
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Figure 9.1 Primary pages of report for participant laboratory in 
UKEQAS for General Clinical Chemistry
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Figure 9.2 Example secondary pages of report for participant 
laboratory in UKEQAS for General Clinical Chemistry
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average performance of laboratories broadly similar in terms of 
workload. The laboratory is in group III, representing an annual 
workload of >500,000 tests/year, and the comparison figure is 56. 
Thus this laboratory's performance is somewhat worse than the 
average for larger laboratories, and may indicate a cause for 
concern.
Further evidence is provided by the frequency distribution 
(histogram) of the OMRVISs for participants in this size group. 
This shows not only that the laboratory's OMRVIS of 66 is worse 
than the average but also that an appreciable proportion of 
laboratories in a similar situation can attain an OMRVIS <50, and 
about 10% a score below 40. The best performance attained should 
be the goal of each participant, and even those with better than 
average performance should ideally also strive for this (subject 
to the reservations discussed in section 2.2).
Thus the evidence available suggests that the laboratory's 
performance is less satisfactory than that of others, indicating 
a need for more detailed investigation.
9.2.2 Assessment: of performance for individual analytes
What is then the source of this apparent deficiency? This 
information is essential before proceeding further. It is also 
useful in assessing priorities for allocating improvement effort, 
since effort will be most effectively applied where performance 
is initially worst.
Examination of the BISs for this distribution shows particularly 
poor scores for potassium, urea, glucose, ALT and amylase, so are 
these the analytes requiring attention? Possibly not, since the 
quality of individual results and hence the resulting BISs is
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influenced by the analyte concentrations (see Chapter 6) in the 
specimen distributed and by random variation.
To gain the benefit of cumulation over time (and hence over a 
range of analyte concentrations) the MRVIS for each analyte must 
be considered. This is the mean of the 10 most recent VISs for 
the analyte, usually derived from about 6 months' distributions. 
In this case the MRVISs for most analytes appear satisfactory, 
apart from the values of 164 for amylase, 106 for urea, 72 for CK 
and 71 for potassium. These indicate clearly that the 
laboratory's higher than average OMRVIS stems primarily from the 
unsatisfactory performance for these 4 analytes, and attention 
must be given to improving performance for these before the 
overall situation can be improved.
Is the performance for these analytes in fact unsatisfactory, or 
is it merely poor relative to that of other participants but 
quite adequate for the clinical application of the assay? 
Certainly the CCVs, which 'scale' the VISs and MRVISs for each 
analyte, are based solely on the state of the art (in 1972; their 
continuing validity is discussed in section 4.8) and might 
therefore prove misleading; the issues are discussed in section 
9.6 below. Removal of this scaling, however, reveals these MRVISs 
to represent average deviations from the DV of 18.9% for amylase, 
13.3% for CK, 6.0% for urea and 2.1% for potassium. Intuitively 
such errors still appear significant. Though they satisfy the 
analytical goals proposed for within-laboratory CVs (Tables 2.1 
and 9.1), the appropriateness of the goals for urea and for 
enzymes is questioned in section 9.6.
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Table 9.1 Comparison, in terms of VIS, of performance attained in 
UKEQAS for General Clinical Chemistry with analytical goals
(Fraser CG, personal communication)
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
Osmolality
AST
ALT
LD
CK
ALP
Amylase
ccv
1.6
2.9
2.2
5.7
7.7
4.0
7.8
15.0
7.7
8.9
19.2
3.9
7.5
7.6
11.0
10.0
2.9
12.5
17.3
13.2
18.5
15.5
11.5
Average VIS A
61
55
77
55
44
64
54
46
64
45
37
66
53
48
34
55
46
59
52
58
62
57
80
nalytici
25
90
36
119
29
20
50
89
56
26
66
36
23
36
—
11
-
62
114
27
194
17
-
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9.2.3 Appraisal of contributory factors
To obtain more detailed performance data the secondary pages 
(Figure 9.2) must be considered; if no potential problems had 
been revealed by the assessment above then consideration could 
have been confined to the primary page of the report.
These pages give additional guidance in the form of data for each 
analyte, including the MRBIS and SDBIS (Appendix II.2; Bullock 
and Wilde, 1985). These provide information on the components of 
variance contributing to the MRVIS, the MRBIS representing a 
cumulated estimate of bias relative to the DV (the method mean in 
this scheme) and the SDBIS the consistency of this bias.
Thus a large (positive or negative) MRBIS and small SDBIS 
indicate a consistent proportional bias, a small MRBIS and large 
SDBIS an inconsistent bias, and large MRBIS and SDBIS a mixed 
picture. For ideal perfomance both MRBIS and SDBIS (and hence the 
MRVIS) should be small. These situations are exemplified in 
Figure 9.3, showing contributory results. Imprecision provides 
the source of the inconsistent bias for urinary oestrogen assay 
(Bullock and Wilde, 1985).
Apart from the simple case of consistent proportional bias, due 
in most cases to use of an inappropriate calibrant value, the 
differential diagnosis requires appraisal of the actual results 
contributing to the poor scores. Thus the scoring system reaches 
the limit of its usefulness, having indicated the existence of a 
problem and some of its likely causes, and there is no 
substitute in these circumstances for examination of individual 
results.
Here a graphical presentation as in Figure 9.3, discussed in more
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Figure 9.3 Demonstration of the effects of bias and imprecision
(inconsistent bias) upon the relationship between laboratory 
result (y axis) and designated value (x axis)
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detail in section 10.5.2, proves invaluable in identifying the 
underlying analytical problem. Figures 9.4 and 9.5 show the 
relation of the results for the 4 problem analytes to the 
corresponding DVs. These demonstrate the consistent proportional 
negative bias for amylase, apparent compensated bias (probably 
arising from a combination of inappropriate calibration and 
blanking procedures; Lever et al, 1981) for urea, inconsistent 
bias (probably reflecting an imprecise assay) for CK, and 
somewhat inconsistent positive bias for potassium. Examination of 
the individual results revealed no consistent trend with time 
(section 10.5.2).
9.2.4 Method assessment
The secondary pages also provide information on method-related 
performance. This is of great benefit in assessing whether and 
how a laboratory should change method, as discussed in Chapter 8.
The data are presented as mean, SD and CV for the specimen 
distributed, which suffer from the problems outlined in section 
9.2.2 for individual VISs. Cumulative information is, however, 
available from the scheme Organisers in the form of average 
scores for each method group and for more detailed 
subclassifications, exemplified for sodium in Table 9.2. Here the 
average MRVISs provide guidance on the relative overall 
performance of each group, and the average SDBISs on the 
robustness of the method. The average MRBISs indicate any 
consistent biases between the method groups (eg Bullock et al, 
1986c), though if the method mean is used as DV (as in the UKEQAS 
for General Clinical Chemistry) these indications will only be 
valid for the subclassifications within each method group. These 
aspects are discussed in more detail in sections 8.3 and 12.3.
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Figure 9.4 Relationship between laboratory result (y axis) and
designated value (method mean; x axis) for amylase and urea 
in UKEQAS for General Clinical .Chemistry. * denotes result 
outside graph limits; lines are x=y and at BIS=+100
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Figure 9.5 Relationship between laboratory result (y axis) and
designated value (method mean; x axis) for CK and potassium 
in UKEQAS for General Clinical Chemistry
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Table 9.2 Average running scores for method groups and subgroups 
for sodium assay in UKEQAS for General Clinical Chemistry, 
1987. The Miscellaneous group is scored against the overall 
mean; no scores are calculated for the Other group, nor for 
groups with <15 results contributing to the method mean; 
*direct ISE is direct potentiometery on undiluted sample
n MRVIS MRBIS SDBIS
Overall 487 63.0 71.9
Continuous flow flame photometry
Overall
Technicon flame photometer 
Other instrument
102
90
12
57.2
55.7
68.3
-1.2 
+20.0
65.6
63.9
78.8
Flame photometer with integral dilutor
Overall
IL
Corning
Other instrument
132 61.8 71.9
66
51
14
63.7
58.8
62.8
+ 1.2
+ 8.4
-28.2
75.4
68.1
67.4
Indirect ion-selective electrode
Overall
Technicon
Beckman
Other instrument
227 65.0 73.2
76
100
49
65.4
58.5
77.9
-2.2
+ 7.5
-8.0
75.0
65.2
87.0
Miscellaneous
Flame photometer without dilutor 10 84.3 -18.2 91.2
Other method
Overall
Direct ISE* - IL
Direct ISE* - Corning
Direct ISE* - Nova
Direct ISE* - other instrument
38
4
21
1
12
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9.3 Assessment of performance relative to other laboratories
One of the first thoughts of many EQAS participants on receiving 
a report is how their performance compares with that of their 
colleagues in other laboratories. This desire may be motivated by 
scientific curiosity or by the human competitive instinct.
A frequency distribution (histogram) of results provides such a 
means of comparison, but has limitations. The main disadvantage 
is that the comparison is based solely on analysis of a single 
specimen whereas scoring systems incorporate cumulation of data 
from a number of specimens over a period and a range of 
concentrations. Assuming that this is not an objection, however, 
how useful is a histogram for such comparison?
Certainly it shows how close the laboratory's result is to the 
target (mean, median, mode or externally-assigned designated 
value) relative to other participants' results. This may be 
useful on a qualitative basis, but the judgement is thus 
dependent upon the state of the art since histograms are usually 
presented in a 'scaled' form to fit consistently within the 
report. Thus the range commonly approximates to +2 SD limits from 
the mean and this is often interpreted as defining 'acceptable 
performance', with many participants assessing acceptability 
merely by whether their result falls within the histogram limits. 
Such interpretation is obviously superficial, reducing to an 
arbitrary 'pass/fail' criterion. Furthermore results lying close 
to the histogram limits have been known to be rationalised as 
showing that "there are 6 laboratories further away than we are".
More importantly these judgements are based on the general 
standard of performance of participants in this scheme, which may
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in turn be unsatisfactory. For this reason the same laboratory's 
result might appear unacceptable in one EQAS but relatively 
satisfactory in another with worse interlaboratory agreement.
A 'hybrid' presentation incorporating scoring parameters may 
therefore be more useful. Such a presentation is illustrated in 
Figure 9.6, taken from the International EQAS (Appendix 1.3.1). 
This uses an 'orthodox' histogram format for the central portion, 
taken as the range of concentrations which would give a VIS of 
100 or less, with results further from the mean being grouped 
into VIS bands and denoted by symbols also suggesting their less 
satisfactory character.
For reliable comparison with other participants' performance, 
however, a scoring system is essential, which may take one of a 
number of forms, as reviewed in section 4.2. Assessment in terms 
of SD difference (SDD or 'Z score'; eg Wellcome Diagnostics, 
1984) appears simple and reliable, and has the added attraction 
of scaling for differences in attainable performance between 
analytes, so it is ideal for comparing simply with other 
participants in the scheme. It suffers, however, from the same 
deficiency as the histogram presentation, ie dependence upon the 
performance of other participants and consequently does not offer 
an objective performance assessment.
Consider for example a laboratory which obtains a result of 146 
mmol/1 for sodium, for which the DV is 140 mmol/L. In a scheme 
such as the UKEQAS for General Clinical Chemistry a typical SD 
would be 1.7 mmol/L, yielding an SDD of 3.5, but interlaboratory 
agreement in the International EQAS is worse and the typical SD 
of 3.2 mmol/L yields an SDD of only 1.9. Thus SDDs do not provide 
an objective appraisal of a laboratory's performance, though they
228
Figure 9.6 'Hybrid 1 histogram format used in International EQAS.
Central portion represents the concentration range yielding 
a VIS <100, with results lying outside being grouped into 
bands according to VIS
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do yield a reliable assessment relative to that of the other 
scheme participants and cumulation in terms of average SDDs is 
possible both over analytes and over time.
Variance Index scoring, however, overcomes this problem through 
use of a fixed Chosen Coefficient of Variation (CCV). This 
provides a means of scaling according to analyte to give scores 
in a 'common currency' (as are SDDs), but the score is also 
independent of the other participants' performance. Cumulation 
over both time (giving analyte MRVISs) and analytes and time 
(giving an OMRVIS) is also desirable. Average scores and their 
distribution then provide a ready comparison with 
other laboratories' performance, as described in section 9.2.1 
above.
9.3.1 Competition in EQA
The competitive instinct was cited above as one factor 
motivating attempts to improve performance, and scoring 
facilitates competition in EQA, particularly when it includes a 
'league table' presentation of scores. Anything which improves 
comparability of results should be welcomed as benefiting 
patient care, but care must be exercised in exploiting this 
urge. Firstly it may encourage an attitude of improvement for 
improvement's sake, irrespective of clinical requirements, so 
that attaining good performance in EQASs becomes an end in 
itself.
More disturbingly, this may lead to a dissociation between the 
procedures used for EQA specimens and clinical specimens. Thus 
if assay replication and other favourable treatments (eg Rumley 
and Roberts, 1982; Rowan et al, 1984) are used EQAS performance
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will no longer be an objective reflection of that normally 
attained in the laboratory. This is fundamentally dishonest, 
though such 'cheating' only deceives the participant laboratory 
into a false impression of the reliability of their assays.
For these reasons most scheme organisers try to avoid an 
excessive competitive element while still encouraging a healthy 
striving to emulate the performance of the best laboratories. 
For example, presentation of OMRVISs in a league table format in 
the UKEQAS for General Clinical Chemistry was discontinued in 
the late 1970s because some participants were reportedly more 
concerned with their position than with the OMRVIS itself.
9.4 Assessment of improvements in performance
Similar arguments apply to this application of EQAS data, which 
is critical for EQA to be successful in stimulating and 
monitoring improvement. Participants need a robust and reliable 
reflection of their current performance to appraise their 
progress.
As described in section 9.1, simple comparison with DVs or 
histogram presentations is most unlikely to be sufficiently 
sensitive and discriminating to be helpful. 'Pass/fail' 
assessment systems are also far too crude a reflection of 
performance.
SDDs could be used, but are not reliable in this context. Their 
dependence upon the observed SD makes them susceptible to 
influence from changes in the state of the art, which may be 
greater than changes for individual laboratories. In most schemes 
there is (or should be) a continuing trend towards better 
interlaboratory agreement, leading to decreasing SDs and
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consequently higher SDDs for a participant with unchanging 
performance. Any appraisal of individual laboratories' 
performance would thus have to take these changes into account, 
again a complex procedure.
The VI scoring system, however, overcomes this problem by scaling 
using a fixed denominator, the CCV- The influence of other 
participants' performance is then confined to their contribution 
to the DV if consensus values are used, and interlaboratory 
variability appears to be reflected only in the reproducibility 
of consensus values and not their accuracy (see section 5.2).
9.4.1 VI scoring in assessing changes
Examples demonstrate this application of VI scoring. Here 
deteriorating overall performance in the UKEQAS for General 
Clinical Chemistry is clearly shown by plotting OMRVIS against 
time, the graph covering a period of about two and a half years 
as discussed in section 10.4.1 below (Figure 9.7). For a single 
analyte, such as blood lead assay, similar treatment of the MRVIS 
reveals trends in performance (Figure 9.8).
Is this pattern seen in all such schemes? Figure 9.9A shows the 
changes in the average OMRVIS for all participants in the Middle 
East EQAS. There was for some time no appreciable improvement in 
the average score, and only a 10% improvement over 6 years 
despite the inclusion of scoring from the start of the scheme. 
This differs considerably from the experience with UKEQASs, as 
described above. The situation for individual laboratories, 
however, may be much more encouraging (Figure 9.9B).
Why is this? Possible reasons relate to changes in participant 
composition during the operation of the scheme. Two main factors
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Figure 9.7 Graph of OMRVIS against time for a participant with 
deteriorating performance in UKEQAS for General Clinical 
Chemistry
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Figure 9.8 Graphs of OMRVIS against time for participants with 
(A) improving and (B) deteriorating performance in UKEQAS 
for Lead in Blood
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are likely to affect the situation. Firstly, experience suggests 
that laboratories joining an EQAS go through a 'learning phase'. 
During this period they discover from the reports that their 
performance is not optimal, they investigate the problems 
revealed, and when they resolve these their performance begins to 
improve. Figure 9.9B shows an example of this.
Some participants, however, unfortunately do not respond to EQA 
reports in this way, and following a period of apparent poor 
performance they seem to lose their confidence in the scheme and 
cease to return results. In the MEEQAS such behaviour led to 
removal of the laboratory, to direct resources towards those 
laboratories willing to learn from their EQA performance and 
participate regularly and fully. It is also not feasible, for 
economic and geographic reasons, to offer advice and assistance 
to participants experiencing problems in any more than a cursory 
way through correspondence. Again the situation differs from that 
within the UK, where National Quality Assurance Advisory Panels 
(Browning, 1984; Walker, 1985) have been established for this 
purpose.
Overall, therefore, a continued influx of new participants 
coupled with the gradual removal of those, usually with high 
OMRVISs reflecting performance problems, which did not return 
results regularly can lead to an average OMRVIS which is 
relatively stable. As more laboratories were recruited and 
confidence in the scheme increased, however, there was a growing 
tendency towards improvement in performance as assessed by the 
average OMRVIS (Figure 9.9A).
The additional potential of the VI scoring system can also be 
exploited by plotting the MRBIS and SDBIS as well. Thus Figure
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9.10 shows the effect on performance indices for paracetamol of 
changing from an unsatisfactory chemical procedure to one of the 
more specific and reliable enzymic procedures (Bullock, 1987; see 
section 8.4.1). After this change the gradual trend to less bias 
(smaller MRBIS) and better overall performance (lower MRVIS) over 
10 distributions (the running scores being cumulated from 10 BISs 
or VISs) can be seen. During this period the SDBIS increased, 
since there are two groups of differing BISs contributing, before 
falling again to reflect the true performance of the enzymic 
procedure.
9.4.2 Cumulation period
This 'lag' prompts consideration of another point relevant to 
scoring system design, namely the period over which data should 
be cumulated.
Ideally the scoring parameter used should be robust and stable, 
yet respond immediately to reflect fully any change in 
performance. Obviously, however, these are incompatible and a 
compromise must be reached through balancing the conflicting 
requirements. The balance chosen depends upon circumstances and 
priorities, so if interlaboratory agreement is good a shorter 
period may be allowable since individual scores are likely to be 
more homogeneous.
For example, OMRVIS is calculated in the UKEQAS for General 
Clinical Chemistry from 40 contributing VISs. During the 1970s 
and early 1980s many laboratories received scores for about 10 
analytes in each two-weekly distribution, giving an OMRVIS 
covering a period of about two months which was thus fairly 
sensitive to changes in performance but reasonably stable for
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Figure 9.10 Graph of running scores for paracetamol against time 
for a participant in the UKEQAS for Salicylate & 
Paracetamol, 1984-1987, showing effect of changing from 
chemical to enzymic assay procedure
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most participants. With the increase in 1986 to survey of 18 
analytes per distribution the OMRVIS perhaps covers too short a 
period and a change to use of 50-60 scores may now be indicated. 
In contrast, the monthly distribution frequency and return of 
results for fewer analytes by many participants in the 
International EQAS indicated 30 scores as a more appropriate 
basis.
For individual analytes a longer period must be tolerated, or 
instability could result. Here a 6-month period appears 
realistic, and thus 10 scores were selected for MRVIS, MRBIS and 
SDBIS calculation. Though some have suggested a longer cumulation 
(eg 40 scores; Wilson D et al, personal communication) deriving a 
running score from two years' performance will fail to reflect 
adequately changes in performance. Is 6 months too long, however? 
UKEQASs for hormone assay, though including more (24-30) specimen 
assessments, still use a 6-month window for performance 
assessment in terms of BIAS and VAR (Bacon et al, 1983) and this 
compromise appears to be generally acceptable to participants.
9.5 The detection of unsatisfactory performance
How can one determine which participants (if any) do not perform 
to a satisfactory standard? Again simple comparison with means is 
a complex procedure. Identification of laboratories producing 
'outliers' or results at the extremes of the distribution might 
be helpful, but neither lends itself to ready examination of 
results from more than a single distribution. Thus this appears 
another potential application for a scoring system.
Though it does permit cumulation, use of SDDs will always 
identify some laboratories as deficient, eg the worst 5% of 
participants, whereas their performance may be adequate for
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clinical application. More importantly, the criterion is 
dependent upon the performance of other participants, as 
described in section 9.3 above, so a laboratory is more likely to 
escape such classification if the general standard is poor.
Here a simple 'pass/fail' system seems ideal. If a sufficiently 
high proportion of a laboratory's results are classified as 
unacceptable, then the laboratory itself may be deemed 
unsatisfactory. There is flexibility in selection of the 
proportion required to fulfil this criterion, but it is 
inflexible with respect to the original definition of 
acceptability: if this is adjusted then considerable reprocessing 
of past data will be needed to provide continuity of 
surveillance.
Systems similar to VI scoring are more flexible in application. 
Firstly the basic scores calculated are objective, in that they 
are independent of other participants' performance. Secondly the 
thesholds applied for appraisal can be varied: they are not 
'tied' to any definition of the acceptability of individual 
results. Finally scores may be cumulated either across the range 
of assays offered by each laboratory (as an OMRVIS) or for 
individual analytes (as MRVISs), and in the latter case the MRBIS 
and SDBIS can also be appraised.
9.5.1 Application to UKEQASs
Such flexibility offers procedures suited to a wide range of 
applications. Within the UKEQAS for General Clinical Chemistry, 
participants' OMRVISs were used to select participants whose poor 
performance relative to other laboratories appeared to merit 
further examination. Initial appraisal was then through graphs of
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OMRVIS against time, to assess whether this selection represents 
an isolated instance or a continuing situation. Consideration of 
this information, together with graphical presentations of 
results for individual analytes (see sections 9.2.3 above and 
10.5.2), facilitated decisions on the need to approach the 
participant with an offer of advice and assistance.
These procedures were initially carried out by the scheme's 
Steering Committee, and later assumed by the National Quality 
Assurance Advisory Panel for Chemical Pathology (Browning, 1984; 
Walker, 1985) after the inception of these Panels in 1976. 
Similar protocols were subsequently applied using MRVISs for 
individual analytes within the UKEQASs for Lead in Blood, Urinary 
Pregnancy Oestrogens and Salicylate and Paracetamol. Within the 
urinary oestrogens scheme the SDBIS was used as an additional 
screeening index, since within-laboratory consistency of 
performance is the prime determinant of acceptability in the 
clinical application of serial monitoring within individual 
patients (Oakey, 1980; Bullock and Wilde, 1985).
With the continuing expansion of the general clinical chemistry 
scheme, which now includes 25 analytes, the risk of unacceptable 
performance for one or more analytes being concealed by 
satisfactory performance for the others (leading to a 
satisfactory OMRVIS) is increased. This indicates a need for 
closer surveillance of individual analytes in addition to 
surveillance of overall performance, and this has been addressed 
through the MRVISs.
Thus at each distribution graphs of laboratory result against DV 
(section 10.5.2) are produced for all participants with an MRVIS 
exceeding a threshold for each analyte. These are assessed in
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conjunction with the participant's MRVIS, MRBIS, SDBIS and 
method, and helpful interpretive comments are added by the scheme 
Organisers. The purpose is twofold: to ensure that the laboratory 
is aware of the apparent problem, and to assist in its 
resolution. The activity is conducted by the organisers rather 
than the Panel since such problems are mostly isolated analytical 
difficulties and do not appear to result from the major disorders 
of laboratory management which require Panel intervention 
(Browning, 1984).
Initially all thresholds were set at an MRVIS of 150, so that 
performance similar relative to the overall state of the art was 
highlighted for each analyte. This appeared undesirable, however, 
and adjustments were made to emphasise those analytes which are 
more critical for patient care. Thus for example the thresholds 
for potassium and calcium were lowered, whereas those for 
chloride and urate were raised. These changes were, however, 
relatively minor (giving a range of 130-160) and arbitrary in 
that they were not derived from medical requirements expressed as 
analytical goals.
9.6 The basis of assessment - state of the art or clinical 
requirements?
The relative merits of assessing laboratory performance against 
attainable standards or medical needs has always generated 
controversy. In the early years of EQA assessment against the 
state of the art was the only feasible procedure, tempered by 
later consideration of the effects of any errors on clinical 
care. Indeed, there had been no realistic estimate of clinical 
requirements, apart from Tonks' criterion of errors not to exceed 
one quarter of the 'normal range', as the reference interval was
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then called (Tonks, 1963) and various statements derived from 
subjective or even arbitrary views of individual clinicians (eg 
Barnett, 1968), as discussed by Fraser (1983).
Against this background many scoring systems were established 
using attainable performance as a baseline. For example, scoring 
in terms of SDDs or ! Z scores' had been widely practised in many 
surveys as a way of compensating for differences in 
interlaboratory agreement at varying analyte levels (Ley and 
Ezer, 1974; Wellcome Diagnostics, 1984). This also enabled 
expression in terms of a 'common currency' for all analytes, with 
similar performance relative to other laboratories giving scores 
of similar magnitude. In GFR the concept was amended to define 
limits of acceptability in terms of the SD obtained by reference 
laboratories, though the effect was similar (Stamm, 1975).
SDDs, however, remained dependent upon the general standard of 
performance, as shown in sections 9.3 and 9.4 above, and an 
advance was required. This came with the adoption of the best 
interlaboratory trimmed CVs attained in the UK in 1972 as the 
Chosen Coefficients of Variation (CCVs) in the VI system 
(Whitehead et al, 1975). The objective was to scale against 
analyte level and analyte performance in deriving an index of 
overall performance which could be used as an indicator of 
changes over time.
Other schemes chose systems related in some way to perceived 
clinical needs. Thus the Netherlands scheme (Jansen et al, 1977) 
assessed deviations from the DV in terms of a points scale, with 
for example the same percentage deviation giving a worse score 
for calcium than for urate. The principal disadvantage of this
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type of system is that it precludes combination of the scores 
obtained for the analytes surveyed unless all participants offer 
the same range of analytes. Otherwise a laboratory could 
artefactually 'improve' their assessment by refraining from 
reporting calcium results, which would score poorly.
In recent years more objective analytical goals for imprecision 
and total laboratory error have been established for many 
commonly-determined analytes, in relation to biological variation 
(Subcommittee on Analytical Goals, 1979; Eraser, 1983). These 
have been adopted as criteria of acceptability in some EQASs, 
such as that in Australia (Bowyer et al, 1981), giving 
performance standards which should be realistic estimates of 
clinical requirements. Performance criteria of similar derivation 
have also been proposed for use in GFR (Stamm, 1982), though 
they have not yet been endorsed in full.
These introductions have largely been in schemes using 
'pass/fail' criteria, for licensing or educational purposes. 
Since analytical goals are not at present met for most analytes 
(see Tables 2.1 and 9.1), these goals have not been implemented 
in their entirety or almost all laboratories would fail; this 
entails a further assumption of the level of performance which is 
acceptable. The quantitative performance information supplied 
through such schemes is rather limited in most cases, so the main 
emphasis in performance assessment remains on scoring systems 
based on the state of art. The problem of combining scores for 
different analytes remains, irrespective of the advances in 
derivation of the medical needs.
With the availability of analytical goals, state of the art 
systems can now be related to clinical requirements. Thus for
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example the goal for calcium of 0.8% (Eraser CG, personal 
communication) can be combined with the CCV of 4.0% to yield an 
acceptability criterion of 20 VIS (Table 9.1). Comparison of this 
figure with the average MRVIS of 67 for calcium at December 1986 
in the UKEQAS for General Clinical Chemistry emphasises the 
problems entailed by the use of medical needs in EQA.
Table 9.1 demonstrates that among the non-enzyme analytes average 
performance satisfies such goals only for potassium, urea, iron 
and bilirubin. For urea and bilirubin, however, clinical 
situations such as the detection of changes at elevated 
concentrations may make more stringent demands than the 
biological variation in normal subjects upon which these goals 
are primarily based. Similar arguments apply also to enzymes such 
as ALT and CK, for which the derived 'goals' of 19.7% and 35.8% 
CV (Eraser CG, personal communication) appear intuitively too 
permissive.
Given this continuing controversy, which basis is better? The 
choice depends on the purpose of the assessment, with state of 
the art assessment being more convenient and versatile in most 
EQASs, and clinical requirements providing a more objective 
appraisal of the extent to which the results of laboratory 
investigations can fulfil their potential in patient care. On 
balance, the best approach seems to be the use of a system such 
as VI for 'routine' application, with analytical goals being used 
to assist rational choice where particular decisions (such as the 
relative need for improvement for two analytes) have to be made.
9.7 Summary
A satisfactory scoring system facilitates participants'
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interpretation of information derived from EQA. Ideally the 
system should allow stepwise interpretation of increasingly 
detailed information:
- indication of whether overall performance is satisfactory
- indication of which analytes contribute most to overall 
variance
- indication of source of problem for each analyte
The scoring system should allow participants to compare their 
performance with that of other laboratories at the same time, and 
with their own past performance.
The scoring system should also assist in the detection of 
participants experiencing performance difficulties, so that 
assistance may be offered to them.
Variance Index (VI) scoring appears to fulfil these requirements 
for a scoring system, though it has some disadvantages. These 
relate to its being based upon the state of the art, and to 
potential problems caused by changes in this among analytes.
Scoring systems may be based on the state of the art or clinical 
requirements, though choice of the latter precludes combination 
of scores for several analytes. The best compromise is to use the 
former, and incorporate the latter to assist in appraisal of the 
clinical relevance of the scores.
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ASSESSMENT OF INDIVIDUAL LABORATORY PERFORMANCE
Chapter 10:
THE USE OF GRAPHICAL PRESENTATIONS OF EXTERNAL QUALITY 
ASSESSMENT DATA
10.1 Introduction
In any situation involving the appraisal of information graphical 
presentations can make the data much more readily comprehensible. 
EQA data are no exception to this general principle, though such 
presentations have not been used extensively by many schemes.
Graphical presentations of data can assist at each stage of the 
interpretive process in EQA, and examples of these will be 
presented in turn. Finally the reasons for their relatively 
sparse use will be examined.
10.2 Youden plots
The first true graphic presentations used in EQA were Youden 
plots, in which each participant's result for one specimen is 
related to their result for another specimen assayed at the same 
time (Skendzel and Youden, 1969). This was a natural extension of 
the application of such graphs in IQC procedures. It yields a 
crude impression of the contributions of bias and imprecision to 
overall variance, as discussed in section 3.2.3.
The presentation is therefore of limited value, and may be best 
employed in licensing or other schemes using an externally- 
derived DV to summarise participants' results without emphasising 
the consensus value. The licensing scheme in GFR provides an 
example of such use (Figure 10.1). Unfortunately, to provide 
uniformity of interpretation (since the acceptability limits are 
±3 SD) the axes are rescaled in multiples of the SDs obtained by
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Figure 10.1 Youden plot of results in participants' reports from 
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the reference laboratories, which makes location of the 
individual participant's result pair difficult.
10.3 Frequency distributions
Frequency distributions, in the form of histograms, scattergrams 
and bar charts, have been the main graphical representation used 
in EQA from the earliest surveys (Belk and Sunderman, 1947; 
Wootton and King, 1953) to demonstrate the dispersion of 
participants' results.
10.3.1 The distribution of results
Such histograms continue to enjoy wide use in EQA reports as a 
convenient means of displaying all results received. For use in 
participants' reports they are usually scaled (often at the DV +2 
SD) to fit into a defined space within the report, and other 
refinements include the indication of where the individual 
laboratory's result lies. This type of presentation is 
exemplified in Figure 10.2 for lead and cadmium in the UKEQAS for 
Lead in Blood.
Despite their ready production and wide usage, however, these 
histograms convey only limited information, as discussed in 
section 9.3. Their principal contribution is to reveal the nature 
of the distribution of results, whether Gaussian or other, as a 
reassurance for scheme organisers and participants. The 
interpretation of individual performance on this basis is 
frequently ineffective (see section 9.3), though modification of 
their format to reinforce criteria of acceptability, as in Figure 
9.6, may extend their utility.
It therefore appears appropriate to suppress their inclusion in 
participants' reports when a scheme reaches a certain maturity.
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Figure 10.2 Histogram presentation of results for lead and 
cadmium in UKEQAS for Lead in Blood
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This stage is dependent upon balancing the useful content against 
the resources consumed in their production. The principal factors 
are the assay maturity, reflected in the interlaboratory 
agreement, and the number of participants. Thus the information 
content is minimal where a large number of laboratories produce 
gaussianly-distributed results with very close agreement; sodium 
assay in many schemes is a prime example. The UKEQAS for General 
Clinical Chemistry therefore ceased during 1984 to provide 
histograms of results in participants' reports. Where there are 
few participants, however, the distribution of results is more 
variable (especially with less reliable assays) and there would 
also be less saving from their omission.
10.3.2 The distribution of scores
The distribution of scores can be more informative. Such 
histograms (eg that in Figure 9.1) show the best performance 
attained by participants and thus provide an additional stimulus 
to improvement by other laboratories, as explained in section 
9.2.1.
In the more detailed examination of performance for an individual 
analyte, a graphical presentation of bias against consistency of 
bias conveys useful information on the performance of individual 
participants and of analytical procedures. Figure 10.3 shows an 
example of a 'football pitch' presentation of BIAS and VAR data 
for TSH in the UKEQAS for Thyroid-related Hormones. The limits of 
acceptable performance form the 'goal area', with the origin 
representing the ideal performance of a consistent zero bias from 
the ALTM. In such a summary presentation it is easy for a 
laboratory to assess its performance in terms of bias and 
consistency, relative to other laboratories and to criteria of
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Figure 10.3 Presentation of participants' BIAS against VAR for 
TSH in UKEQAS for Thyroid-related Hormones. 'Goal area' 
represents limits of acceptable performance (+_25% for BIAS, 
25% for VAR)
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acceptability.
This also provides a means for a combined assessment of these two 
aspects of performance, which are usually interpreted separately, 
as an indication of overall performance. Thus a laboratory may be 
content with its BIAS and VAR of +17% and 17%, since they are 
well within the criterion of <25%, and believe its performance 
superior to that of a participant with a VAR of 23%. If, however, 
equal weight is attached to both indices (which is in turn a 
matter to be decided for each analyte) then the other laboratory 
will be closer to the ideal if it has a bias of less than 7%. 
Indeed, the rectangular 'goal area' might be better replaced by a 
semi-oval objective of weighted total error; a similar argument 
would replace the square zone of acceptability in Figure 10.1 
with a circle (in SDs: in reality an ellipse; Roehle et al, 1986)
The separate presentations in Figure 10.3 permit method 
performance to be evaluated more readily than can be done from 
the average scores alone. This can be purely by eye, as for 
example the pattern of negative bias for the Wellcome group in 
Figure 10.3, or using pattern recognition techniques (Jansen et 
al, 1981; Jansen, 1983). The use of such information is discussed 
in Chapter 8.
10.4 Assessment of performance over time
The graphical presentation of performance, usually in the form of 
scores, over a period can be most valuable in the assessment of 
any changes which have occurred. Such considerations apply both 
to any cumulation over analytes as an index of overall 
performance and to scores for a single analyte.
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10.4.1 Overall performance
Section 9.2.1 describes the procedure for appraisal of 
laboratories with apparently poor overall performance in the 
UKEQAS for General Clinical Chemistry, using plots of OMRVIS 
against distribution. An example of such a laboratory is given in 
Figure 9.7, and Figures 10.4A and 10.4B show further examples of 
consistently good and improving performance. This presentation 
summarises performance over about two and a half years, including 
contribution from around 7500 individual results or scores for 
this laboratory, in a readily comprehended format. Similar 
presentations have been or could be devised for other schemes and 
scoring systems.
By use of conventions, other information can also be included. 
For example non-return of results for a distribution is denoted 
by the lack of a line connecting this score to that for the 
preceding distribution. The OMRVIS remains the same because it is 
not updated; Figure 9.8 contains many such examples.
10.4.2 Performance for individual analytes
Scores for individual analytes within multi-analyte EQASs or in 
single-analyte schemes can be treated in exactly the same manner. 
Thus Figures 10.5 and 10.6 show plots of MRVIS against 
distribution for calcium in the UKEQASs for General Clinical 
Chemistry and for blood lead assay. Interpretation is exactly as 
for the overall situation discussed above, except that only 60 
results are covered by the period of the graph.
The same format can be used for more detailed performance 
indices, such as MRBIS and SDBIS. Figure 10.7 gives an example of 
these in conjunction with the MRVIS. Here the laboratory has a 
negative bias, consistent apart from specimen 270 (BIS = -379).
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Figure 10.4 Changes in OMRVIS for participants with (A) good and 
(B) improving performance in UKEQAS for General Clinical 
Chemistry
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Figure 10.5 Changes in MRVIS for calcium for a participant in 
UKEQAS for General Clinical Chemistry
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Figure 10.6 Changes in MRVIS for a participant in UKEQAS for Lead 
in Blood
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Figure 10.7 Changes in MRVIS, MRBIS and SDBIS for a participant 
in UKEQAS for Urinary Pregnancy Oestrogens
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The interpretation of Figure 9.10, showing changes in performance 
for paracetamol assay, is similarly discussed in section 9.4.
10.5 Assessment of results for an individual analyte
Useful though graphical presentations are in the assessment of 
overall and analyte-related performance, it is in the appraisal 
of the individual results obtained for an analyte that they are 
of most advantage in EQA data interpretation. The procedures used 
depend upon the scheme design.
10.5.1 Linearly-related specimens
The general procedures have been discussed in section 3.2.3 
above. In summary, the results are related to the proportions in 
each specimen to yield a plot of result against analyte 
concentration, as demonstrated in Figure 10.8. Here the data 
reveal patterns of bias, imprecision and nonlinearity. Regression 
analyses can provide statistical evidence to suggest and confirm 
such patterns, but they are much more obvious and striking when 
presented in graphical form.
Though the specimens involved are not linearly-related, the 
'intensive EQA' scheme design described in section 3.2.3 also 
uses this type of presentation in addition to VIS parameters. 
Interpretive comments are added after consideration by the scheme 
organisers, since three points provide only an approximate guide 
to the laboratory's true performance and experience is needed to 
extract maximal information. Interpretations are clear in many 
cases, however, such as the patterns of bias and imprecision 
revealed in Figure 10.9.
10.5.2 Cumulation procedures
An alternative procedure to obtain similar information on the
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Figure 10.8 Example plots of laboratory result against analyte 
concentration for a set of linearly-related specimens.
Patterns of bias, imprecision and nonlinearity shown
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Figure 10.9 Graphs of laboratory result against designated value 
for participants in an 'intensive' EQA scheme, showing (A) 
bias and (B) imprecision
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relationship between a laboratory's results, as outlined in 
section 3.2.3, is to cumulate data from a number of 
distributions.
Appraisal of scores such as the MRBIS and SDBIS or BIAS and VAR 
gives a reasonable impression of the errors contributing to a 
laboratory's overall performance, but unless there is excellent 
performance or simply a consistent proportional bias (eg for 
amylase in Figure 9.4) examination of this type of presentation 
is essential to gain a reliable assessment. This is necessary in 
particular to prevent equating an index such as SDBIS or VAR with 
within-laboratory imprecision, since these in fact reflect 
consistency of bias and an inconsistent bias may be due to one or 
more of a number of factors.
These presentations, exemplified in Figure 10.10 for two analytes 
in the UKEQAS for General Clinical Chemistry, thus reveal the 
type of errors contributing to the laboratory's overall variance. 
As outlined in section 9.2.3 above, a number of patterns are 
commonly seen:
- good performance
- consistent proportional bias
- compensating proportional and constant biases
- nonlinearity
- imprecision
- short-term changes in bias
To distinguish between imprecision and short-term bias changes 
and to assess whether performance is improving it is essential to 
have information on the temporal relation between the points. 
Such plots, however, do not contain this unless the points are
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Figure 10.10 Graphical displays of results against designated
values for sodium and amylase for participants in UKEQAS for 
General Clinical Chemistry. See Figure 10.11 for tabular 
displays
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identified by their distribution number (eg Figure 10.9). 
Simultaneous comparison with a chronological tabulation of the 
data, as shown in Figure 10.11, is a convenient means of gaining 
this extra dimension; the contribution of any changes in method 
can also be thus assessed. Here the variability indeed appears to 
reflect imprecision for amylase, but a change from positive to 
negative bias in the case of sodium.
The benefit of the graphical presentation can be gauged from 
comparison with Figure 10.12, a tabular display of similar data 
for TSH from the UKEQAS for Thyroid-related Hormones. This gives 
the result and ratio to the DV for each result in a 6-month 
period, arrayed in chronological (left to right) and 
concentration (top to base) order. This presentation has 
advantage in schemes with multi-specimen distributions and if 
each specimen is distributed repeatedly, especially if changes in 
bias from distribution to distribution are common. In most cases 
it is more difficult to distinguish concentration-dependence, 
however, and the format is much less informative in schemes with 
single-specimen distributions and few repeated distributions.
How many distributions should be included in these plots? The 
number used should be sufficient to delineate the relationship, 
yet not cover such a long period as to allow changes in 
performance to obscure it. This obviously requires compromise, 
with choice extending from one (as in the intensive scheme design 
mentioned above) to over 20, though 10 results (covering 5-10 
months with fortnightly or monthly single-specimen distributions) 
appears suitable for many applications. Even so, the temporal 
relationship must always be examined to identify any changes in 
bias which have occurred during the period covered.
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Figure 10.11 Tabular displays of results and designated values 
for sodium and amylase for participants in UKEQAS for 
General Clinical Chemistry. See Figure 10.10 for graphical 
displays
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Figure 10.12 Tabular display of results and ratio to designated 
value for TSH for a participant in UKEQAS for Thyroid- 
related Hormones
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10.6 Use of graphical presentations by EQASs
Since graphical presentations are of great benefit in improving 
the convenience and reliability with which conclusions may be 
drawn from EQA data, why have they not been used much more 
widely? The main reasons relate to their applicability and the 
resources required.
10.6.1 Application
In most schemes covering reasonably 'mature' assays the majority 
of participants have acceptable performance. Though general 
improvement remains a goal of the scheme, across-the-board 
provision of detailed graphical information is probably 
unnecessary, since most participants probably do not require it, 
and potentially counter-productive, since reports (as discussed 
in section 3.4.1) should be concise and routine provision of 
overly detailed information can lead to it being ignored.
Resources should therefore be concentrated on the areas where 
they will be of most use in improving the reliability of patient 
care, ie in addressing first the problems of those participants 
with the worst performance. Such presentations convey the 
greatest amount of information where a problem exists, as 
discussed in section 9.2. Where performance is good they provide 
little more than reassurance, which could be derived more 
economically from a well-designed scoring system: eg if a 
laboratory has an MRVIS of 30 there is probably little scope for 
improvement and a plot of results against DV would reveal no more 
than do their MRBIS and SDBIS of -23 and 29 respectively.
Provision of graphical presentations only for participants with 
apparent problems also has other benefits. The laboratories are
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much more likely to take note of them, since they do not form 
part of the usual report from the scheme and should therefore 
stimulate awareness that a problem exists and hopefully activity 
towards its resolution. The laboratory may also gain the 
psychological benefit of feeling the someone is aware of their 
existence and problems and is taking an interest in them.
Though provision of the more detailed graphical presentations 
should be concentrated on those most in need, the periodic 
distribution of graphs summarising performance scores against 
time appears beneficial. This can be combined with a review by 
the scheme organisers and relevant comments added where there 
appear to be problems, and may also stimulate participants to 
maintain such graphs on a prospective basis.
10.6.2 Resource implications
In essence provision of true graphical presentations is very 
expensive in resource terms. This has been so from the earliest 
days, when they had to be prepared by hand, and the advent of 
computers has not so far altered this.
Histograms, however, can readily be produced on any printer, and 
this may explain their continued popularity in EQAS reports. 
Participants and organisers alike feel that graphical 
presentations are useful, and provision of histograms in some way 
satisfies participants' appetites and salves organisers' 
consciences. As outlined in sections 9.3 and 10.3.1 above, 
however, these formats are far from ideal and their suppression 
should be considered since they may be conveying little useful 
information.
'True' graphics have required investment in computer hardware
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dedicated to their production. Initially this would have been a 
plotter, expensive and very slow though capable of producing very 
high quality output, and the associated software for data 
extraction and display; graphical output was therefore restricted 
to the most essential cases. A later introduction was the 
graphics terminal with associated printer, still expensive but 
faster (especially when combining text with graphics); though the 
quality available was inferior output was sufficiently detailed 
for most purposes. More recently development of increasingly 
sophisticated software has permitted use of much cheaper dot 
matrix printers to produce output of quality similar to that of 
graphics terminals even from microcomputers. Such production, 
however, remains relatively slow and it is still difficult to 
combine graphical presentations within the body of a printed 
report, especially since large schemes require use of a line 
printer to produce the large volumes of high quality text output 
which are needed.
Greater utilisation of graphical presentations may become 
feasible in the future, as the development of computer 
peripherals continues at an ever-increasing rate. Modern software 
offers flexibilty in the combination of text and graphics within 
the same screen framework, and laser or electrostatic printers 
the possibility of generating very high quality output for report 
production. Figure 10.13 shows an example of such a report 
format, from the Netherlands NEQAS. This combines tabular 
statistical and bar chart presentations of data from the current 
distribution, and also a summary of the laboratory's results from 
past distributions in a composite Youden plot.
Such technology is still new, however, and not yet fully
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Figure 10.13 Eaxample of mixed text and graphical presentation of 
data in participant's report from Netherlands national EQAS
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reliable. It also remains relatively slow, with very high capital 
and operating costs to attain the throughput required. Though its 
use is feasible in a scheme with 150 participants and two-monthly 
distributions, it is not yet practicable for schemes such as the 
UKEQAS for General Clinical Chemistry with its 550 paricipants 
and two-weekly distributions. Such systems nevertheless offer 
great promise for future application; use of colour graphics may 
similarly become feasible as more reliable and economic dot 
matrix and ink-jet printers are developed.
10.7 Summary
Graphical presentations assist greatly in facilitating the 
interpretation of EQA data, for participants and scheme 
organisers.
Simple presentations such as histograms of results have been 
widely used because of their ready production, though their 
information content is limited. Modifications may increase their 
usefulness, but if there is good interlaboratory agreement their 
omission from reports should be considered.
Graphical displays of performance scores against time incorporate 
much information and are very valuable in the assessment of 
participants' progress. Laboratories should be provided with such 
graphs at intervals and encouraged to maintain them between these 
times.
In the investigation of factors contributing to overall error 
for an individual analyte, plotting the participant's results 
against designated values is most valuable. Such graphs may be 
derived from distribution of multiple specimens, or from data 
cumulated over 5-20 distributions. Where information is cumulated
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the presentation must include, or be supported by, information on 
the time relationship of the results.
Presentations other than simple histograms have been used only 
infrequently by most schemes, partly to confine such effort to 
cases where special effort is needed to stimulate improvement. A 
major limitation, however, has been the cost and time involved in 
such production. Newer technology now offers the prospect of 
cheaper and faster systems to provide high quality output, 
combining graphical and text elements.
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ASSESSMENT OF INDIVIDUAL LABORATORY PERFORMANCE
Chapter 11:
STUDIES OF FACTORS AFFECTING PERFORMANCE
11.1 Introduction
External quality assessment provides an excellent means of 
assessing the analytical performance of individual laboratories 
and stimulating improvements where these are needed, and also of 
assessing the overall state of the art and any changes, as 
discussed above. For participants to improve, however, guidance 
on factors which may affect performance is helpful so they can 
take any necessary action.
The analytical procedure (instrument, reagents and method) 
used is one of the major factors involved, and EQA data have been 
shown in Chapter 8 to be valuable in assessing the relative 
reliability of the procedures used by scheme participants. Can 
information derived from EQA surveys and schemes also assist in 
the appraisal of other contributory factors? Experience confirms 
this expectation, and the application of EQAS data in the 
Nuffield survey will first be reviewed to illustrate general 
principles.
11.1.1 The Nuffield survey of factors affecting analytical 
performance in clinical chemistry laboratories
Though earlier appraisal of UKEQAS data (Whitehead et al, 1973) 
had revealed that participants with greater workloads performed 
better, this survey (Maclagan et al, 1980), sponsored by the 
Nuffield Provincial Hospitals Trust, was the first major 
systematic attempt to identify factors contributing to laboratory 
performance. The working party, drawn from all clinical chemistry
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professions, obtained information by questionnaire from and 
visited in 1976-1977 an apparently representative sample of 68 
UKEQAS participants. The indicator of performance used was the 
OMRVIS, shown in those 40 laboratories participating in both 
schemes to correlate significantly with repeatability-related 
indices in the Wellcome Group QC Programme. The lesser 
correlation with the Wellcome bias index might be expected, since 
VISs are calculated relative to method means in the UKEQAS.
Using a variety of statistical procedures, the study identified 
several factors which were related to analytical performance. 
The elements considered included both objective data, such as 
laboratory costs and workload, and subjective impressions of 
staff quality and morale. Factors aiding differentiation of 
laboratories with good and poor performance were also studied. 
Factors with the strongest relation to performance included:
- large laboratory size (whether assessed by workload, 
staffing, area, equipment cost, etc), though the 
relationship was no longer significant when workload 
was expressed relative to other size parameters (eg 
as requests/staff)
- cost of calibration serum/request, and use of serum-based 
calibrants
- management team scores (rather than scores from individual 
professional groups)
- independence of clinical chemistry laboratory, with a full- 
time head of department
Causal relationships could not be inferred, however, and many 
factors were significantly inter-related. Though the working 
party noted exceptions to these relationships, consideration of
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the various factors appeared to enable identification of a 
general pattern likely to be associated with good performance. 
Elements such as management and organisation are also vital, 
since no single factor or combination could predict accurately 
the performance of all laboratories. Importantly, the study 
excluded consideration of the choice of analytical method, 
discussed in Chapter 8 above, though automated equipment 
(predominantly SMA systems) appeared to yield better performance, 
as noted earlier (Whitehead et al, 1973).
The Nuffield survey thus delineated a number of often inter­ 
related factors associated with performance for general clinical 
chemistry analyses, and stressed the importance of laboratory 
management and organisation within the general meaning of quality 
assurance. Are these conclusions still valid, and do they apply 
equally to all clinical chemistry investigations?
11.2 The influence of laboratory workload on performance
Overall laboratory workload influences and is influenced by many 
other aspects of laboratory size, as reported above. Thus for 
instance departments with high clinical chemistry workloads are 
likely to use automated rather than manual procedures, to have 
more and better-qualified staff, and to be independent of other 
pathology disciplines. All these would intuitively be expected to 
be conducive to better performance for at least those assays 
forming the bulk of this work.
When workload becomes excessive in relation to the resources, 
however, performance is likely to suffer. Thus a significant 
relationship between performance ranking in the Wellcome scheme 
and technologist workload was found in Canada by Whitlow and 
Campbell (1983).
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11.2.1 Effects on overall performance
Data from the UKEQAS for General Clinical Chemistry, exemplified 
by the observations of Whitehead et al (1973) and Maclagan et al 
(1980), have continued to bear out the main expectation. This 
effect remains substantial, with in 1987 average OMRVISs of 64 
and 56 for laboratories with workloads of <100,000 and >500,000 
tests/year (Figure 9.1).
The relationship is consistent, as demonstrated in Figure 11.1 
where the differences persist through increases in average 
OMRVIS. These increases were due to a period in which 
distribution of a succession of 'normal' materials, and to the 
incorporation of VISs for enzyme activity assays into OMRVIS 
calculation. Table 11.1 demonstrates that similar relationships 
also hold within sub-groups of UKEQAS participants, eg those 
in Eire.
11.2.2 Effects for single analytes
The balance of contributions changes when individual 
determinations are considered. Though the overall factors should 
still have an effect, other more specific aspects also become 
important. These relate mostly to familiarity with the procedure 
used, which is likely to be greater with the assay of more 
frequent and larger batches. IQC procedures are also facilitated 
and more efficient in such circumstances.
Table 11.2 demonstrates this association for blood lead assay 
(Bullock et al, 1986c). Plotting performance (as MRVIS) against 
workload did not show a clearcut relationship, but classification 
according to the criterion of acceptability for occupational 
monitoring under the Lead at Work Regulations (Health and Safety
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Figure 11.1 Average OMRVIS for groups of participants in UKEQAS 
for General Clinical Chemistry, 1984-1986. Size group I 
<100,000, II 100,000-500,000, and III >500,000 tests/year; 
arrows show a period of predominantly 'normal' materials and 
the inclusion of VISs for enzymes in OMRVIS calculation
260 280 300 320
Distribution (1984-1986)
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Table 11.1 Performance (average OMRVIS) for groups of
participants in UKEQAS for General Clinical Chemistry,
December 1986. See Figure 11.1 for size group definitions
	n Average OMRVIS
All participants 531 57
- size group I 195 62
- size group II 208 55
- size group III 123 53
UK NHS 405 55
- size group I 99 60
- size group II 192 55
- size group III 114 53
UK private sector 59 63
- size group I 56 65
Eire 25 62
- size group I 11 64
- size group II 11 62
- size group III 3 52
Armed forces - UK 8 63
- overseas 6 81
Pharmaceutical industry 11 63
Overseas 5 70
Veterinary 5 71
University (clinical research) 3 53
Equipment/reagent manufacturer 3 43
Other laboratory 2 59
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Table 11.2 Performance (1981) of participants in the UKEQAS for 
Lead in Blood classified according to annual blood lead 
assay workload (1980) and interval between batches, p <0.001 
in both cases
Number of laboratories
MRVIS 0-80 MRVIS >80
Annual workload:
0 - 1000 tests/year 
>1000 tests/year
25
39
16
Average batch interval:
1 day - 1 week
>1 week
54
10 10
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Commission, 1980) reveals significant associations for both 
workload parameters. The assay is specialised and technically 
demanding, so correlation with the workload for the individual 
analyte would be expected, whether carried out in a specialised 
occupational or environmental monitoring laboratory or in a 
section within a much larger clinical laboratory.
Neonatal PKU screening provides a similar situation, and Figure
II.2 shows a graphical presentation of performance (Appendix
III.3.1) against annual workload. Performance can be expressed in 
terms both of average scores and of turnround time (see section 
8.4). Here there is also no clearcut relationship, but a definite 
association with both aspects of performance is apparent.
For urinary pregnancy oestrogen assay the IQC problems have
/ 
probably become increasingly important as the clinical use of
this determination has declined in recent years. Many 
laboratories have ceased to offer a service as physical 
monitoring of foetal well-being has superseded biochemical means, 
and most other participants have a decreasing workload. Batch 
frequency has also tended to decrease, despite the dependence of 
clinical usefulness upon rapid availability of results (Wilde and 
Oakey, 1975). The situation in 1985 is summarised in Figure 11.3. 
Again no clearcut distinctions can be made, but definite trends 
are apparent. Recent deterioration in overall performance, 
following previous major improvements (Figure 3.1; Bullock and 
Wilde, 1985), confirms that an assay done in smaller numbers and 
(in many laboratories) less frequently is likely to show 
suboptimal performance.
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Figure 11.2 Relationship to annual workload of (A) average score 
for Surveys 15-19 and (B) turnround time in UKEQAS for PKU 
Screening
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Figure 11.3 Relationship to (A) 1984 annual workload and (B) 1985 
batch fregency of performance (MRVIS at June 1985) in UKEQAS 
for Urinary Pregnancy Oestrogens
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11.3 The influence of laboratory type on performance
The type of laboratory may also have a bearing upon performance. 
In some cases this might be due to differing assay requirements, 
and in others to variation in the facilities available.
Thus examination of performance in the UKEQAS for Lead in Blood 
(Table 4.1; Bullock et al, 1986c) reveals differences in average 
MRVIS. The laboratories carrying out the assay for environmental 
monitoring purposes perform better, perhaps reflecting their need 
to provide precise and accurate results at lower lead 
concentrations. Differences according to the type of 
establishment were much less consistent, suggesting that the 
assay purpose is the primary factor determining performance for 
an individual determination.
For overall performance, however, the only main distinction that 
might be made would be between assays carried out for diagnosis 
or monitoring of therapy and those for screening. Since very few 
UK laboratories deal primarily with the latter, this is not 
susceptible to reliable study. The type of laboratory providing 
the analytical service may also be a determinant of performance, 
and this can be studied more readily through UKEQAS data.
Table 11.1 thus gives average performance data for the various 
groups of laboratory participating in the UKEQAS for General 
Clinical Chemistry. The overwhelming majority are UK National 
Health Service (NHS) laboratories, with several small more 
specialised groups such as those in the pharmaceutical industry 
conducting assays in drug toxicity testing. The other groups of 
appreciable size whose performance may then be compared with that 
of the UK NHS laboratories are the UK private sector and 
laboratories in Eire.
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On overall appraisal the performance in the private sector 
appears considerably worse than that of NHS laboratories. One 
potential confounding factor is laboratory size, discussed in 
section 11.2.1 above. Most of the private sector laboratories are 
in size group I (<100,000 tests/year), and comparison should 
therefore be with this group. This, however, fails to account 
fully for the difference seen. Other factors are undoubtedly 
involved, therefore, and it must be remembered that many of these 
laboratories are small multidisciplinary units without full-time 
supervision by a medical or non-medical clinical chemist. The 
association of such factors with poor performance was highlighted 
by the Nuffield survey (section 11.1.1 above; Maclagan et al, 
1980) and later by the Advisory Panel, who described a "small 
laboratory syndrome" deriving primarily from professional 
isolation which appeared to be linked with poorer performance 
standards (Browning, 1984). The performance of the three larger 
private sector laboratories (average OMRVIS 29) compares 
favourably with that of the larger NHS laboratories. An 
additional influence is the relatively recent (1984-1986) 
establishment of some private sector laboratories, and their 
consequent position on the 'learning curve' of EQAS participation 
as discussed in section 9.4.1.
The performance of the Irish laboratories also appears worse to 
that in the UK NHS. Again many of these are smaller laboratories 
and the comparison should therefore be with the corresponding 
size groups in the UK, though this still suggests inferior 
performance. These participants are mainly the larger 
laboratories in Eire, so the factors described above apply to a 
lesser degree. Nevertheless, geographical isolation may also
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contribute to their problems. Examination of data from previous 
years suggests that improvement is occurring gradually. For 
example their average OMRVIS in 1982 was 77 (UKEQAS overall 
average 62), with 4 of 25 laboratories having a OMRVIS >100, 
whereas now none have such a score.
11.4 Summary
EQA data provide a convenient means for identifying factors which 
may be associated with good or poor performance. The Nuffield 
survey provides a good example of a systematic study of such 
factors. Problems of such studies include the inability to 
establish a causal relationship and the strong inter-relation 
among many of the factors. This may lead to identification of a 
general pattern rather than of specific factors.
The main factor identified is large laboratory size, conveniently 
reflected as annual workload, provided resources are commensurate 
with the workload undertaken. UKEQAS data confirm this 
association of laboratory size with better overall performance. 
For individual determinations there is also an association with 
batch frequency. The clinical application of the assay may be 
important, eg in blood lead assay for environmental monitoring.
A second important factor is the laboratory's organisation and 
general attitude to maintaining professional standards. The 
effects of professional and geographical isolation in inducing a 
"small laboratory syndrome" associated with poor performance are 
seen through comparison of UK private sector and Irish 
laboratories with those in the UK NHS. Such comparisons must also 
take into account the association of laboratory size with 
performance.
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ASSESSMENT OF QUALITY CONTROL MATERIALS
Chapter 12:
THE SUITABILITY OF QUALITY CONTROL MATERIALS FOR EXTERNAL 
QUALITY ASSESSMENT
12.1 Introduction
Any quality assurance activity can only be as reliable as the 
reference or QC material used. Effective EQA thus demands that 
the specimens distributed are stable and have properties which 
reflect faithfully the behaviour of clinical specimens; defined 
as "fidelity" by Fasce et al (1973).
As described in section 3.3, clinical chemistry is concerned 
primarily with determinations on serum or plasma specimens from 
(human) patients and subjects; serum will be used as the main 
example, though similar considerations apply to other biological 
fluid or tissue specimens. To be most effective, therefore, QA 
procedures should ideally use serum from these patients or 
subjects as the QCM. Such materials, however, present problems 
of instability, infectivity and restricted availability. 
Commercial products, especially those stabilised by freeze- 
drying, are convenient and relatively free from these problems 
and are therefore used widely. The properties and limitations of 
such specimens must be considered, and in relation to their 
intended use since a QCM may be suitable for one analytical 
situation but not another (Stamm, 1979; Btittner et al, 1980a).
The main categories of QCM use, also discussed in Chapters 13 and 
14 are:
- precision control in IQC
- bias control in IQC
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- bias control in EQA
- calibration of assays
- method comparison
12.1.1 Precision and bias control in IQC
Where QCMs are used in IQC, their properties must be as close as 
possible to those of clinical specimens to ensure that faults in 
the analytical method leading to erroneous results for specimens 
from patients are detected.
Ideally, therefore, materials used for IQC should be as 
responsive to changes in assay conditions as are clinical 
specimens, since in this way all 'out of control' situations 
should be detected while no satisfactory batches would need to be 
repeated. These requirements apply irrespective of whether the 
material is used for precision control only (with a value defined 
within the user laboratory), or has an assigned value for the 
method used and is also used in bias control.
12.1.2 Bias control in EQA
In EQA, the QCM must be stable, and the precision for the QCM 
should be identical to that for clinical specimens. If the 
designated value against which a participant's result is assessed 
is derived using an identical analytical procedure, eg for CK an 
assessment of laboratories using the 'European' NAC-activated 
procedure at 37°C against the consensus value for that method, 
there is no further requirement on QCM properties (though an 
animal-based QCM would not be ideal for assessing, for example, 
albumin assay).
In other cases, however, the designated value is for all methods, 
or for a group of methods (eg methods for AST without addition of
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pyridoxal phosphate). Such applications are exemplified by the 
'new concept 1 proposed in GFR (Stamm, 1982). Here the QCM's 
response to differing analytical procedures within the grouping 
used should be the same as the response of clinical specimens. 
This requirement is for 'commutability'.
This property was defined originally by Fasce et al (1973) as 
"the ability of an enzyme material to show interassay activity 
changes comparable to those of the same enzyme in human serum", 
but the clearer and more general definition "the consistency of 
the relationship between results obtained by different analytical 
methods for control specimens and patients' specimens" (Bullock 
et al, 1980b; Broughton et al, 1981) is preferable.
Commutability is of vital importance in EQA if information on 
laboratory and method performance is to be reliable (Bretaudiere 
et al, 1974 and 1981a; Rej et al, 1984). The QCMs distributed 
must therefore be commutable or the scheme design be such as to 
render negligible the effects of any lack of commutability: the 
use of method means as designated values is one such solution. If 
not, participants will not have confidence in the information 
generated by the EQAS and the scheme will fail in its objectives.
12.1.3 Calibration of assays
For a calibration material used for a single method, which is 
assumed to be in control, the only requirements are for a known 
activity (ie reliable assigned value) by that method and for this 
activity to be stable. If a calibration material is to be used 
to convert results obtained by different methods, however, there 
is also a requirement for it to be commutable with fresh human 
sera for the methods concerned, as discussed in Chapter 13 and 
for enzyme activity assays by Moss et al (1985).
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12.1.4 Method comparison
Again for method comparison the primary requirement is for 
commutability, with long term stability being of lesser 
significance. Methods for any analyte should, however, be 
evaluated primarily with clinical specimens rather than with 
QCMs.
Additionally, comparisons or cross-calibration between methods 
are valid only if specimens from patients are also commutable 
between the methods: ie there is no between-specimen variation in 
the relationship between results obtained using the two methods. 
Any link between methods must therefore be made by assaying 
clinical specimens by both methods, and then checking that use of 
the reference material as a calibrant leads to full recovery of 
the activities (ie obtaining the same numerical results) for the 
specimens (Moss et al, 1985).
High density lipoprotein (HDL) cholesterol assay provides a good 
example of the problems which may be encountered in the 
application of QCMs in IQC and EQA, due to differences in 
properties. The use of lyophilised materials with direct-reading 
ISE instruments for sodium and potassium assay provides further 
examples of such difficulties. The requirements for enzyme 
reference materials and calibration materials are considered in 
more detail in Chapter 13.
12.2 High density lipoprotein (HDL) cholesterol assay
Following the demonstration of an inverse correlation with the 
incidence of ischaemic heart disease in epidemiological studies 
such as the Framingham Study (eg Castelli et al, 1977, Gordon et 
al, 1977) there has been considerable interest in recent years in
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the measurement of HDL cholesterol in serum. Though the 
interpretation of results in individual subjects remains 
controversial, many laboratories have introduced this assay (eg 
Ballantyne, 1984).
Methods for HDL isolation have been known for many years (eg Cohn 
et al, 1946; Burstein et al, 1970). Based on this work, many 
methods and variants thereof have been proposed for selective 
precipitation of other lipoproteins followed by estimation of 
cholesterol in the supernatant; such methods are widely used and 
have been compared (eg Warnick et al, 1979). Ultracentrifugal 
separation of HDL, though regarded as a reference procedure, is 
unsuitable for routine use, and though electrophoretic separation 
has been proposed it has been shown to be insufficiently precise 
(Goldberg, 1978; Bullock et al, 1980a).
Since interlaboratory agreement must be excellent to permit the 
use of common criteria for interpretation, and this had been 
shown to be poor in the UK (Bullock DG, Carter TJN, Whitehead TP, 
personal communication) and overseas (Boerma, 1979; Hainline et 
al, 1980; Warnick et al, 1980), a move towards towards 
standardised methods, previously shown to be effective in lipid 
assays (Lippel et al, 1978), appeared desirable. To this end, 
provisional recommendations for the two precipitation procedures 
- those based on phosphotungstate/Mg2+ (PhT) and heparin/Mn2+ 
(Hep) - used most widely were published for comment (Whitehead et 
al, 1979).
For this or other initiatives to be successful, however, suitable 
materials must be available for calibration, IQC and EQA. The 
choice of a QCM for HDL cholesterol assay is particularly
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difficult: lipoproteins are complex entities of variable and 
species-dependent composition and have limited stability, and the 
precipitation procedures rely on their physical rather than 
chemical properties. Fresh human serum is therefore the ideal, 
but this is neither possible for IQC nor practicable for EQA and 
it would therefore be of great advantage to supplement the 
inadequate procedures (Bullock et al, 1980b) with lyophilised 
materials.
Some lyophilised QCMs, however, were known to lack fidelity and, 
in particular, shown to be non-commutable with fresh sera even 
for simple organic analytes and for enzyme activity assays (eg 
Bretaudiere et al, 1974; Saidi, 1979; van Helden et al, 
1979). Combination of factors such as non-human origin of 
the base serum, lack or excess of physiological 
interferents, addition of impure or non-physiological 
compounds and extracts with the disruptive effects of 
freeze-drying on lipoproteins suggests that the situation 
for HDL cholesterol assay could be considerably worse.
In this situation empirical study of a broad selection of 
materials is essential, and such an investigation was therefore 
undertaken. Several of the materials appearing to have properties 
suitable for use in EQA were then distributed to a small group of 
laboratories in a limited survey, to validate this conclusion.
12.2.1 Investigation of commercial QC sera
The study (Appendix III.5; Bullock et al, 1980b) comprised 
assessment of the mean HDL cholesterol concentration and within- 
batch imprecision for each QCM, by both provisionally recommended 
precipitation procedures (Whitehead et al, 1979). These methods 
had previously been shown to yield good agreement for clinical
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specimens of fresh serum. Pooled fresh serum from patients and 25 
commercial and commissioned sera (Table III.3), chosen to cover a 
range of manufacturing procedures, species of origin, additives, 
constituent concentrations and presentation (liquid or 
lyophilised), were studied.
Table 12.1 shows the great diversity in results obtained, with 
some sera (eg serum S) exhibiting very poor precision. With 
clinical specimens giving SDs of 0.015-0.02 mmol/L, a criterion 
for acceptability for use in IQC of an SD 0.03 mmol/L or less and 
a CV of 4% or less was proposed (Bullock et al, 1980b). Most sera 
(15 for the PhT and 14 for the Hep procedure) satisfied this 
criterion, but in some cases (eg sera K, Q, T and Y) there were 
striking differences in behaviour. For some of these (K and Q) 
the methods also differed in accuracy.
When the results were expressed in terms of the difference in 
mean (Figure 12.1A) or SD (Figure 12.IB) for the two procedures 
further differences were revealed. Differences in accuracy were 
not confined to the Hep procedure, and appeared to be related to 
incomplete precipitation of other lipoproteins. Major 
differences, indicating potential unsuitability for at least one 
method, would preclude use in EQA. A criterion of a maximum 
difference of 20% between the mean concentrations, which should 
(unlike those for sera E and F) not exceed the range usually 
encountered, was therefore taken.
Application of these criteria left eight sera, indicated by 
arrows in Figure 12.1, which appeared to be suitable for EQA. 
None of these was of bovine origin, but all the equine sera 
studied and only a quarter of the human-based materials satisfied
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Table 12.1 Mean and within-batch precision (SD) of HDL
cholesterol assay by PhT and Hep procedures on pooled 
patients 1 sera and 25 QC sera. In mmol/L; n = 10 (n = 20 for 
pooled sera) unless specified (* n = 9; + n = 5)
Serum
Phosphotungstate/Mg 
Mean SD
2+ Heparin/Mn2"1" 
Mean SD
Pools
A
B
C
D
E
F
G
H
I
J
K
L
M
N
P
Q
R
S
T
U
V
W
X
Y
Z
1.40
1.50
0.87*
2.14
0.77
2.32
3.17
4.03
2.09
1.23
1.47
0.92
1.42
0.88
1.43
2.55
1.38
1.61
1.56
2.04
2.14
1.22
1.27
3.29
0.78
1.71
0.79
0.017
0.02
0.02
0.03
0.03
0.09
0.02
0.04
0.03
0.01
0.08
0.02
0.03
0.01
0.06
0.03
0.02
0.02
0.06
0.29
0.13
0.01
0.02
0.05
0.03
0.06
0.02
1.39
1.43
0.80*
1.09
0.61
0.83
4.00
4.17
2.11
1.28
1.80*
0.84
2.99
0.94
1.58
2.50
1.40
5.78
0.77 +
5.48+
2.43
1.06
1.24
3.62
0.64
1.90
0.70
0.015
0.015
0.02
0.02
0.03
0.06
0.06
0.10
0.08
0.02
0.05
0.02
0.48
0.01
0.02
0.04
0.03
0.69
0.02
0.32
0.03
0.03
0.02
0.02
0.03
0.01
0.02
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Figure 12.1 Differences between the PhT and Hep precipitation
procedures for the 25 sera studied, in (A) mean results and 
(B) within-batch SD. Arrows denote sera meeting the criteria 
for use in EQA (CV <4%, SD <0.03 mmol/L, and difference 
between means <20%)
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the criteria, as did the single liquid (equine) serum. Only one 
of the 6 human-based sera intended for control of lipid assays 
appeared suitable.
To confirm that the between-day precision was reflected by the 
within-batch data obtained in Table 12.1, 6 sera with a variety 
of properties were then assayed on 10 successive working days. 
The CVs (Table 12.2) were, as expected, greater than the within- 
batch imprecision, especially by the Hep procedure. 
Correspondence appeared reasonable in most cases, and the within- 
batch data could then be taken to represent performance for this 
assay.
The study thus demonstrated that some of the materials were 
suitable for IQC of one or both of the analytical procedures 
investigated. A more restricted group appeared acceptable for use 
in EQA as well, with comparable concentrations by both procedures 
which lay within the physiological range, though only fresh serum 
serum specimens should be used to assess intermethod differences. 
Surprisingly, suitability was not confined to human-based 
products, with equine sera performing well and 'special 1 lipid 
controls badly.
12.2.2 Use of lyophilised sera in an EQA survey
Having determined which of the materials in the single-laboratory 
study appeared to be suitable for such use, 6 were distributed in 
an EQA survey. This included a relatively small number (14) of 
laboratories collaborating in the method standardisation 
initiative (Whitehead et al, 1979), and which had previously 
received specimens of fresh liquid human serum (John, 1983; see 
Appendix 1.5.1).
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Table 12.2 Comparison of within-batch and between-day mean
and precision (CV) of HDL cholesterol assay for 6 sera, n
10 unless specified (* n = 9); means in mmol/L
Serum D
Mean 
CV (%)
Phosphotungstate/Mg
Within Between
2+
2.32
3.7
2.46
4.7
2+Heparin/Mn
Within Between
0.83
7.5
0.74
7.1
Serum G
Mean 
CV (%)
2.09
1.4
1.98
4.1
2.11
3.7
2.13*
4.6
Serum N
Mean 
CV (%)
2.55 
1.0
2.39 
3.4
2.50 
1.7
2.36 
2.2
Serum P
Mean 
CV (%)
1.38 
1.8
1.36 
3.3
1.40 
1.9
1.37 
6.3
Serum U
Mean 
CV (%)
1.22 
0.8
1.23 
3.3
1.06 
3.3
1.06
6.0
Serum W
Mean 
CV (%)
3.29 
1.5
3.18 
5.5
3.62
0.7
3.46
1.9
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Table 12.3 shows the interlaboratory agreement obtained for HDL 
and total cholesterol in Survey 3, using the commercial 
materials. This is compared in Table 12.4 with data obtained in 
surveys using fresh sera. In addition to groups using the PhT and 
Hep procedures, two laboratories employed polyethylene glycol 
(PEG) as precipitant.
The wide spreads of CVs are attributable primarily to the small 
numbers of participants in each group and to the effects of 
analyte concentration upon interlaboratory agreement (shown for 
the Hep group in Figure 12.2A, and discussed in general terms in 
Chapter 6). Nevertheless the same conclusions could be drawn from 
the lyophilised specimens as from the liquid sera, namely the 
positive bias of Hep relative to PhT procedures and the similar 
between-laboratory variability for these two methods (Table 
12.4). The apparently worse performance for total cholesterol was 
attributable to the rather lower analyte concentrations in this 
group of predominantly animal-based materials (Figure 12.2B).
12.3 Sodium and potassium assay using direct-reading ion- 
selective electrodes (ISEs)
Instruments employing potentiometry on undiluted sample have been 
used increasingly both within and outwith laboratories for sodium 
and potassium assay (Buckley et al, 1984). Factors contributing 
to this growth include their greater convenience for emergency 
situations, particularly the capability for whole blood samples 
thus obviating the need for specimen centrifugation and 
separation, and commercial pressure.
In contrast to flame photometry and ISE systems incorporating 
sample dilution prior to measurement (indirect ISEs), such 
procedures should in theory estimate the ionic molal activity,
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Table 12.3 Intralaboratory precision, mean results and between- 
laboratory agreement for HDL and total cholesterol in Survey 
3, 1980
Serum 
H J L P U Z
HDL cholesterol (mmol/L)
Intralaboratory
CV(%) 0.7 2.5 3.8 1.9 3.1 2.5
Overall (n=14 laboratories)
Mean
CV (%)
PhT (n=7) 
Mean 
CV (%)
HepT (n=5)
Mean
CV (%)
PEG (n=2)
Mean 1.27 0.79 1.02 1.04 1.09 0.89
1
13
1
13
1
12
.32
.3
.25
.7
.43
.3
0
20
0
16
1
17
.93
.3
.88
.3
.07
.9
1
15
0
15
1
12
.00
.2
.92
.7
.10
.9
1
17
1
15
1
11
.35
.1
.34
.2
.51
.7
1.
16.
1.
14.
1.
17.
27
1
26
4
37
4
0.
10.
0.
9.
0.
13.
91
5
90
4
94
8
Total cholesterol (mmol/L)
Intralaboratory
CV(%) 1.8 2.4 1.9 3.9 3.1 3.4
Enzymic (n=12)
Mean
CV (%)
2.14 
7.7
3.44 
9.0
4.40 
6.1
2.27 
10.3
1.87 
10.3
3.84 
5.5
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Table 12.4 Summary of intralaboratory precision, mean results and 
between-laboratory agreement for HDL and total cholesterol 
in Surveys 2 (1979), 3 (1980), and 4 or 5 (1981). 10
specimens in Survey 2, 6 in Survey 3 (Table 12.3), 4 in 
Survey 4 and 3 in Survey 5
Survey 2 Survey 3 Survey 4 or 5 
HDL cholesterol (mmol/L)
Intralaboratory
CV (%) 3.81 2.42 0.81
Overall (n=12-14 laboratories)
Mean 1.07 1.13 1.51 
(Range) (0.55 - 1.52) (0.91 - 1.35) (1.37 - 1.66)
CV (%) 12.7 15.4 12.6 
(Range) (7.1 - 21.4) (10.5 - 20.3) (11.8 - 13.3)
PhT (n=6-7)
Mean 1.05 1.09 1.43
CV (%) 10.2 14.1 16.8 
(Range) (5.0 - 19.0) (9.4 - 16.3) (15.4 - 17.7)
Hep (n=5)
Mean 1.11 1.24 1.58
CV (%) 15.4 14.3 13.9 
(Range) (9.1 - 22.6) (11.7 - 17.9) (12.3 - 115.5)
PEG (n=l-2)
Mean 1.03 1.02 1.58
Total cholesterol (mmol/L)
Intralaboratory
CV (%) 2.11 2.75 1.71
Enzymic (n=12-13)
Mean 4-95 2.99 6.93 
(Range) (2.57 - 6.04) (1.87 - 4.40) (3.87 - 10.61)
CV(%) 5.1 8.2 5.2 
(Range) (3.0 - 10.2) (5.5 - 10.3) (3.5 - 6.2)
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Figure 12.2 Relationship with (A) HDL and (B) total cholesterol 
concentration of between-laboratory agreement (CV) for 
liquid and lyophilised sera. HDL cholesterol determined by 
Hep procedure
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claimed to be the most useful indicator of physiological 
activity. The results and reference intervals should then differ 
appreciably from those for plasma sodium concentration. The 
systems are, however, complex and most manufacturers have 
endeavoured to provide results comparable with concentrations, 
through manipulation of the electrodes, liquid junctions and 
calibration material composition and assigned values (Broughton 
and Maas, 1984; Buckley et al, 1984).
These factors lead to considerable difficulties for measurements 
on clinical specimens (eg Broughton et al, 1985; Smith et al, 
1986), in view of the complex interrelationships with 
specimen composition, especially protein and lipid content. It 
has been recommended that such instruments should yield results 
in agreement with those by flame photometry for specimens with 
normal protein and lipid concentrations, ie the same reference 
intervals should be applicable (Broughton and Maas, 1984).
The problems associated with provision of suitable materials for 
calibration, IQC and EQA may be correspondingly large. 
Calibration cannot be dissociated from instrument design, and is 
therefore essentially a matter for manufacturers rather than 
users. For precision control, the requirement is for precision 
comparable with that for clinical specimens (see section 12.1.1 
above). Requirements for accuracy control in IQC and for EQA are, 
however, more stringent, requiring either commutability with 
clinical specimens or an appropriate grouping of methods and 
instruments to avoid any adverse effects of a lack of 
commutability.
301
12.3.1 UKEQAS for General Clinical Chemistry
Throughout the development of the scheme new method groups have 
been introduced as new analytical procedures, using novel 
principles or instruments, came into use. Thus separate groupings 
were provided for direct and indirect ISE procedures, which were 
increasing in use during the early 1980s. When more than 15 
results were received VISs were calculated; as indirect ISEs are 
used more widely in laboratories, particularly in the Technicon 
SMAC and Beckman Astra instruments, this stage was reached 
earlier for this group. No problems were apparent from the EQA 
data and such use has continued to increase, with 43% of sodium 
results in December 1986 being obtained by indirect ISE methods.
The direct ISE group acquired VISs later, and observation that 
the scores seemed to be higher than those for other methods 
prompted a more detailed analysis in December 1984. Table 12.5 
compares the average scores obtained by the direct ISE group with 
those for all participants, with further analysis of the 
performance of the sub-groups using IL, Corning and other 
instruments.
The worse than average performance is confirmed by the higher 
average MRVISs, both for the group as a whole and for the sub­ 
groups. Differences in bias among the various manufacturers' 
instruments are revealed by the non-zero average MRBISs for the 
sub-groups. In addition to these between-manufacturer 
differences, the variations in MRBIS within each sub-group (eg 
for Corning instruments the ranges were -70 to +25 for sodium and 
-107 to +47 for potassium) indicate differences between 
individual laboratories. These may result from differences 
between instrument models or from differences between
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Table 12.5 Comparison of performance (average running scores) for 
sodium and potassium assay by direct: ISE instruments in 
UKEQAS for General Clinical Chemistry, 1984 |MRBIS| is the 
average MRBIS disregarding its sign
Overall
All
Direct ISE
IL Corning Others
n 429 26 15
Sodium
MRVIS 64
MRBIS
[ MRBIS |
SDBIS 71
Potassium
MRVIS 61
MRBIS
| MRBIS |
SDBIS 69
77
-
39
90
89
—
42
99
98
-23
29
118
107
+ 10
18
127
71
-28
42
83
87
-41
52
94
69
+39
45
74
76
+26
46
81
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laboratories in the settings used. These factors combine to give 
an average CV during 1984 of 1.67% for sodium by direct ISE, 
considerably greater than the average of 1.30% for all 
participants.
More importantly the high SDBISs, with only three laboratories 
achieving scores lower than the average for all participants, 
suggest that inconsistent bias could stem from interactions 
between these methods and the materials distributed. Could this 
then be due to non-commutability?
Studies (eg Broughton et al, 1985; Smith et al, 1986) have shown 
a consistent relationship for clinical specimens between total 
protein concentration and 'ISE - flame difference' (the amount by 
which the direct ISE result exceeds the result by flame 
photometry) for several commercial instruments. The exact 
relationship differed but in each case a positive correlation was 
observed. Did the UKEQAS data also show this pattern?
Figure 12.3 provides this comparison for the 21 materials 
distributed during 1984, from which no consistent pattern 
emerges, in apparent confirmation of non-commutability. 
Examination of the materials involved (Table 1.2) reveals several 
with divergent manufacturing process. In particular one contained 
Tris buffer, 4 were to be reconstituted with a Tris/carbonate 
diluent rather than distilled water and two QCMs contained an 
(unspecified) 'stabiliser'. These are identified separately 
in Figure 12.3, and indeed behave differently from the 
remaining materials.
The scatter for the remainder, however, still appeared 
substantially greater than that for clinical specimens though no
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Figure 12.3 Relationship with total protein of difference for 
sodium between direct ISE and overall mean in UKEQAS for 
General Clinical Chemistry, 1984. Materials with 
Tris/carbonate diluent, containing Tris buffer and 
containing 'stabiliser' are identified
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further specimens with unusual additives or manufacturing 
treatments were apparent. The overall conclusion was thus that 
the materials distributed in the UKEQAS did not truly reflect the 
performance obtained with clinical specimens and corrective 
action was therefore required.
The basic problem is one of diversity within the grouping, 
leading to a mean which is not representative of each instrument. 
Even classification separately by manufacturer would not provide 
homgeneous groups capable of yielding valid method means, the 
primary way in which the effects of non-commutability can be 
circumvented. The alternative procedure of not scoring for 
distributions where the material shows atypical properties was 
also infeasible, since firstly there appeared to be no ready 
means to determine unsuitability in advance and secondly the 
UKEQAS computer programs do not provide the facility to exclude 
individual method groups (in addition to the 'Other' group) from 
scoring.
The action taken in January 1985 was to reclassify these 
procedures within the 'Other' group, so they no longer received 
VISs for any distribution. This also took account of the 
relatively small proportion of participants (still only 8% at 
December 1986) using direct ISE instruments. Users were advised 
to monitor their performance in the scheme, and to contact the 
instrument manufacturer if their bias appeared to be consistent.
Subsequent re-examination of data from the scheme confirmed the 
continuation of these problems, as would be expected without 
drastic changes in the type of material distributed. Indeed the 
very design of these instruments, with undiluted serum, plasma or 
whole blood being presented to the potentiometric system, should
306
suggest the likelihood of major matrix effects. The situation 
thus remains unresolved, though the possible future growth in the 
use of direct ISE procedures suggests that a procedure similar to 
that described in section 12.2.1 above for HDL cholesterol be 
applied to determine the suitability for direct ISE instruments 
of materials to be distributed in the scheme.
12.4 Summary
The primary requirements for materials to be used in internal 
quality control are stability and precision similar to that for 
clinical specimens. Materials for external quality assessment, 
however, must be commutable with clinical specimens, unless 
designated values are obtained by the same method.
A protocol for assessment of suitability was tested for HDL 
cholesterol assay. This included comparison of the within-batch 
CVs and relationship between the mean values for two common 
analytical procedures. Criteria based on the findings for fresh 
sera from patients were proposed, which were satisfied by 8 of 
the 25 QC materials studied. Such a design could form the basis 
of a general procedure for assessing the suitability of QCMs for 
use in EQA.
The suitability of 6 of these was further tested by use in a 
survey of HDL cholesterol assay in 14 laboratories. Taking 
account of the effects of analyte concentration, the results were 
similar to those obtained previously and subsequently by these 
participants on fresh sera, supporting the validity of this 
protocol.
Examination of UKEQAS data revealed inhomogeneity both among and 
within instrument groups for sodium and potassium using direct
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potentiometry on undiluted specimen (direct ISE). This divergence 
was further manifested in different behaviour than for clinical 
specimens. The inhomogeneity reflects the susceptibility of these 
procedures to matrix effects, resulting in a lack of 
commutabi1i ty.
Such effects prevented scoring of the performance for direct 
ISEs, since the small number of participants using them precluded 
the allocation of individual method groups. Application of a 
protocol similar to that used for HDL cholesterol assay might 
enable identification of commutable materials and thus permit 
some reliable assessment of their performance.
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ASSESSMENT OF QUALITY CONTROL MATERIALS
Chapter 13:
THE EFFECTS OF CALIBRATION ON INTERLABORATORY AGREEMENT
13.1 Introduction
The results obtained for an assay in clinical chemistry are 
dependent not only upon the specimen analysed and the method used 
but also upon the calibration procedure. Where pure compounds in 
aqueous solution (primary calibrants; Buttner et al, 1979a) are 
available and applicable their use is recommended. This procedure 
derives from good practice in analytical chemistry, and the 
inclusion of calibrants (then termed "standards"; "calibrant" is 
preferred, to avoid confusion with standards of performance) with 
each analytical batch has long been recommended to improve 
performance by compensating for variations in conditions (eg 
Henry and Segalove, 1952).
Such primary calibrants are not, however, available for all 
analytes (eg many protein species) nor are they applicable in all 
analytical procedures. If the procedure is susceptible to matrix 
effects (see Chapter 12 above) a secondary calibrant (eg a serum- 
based material; Buttner et al, 1979a) is essential to avoid 
errors due to lack of commutability between calibrant and 
clinical specimens. Such secondary calibrants must then be 
calibrated (ie values be assigned to them) against the relevant 
primary calibrant or other reference point, eg an International 
Reference Preparation.
Some potential problems in the assignment of values to QC and 
calibration materials have been discussed in Chapters 3 and 12 
above. Discordant results arising from use of individual
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suppliers' calibrants have indeed been reported, eg from EQA 
surveys of immunoglobulin assay (Ritchie and Rippey, 1982; 
Chambers et al, 1984). In these cases the manufacturer's protocol 
for calibrating against the WHO International Reference 
Preparation was presumably in error, and recalibration was 
undertaken when this deficiency was exposed by the EQA data. 
Similar studies have shown that use of a single method and 
calibrant yields better between-laboratory agreement (Rowe et al, 
1970 and 1972).
Further problems arise when the analyte is not a defined 
chemical or protein species. For example, "pregnancy oestrogens" 
in urine vary in relative composition from subject to subject and 
from day to day in individual subjects. The relative non- 
specificity of many of the methods used further compounds the 
difficulties, and though the primary clinical interest is in day- 
to-day changes in oestrogen excretion within individuals (Wilde 
and Oakey, 1975) there are obvious advantages of between- 
laboratory agreement in terms of common criteria for 
interpretation. Similar considerations apply in any assay for a 
heterogenous mixture of species, such as total protein in urine.
Enzyme activity assays pose a particular problem, in that the 
numerical result is entirely dependent upon the analytical 
conditions used. Here attention has focused primarily on the 
reaction temperature in view of its large effect on activity, but 
substrate, cofactor and buffer identity and concentrations are 
probably more important. The trend towards the use of agreed or 
recommended methods, such as those proposed by the IFCC Expert 
Panel on Enzymes (Bowers et al, 1979) and national societies in 
for example GFR (German Society for Clinical Chemistry, 1970 and
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1972), Scandinavia (Committee on Enzymes, 1974) and the UK 
(Association of Clinical Biochemists, 1980), has reduced but not 
eliminated this problem. Several different method recommendations 
are current, however, and with many clinical chemists unwilling 
to change their methods (Fleck and Colley, 1982) and the 
increased use of instrument-dependent methods it seems unlikely 
that the goal of a single method only for each enzyme will ever 
be reached. Lack of comparability of enzyme results will thus 
probably remain a problem in the foreseeable future, if the 
present practice of calculating results on the basis of the known 
absorption coefficient of a reaction product (Peake et al, 1984) 
continues to prevail. Such considerations have led to questioning 
of whether the standardised method approach alone can bring about 
interlaboratory agreement, and the potential benefits of using 
calibration materials for enzyme activity assays have been 
explored by a number of authors in recent years (eg Jansen and 
Jansen, 1983; Bowers and McComb, 1984; McComb and Bowers, 1985; 
Moss et al, 1985; Bullock et al, 1986b).
In such circumstances use of a common calibration material by all 
laboratories might be expected to improve interlaboratory 
agreement. Indeed an ability of laboratories more reliably to 
compare the analyte content of two specimens than to determine 
their absolute concentration was apparent from the earliest EQA 
surveys (Wootton, 1956). EQA offers a valuable means to study 
this important hypothesis, through the distribution of two or 
more specimens for analysis together in the same analytical batch 
with recalculation of results to mimic the use of one as a common 
calibrant. The data thus obtained fairly reflect the likely 
impact of such calibration, being derived from routine conditions 
and from the many method variants used in participant
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laboratories.
13.2 Specific proteins in serum
In an attempt to overcome the problems mentioned above, a working 
calibrant for these assays (SPS-01) has been developed for use in 
the UK and calibrated against WHO preparations (Milford Ward et 
al, 1984). The UKEQAS for Specific Proteins (Appendix 1.2.5; 
Chambers et al, 1984 and 1987) was used to assess the effects of 
using this as a common calibration material, both in validating 
its proposed utility and in monitoring the effects of its 
availability.
13.2.1 SPS-01 calibration study
The response of many immunochemical methods for protein assay is 
non-linear, so participants were asked to use this material as 
calibrant for the survey. Thus results using routine calibration 
procedures were thus not available for the same specimens, and 
data from the preceding and following surveys were therefore used 
for comparison purposes (Appendix III.4.4; Chambers et al, 1987).
The improvements in interlaboratory agreement are demonstrated in 
Tables 13.1 and 13.2 (which show the average CVs for distributions 
before, with and after SPS-01), and also in Figure 13.1 for IgG, 
IgM and C3. The CVs with SPS-01 were lower and their scatter less 
than before; patterns for IgA and Al-AT were similar to IgG, and 
that for C4 to C3.
It is clear from this study that overall between-laboratory 
variation is significantly reduced when a common reference 
preparation is used for assay calibration. The most marked 
changes were for C3 (Figure 13.1) and Al-AT, with an approximate 
halving of the CV from 23-24% to 12-13% (Table 13.2). The
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Table 13.1 Mean bet ween-laboratory CV for immunoglobulins
before, with and after SPS-01. p denotes the probability of 
the CV with or after SPS-01 differing significantly from 
before SPS-01, calculated by the Mann-Witney U test. NS = 
not significant, i.e. p>0.05
Method group
Overall Turb Neph RID
igG Before
With 
P
After 
P
11.6
7.5 
<0.001
9.0 
<0.001
10.8
6.5 
<0.001
8.3 
0.01
12.6
6.8 
<0-001
9.1
0.001
11.8
8.2 
<0.001
8.8 
<0.001
IgA
igM
Before
Before
14.9
17.8
18.3 15.6
16.5 16.3
12.6
With 
P
After 
P
8.5 
<0.001
11.9 
0.04
7.9 
<0-001
12.5 
0.005
8.7 
0.002
12.0 
0-05
9.2 
0.002
9.3 
0.002
16.1
With
P
After
P
10.1
<0.001
17.4
NS
8.1
<0.001
17.9
NS
9.0
<0.001
18.1
NS
10.0
<0.001
15.0
NS
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Table 13.2 Mean bet ween-laboratory CV for C3, C4 and Al-AT
before, with and after SPS-01. For explanation see Table 
13.1
Method group
Overall RID-Behring RID All others
C3 Before
With 
P
After 
P
23.8
12.0 
<0.001
21.9
NS
16.5
13.8
NS
15.3 
NS
27.2
12.6 
<0.001
18.0 
NS
22.4
9.3 
<0.001
13.7 
0-002
C4 Before
With 
P
After 
P
18.8
13.6 
<0.001
21.8 
NS
15.4
14.1 
NS
13.2 
NS
18.0
17.3 
NS
17.7
9.8 
<0.001
20.4 
NS
Al-AT Before 23.1 15.9 21.9 26.0
With 
P
After 
P
12.7 
<0.001
18.6 
0.005
14.1 
NS
13.5
NS
16.7 
NS
16.5 
NS
7.7 
<0.001
10.0 
<0.001
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Figure 13.1 Inter laboratory agreement (CV) before, with and after 
SPS-01 for IgG, IgM and C3 in UKEQAS for Specific Proteins
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magnitude of this improvement indicates the extent of differences 
existing between the various calibrants currently available for 
these proteins. The improvement for C4 was less marked (from 19% 
to 14%), reflecting greater consistency among calibrants for this 
protein.
The significant improvements observed in immunoglobulin assays 
(Table 13.1, Figure 13.1) are important. Recognised reference 
preparations for these proteins have been available for some 
years and commercial calibrants should be standardised against 
them, but these results demonstrate that considerable diversity 
still exists, in particular for IgM (Figure 13.1).
The results for individual method groups yield further evidence 
that the higher CVs before SPS-01 are due largely to inter- 
calibrant variation. The homogeneous groups, ie those comprising 
a single method and calibrant (eg for C3, C4 and Al-AT the RID 
group using Behring plates and reagents), showed no significant 
improvements. The remaining method groups are all heterogeneous 
with respect to calibrant and in these significantly lower CVs 
were observed with SPS-01; the two exceptions were the RID groups 
for C4 and Al-AT, which may in part reflect their homogeneity 
with respect to procedure. Also, commercial calibrants for C4 
are known to show little variation, and before SPS-01 the RID 
group for Al-AT included four calibrants only: in the same group 
for C3, with 7 different calibrants being used initially, a 
significant improvement with SPS-01 was observed (Table 13.2).
Thus the major potential for improvement appears, as
might be expected, to be where there is greatest diversity in
the methods and calibrants used.
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13.2.2 Potential confounding factors
Could these improvements have been due to factors other than the 
use of a common calibrant? The scheme design allows such 
potential factors to be studied.
The lower CVs observed with SPS-01 cannot be ascribed to 
differences in the material distributed. All specimens before 
and with SPS-01 comprised pooled normal human serum, prepared in 
the same manner and examined by high resolution agarose gel 
electrophoresis to exclude protein deficiencies or the presence 
of abnormal proteins (e.g. paraproteins, high molecular weight 
immune complexes, rheumatoid factor).
Analyte concentrations may also influence between-laboratory 
agreement, as discussed in Chapter 6. Here, however, improvements 
cannot be ascribed to differences in analyte concentration since 
CVs were independent of concentration, as illustrated in Figure 
13.2 for IgM and C3; patterns for C4 and Al-AT were similar to 
C3, and those for IgG and IgA to IgM. Also, no significant 
differences were observed apart from an increase for C4 (Table 
13.3); this apparent change probably only reflects differences in 
assigned values between SPS-01 and other calibrants since the 
material distributed in both periods was normal human serum.
The average within-laboratory CVs (Appendix 1.2.5; Chambers et 
al, 1984) for distributions with SPS-01 were in general lower 
than the corresponding CVs before but, apart from IgM, not 
significantly so. This improvement was unexpected, since within- 
laboratory precision should be independent of calibration 
procedure. It may, however, be related to the small effect that 
'special treatment' of EQAS specimens may have on performance
317
Figure 13.2 Relationship between interlaboratory agreement (CV) 
and concentration for IgM and C3 in UKEQAS for Specific 
Proteins
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Table 13.3 Average and range of overall means before, with and 
after SPS-01. For explanation see Table 13.1
Before With After
IgG 
P
IgA 
P
IgM 
P
C3 
P
C4 
P
Al-AT 
P
12.95 
5.7-20.0
2.46 
1.4-4.8
1.45 
0.68-2.3
1.31 
0.76-2.0
0.32 
0.18-0.48
2.29 
1.3-3.6
13.88 
8.6-18.7
NS
2.26 
1.3-3.3
NS
1.81 
1.1-2.5
NS
1.73 
1.0-2.4
NS
0.55 
0.34-0.75 
0.01
2.16 
1.2-3.0
NS
15.16 
10.7-19.2
NS
3.02 
2.6-3.4 
0.02
2.67 
1.8-4.0 
<0.001
1.68 
1.2-2.0 
NS
0.44 
0.36-0.53 
0.02
3.05 
2.5-3.4 
0.02
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(Rumley and Roberts, 1984; Rowan et al, 1984), with the extra 
attention involved in the distributions including SPS-01 leading 
to better precision. Such marginal effects, however, are unlikely 
to have contributed significantly to the major improvements in 
interlaboratory agreement.
13.2.3 Period following SPS-01 study
Did this exercise have any educational effect on participants or 
manufacturers of calibration materials? Apparently so, since 
between-laboratory agreement for IgG, IgA and Al-AT remained 
significantly better after SPS-01 than before (Tables 13.1 and 
13.2), reflected for IgG in Figure 13.1 by the continued lower CVs 
and decreased scatter during the period after SPS-01. This 
improvement was also maintained within the more heterogeneous 
method groups, particularly the 'other methods' group for Al-AT.
The CVs for C3, C4 and IgM initially reverted to levels that were 
not significantly different from those before SPS-01, thus the 
improvement with SPS-01 was not due to coincidental improvement 
in performance. This may have also been related to the 
introduction into the scheme of pathological material. IgM in 
particular (Figure 13.1) has shown marked method biases and 
significantly worse between-laboratory agreement for the majority 
of pathological samples, due apparently to positive interference 
by rheumatoid factor. However, performance for IgM and C3 (Figure 
13.1) and for C4 now seems to be improving, perhaps reflecting a 
longer-term influence of this study on participants' routine 
calibration procedures and manufacturers' practices, and 
increasing sales of SPS-01.
13.3 Pregnancy oestrogens in urine
Studies (detailed in Appendix 111.4.2) through the UKEQAS for
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Urinary Pregnancy Oestrogens (Appendix 1.2.4; Bullock and Wilde, 
1985) illustrate two further important points regarding 
calibration. The first concerns the importance of commutability 
between specimens and calibrant, and the second the influence of 
between-laboratory agreement on the effectiveness of a common 
calibration procedure.
13.3.1 Commutability between specimens and calibrant
The initial study investigated the use of a common primary 
calibrant, two aqueous solutions of oestriol, to improve 
interlaboratory agreement of oestrogen assay (Bullock and Wilde, 
1985). The results (Table 13.4) show no major improvement and in 
some cases a worsening of agreement. This effect might be 
attributable to differing responses of the several methods in use 
to varying oestrogen species: thus the 'unknown' specimen was 
pregnancy urine containing a mixture of oestrogens, whereas the 
calibrant consisted of a single species only. The hypothesis is 
supported by the known variation in response to different 
oestrogens, ie lack of perfect cross-reactivity, among methods 
(Wilde and Oakey, 1975).
Later studies therefore used a common secondary calibrant, for 
convenience another specimen prepared for use in the scheme. 
Table 13.4 also shows the results of other studies (Bullock and 
Wilde, 1985). In study B, where both specimens originated from 
the same set and therefore contained virtually identical mixtures 
of oestrogen, the improvement in agreement with 'calibration' was 
most impressive. This even stimulated suggestions that a common 
working calibrant be prepared for provision to UK laboratories to 
improve the then unsatisfactory situation (Oakey, 1980; Bullock 
and Wilde, 1985).
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Table 13.4 Effect of 'calibration1 on bet ween-laboratory
agreement for urinary pregnancy oestrogen assay. Calibrants 
were aqueous oestriol (Study A), or lyophilised urine from 
the same (Study B) or a different (Studies C and D) set of 
specimens
n
Study A (March 1981)
Survey data Recalculated
Overall
Lever
Brombacher
RIA
Oakey
Study B (May
Overall
Lever
Brombacher
RIA
Oakey
106
43
41
12
6
1981)
111
47
41
13
7
14.9
9.4
10.3
11.3
13.0
17.4
12.0
14.4
17.8
7.6
12.9
11.4
9.6
7.5
17.9
8.4
6.4
9.4
7.3
11.7
Study C (November 1982)
Overall
Lever
Brombacher
RIA
Oakey
Study D (July
Overall
Lever
Brombacher
Miscellaneous
103
57
31
10
5
1986)
54
37
10
6
9.7
6.5
8.3
15.1
18.4
20.2
19.9
10.0
29.0
7.0
4.5
6.5
6.6
15.3
21.0
24.5
9.1
22.6
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Specimens from different sets, and hence probably with differing 
oestrogen composition, were used in study C (Table 13.4). Here the 
improvement in agreement was less marked, confirming the 
importance of similarity of composition between calibrant and 
clinical specimens. For this assay, however, there are certain to 
be differences among the clinical specimens and any calibrant 
must therefore represent a compromise.
13.3.2 Relationship to interlaboratory agreement
An additional factor bearing on the lesser improvement shown in 
study C is the improving state of the art over this period (see 
Figure 3.1). Thus the 'uncalibrated' (survey) CVs were lower in 
study C than in study B, providing correspondingly less scope for 
improvement. This factor is further demonstrated in the more 
recent study D (Table 13.4). Here calibration, again using 
specimens from different sets, failed to yield any improvement 
other than within the heterogeneous 'Miscellaneous' group.
As agreement improves the susceptibility to the confounding 
effects of errors such as specimen or result transposition 
becomes more marked. In general the need to improve agreement 
by means such as common calibration also becomes less urgent as 
agreement itself improves. The improvement (Figure 3.1) observed, 
which may have been related to participants' review of their 
calibration procedure following study B or of critical features 
in their method following the recommendation of a modified Lever 
procedure (Working Party on Urinary Pregnancy Oestrogens, 1981), 
thus obviated the need for production of a common calibration 
material for the UK.
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13.4 Total urinary protein
This determination also concerns mixtures of analytes which 
differ from patient to patient. Methods should therefore show 
minimal differences in response to protein species (Dilena et al, 
1983), both to yield reliable results on all specimens and to 
facilitate accurate calibration. Three UKEQAS surveys were 
conducted, with investigation of the effects of participants' own 
calibration procedures and of 'calibration' using another 
specimen (Appendix III.4.3) on agreement.
Table 13.5 summarises the survey and calibrated data, both overall 
and for the main method groups, for Survey 2 and 3; transposition 
and other errors by participants precluded reliable analysis of 
data from the first survey. Despite the very poor agreement in 
the survey data, these show negligible improvement within method 
groups and only a slight improvement overall. This finding was 
unexpected, and was not completely explicable in terms of 
transposition and similar errors.
Indeed the effects of the calibration material used routinely by 
participants are difficult to explain. For example, specimen 4 
(Survey 2) comprised human albumin in normal urine yet even the 
subgroup of laboratories calibrating their sulphosalicylic acid 
(SSA) turbidimetric method against human albumin showed an 
overall over-recovery of about 100%; the similar specimen 6 
(Survey 3) and specimen 1 (Survey 1; human albumin in saline) 
gave overestimations of 30% and 60%. The overestimation is 
somewhat greater than the 10% observed for urine from nephrotic 
patients (specimens 5 and 7 in Surveys 2 and 3), which contained 
almost exclusively albumin. Thus there appears to be some non- 
commutability between participants' calibrants and the specimens
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Table 13.5 Effect of 'calibration1 on bet ween-laboratory
agreement for urinary total protein assay in Surveys 2 and
3. The value for the reference specimen was 3.4 g/L in 
Survey 2, and 5.0 g/L in Survey 3; means in g/L, CV as %
Survey 2 Survey 3
n Survey Recalculated Survey Recalculated
Mean CV Moan CV Mean CV Moan CV
Overall 348 5.30 23.3 4.17 25.0 5.06 31.0 4.83 18.1
SSA 92 6.40 23.7 3.25 33.7 6.92 41.6 4.54 25.1
SSA/Na2SO4 47 4 - 91 16 - 7 4 - 30 18 - 3 4 - 78 19 - 9 4 - 85 8- 1
TCA 29 4.83 13.6 5.21 9.1 4.00 18.9 4.96 7.8
Dye binding 34 4.73 19.7 4.34 9.3 4.75 17.7 4.98 6.8
Biuret 28 4.89 18.7 5.00 12.6 4.72 12.6 5.14 7.8
Direct biuret 6 5.56 20.1 4.91 15.4 6.61 24.0 5.66 11.6
Direct Cocmassie 44 4.93 19.2 4.30 9.6 4.87 14.4 4.79 6.7
Benzethonium 7 4.95 12.9 4.51 7.2 4.35 7.5 4.44 6.4
Miscellaneous 7 4.97 24.0 4.57 10.8 4.78 21.6 4.86 8.6
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distributed. This is not, however, necessarily a reason for 
rejecting the survey findings. If it is due to some ageing 
process (the specimens were prepared in Bristol, bottled in 
Sheffield, and finally distributed from Birmingham several weeks 
later) then susceptibility to ageing effects could still be 
important in the routine application of this assay.
13.5 Assays of enzyme activity in serum
Calibration studies were carried out for the enzymes shown in 
Table 13.6 in four UKEQAS Enzyme Surveys (Appendices 1.2.2 and 
III.4.1; Bullock et al, 1986b). The objective was to obtain 
information on the applicability of calibration to these assays.
13.5.1 Calibration studies
The effects of recalculating results using one material as a 
'calibrant' are exemplified in Table 13.7 for CK in Survey 17. 
Major improvements were seen both in within-method CVs and in the 
numerical agreement among the mean values for the various method 
groups. This is also demonstrated for AST, ALP and amylase in 
Figures 13.3 to 13.5. Table 13.7 also demonstrates that 
calibration can compensate for differences in factors such as 
activator (NAC or glutathione) and temperature (30°C or 37°C). 
Indeed, calibration could have particular application in CK 
assay, where reagent instability can cause significant day-to-day 
variations in accuracy. Table 13.6 demonstrates the greatly 
improved concordance in terms of overall agreement, irrespective 
of method, for all laboratories in Surveys 14-18, and the data 
for amylase are reviewed in Table 13.8.
At least part of the improved within-group agreement must be 
attributed to the elimination of variations, affecting the 
'survey' and 'calibrant 1 specimens equally, in methodology,
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Table 13.6 Overall statistics, irrespective of method, after 
'calibration1 (after exclusion of results more than 2 SD 
from the untrimmed mean) in UKEQAS Enzyme Surveys 14-18
Survey
Average 
14 15 16 17 18
AST n 306 293 294
Mean (U/L) 99 164 98
SD (U/L) 7 20 7
CV 7.8% 12.3% 7.6% 9.2%
ALT n 215 225
Mean (U/L) 120 46
SD (U/L) 11 8
CV 9.3% 16.6% 13.0%
LD n 178 170 174
Mean (U/L) 1138 862 966
SD (U/L) 124 151 34
CV 10.9% 17.6% 3.6% 10.7%
CK n 249 272 265 270
Mean (U/L) 225 279 520 175
SD (U/L) 23 45 53 32
CV 10.3% 16.3% 10.3% 18.3% 13.8%
ALP n 299 286 302
Mean (U/L) 493 450 410
SD (U/L) 69 46 93
CV 14.0% 10.3% 22.7% 15.7%
Amylase n 290 284 308 292 279
Mean (U/L) 548 397 525 547 609
SD (U/L) 54 32 56 57 41
CV 10.0% 8.2% 10.8% 10.5% 6.8% 9.3%
Overall weighted average (n=20) 11.7%
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Table 13.7 Effect of 'calibration' for CK in Survey 17, October 
1984. Each laboratory's result for the survey specimen was 
recalculated using the survey mean (582.0) for the reference 
specimen in conjunction with the laboratory's result for the 
reference specimen, ie using this material as a 'calibrant'. 
In each case results more than 2 SD from the untrimmed mean 
were excluded.
Survey specimen 
Survey data for 
reference specimen Survey data Recalculated
SCE NAC 37°C:
n 149 153 151
Mean (U/L) 582.0 526.6 523.4
SD (U/L) 47.9 59.1 53.2
CV 8.2% 11.2% 10.2%
Glutathione 37°C:
n 23 21
Mean (U/L) 470.1 520.1
SD (U/L) 100.6 33.2
CV 21.4% 6.4%
ACB/DGKC NAC 30°C:
n 16 17
Mean (U/L) 351.2 504.1
SD (U/L) 44.1 41.4
CV 12.6% 8.2%
Other:
n 68 65
Mean (U/L) 379.9 522.4
SD (U/L) 151.2 40.7
CV 39.8% 7.8%
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Figure 13.3 Effect of 'calibration' for AST in UKEQAS Enzyme
Survey 17, October 1984. The points and solid bars around 
the periphery represent the survey mean -H! SD for the method 
groups; for each method group these are connected to a point 
and solid bar towards the centre which represent the mean 
SD for the 'calibrated' data. The star and dashed bar at 
the centre represent the survey mean ^ 1 SD for the SCE 
optimised 37°C method group as 'target 1
200 — Continuous 
flow 37°C
150
Other optimised 
37°C
Other optimised 
30°C
329
Figure 13.4 Effect of 'calibration' for ALP in UKEQAS Enzyme 
Survey 17, October 1984. See Figure 13.3 for explanation
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Figure 13.5 Effect of 'calibration1 for amylase in UKEQAS Enzyme 
Survey 17, October 1984. See Figure 13.3 for explanation 
(Phadebas 37°C method group as 'target')
BCL Colorimetric
700~i
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300 —
100
Phadebas
Other 
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Saccharoqenic
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Table 13.8 Effect of 'calibration1 for amylase in Surveys 14-18
All figures are CV (%); see Table 13.7 for explanation
Phadebas
(n = 238 - 252)
Reference Survey
Other method
(n = 41 - 56)
Reference Survey
Survey 14
Survey data
Recalculated
11.8 11.9 
7.5
48.1 47.6
16.5
Survey 15
Survey data
Recalculated
10.8 10.1 
6.0
70.9 58.4
16.2
Survey 16
Survey data
Recalculated
12.2 13.1 
8.2
67.2 58.8
18.6
Survey 17
Survey data
Recalculated
10.8 9.7 
8.3
63.8 58.4
18.5
Survey 18
Survey data
Recalculated
14.0 12.5
4.7
61.8 58.8 
8.8
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reagents and measurement conditions. These results are in general 
agreement with those of studies in the Netherlands (Jansen and 
Jansen, 1983) in which, as here, the major effect of calibration 
was seen for non-optimised methods. This is consistent with the 
observation above for specific protein assays that the greater 
the heterogeneity within a group the greater is the effect of 
common calibration.
13.5.2 Commutability considerations - amylase assay
Though almost all amylase assays in the UK are at present carried 
out by the Phadebas dyed substrate method, agreement between 
laboratories remains poor: the method is manual and depends upon 
a predetermined calibration curve. Here, the use of a common 
calibrant produced the expected improvement in comparability, 
from an average CV of 11.5% to 6.9% for the Phadebas method group 
in Surveys 14-18.
If only a single method is being calibrated the problem of 
isoenzyme bias (manifested in non-commutability) does not arise. 
Attempts to use a single calibrant to provide comparable results 
from a variety of amylase methods would, however, have to address 
the problem of differences between enzymes of human and animal 
origin (Bretaudiere et al, 1981b) and between the major 
isoenzymes of human amylase in their relative activities on long- 
chain and short-chain saccharides.
The effect of this latter difference is seen in the results for 
the short-chain substrate BCL colorimetric method in Survey 17 
(Figure 13.5). Other differences, such as those represented 
within the "Other method or temperature" group, appear less 
important in this respect, as can be seen from the improvements
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brought about by 'calibration'. The extent of improvement within 
this heterogeneous group varied from survey to survey (Table 
13.8), reflecting the magnitude of differences in isoenzyme 
composition between the survey and reference specimens. For 
example, in Survey 14 both were human sera enhanced with porcine 
amylase.
Since in many cases between-laboratory concordance can be 
improved by 'calibration', the possibility arises that enzyme 
reference materials could be used to transfer values from one 
method (procedure and instrumentation) to another, ie for the 
calibration of assays. However, such a transfer is valid only 
within carefully defined conditions, and when methods similar in 
principle are considered. Thus the materials must be commutable 
(Fasce et al, 1973; Broughton et al, 1981; Moss et al, 1985) 
among the methods used, with no specimen-to-specimen variability 
in the relationship between the methods. For example, variations 
in isoenzyme composition preclude transfer between methods for 
amylase which differ in substrate chain-length, eg starch and 
oligosaccharide (Gerhardt et al, 1985). Similarly, it is not 
possible to transfer values between methods for AST or ALT which 
differ in whether pyridoxal phosphate is present (Jansen, 1985), 
because of serum-to-serum variations in coenzyme content. Any 
link between methods must be made by assaying clinical specimens 
by both methods, and checking that use of the reference material 
as a calibrant leads to full recovery of the activities for the 
specimens.
These and other (eg Jansen and Jansen, 1983; Gerhardt et al, 
1985) calibration studies have demonstrated the potential benefit 
of using a calibration material in improving agreement for enzyme
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activity assays. Bowers and McComb have also recently proposed a 
similar reference system based on IFCC reference methods (Bowers 
and McComb, 1984; McComb and Bowers, 1985), though their studies 
on EQAS data dealt only with method means rather than results 
from individual laboratories.
It now seems appropriate therefore to consider changing the 
direction of standardisation efforts in clinical enzymology, to 
consideration of the use of enzyme calibration materials. The 
introduction of suitable calibrants (Moss et al, 1985), in 
parallel with the adoption of reliable analytical procedures, 
could remove the remaining disagreements caused by the existence 
of several different recommended methods. This should also allow 
the results from any analytical system to be made comparable with 
those given by recommended or reference methods. Even more 
importantly, it could end the present sterile controversy over 
the choice of an agreed temperature for enzyme measurement, and 
be applied internationally. Such developments will, however, 
require critical evaluation, as discussed by Moss et al (1985) 
and Colinet et al (1986), and must not be used in an attempt to 
compensate for deficiencies in the methods used.
13.6 Summary
EQA surveys can be used to study or mimic the effects on 
interlaboratory agreement of using a common calibration material.
In most circumstances a substantial improvement can be 
demonstrated, with the extent of the improvement being directly 
related to the diversity in methods and calibration procedures.
Where the analytical procedures have differing specificities, 
any differences in properties (ie lack of commutability) between
335
the calibrant and clinical specimens reduce and may even negate 
such improvements in agreement.
In the case of enzyme activity estimations the use of suitable 
calibration materials, preferably but not necessarily in 
combination with standardisation of methods, should lead to 
improved numerical concordance between the results obtained in 
different laboratories.
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ASSESSMENT OF QUALITY CONTROL MATERIALS
Chapter 14:
THE EFFECTS OF SPECIES OF ORIGIN AND MANUFACTURING TECHNIQUE 
ON QUALITY CONTROL MATERIAL BEHAVIOUR
14.1 Introduction
A wide range of serum-based materials is available commercially 
and these products are used extensively for IQC and calibration 
in clinical chemistry. The choice of and quality of such 
materials are obviously of profound importance for the 
reliability and consistency of laboratory results, and a number 
of questions about these aspects require further study. As 
discussed in Chapter 3, these include:
- the species of origin of the base serum
- the production procedures used by material manufacturers
- the presentation of the material
Though it is stated both that materials based on human serum are 
essential for the calibration and day-to-day IQC of laboratory 
methods, and that animal-based materials are equally satisfactory 
for most inorganic and organic analytes, the issues have never 
been studied fully. There is thus no basis for consensus, and 
the reasons for selection are varied and often arbitrary since 
there is virtually no published information on the relative 
merits of these types of material. Studies within a single 
laboratory will be prone to error due to statistical artefacts 
and to the individual methods and QC materials used, whereas 
interlaboratory studies using a range of materials provide the 
basis for a more satisfactory investigation of the subject, and 
hence a more rational approach to material selection.
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The World Health Assembly has tried to stimulate member states to 
become self-sufficient with regard to human blood and blood 
products, including QCMs. Several countries, including the UK, 
have made steps in this direction but it would appear that for 
developed countries the present demand for human blood products 
and QCMs cannot be met fully from blood collected within the 
country, and priority is rightly given to therapeutic uses. In 
contrast the supply of animal serum is effectively inexhaustable, 
which has been one of the primary reasons for encouraging its use 
in developing countries (Kenny and Eaton, 1981). Use of animal 
products should also eliminate the potential for transmission of 
hepatitis B (one study found that all of 22 commercial human- 
based QCMs were positive for one or more hepatitis virus markers; 
Compton et al, 1979) or acquired immunodeficiency syndrome 
(AIDS), though both manufacturers and health authorities have 
reaffirmed that it is good laboratory practice to treat all QCMs 
as if they were specimens from patients with potentially 
transmissible diseases. A demonstration that the behaviour of 
animal-based QCMs is as satisfactory for most common analytes as 
that of those derived from human sources would also have 
beneficial financial consequences for health care.
The serum matrix in QCMs may be considered to provide the analyte 
under consideration, the physicochemical milieu and a variety of 
interferences both defined and undefined. The potential effects 
of the matrix on QCM behaviour are discussed in Chapter 12, and 
the concept of commutability in Chapters 3, 12 and 13. When 
lyophilised material is considered, more modification of the 
physicochemical properties (and interferences) may be introduced 
by the freeze-drying process and by other aspects of the 
production procedure (eg addition of buffers or stabilisers) than
338
exist for example between sera from different species. Such 
procedures can be studied using data from EQASs which distribute 
a variety of materials through classification according to 
production method, which effectively reduces to consideration of 
materials grouped by manufacturer. Such matrix effects are most 
likely to have an influence through 'interference' effects, which 
are often subtle and undefined. As in the study of the influence 
of the species of origin, here one must rely heavily on empirical 
evidence gathered through EQA rather than theory (eg Stamm, 
1979).
Since they were first described by Maurukas (1973), interest in 
serum-based QCMs incorporating ethylene glycol has been 
stimulated over recent years by the commercial availability of 
such materials. These may be advantageous because they are said 
to remain liquid even at usual freezer temperatures (ie -20°C), 
and hence the degradative processes associated with freezing and 
thawing are avoided. Furthermore they would offer convenience and 
economy in use since they can be stored in the refrigerator for 
more prolonged periods than reconstituted lyophilised materials 
due to an antimicrobial action of the ethylene glycol. These 
factors are particularly important in developing countries, as 
discussed in section 3.3.2. One batch of such material was 
distributed in the UKEQAS for General Clinical Chemistry and a 
UKEQAS Enzyme Survey to assess the effects on interlaboratory 
agreement. This also provided a check on the efficacy of the 
protocol used (Bullock et al, 1979 and 1986b) in minimising the 
influence of post-reconstitution changes in enzyme activity.
14.2 Study of the effects of species and of material manufacturer
The objective was to assess the quality of the currently
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available quality control materials for clinical chemistry by 
investigating the effects of the manufacturer and of the base 
serum's species of origin on interlaboratory agreement in the 
UKEQAS for General Clinical Chemistry. Since the scatter in 
results from participants depends upon the quality of the 
material distributed as well as upon the performance of 
individual laboratories, such questions are eminently suited to 
evaluation using EQA data. The 'state of the art' and its 
relation to factors such as analyte level must first be 
characterised, however, as described in Chapter 6.
Initial misgivings of the UKEQAS organisers regarding the use of 
such data to assess with any confidence the quality of the 
specimen distributed had been overcome by experience with more 
than 250 distributions over 13 years. Consensus values (both 
overall and method means) and interlaboratory coefficients of 
variation had proved reproducible on repeated distribution of the 
same (stable) material (see section 5.2.1), and CVs appeared 
similar for similar materials at similar analyte levels. With 
the relatively large number of participants (about 400 results 
for each distribution) there had appeared to be little 
fluctuation from distribution to distribution in the spread of 
results provided that materials distributed were of satisfactory 
quality. The scatter in results is indeed examined for each 
distribution before the results are used for assessment of 
laboratory performance.
Using a similar approach, assessments of QC material quality 
(Jansen et al, 1978; Jansen, 1980) and interactions between QC 
materials and analytical methods (Jansen et al, 1981) on the 
basis of data from smaller EQASs have been reported, and a
340
systematic study of UKEQAS data appeared justified. A two-year 
period, including 40 distributions, should have yielded a 
sufficiently large database for assessment without excessive 
complications from improvement in participants' performance. It 
should be noted that, though a wide range of manufacturers and 
types of product are covered, the materials distributed through 
this scheme are not fully representative of those materials used 
in the UK in two ways. Not all manufacturers are represented, and 
materials with assigned values and those intended for calibration 
purposes are distributed only infrequently.
The details of the studies are given in Appendix III.2, and 
follow the same pattern as the prior examination of relationships 
between analyte level and interlaboratory agreement described in 
Chapter 6. The basic design comprised the examination of data 
from a two-year study period, the conclusions drawn being 
reexamined in a further two-year validation period; validation 
was essential because previous work (Wilding et al, 1979) had 
demonstrated the importance of testing findings on an independent 
set of data. As before, (Appendix III.2.1) materials with 
discrepant and apparently unsatisfactory agreement were excluded 
from consideration for the relevant analytes. There was a uniform 
method classification throughout each period, though the 
classification was different in the study and validation periods.
14.3 The effects of species of origin
The reduced range of indicators (Table 6.1; see section 6.2.1 and 
Appendix 111.2.2) were examined with respect to the species of 
origin of the base serum. The materials studied (Table 14.1) 
originated almost equally from human and bovine serum, with 
rather fewer equine sera, spread throughout the period.
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Table 14.1 Classification of materials studied by species of 
origin and manufacturer
Code
Species of origin:
B
H
Identification
Animal (unspecified)
Bovine
Equine
Human
Study 
period
(n = 37)
13
16
Validation 
period
(n = 40)
18
11
Manufacturer;
a 
b 
c
d 
e 
f
g
h 
k 
m
n 
o
P
q
Wellcome Diagnostics 6 
Puree Associates/Rosslab 5
Scottish Blood 5 
Transfusion Service
Roche Diagnostica 4
Ortho Diagnostics 4
Technicon Instruments 4
Nyegaard 3
Boehringer Mannheim 1
Tissue Culture Services 1
Hyland Division, 1 
Travenol Laboratories
General Diagnostics 1
DADE Division, American 1 
Hospital Supply
Gibco 1 
Biotrol
4
8
1
8
9
6
1
2
1
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14.3.1 Examination of overall data
In most cases no consistent difference in performance between the 
types of material could be discerned, but in others two or three 
of the graphs of the percentage of results excluded or of VISs 
>200, >300 or 400 suggested a possible difference in behaviour. 
Thus, for example, performance for bovine-based sera appeared 
worse for urate and better for urea.
A more consistent picture, with apparent differences discernible 
in recalculated CV and average VIS, emerged for other analytes. 
For glucose, phosphate, bilirubin and total protein worse 
performance was seen for materials with human base serum, whereas 
performance for iron was worse for bovine-based sera. Figure 14.1 
illustrates these effects for glucose and total protein. In no 
case was the situation clear-cut, however, and the differences 
were not supported by the graphs of all the indicators of 
discrepant performance.
Materials of bovine origin formed a greater proportion of those 
distributed during the validation period, with similar numbers of 
human and equine sera (Table 14.1). The poorer agreement for 
human-based materials was confirmed for glucose, phosphate, 
bilirubin (Figure 14.2) and total protein, and was suggested for 
cholesterol. The apparently worse agreement for iron in 
materials based on bovine serum was not confirmed (Figure 14.3).
14.3.2 Examination of method-related data
This confirmed in general the impressions gained from examination 
of the overall data. For example, Figure 14.4 shows the expected 
worse agreement for non-human sera for albumin by one of the BCG 
method groups and Figure 14.5 the exaggeration of this effect for
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Figure 14.1 Relationship with recalculated CV for glucose and
with average VIS for total protein, classified by species of 
origin
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Figure 14.2 Relationship with average VIS for bilirubin
classified by species of origin, in study and validation 
periods
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Figure 14.3 Relationship with average VIS for iron, classified by 
species of origin, in study and validation periods
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Figure 14.4 Relationship with recalculated CV for albumin by 
Manual BCG, classified by species of origin
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Figure 14.5 Relationship with recalculated CV and percentage 
difference from recalculated mean for albumin by BCP, 
classified by species of origin
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the more specific BCP method. Figure 14.5 also confirms the much 
lower affinity of BCP for bovine albumin.
For sodium, differences in bias relative to the overall 
recalculated mean were seen. There was a consistent difference at 
all concentrations for the Corning 430/450 flame photometer group 
but apparent negative bias at low concentrations and positive 
bias at high concentrations for the Ion-selective electrode group 
(Figure 14.6); these were independent of the species of origin of 
the base serum. The latter pattern was again seen for the 
Indirect ion-selective electrode method grouping in the 
validation period (Figure 14.7). Comparison of this pattern with 
that for the Direct ion-selective electrode group yields a 
definite difference in behaviour, and also an apparently 
different response of the direct-reading instruments to materials 
based on human serum (Figure 14.7). This may reflect the lack of 
dilution prior to measurement in this group, giving greater 
susceptibility to matrix effects.
Individual methods occasionally suggested differences in 
performance in the study or validation period data. Thus human- 
based sera appeared to give better performance for calcium by 
Corning titrator but worse performance for phosphate by manual 
methods, and bovine sera to give worse performance for iron by 
Bathophenanthroline and a negative bias for iron by AAII/SMA 
procedures. The overall apparent inferiority of human-based 
materials was not seen for either of the YSI or Beckman Glucose 
Analyzer groups, but was noted for all the other three GOD method 
groups. The differences in performance between materials derived 
from different species were largely confirmed in the validation 
period, as shown in Figure 14.8 for phosphate by Manual and
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Figure 14.6 Relationship with percentage difference from
recalculated mean for sodium by Corning-EEL 430/450 and 
Ion-selective electrode, classified by species of origin
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Figure 14.7 Relationship with percentage difference from
recalculated mean for sodium by Indirect ion-selective 
electrode and Direct ion-selective electrode, 
classified by species of origin
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Figure 14.8 Relationship with average VIS for phosphate by 
Manual/discrete analyser colorimetric, classified by 
species of origin, in study and validation periods
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discrete analyser colorimetric procedures. Apart from these 
isolated instances, albumin (see above) and total protein, there 
was no evidence of species-related differences in behaviour.
For total protein, with an overall tendency for worse agreement 
for human-based materials, there was clear evidence of species- 
related bias. Here, relative to equine and bovine sera, there 
were negative biases for human-based materials for continuous 
flow and positive biases for manual and discrete analyser 
procedures, exemplified in Figure 14.9 by the AAII/SMA and 
Vickers M300/D300 groups respectively. In the validation period 
these differences seemed to be confined to (or at least much more 
obvious between) the continuous flow group including a serum 
blank and the unblanked manual and discrete analyser grouping 
(Figure 14.10).
14.3.3 Appraisal of the results
Similar numbers of materials based on bovine (31) and human (27) 
serum were distributed during the study and evaluation periods 
combined, with rather fewer equine-based sera (16) and slightly 
different relative proportions in the two periods (Table 14.1). 
Reliable conclusions could therefore have been expected, but 
unsupported (and hence presumably artefactual) indications of 
differences in performance were nevertheless apparent.
This study was confined to analytes in the UKEQAS for General 
Clinical Chemistry, ie electrolytes and simple organic compounds; 
albumin (on which results are now rarely requested on non-human 
based sera) was assessed primarily to provide contrast. It did 
not include radioimmunoassays (RIAs), nor analytes (eg 
immunoglobulins) which are species-specific and for which human
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Figure 14.9 Relationship with percentage difference from 
recalculated mean for total protein by AAII/SMA and 
Vickers M300/D300, classified by species of origin
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Figure 14 10 Relationship with percentage difference from
recalculated mean for total protein by Continuous flow 
blanked biuret and Manual/discrete analyser unblanked 
biuret, classified by species of origin
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based sera appear indispensable a priori. In order to study 
subtle aspects of QC material behaviour due to species of origin, 
it is essential to examine data from individual method groups 
rather than overall statistics. The overall data, however, 
constituted the best practical starting point, both in providing 
an overall assessment and in eliminating from further analysis 
materials with obviously discrepant behaviour.
The study period provided definite evidence of worse 
interlaboratory agreement for human-based sera for four analytes 
(glucose, phosphate, bilirubin and total protein), corroborated 
by the data from the validation period. It is surprising that 
agreement was worse for human-based materials since it is 
frequently argued that, as assays are optimised for clinical 
specimens (ie fresh human serum), agreement between both 
individual laboratories and method groups is likely to be 
inferior for animal-based sera. It is possible that the usually 
higher turbidity of the human-based materials contributed to 
greater variability within method groups, due to differences in 
blanking procedures applied in participants' laboratories. 
Greater differences in bias between method groups for human-based 
sera cannot be the full explanation, since the inferiority was 
seen for VISs as well as CVs, but method-related data were also 
studied to investigate this further.
The concentration-dependent biases for sodium in the ion- 
selective electrode groupings are intriguing. They show a clear 
divergence in behaviour between indirect- and direct-reading 
instruments (ie those with and without dilution of the sample 
prior to measurement), and a dependence of the bias for the 
direct group upon the species of origin of the specimen.
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Surprisingly, the greatest difference in mean from the other 
methods was seen for human-based materials, whereas the response 
of these instruments should be optimised for fresh human serum. 
It may therefore be that the effects of commercial processing and 
material lyophilisation predominate, and somehow counteract in 
part the 'deficiencies' of animal sera or alter the properties of 
the human-based materials.
In fact, in almost all instances of apparent species-related 
differences in behaviour the worst performance was seen for 
human-based materials. This better agreement for animal-based 
materials may be due to a lack of (or a lesser degree of) 
interfering substances or turbidity than in fresh human sera or 
in human-based QCMs, to an excess of such interferences in human- 
based lyophilised materials, or to a combination of both. 
Without similar data (which cannot practicably be obtained) for 
fresh human sera it is impossible to establish the cause with 
certainty, and it remains debatable which materials are 
reflecting more accurately the situation for clinical specimens. 
Ideally, to prevent acceptance of clinical results from 
unsatisfactory analytical batches, a material used for IQC should 
have slightly greater sensitivity than clinical specimens to 
analytical variables and the human-based sera are therefore 
perhaps better for that purpose.
With the exception of albumin (where species differences were 
expected) and total protein, such instances were very infrequent, 
however. It was usually difficult to discern for individual 
methods the differences which were apparent from examination of 
the overall data: most method groups are considerably smaller 
than the overall data set and a large number of results may be
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necessary to reveal such differences. Furthermore the 
differences were small, and in most cases the data indicate no 
appreciable difference in performance for materials based on 
human and animal (bovine or equine) serum for the non-protein 
analytes studied.
For total protein, however, human-based specimens do behave 
differently from those based on animal serum and the differences 
are appreciable, with average VISs differing by 10-20. This 
indicates a need for further study, with consideration of whether 
performance should be assessed, ie VISs calculated, for total 
protein only when the material distributed is of human origin, as 
is the current practice for albumin.
14.4 The effects of material manufacturer
The examination outlined for species of origin (section 14.3) was 
repeated, but with the materials classified according to their 
manufacturer (Appendix 11.2.3). However, only three manufacturers 
were represented by five or more materials (Table 14.1).
The proportions of manufacturers whose materials were distributed 
differed substantially between the study and validation periods 
(Table 14.1) and the conclusions concerning Nyegaard and Scottish 
Blood Transfusion Service materials could not be checked. The 
other five manufacturers were represented by larger numbers of 
materials, however, and interpretation was correspondingly 
facilitated.
14,4.1 Examination of overall data
No completely consistent evidence of superiority or inferiority 
of any manufacturer's products was found, though in many cases 
examination of the recalculated CV or average VIS graphs
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suggested this. In some this impression was supported by a 
similar interpretation of the graph of one or other of the 
indicators of discrepant performance. Thus, agreement appeared 
better for materials from Roche Diagnostica for glucose, calcium, 
phosphate, iron and bilirubin (Figure 14.11), from Wellcome 
Diagnostics for sodium and glucose, from Technicon Instruments 
for urea and phosphate, and from Nyegaard for iron. Wellcome 
Diagnostics' materials seemed inferior for magnesium (Figure 
14.12A).
Data from the validation period suggested better interlaboratory 
agreement for materials from Roche for calcium, phosphate and 
bilirubin, from Wellcome for sodium, urate and total protein, 
from Technicon for creatinine and bilirubin, from Puree 
Associates for sodium, and from Ortho Diagnostics for chloride. 
Only in the first four cases did these conclusions correspond to 
those from the study period. The suggestion of worse agreement 
for magnesium with Wellcome materials was confirmed (Figure 
14.12B).
14.4.2 Examination of method-related data
For sodium, the better agreement for Wellcome materials was 
confirmed for the flame photometric groups, but not for ion- 
selective electrodes (Figure 14.13).
Examination of the recalculated CVs for creatinine revealed 
(Figure 14.14) that although similar patterns exist for the 
Manual/discrete analyser endpoint Jaffe, AAII/SMA and Other (ie 
kinetic Jaffe) groups, the variability within the kinetic group 
is almost twice that within the continuous flow group (Figure 
6.5). The effect of manufacturing procedures is exemplified by 
the Hyland material, with a CV of 35% by kinetic Jaffe but only
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Figure 14.11 Relationship with average VIS and percentage of 
VISs >200 for bilirubin, classified by manufacturer
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Figure 14.12 Relationship with recalculated CV and percentage of 
VISs >200 for magnesium, classified by manufacturer
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Figure 14.13 Relationship with average VIS for sodium by 
Continuous flow flame and Ion-selective electrode, 
classified by manufacturer
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Figure 14.14 Relationship with recalculated CV for creatinine by 
Manual/discrete analyser endpoint and Other, 
classified by manufacturer
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of 7.5% by AAII/SMA; Puree Associates' materials also seemed to 
show a similar effect, but of lesser magnitude. No material from 
Hyland was distributed during the validation period, so the 
discrepant performance could not be confirmed. There seemed to be 
no confirmation of the suggested worse agreement for Puree 
Associates' sera, which by then no longer contained Tris buffer; 
this interpretation would be supported by data for the Gibco 
sera, which do contain Tris (Figure 14.14).
14.4.3 Appraisal of the results
UKEQAS distributions do not constitute a fully representative 
selection of the materials available from different 
manufacturers, and only a limited number of manufacturers 
provided a sufficient number of materials to form an 
interpretation (Table 14.1). To be reliable, however, 
conclusions should obviously be based on substantially more than 
the two to five usually considered here. It is in this situation 
that the validation of conclusions by assessment of the 
independent set of data assumes paramount importance. It was 
thus more doubtful that definite conclusions on this aspect could 
be drawn, especially since it is UKEQAS policy not to distribute 
materials from manufacturers previously found to have products of 
inferior quality.
Nevertheless, three manufacturers were represented by 4-6 
materials, ie 10-15% of the database, and several manufacturers' 
materials did appear to yield better interlaboratory agreement, 
as assessed by more than one of the performance indicators, for 
one or more analytes. There were fewer unsupported (and hence 
presumably artefactual) indications of differences from the 
validation than from the study period. This might have been
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expected, since fewer manufacturers, each represented by more 
materials, were considered.
Similar conclusions were drawn from both periods, for materials 
from Roche Diagnostica of better agreement for calcium, phosphate 
and bilirubin, and for materials from Wellcome Diagnostics of 
better agreement for sodium and of worse agreement for magnesium. 
It is difficult to attribute causes to these observations, though 
better agreement for sodium might reflect better vial-filling 
precision. They are unlikely to be due to a relative lack of 
intermethod bias since these conclusions were drawn from average 
VISs as well as recalculated CVs, and might simply reflect more 
homogeneous (and perhaps less turbid) materials. The worse 
agreement for magnesium is particularly difficult to interpret as 
the same manufacturer's materials appeared the best for sodium, 
though some change in the matrix affecting magnesium chelation is 
possible.
14.5 Effect of addition of ethylene glycol
This was assessed by distribution in 1982 and 1983 of a 
commercial liquid material (Link II, Beckman Instruments) based 
on human serum and preserved with ethylene glycol (Maurukas, 
1973) in the UKEQAS for General Clinical Chemistry and UKEQAS 
Enzyme Surveys.
14.5.1 UKEQAS for General Clinical Chemistry
This distribution followed the usual procedures (Appendix 1.2.1), 
except that, on the suppliers' recommendation, participants were 
requested to freeze the specimen on receipt. Table 14.2 compares 
the overall mean values and CVs obtained with those from the 
preceding and following distributions of lyophilised human sera
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Table 14.2 Interlaboratory agreement obtained for human serum 
stabilised with ethylene glycol in the UKEQAS for General 
Clinical Chemistry, April 1982, compared with that for 
lyophilised serum. Beckman Link II, lot Cl 11047, compared 
with Ortho Unassayed Human Serum Level II, lot W24X02B 
(UKEQAS human serum, lot HIQC/5, for potassium and 
cholesterol)
Serum with ethylene glycol Lyophilised serum 
Mean CV Mean CV
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
145.6
5.77
110.7
18.1
14.2
3.26
1.7
50.7
0.55
545
65.1
76.8
47.8
5.41
3.9
4.6
2.9
5.3
5.8
5.0
11.1
12.7
7.6
10.4
11.9
4.3
6.5
7.9
148.1
4.11
112.1
13.9
13.8
2.85
2.4
56.7
0.53
242
42.1
61.1
41.0
4.19
1.2
2.1
2.1
3.9
4.5
2.7
5.3
7.5
5.0
5.0
15.0
2.8
5.5
7.5
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with similar analyte levels.
The interlaboratory agreement was obviously far inferior to that 
usually obtained, and thus no VISs were calculated. Investigation 
and further discussion with Beckman revealed that this was 
probably due to differing treatment of the material by 
participants, with some (correctly) having allowed the serum to 
equilibrate at ambient temperature before thoroughly mixing it 
and assaying it. Others had probably taken it directly from the 
freezer, with possibly inadequate mixing, before assay, and yet 
others adopted intermediate procedures.
The temperature-dependence of the material's viscosity had then 
interacted with the analytical procedures to generate the 
additional variability in results. Laboratory investigation 
confirmed this for sodium assay by means of a flame photometer 
(IL 453) incorporating a viscosity-dependent dilutor: results for 
successive samplings of the material taken directly from the 
freezer declined steadily, until aspiration stopped completely.
Thus correct specimen handling is essential for EQA data to 
reflect the true performance of participants and the material 
distributed. Such assessment is invalidated if additional 
variance is introduced.
14.5.2 UKEQAS Enzyme Surveys
Particular care was therefore taken to ensure that participants 
followed the correct procedure (to store the material at 4°C, but 
allow it to equilibrate to ambient temperature with adequate 
mixing before assay) for handling this specimen when it was 
distributed for enzyme activity assays. Here the primary aim was 
to assess the efficacy of the usual protocol (Appendix 1.2.2;
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Table 14.3 Inter laboratory agreement obtained for human serum
stabilised with ethylene glycol in UKEQAS Enzyme Survey 13, 
1983, compared with that in Enzyme Survey 14 for 'reliable' 
method groups. SCE optimised 37°C for all except amylase 
(Phadebas Tablet Test 37°C); Beckman Link II, lot C111047, 
compared with Ortho Unassayed Human Serum Level II, lot 
X40Y02B
Serum with ethylene glycol Lyophilised serum
Mean CV
(U/L) (%)
AST
ALT
LD
CK
ALP
Amylase
Mean
(U/L)
89
89
987
307
267
747
CV
(%)
7.6
9.8
9.5
9.0
10.8
11.6
159 6.7
122 7.4
881 8.5
531 11.7
470 11.4
546 11.9
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Bullock et al, 1979 and 1986b) in minimising the effect of post- 
reconstitution changes in enzyme activity with lyophilised 
specimens.
Table 14.3 shows the interlaboratory agreement obtained for 
'reliable' method groups for the 6 enzymes surveyed, with 
comparison data from Survey 14. The average CVs of 9.7% and 9.6% 
for the 6 enzymes surveyed indicate there is no substantial 
difference between the two types of specimen. Assuming the liquid 
material contributed no excess variance, the protocol for 
lyophilised sera has thus been successful.
14.6 Summary
External quality assessment data are an excellent means of 
examining properties of the materials distributed. Before such 
detailed investigation, however, the concentration-dependence of 
interlaboratory agreement must first be characterised, as 
discussed in Chapter 6.
Assessment of data from the UKEQAS for General Clinical Chemistry 
demonstrates that animal-based quality control materials are 
generally as satisfactory as those based on human serum for the 
non-protein analytes studied. In a few instances human products 
gave worse interlaboratory agreement, due perhaps to their 
greater turbidity or a relative lack of interferents in the 
animal sera. More detailed examination suggested that such 
instances may arise in some individual method groups, eg kinetic 
Jaffe procedures for creatinine assay.
Similar assessment failed to reveal major differences among 
materials from different manufacturers, perhaps reflecting the 
Organisers' exclusion of previously unsatisfactory material types
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from future distribution. A few cases were found, however. Apart 
from the interference of Tris buffer in some kinetic Jaffe 
procedures for creatinine assay as well as its known effect on 
some urea assay methods employing urease, no explanations for 
these were apparent.
Studies of materials including ethylene glycol emphasised the 
importance of correct specimen handling procedures, and supported 
the efficacy of existing procedures to minimise changes in enzyme 
activity following reconstitution of lyophilised sera.
370
ASSESSMENT OF QUALITY CONTROL MATERIALS
Chapter 15:
ASSESSMENT OF THE EFFECTS OF HEAT-TREATMENT ON THE BEHAVIOUR 
OF LYOPHILISED HUMAN SERUM
15.1 Introduction
Increasing awareness of the potential infectivity of specimens of 
human origin, including calibration and quality control 
materials, has led to greater precautions in clinical laboratory 
work (Advisory Committee on Dangerous Pathogens, 1986; DHSS, 
1986a). Among these is the policy of UK External Quality 
Assessment Schemes (UKEQASs) to distribute human-based materials 
only if they have been tested and found negative for antibody to 
human immunodeficiency virus (HIV; human lymphotropic virus type 
III or lymphoadenopathy-associated virus) at the individual donor 
stage or have been adequately treated to inactivate retroviruses 
such as HIV. Such treatment may be heating (eg at 56°C for a 
minimum of 30 min) or chemical (eg beta-propiolactone).
It is not always possible at present to ensure testing of 
individual donations in all circumstances, and inactivation 
treatment may therefore be needed. Before preparing large 
quantities of such material it is essential to study the effects 
of the treatment on the properties of the product, to ensure that 
its intended use is not compromised.
The UKEQAS for General Clinical Chemistry has since 1980 processed 
human serum and provided this, with assigned values derived from 
distribution through the UKEQASs for General Clinical Chemistry, 
Steroid Hormones and Thyroid-related Hormones, to National Health 
Service laboratories in the UK for use as a check on bias
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(Appendix IV). Much of the stock of serum (collected by the 
National Blood Transfusion Service) for use in preparing this 
HIQC material was obtained, and stored in 5 litre pools, before 
tests for antibody to HIV were available. Thus treatment of the 
base serum would be necessary before these stocks could be used. 
Heat treatment was preferred since only the base serum need be 
treated, whereas chemicals would persist in the processed 
material and affect also the analyte supplements added during 
processing and interact with analytical procedures on the final 
product. In addition, such chemicals could interfere with the 
lyophilisation of the serum and are suspected to be carcinogenic. 
Heat treatment, however, is not an established procedure in serum 
processing and no purpose-designed equipment is available to 
accomplish this.
Preparation of a pilot-scale batch was therefore undertaken in 
1986, in collaboration with Wellcome Diagnostics, who also 
processed the HIQC material at that time. Conventional evaluation 
would yield only limited information on the properties of the 
material, and thus an appraisal of the between-laboratory 
agreement obtained in EQASs constituted the main means of 
assessment. The objective was to assess the effects of this heat- 
treatment on the wide variety of analytical procedures adopted by 
scheme participants, ie to assess the degree to which alterations 
in the serum matrix affected these methods, through comparison 
with the performance of a batch of similar but untreated serum.
15.2 Effects of heat-treatment
The study (Bullock et al, 1986a) compared the behaviour of this 
batch (lot K466610) with that of preceding batches of HIQC 
material, and with HIQC/12 (processed two months later to a
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similar specification but from serum donations which had been 
tested and found negative for antibody to HIV) in particular. 
Full details are given in Appendix III.6.
15.2.1 Evaluation data
The physical properties evaluated at WRL showed few differences 
of the heat-treated serum from previous batches of HIQC material 
(Table 15.1). The turbidity was lower, perhaps reflecting 
aggregation of unstable proteins which were then removed during 
filtration rather than aggregating during lyophilisation. A 
number of other factors, including pool-to-pool variation in 
protein (eg lipoprotein) content and serum ageing processes may, 
however, be involved as evidenced by the variations in turbidity 
among HIQC/9 to HIQC/12.
No microbiogical growth was reported in vials from any of the 
batches studied. Lot K466610 was more stable than lot HIQC/12, 
which was of similar stability to the preceding batches. Thus the 
stability of the inorganic, organic and enzyme components studied 
seemed unaffected by the heat-treatment, as might be expected 
since the addition of exogenous analytes was made after 
completion of heat treatment.
15.2.2 Inorganic, organic and enzyme constituents
There was little difference in the overall performance for the 
analytes in the UKEQAS for General Clinical Chemistry as judged 
from inter laboratory CVs (Table 15.2); the figures for enzymes are 
for a 'reliable' method group (Bullock et al, 1986b). This 
impression is borne out by the average VISs (Table 15.3), which 
are calculated relative to the mean for each laboratory's method 
and thus contain no contribution from differences among method 
means.
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Table 15.1 Comparison of pH, turbidity and vial-to-vial
variability for heat-treated batch and lots HIQC/9 to 
HIQC/12. pH and turbidity data are the mean for three vials; 
vial-to-vial variability derived from sodium assay on 40 
vials
Heat-treated batch HIQC/9 - 12
Average Range
pH 8.87 8.87 8.60-9.07
Turbidity
A400nm 0.450 0.488 0.406 - 0.538 
A500nm 0.282 0.338 0.297 - 0.399 
A600nm 0.129 0.161 0.135 - 0.188
Vial-to-vial variability
CV (%) 0.18 0.31 0.22 - 0.47
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Table 15.2 Comparison of inter laboratory agreement (CV) for heat- 
treated batch and lots HIQC/9 to HIQC/12, with mean value 
for heat-treated batch. CVs (%) are irrespective of method 
after exclusion of outliers, apart from those for enzymes: 
SCE optimised 37°C for AST, ALT, LD, CK and ALP, Phadebas 
37°C for amylase, carboxynitroanilide substrate 37°C for 
GGT.
Analyte Heat-treated batch HIQC/9 - 12
Average Range
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
Osmolality
TIBC
AST
ALT
LD
CK
ALP
Amylase
GGT
1.2
2.1
1.8
3.9
4.1
3.0
5.7
10.6
6.2
8.6
8.6
3.5
5.1
5.7
3.9
7.5
1.8
19.0
9.7
13.0
8.9
19.9
9.6
11.6
8.5
1.3
2.1
1.9
4.0
4.0
2.7
5.4
11.2
5.8
7.0
9.8
3.6
4.6
5.5
4.5
6.7
2.0
20.2
9.3
14.0
9.0
19.5
10.4
11.3
8.7
1.2
2.1
1.8
3.6
3.8
2.6
4.9
9.8
5.4
5.7
9.0
3.3
4.4
5.2
3.9
5.8
1.8
13.3
8.1
12.0
8.2
13.1
8.4
8.5
- 1.3
- 2.4
- 1.9
- 4.4
- 4.2
- 2.8
- 6.1
-12.9
- 6.3
- 7.5
-10.8
- 4.1
- 5.0
- 5.7
- 4.9
- 7.2
- 2.1
-26.2
-11.1
-17.8
-10.2
-27.1
-14.3
-13.1
_
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Table 15.3 Comparison of average Variance Index Scores (VISs) for 
heat-treated batch and lots HIQC/9 to HIQC/12. No VISs 
calculated for TIBC or GGT (CCVs not yet established)
Analyte Heat-treated batch HIQC/9 - 12
Average Range
Sodium
Potassium
Chloride
Urea
Glucose
Calcium
Phosphate
Iron
Urate
Creatinine
Bilirubin
Total protein
Albumin
Cholesterol
Lithium
Magnesium
Osmolality
AST
ALT
LD
CK
ALP
Amylase
54
55
65
50
39
60
54
55
63
55
34
65
47
61
32
54
48
63
58
63
91
55
75
58
56
68
56
42
52
54
58
58
51
42
69
48
57
32
50
57
66
69
72
85
58
72
56
55
65
50
40
50
48
53
53
41
39
66
45
56
27
47
61
65
69
52
70
- 64
- 56
- 70
- 62
- 43
- 54
- 59
- 68
- 64
- 56
- 46
- 74
- 52
- 59
- 34
- 55
—
- 71
- 72
- 75
-
- 64
- 74
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Repeated distribution of lot K466610 in October 1986 showed 
excellent agreement with its initial distribution 6 months 
earlier. The consensus values for the 14 non-enzyme analytes 
requested differed by no more than 0.9%, apart from a reduction 
in glucose of 0.1 mmol/L (1.9%); there was no indication of 
deterioration of any analyte. The CVs were also reproducible, and 
the average VISs for each analyte differed by no more than 6.
Lots HIQC/12 and K466610 were prepared to a similar analyte 
specification and thus the ratio of mean values should be close 
to 1.0, though the most important observation is the consistency 
of the ratio for the individual methods. Table 15.4, however, does 
show minor differences in behaviour among the methods for iron, 
but not for sodium or calcium. For all other analytes, the range 
of ratios was less than 0.05.
15.2.3 Thyroid-related and steroid hormones
Tables 15.5 and 15.6 give data for these hormones for lots 
K466610 and HIQC/12, classified according to method, with the 
ratio of the means for the two materials for each method group. 
Since the numbers in most groups are small, tests of statistical 
significance are of limited use. An arbitrary criterion of a 10% 
difference in ratio from that for the overall means was therefore 
used to identify discrepant method groups; these are denoted by 
an asterisk.
There was similar behaviour among methods for the thyroid-related 
hormones, apart possibly from the in-house polyethylene glycol 
(PEG) precipitation group for thyroxine. For the steroid 
hormones, however, gross discrepancies were seen for many of the 
method groups (Table 15.6).
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Table 15.4 Comparison of met hod-related data for general clinical 
chemistry analytes for heat-treated batch and lot HIQC/12.
Ratios are mean for heat-treated batch divided by mean for 
lot HIQC/12
HIQC/12 Heat-treated batch
CV n Mean CV
Ratio
Sodium (mmol/L) 
Overall
Indirect ISE 
Flame with dilutor 
Continuous flow flame 
Direct ISE
1.3 426 143.7 1.2 0.99
1.2
1.0
0.9
1.9
164
121
106
29
144.3
143.5
143.5
140.5
1.1
1.0
0.9
1.6
0.99
0.99
0.99
0.99
Calcium (mmol/L) 
Overall
Manual/discrete CPC 
Continuous flow CPC 
Methylthymol blue 
Corning titrator 
Atomic absorption
2.7 399 2.873 3.0 0.97
2.7
2.3
4.2
2.3
2.6
189
131
25
26
23
2.892
2.871
2.852
2.815
2.827
3.2
2.2
4.2
2.1
2.6
0.97
0.97
0.98
0.97
0.98
Iron (umol/L) 
Overall 12.9
Manual/discrete ferrozine 13.5 
Continuous flow ferrozine 8.0 
Bathophenanthroline 23.2 
Continuous flow TPTZ 5.2
232 19.2 10.6 1.08
107
63
21
20
19.1
19.3
18.6
19.1
11.4
6.9
12.1
9.1
1.04
1.12
1.06
1.06
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Table 15.5 Comparison of method-related data for hormones for 
heat-treated batch and lot HIQC/12. Ratios are mean for 
heat-treated batch divided by mean for lot HIQC/12; 
asterisks denote ratios differing by >10% from that for the 
overall means
Thyroxine (nmo1/L) 
Overall
In-house PEG 
In-house double Ab 
In-house double Ab/PEG 
Amersham 
NETRIA
HIQC/12 
CV
8.8
Heat-treated batch
n Mean CV
135 145.4 9.8
Ratio
1.17
11.1
2.5
8.4
7.7
6.8
23
13
12
11
11
136.4
148.6
152.0
136.8
152.2
10.5
11.5
6.9
6.6
8.0
1.10
1.21
1.19
1.15
1.20
Triiodothyronine (nmol/L) 
Overall
Amersham
Excluding Amersham 
In-house double Ab
12.4 99 2.6 13.7 0.87
8.3
11.9
8.8
33
54
15
2.4
2.8
2.8
6.0
14.4
12.3
0.86
0.90
0.90
TSH (mU/L) 
Overall
Monoclonal IRMA 
RIA
Serono MAIA IRMA 
Amersham RIA 
In-house RIA 
Corning IRMA 
Boots-Celltech IRMA 
NETRIA IRMA
30.6 200 1.8 33.6 0.95
15.3
26.5
11.5
20.3
48.5
33.1
9.2
13.2
67
64
57
37
24
21
15
11
1.5
2.3
1.6
2.2
2.6
2.2
1.7
1.8
16.2
27.9
10.5
13.8
52.5
26.8
9.5
14.6
0.88
1.00
0.94
0.92
1.18*
1.05*
0.94
1.05*
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Table 15.6 Comparison of method-related data for steroid hormones 
for heat-treated batch and lot HIQC/12. For explanation see 
Table 15.5
Cortisol (nmol/L)
RIA 
Fluorimetric
Amerlex
DPC
Farmos
In-house direct
Becton-Dickinson
Abbott TDx
Travenol
Serono
NEN
Corning
Oestradiol (pmol/L) 
Overall
Steranti/EIR
DPC
In-house extraction
Sorin
Progesterone (nmo1/L) 
Overall
DPC
In-house direct
Amerlex-M
NETRIA pH 10
Gamma-B
In-house extraction
Testosterone (nmol/L) 
Overall
Extraction 
Direct
In-house extraction
Gamma-B
STRIA extraction
DPC
HIQC/12 
CV
19.3
17.7
18.3
Heat-treated batch
n Mean CV
47 530 15.8
93 35.8 24.1
9
17
6
27
7
13
36
15
12
7
7
4
30.6
40.7
36.5
64.9
41.5
33.1
9
36
10
35
7
19
48 9.7 16.1
Ratio
12.4
6.5
12
11
10
11
9
8
6
20
7
4
166
16
49
24
18
20
11
11
8
6
6
5
946
880
947
866
1049
982
861
1072
1028
1199
793
1057
13.1
9.8
18
9
18
35
9
12
8
21
22
9
1.04
1.01
0.98
1.02
1.26*
1.12
1.02
0.98
1.15*
1.30*
0.87
1.06
0.87
15
16
23
9
17
13
10
5
540
481
558
642
13
9
22
9
0.82
0.93
0.76*
1.10*
1.38
1.33
1.47
1.30
1.65*
1.46
1.28
1.17
15.
17.
24
19
8
8
8
8
32
16
22
13
7
6
9
10
9
11
9
9
.4
.6
.6
.4
.7
.3
20.
20.
17
20
13
-
4
9
1
1
1
1
1
1
.07
.39*
.08
.44*
.10
.30*
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15.2.4 Appraisal of the results
Materials used for calibration, for accuracy control in internal 
quality control or in EQA must have assigned values which are 
consistent with the methods used. They must either be commutable 
with fresh clinical specimens (see Chapters 12-14) or have 
method-specific assigned values. The policy of the UKEQAS Value 
Assignment Committee (Appendix IV.2) has been towards the 
assignment to HIQC materials of a single value for all methods 
where the similarity of means and SDs for the individual method 
groups justifies this.
The data presented here indicate that this approach would 
probably also be applicable to the majority of the analytes in 
material which had been heat-treated during processing, though 
careful examination would be required. For the steroid hormones, 
however, it would almost certainly be necessary to assign values 
for individual method groups, and the small numbers of results in 
many of the groups would preclude assignment of a reliable mean 
value. The usefulness of such material in IQC of methods which 
show a substantially different behaviour (in terms of a 
discrepant mean and/or increased variability) might also be 
questioned.
The results in this study differ from those in separate studies 
conducted by the hormone UKEQASs. These studies (Groom et al, 
1986; Swift et al, 1986) used liquid sera distributed through the 
UKEQAS, both untreated and after heating. Such treatment did not 
appear to cause significant differences in behaviour for the 
thyroid-related hormones (Swift et al, 1986). For the steroid 
hormones, the only discernible changes were reductions of about
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5% in cortisol using fluorimetric, Amerlex and Corning methods, 
and an increase in progesterone by the NETRIA pHIO assay (Groom 
et al, 1986).
Hormone immunoassays depend on balancing the conflicting 
requirements of using reagents such as 8-anilino-l-naphthalene 
sulphonic acid to displace completely the hormone from its serum 
carrier protein while maintaining binding of both hormone and 
labelled hormone to antibody. Such assays may not be robust and 
are therefore liable to perturbation by any changes in the 
system. Partial denaturation of the carrier protein would be one 
such change, and both sex hormone binding globulin and thyroxine 
binding globulin (TBG) are potentially unstable at 60°C. The 
findings for lot K466610 may thus be explicable in terms of local 
heating above 60°C at the point of steam injection into the 
vessel jacket. This is supported by the observation of a greater 
apparent free thyroxine concentration relative to total thyroxine 
in lot K466610 than in the other HIQC materials (Table 15.7), 
reflecting possible degradation of TBG.
15.3 Studies on lot HIQC/13
This batch was prepared using procedures similar to those for lot 
K466610, except that the bulk serum was heated at 56°C for 1 h 
rather than 30 min. Distributions through the same UKEQASs were 
made, in September 1986.
The results of both the evaluation and UKEQAS distributions 
resembled closely those for lot K466610. Thus the only major 
differences in behaviour from untreated serum were for the 
steroid hormone assays; poor interlaboratory agreement for 
testosterone may have masked any effects of the heat-treatment.
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Table 15.7 Total and free thyroxine content for heat-treated 
batch and lots HIQC/9 to HIQC/12, and lot HIQC/13 (also 
heat-treated)
Total T4
(nmol/L)
Free T4
(pmol/L)
Free/total
Heat-treated batch 154 60.6 0.039
HIQC/9 
HIQC/10 
HIQC/11 
HIQC/12
71
100
137
127
13.8
21.5
28.1
23.4
0.019
0.022
0.021
0.018
HIQC/13 121 54.8 0.045
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These problems prevented assignment of RIA ALTMs for the steroid 
hormones. The results obtained by participants using 6 commercial 
kits were discrepant for between one and three of these hormones 
(four kits for cortisol and for oestradiol, three for 
progesterone). These discrepancies were in general agreement with 
the data in Table 15.6.
The results of total and free thyroxine assays on this batch are 
also given in Table 15.7, demonstrating that the prolonged heating 
may have caused a slight further degradation of TBG.
15.4 Summary
Studies using EQAS data confirm that heat-treatment (at 56°C for 
30 min or 1 h) prior to lyophilisation of human serum has only 
minor effects on its behaviour for assays of inorganic, organic 
and enzyme constituents. There are similarly no effects which 
limit its usefulness with respect to assays of TSH and of total 
T4 and T3.
Changes are seen, however, in the intermethod differences for 
steroid hormones from those for both lyophilised and liquid 
native sera, and for heat-treated liquid sera. These differences 
preclude assignment of a single value for all methods, though the 
majority of UK laboratories use methods for which a useful value 
might be assigned. The material may still be useful for internal 
QC of apparently discrepant methods, using an appropriate 
assigned value.
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Chapter 16:
GENERAL DISCUSSION
16.1 The contribution to patient care of external quality 
assessment in clinical chemistry
The central position of quality assurance in maintaining and 
improving the reliability of laboratory investigations in the 
diagnosis and monitoring of patients is now well-established. 
Clinical chemical investigations play an ever-increasing role in 
the detection, diagnosis and monitoring of disease and ill- 
health, and must be of excellent quality for the avoidance of 
suffering and provision of efficient and economic health care.
EQA is an essential aspect of quality assurance, being 
complementary to internal quality control procedures. This has 
been reflected in the introduction of many local, regional, 
national and supra-national schemes, and EQA is now practised 
almost universally in developed countries. The development from 
initial restricted EQA surveys, accompanied by the introduction 
of IQC, to national schemes was outlined in Chapter 1.
16.1.1 The relationship of analytical quality to patient 
care
Intuitively, it appears obvious that patient care will benefit 
from all improvements in the quality of analytical performance. 
Consideration (section 2.2.1) of attempts to differentiate 
between populations of individuals, eg normal and diseased 
groups, confirmed that reductions in analytical variance will 
improve test sensitivity, specificity and efficiency.
More recently this view has been challenged (eg Subcommittee on 
Analytical Goals, 1979; Eraser, 1983), with the counter-proposal
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that further improvement is unnecessary when 'analytical goals' 
have been satisfied (section 2.2.2). Such goals are based upon 
biological variation, but remain arbitrary in their relation to 
it. Furthermore, application to monitoring intra-individual 
changes at elevated analyte concentrations in disease states may 
yield more stringent goals for some analytes. Comparison of such 
goals with performance achieved (sections 2.2.2 and 9.6) also 
indicated that they are currently not generally met, and 
analytical variance is not negligible relative to biological 
variation.
16.1.2 Consideration of the requirements, applications and 
benefits of external quality assessment
Despite wide application, EQA scheme design does not seem to be 
based on logical principles. Though their application in 
regulating laboratory performance is obvious, the potential roles 
of EQA schemes in the assessment of interlaboratory agreement, in 
the assessment of analytical methods, in the assessment of 
individual laboratory performance and in the assessment of 
quality control materials, have not been widely appreciated.
These applications of external quality assessment schemes and 
their benefits have therefore been examined in this thesis, 
including consideration of the basic requirements of scheme 
design. The main question addressed is: What has external quality 
assessment to contribute to the scientific development of 
clinical chemistry and to patient care, besides the 'policing 1 of 
laboratory performance?
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16.2 EQA in the assessment of inter laboratory agreement
16.2.1 EQA in assessing the state of the art
Chapter 2 describes the role of EQA surveys in providing an 
assessment of the state of the art, ie the prevailing standard of 
performance, without necessarily committing the organisers to 
establishing a regular EQAS. The use of the information gathered 
in such surveys in determining the most appropriate further 
action is summarised in section 2.5.
Many EQASs (the requirements of which are discussed below) have 
evolved from initial exploratory surveys, as described in section 
2.4 for assays which effectively determine clinical management 
where there was clear evidence of unsatisfactory performance.
Section 2.3 exemplified the application of EQA surveys to extra- 
laboratory assays, which are playing an increasing role in 
patient management. These surveys demonstrated clearly that assay 
quality was generally unsatisfactory. Here, however, EQA alone is 
unlikely to bring about improvement in the absence of adequate 
quality assurance and IQC procedures, and the importance of 
involvement in QA procedures by local laboratory staff was 
emphasised in section 2.3.4.
16.2.2 Fundamental requirements of scheme design
The primary consideration in EQAS design is to ensure the 
confidence of participants in the scheme's assessment of their 
performance, and thus increase the likelihood of their taking 
action on the conclusions drawn.
Chapter 3 emphasises the importance of certain elements and 
factors in interlaboratory survey design (summarised in section 
3.5) which are important in engendering and maintaining this
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confidence.
Though many schemes have broad similarities in design, there are 
individual differences. It is concluded that a scheme design 
employing frequent distributions of single specimens is 
satisfactory, provided data are cumulated over time to provide a 
more robust assessment of performance and changes in performance. 
The purposes of scheme operation also differ, as discussed in 
section 16.4 below.
Several aspects merit more detailed appraisal. Scoring systems 
were therefore examined in Chapters 4 and 9, the validity of 
consensus values in Chapter 5, and the properties of QC materials 
in Chapters 12 to 14.
16.2.3 The application of scoring systems in EQA
EQA schemes and surveys generate large amounts of numeric 
performance data which often lack impact, and much of the 
information content may be lost on the scheme participants. Data 
reduction is therefore essential, and Chapter 4 demonstrates the 
major contribution of scoring systems to the effectiveness of EQA 
in performance assessment.
Though all such evidence is circumstantial and a causal 
relationship cannot be established, experience in UKEQASs 
strongly indicates that scoring is linked with overall 
improvement. The similar patterns of rapid and sustained 
improvement following the introduction of scoring into schemes 
with little evidence of previous improvement were described in 
section 4.5.
Though such systems originated to simplify the assessment of 
performance for individual participants (Chapter 9), Chapter 4
388
describes their contribution to the assessment of:
- the state of the art
- the effects of analytical procedure
- progress over time
- relative performance in different schemes and countries
The unsuitability of many of the systems devised for such use was 
outlined in section 4.9. To be fully useful in the assessment of 
progress and for comparison of performance among schemes, systems 
must be independent of other participants' performance (section 
4.7.2).
The Variance Index system (defined fully in Appendix II) appears 
to overcome many of these problems. Cumulation of VISs (as 
estimators of total error) over time gives performance indicators 
for individual analytes (MRVISs), and over analytes provides an 
index of overall performance (OMRVIS). These running scores are 
robust and readily interpretable, by both scheme participants and 
organisers, in terms of the state of the art (section 9.2).
Potential problems in application of the VI system must also be 
considered. Section 4.8 concluded that readjustment of CCVs to 
restore the 'common currency' may be necessary despite the 
practical difficulties entailed. The data presented in Chapter 6 
confirm the need to maintain a balance of analyte concentrations 
in the specimens distributed; the effects of failure so to do are 
shown in Figure 11.1 (section 11.2.1).
Overall, application of the VI system has proved of great value 
in many schemes, provided care is taken to avoid these potential 
problems.
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16.2.4 Consensus values in EQA
Chapter 5 examines the validity of consensus values (the mean of 
results obtained by all participants or by those using a 
particular method), which have long been used in EQA as target 
values. The deficiencies of alternative value assignment 
procedures using reference laboratories were detailed in section 
3.4.3.
Consensus values have been shown to be highly reproducible on 
repeated EQAS distribution of the same material (section 5.2) and 
may therefore be considered reliable. Are they accurate, however? 
This is of great importance, since the primary aim of EQA is 
numerical comparability of results among laboratories through the 
elimination of bias.
Close agreement between consensus values obtained in even 
completely independent national EQA schemes (NEQASs), has been 
shown (sections 5.3 and 5.5). More importantly, comparisons using 
a variety of specimens showed close agreement of consensus values 
with definitive methods for many organic and inorganic analytes 
(section 5.4.1). Longitudinal study of values assigned using 
reference laboratories and methods confirmed that UKEQAS 
consensus values have not been subject to any 'drift' away from 
accuracy (section 5.4.2).
For practical reasons such studies were not systematic. The novel 
design of the WRL International Intercomparison Scheme (WHS; 
section 5.6) was therefore used to address the question of 
comparability among countries. This feasibility study showed good 
agreement in most cases, especially for the most developed 
countries. UKEQAS values were confirmed to be in good agreement 
with the international consensus from 30 NEQASs.
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Attempts to adjust this comparison to take account of 
participants' bias in their NEQAS led, however, to divergence in 
some cases. Possible reasons were discussed in section 5.6.4, 
including possible influence of participation in the WHS on 
laboratories' performance. This was not intended, but attests to 
the power of EQA in improving interlaboratory comparability.
On balance, consensus values offer the best practical approach to 
providing target values in an EQAS. They must, however, be kept 
under continual scrutiny for the potential problems of inaccuracy 
and 'drift'.
16.2.5 The influence of analyte concentration on 
interlaboratory agreement
'Precision profiles', reflecting dependence of analytical 
precision upon analyte concentration, are useful in IQC (eg 
Ekins, 1983). Similar relationships would be expected in EQAS 
data, but have not been generally reported.
Studies in UKEQASs (sections 6.2 and 6.3), confirmed such 
dependence for many analytes, with interlaboratory agreement best 
at intermediate concentrations. The complex interrelationships 
between concentration-dependence and interlaboratory agreement 
are summarised in section 6.4.
Such concentration-dependence is important to the design of 
reliable EQA schemes, since its effects on performance assessment 
must be minimised, eg by confining scoring to a band of 
concentrations. These studies also underline the need to provide 
a balance of concentrations in the materials distributed, as 
discussed in section 16.2.3 above. Characterisation of such
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dependence is a prerequisite for the assessments of specimen 
properties described in Chapter 14.
16.2.6 EQA of non-quantitative investigations
The requirements for EQA of semi-quantitative and qualitative 
investigations differ from those described in Chapter 3 for 
quantitative assays. They are considered in Chapter 7, using 
blood phenylalanine assay in phenylketonuria (PKU) screening and 
the chromatography of urinary aminoacids as examples. The 
differences are summarised in section 7.4.
It is important that the scheme design approaches the routine 
clinical situation, to avoid the appearance of an 'artificial' 
exercise. Performance assessment must also address the essentials 
of the investigation; patients are most at risk from a laboratory 
which fails in the basic objective, eg does not recognise that a 
chromatographic pattern is abnormal.
Experience shows that EQASs for such investigations can also be 
successful in improving the reliability of patient care, though 
variation between surveys in the specimens distributed may 
complicate performance assessment.
16.3 EQA in the assessment of analytical methods
All clinical chemists face at some time the problem of selecting 
an analytical procedure (method principle and instrument) for 
routine use. Section 8.1 outlined the deficiencies of common 
information sources other than EQA data.
Section 8.2 demonstrated the use of information from EQA, using 
as example the selection of a method for serum calcium assay. The 
conclusions were confirmed by re-examination of subsequent data.
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The assessment of aspects of performance other than 
interlaboratory agreement, such as accuracy, was also considered 
(section 8.4.1). In schemes subject to matrix effects, however, 
less confidence can be attached to conclusions regarding relative 
bias unless the specimens are demonstrated to have properties 
resembling those of clinical specimens (ie to be commutable, as 
discussed in Chapters 12-14).
Though limited by the discrimination in the classification used, 
EQAS data have been shown to be invaluable in assessing the 
routine performance of methods already in general use.
16.4 EQA in the assessment of individual laboratory performance
The main objective of EQASs is the improvement of interlaboratory 
agreement, to facilitate better patient care. The role of such 
schemes should be primarily educational in intent, and the scheme 
design should emphasise this aspect in encouraging participants 
to appraise and improve when necessary their own performance.
The 'policing' of performance undertaken in licensing schemes has 
therefore not been considered. The purpose of such schemes is to 
determine the acceptability of laboratories for registration or 
reimbursement, the main examples being those organised in GFR 
(Bundesarztekammer, 1971) and by CDC in the USA (Boone, 1984). 
The adverse consequences of failure to satisfy the criteria 
imposed also encourage attempts to improve the performance 
assessment through special treatment of specimens (Rumley and 
Roberts, 1982; Rowan et al, 1984), and mutual confidence between 
scheme organisers and participants is lacking. Consequently 
distributions tend to be infrequent, with performance assessment 
by a 'pass/fail' system. The data are thus of very limited 
assistance to participants, who need an objective and detailed
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appraisal of their performance.
16.4.1 Scoring systems for performance assessment
Scoring systems were introduced into EQASs as a powerful means of 
data reduction to facilitate participants' interpretation of 
information derived from EQA. The scoring system must allow 
participants to compare their current performance with that of 
other laboratories and with their own past performance; scores 
must be independent of the standard of other participants' 
performance, as discussed in section 16.2.3.
For optimal efficiency in interpretation the system should allow 
stepwise appraisal by participants of increasingly detailed 
information as appropriate. This was demonstrated in section 9.2 
using the VI system and an example from the UKEQAS for General 
Clinical Chemistry, and summarised in section 9.7.
Section 9.5 outlined the use of scoring systems to detect 
participants experiencing performance difficulties, so assistance 
may be offered to them (eg Browning, 1984). The problems of 
excessive competition in scoring systems were also considered 
(section 9.3.1).
The relative merits of systems such as VI based upon the state of 
the art and of alternatives based on 'medical requirements' and 
'analytical goals' were discussed in section 9.6. The most 
practical and effective approach is to use a system such as VI 
and take clinical requirements into account when interpreting 
scores.
16.4.2 Use of graphical data presentations in EQA
Chapter 10 demonstrates how graphical presentations assist both
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participants and scheme organisers in interpreting EQA data.
The limitations of simple widely-used presentations such as 
histograms of results were considered (section 10.3). Graphical 
displays which facilitate assessment of progress (section 10.4) 
and the investigation of factors contributing to overall error 
for an individual analyte (section 10.5) were discussed in 
detail.
For resource reasons, as outlined in section 10.6, graphical 
presentations have been little used. Newer technology now offers 
the prospect of cheaper and faster systems with high quality 
output, combining graphical and text elements to increase the 
application of EQA data by participants.
16.4.3 Investigation of factors affecting performance
As shown for analytical methods in Chapter 8 and section 16.3 
above, EQA data are useful in identifying factors associated with 
good or poor performance. These are not the only factors 
involved, however, and the Nuffield survey (section 11.1.1; 
Maclagan et al, 1980) provides a good example of a systematic 
study of others.
The association of large laboratory size (expressed as annual 
workload) with performance was examined using UKEQAS data in 
section 11.2, with particular consideration of the problems 
arising from decreasing workloads and the consequent smaller and 
less frequent assay batches.
The laboratory's organisation and general attitude to maintaining 
professional standards is also important. Section 11.3 considers 
the performance of UK private sector and Irish laboratories in 
relation to the "small laboratory syndrome" (Browning, 1984).
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16.5 EQA in the assessment of quality control material 
suitability
Section 12.1 outlines the differing performance requirements for 
quality control materials (QCMs) for use in different 
circumstances. Thus materials for EQA and for calibration must be 
commutable with (ie show intermethod differences similar to those 
for) clinical specimens (Fasce et al, 1973; Rej et al, 1984; Moss 
et al, 1985), unless designated values are obtained by the same 
method. Problems relate to the interaction of differences in QCM 
composition with less than perfectly specific analytical methods, 
and are usually termed 'matrix effects'.
16.5.1 Suitability of QC materials for EQA
The problems in selecting suitable QCMs for HDL cholesterol assay 
and the need for interlaboratory comparability were outlined in 
section 12.2. These stimulated the formulation of a protocol to 
assess QCM suitability for use in EQA, described in section 
12.2.1. The conclusions were validated in an EQA survey (section 
12.2.2).
The inhomogeneity in EQA data for sodium and potassium using 
direct ISE methods, reflecting susceptibility to matrix effects 
and a lack of commutability, was described in section 12.4. It 
was concluded that commutable QCMs could not be identified a 
priori. Application of a protocol similar to that applied for HDL 
cholesterol might, however, thus permit performance assessment 
for direct ISEs.
Such a protocol could form the basis of a general procedure for 
assessing the suitability of QCMs for use in EQA.
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16.5.2 Calibration effects in EQA
Calibration is a further major factor affecting laboratory 
performance, and Chapter 13 describes the use of EQA surveys to 
examine the effects on interlaboratory agreement of using a 
common calibration material.
Most studies demonstrated substantial improvement. The degree of 
improvement was directly related to the diversity in methods and 
calibration procedures, with the most marked improvement seen 
within the most heterogeneous groups (section 13.2). Indeed 
preliminary results from a recent European survey of specific 
protein assays (data not presented) indicate that differences 
among the commercial calibrants used largely account for the 
differences observed among national consensus values for these 
assays, since these differences can effectively be abolished by 
'calibration' of the EQA data using a common assigned value.
Where analytical procedures have differing specificities, any 
differences in properties (ie lack of commutability) between the 
calibrant and clinical specimens become important. The resultant 
effects on improvement were demonstrated for urinary total 
oestrogen assay in section 13.3.1.
Problems of non-commutability and the limitations of calibration 
for enzyme activity estimations were considered in section 13.5, 
though in most cases EQA studies confirmed the favourable effects 
of calibration. Use of suitable calibration materials (Moss et 
al, 1985), preferably but not necessarily in combination with 
method standardisation, thus offers a means to improve greatly 
the unsatisfactory numerical concordance between results obtained 
in different laboratories and consequently contribute to more 
reliable patient care.
397
16.5.3 Effects of material source and processing
Chapter 14 demonstrates the application of EQA data in examining 
properties of the materials distributed, provided the 
concentration-dependence of interlaboratory agreement has first 
been characterised (Chapter 6 and section 16.2.5 above).
The main study was of the relative suitability of materials based 
upon human and animal serum (section 14.3). It was concluded 
(section 14.3.3) that animal-based materials may be used with 
equally satisfactory results for calibration, IQC and EQA of the 
non-protein analytes studied, with important economic and ethical 
consequences for laboratory practice.
EQA data were also used to assess the effects of manufacturing 
procedures on QCM behaviour (section 14.4), and failed to reveal 
major differences among materials.
The advantages of materials including ethylene glycol were 
described in section 14.5, with further characterisation of their 
properties through EQA distribution. These studies also confirmed 
the efficacy of existing procedures to minimise changes in enzyme 
activity following reconstitution of lyophilised sera.
16.5.4 Effects of heat-treatment
The heat-treatment of serum to inactivate viruses in pooled human 
serum exemplifies a non-physiological QCM production process 
which is necessary in some circumstances (section 15.1).
The studies using EQAS data described in Chapter 15 confirmed the 
minor effects of heat-treatment prior to lyophilisation upon QCM 
behaviour for most analytes. An explanation of the discrepant 
findings for steroid hormones was discussed in section 15.2.4.
398
16.6 Conclusion
The role of external quality assessment in 'policing' laboratory 
performance through the operation of licensing schemes is 
obvious. Apart from this, however, its contribution is mediated 
through the four aspects of assessment of interlaboratory 
agreement, assessment of analytical methods, assessment of 
individual laboratory performance, and assessment of quality 
control materials.
This thesis has presented evidence of the requirements, 
applications and benefits in each of these aspects, and thus 
established the importance of external quality assessment to the 
scientific development of clinical chemistry and to patient care.
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APPENDICES 
Appendix I:
EXTERNAL QUALITY ASSESSMENT SCHEMES AND SURVEYS
I.I General aspects of EQA scheme and survey design
The EQASs organised from WRL have many features in common. 
Specimens and the corresponding results document are despatched 
together to participants by the fastest practical means. The 
results document identifies the specimen (with reconstitution 
instructions), the analytes required and the date by which 
results must be received at WRL. Participants write their results 
on the document (which specifies the units) and return it to WRL.
The results received are entered into the WRL computer system by 
two data clerks independently, and any discrepancies are 
investigated. A checklist is produced, indicating any results 
>1.5 SD from the untrimmed mean to be checked by UKEQAS staff 
against the results document received. After this data validation 
procedure the main processing is carried out.
Data processing involves program modules to:
- calculate the overall mean and SD, and recalculate these 
after exclusion of results >2 or >3 SD from the 
untrimmed mean
- calculate similarly means and SDs for each method group
- calculate BISs and VISs (see Appendix II) for each 
laboratory's results
- cumulate BISs and VISs for the calculation of an OMRVIS, 
and of MRVIS/MRBIS/SDBIS for each analyte
- produce reports for participants
Reports are then mailed to participants by the fastest 
practicable means. The reports include the participant's own 
results, overall and method-related consensus values and SDs, 
histograms of results, and VI scoring parameters.
The schemes differ primarily in the:
- distribution frequency
- number and type of specimens constituting a distribution
- analytes surveyed
- unit sets used
- truncation limits
- inclusion of VI scoring
417
- use of overall or method mean as designated value (DV)
- selection of VI scoring parameters reported to 
participants
- detailed report format
1.2 UK External Quality Assessment Schemes (UKEQASs)
Table I.I details the current (1987) characteristics of the full 
schemes, the development of which has been summarised previously 
(Bullock, 1985; DHSS, 1986b). Specimens and reports are 
despatched by first class mail. Results received too late for the 
main computer run, but before report despatch, are scored on the 
basis of the main computer run and the files updated accordingly.
Descriptions of each scheme are confined to the variables 
mentioned above and to major changes during their development.
1.2.1 UKEQAS for General Clinical Chemistry
Vials of lyophilised quality control sera, based on human or 
animal serum and to be reconstituted with distilled water, from a 
variety of commercial sources or commissioned by UK EQAS (Table 
1.2) are distributed. Results received 11 days after specimen 
despatch are included in the main computer run. Outlier 
elimination is by truncation at +3 SD. BISs are calculated using 
the recalculated method mean as DV for each method group except 
Miscellaneous (recalculated overall mean) and Other (no scores). 
Participants' reports now (1987) include all VI parameters, 
though histograms of results were discontinued in 1984.
Prior to 1976 specimens of pooled liquid human serum were used 
(Whitehead et al, 1973). The analytes surveyed are listed in 
Table 4.3; the first 14 have been included since the scheme's 
inception, the others being added later. The enzymes were 
incorporated in 1986. Reporting was changed from mass to molar SI 
units in 1976. No VI parameters were reported routinely prior to 
1974, and the range has been increased steadily from the OMRVIS 
alone, incorporating successively VISs, MRVISs, BISs, and MRBISs 
and SDBISs for each analyte.
1.2.2 UKEQAS Enzyme Surveys
The surveys have been described previously (Bullock et al, 
1986b). Most of the specimens distributed were lyophilised QC 
sera; one batch of liquid serum preserved with ethylene glycol
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Table I.I Description of UKEQASs at January 1987
TJKEQAS for
General Clinical 
Chemistry
Salicylate and 
Paracetamol
Participants Distributions Analytes Established
/year
560
330
24
12
18 1969 
(from 26)
2 1984
Specific Proteins
Lead in Blood
280
140
12 
24
8 
2
1980 
1973
Urinary Pregnancy 
Oestrogens
Pherylketonuria 
Screening
60
35
12
(6 specimens)
1980 
(transferred)
1980
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Table 1.2 Materials distributed in UKEQAS for General Clinical
Chemistry, 1978-1987. * denotes an Enzyme Survey, + a repeat 
distribution; A = animal, B = bovine, E = equine, H = human
131 
132 
133 
134 
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
1
156
157
2
158
159
160
3
161
162
163
164
165
4
166
167
168
169
170
5
171
172
173
174
175
176
6
177
178
Date
06.01.78 
20.01.78 
03.02.78 
17-02.78 
03.03.78
17 •
31.
14
28
12
26
16
30
14
28
18
08
22
06
20
03
17
01
15
12
25
09
09
23
06
27
18
08
15
29
13
27
10
24
07
21
05
19
02
16
23
07
21
14
28
11
25
10
24
•
•
•
•
•
•
*
•
*
•
•
•
•
•
•
•
•
•
•
•
•
•
*
•
•
•
•
•
*
*
•
•
•
.
•
•
•
•
•
•
»
•
•
*
*
•
•
03
03
04
04
05
05
06
06
07
07
08
09
09
10
10
11
11
12
12
01
02
02
03
03
04
04
05
06
06
06
07
07
08
08
09
09
10
10
11
11
11
12
12
01
01
02
02
03
03
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.78
.79
.79
.79
.79
.79
.79
.79
.79
.79
.79
.79
.79
.79
.79
.79
-79
.79
.79
.79
.79
.79
.79
.79
.79
.80
.80
.80
.80
.80
.80
Supplier
DADE 
GD 
Roche 
GD 
GD
Wellcome
Wellcome
Roche
Wellcome
Hyland
Hyland
TCS
Wellcome
DADE
GD
Puree
Puree
TCS
Wellcome
Hyland
DADE
Roche
Roche
GD
Nyegaard
*Roche
Liberton
GD
*Roche
Liberton
TCS
Technicon
*Hyland
Ortho
Roche
Roche
Hyland
Hyland
*DADE
BCL
Miles
Technicon
Biotrol
Miles
*GD
Wellcome
TCS
Liberton
Liberton
Roche
Roche
DADE
Technicon
DADE
Material
Monitrol II.X 
Unassayed 
WHO Reference 
Validate 
Unassayed
NQCS High
NQCS Normal
WHO Reference
NQCS Low
Q-Pak I
Q-Pak II
Equitrol
+NQCS High
+Monitrol II.X
CCQCS
Armtrol
Armtrol
Equitrol
+NQCS High
+Q-Pak I
Monitrol I.X
Control N
Control P
QAS Level II
Seronorm
Enzykon SN
NQCS Trial
+QAS Level II
Enzykon SP
SNBTS
Human
Multisystem
Q-Pak I
Abnormal
Control P
Control N
Q-Pak II
Q-Pak I
Monitrol II.X
Precinorm U
Mytrol
Multisystem
Biotrol -00
Mytrol
Versatol-E Plus
NQCS Internal QC
+Human
+NQCS Trial
NQCS
Control N
Control P
Enzatrol E
Multisystem N
Monitrol I.X
Lot Base
XPT-9568 H 
H 
Serum A H 
0389057 H 
0664107 B
K5439
K5438
77/1
K5437
1779N003AB
1778P002A
0468
K5439
XPT-9568
0247017
387
390
0419a
K5439
1779N003AB
XLT-350
A2137
A0438
4D365
144
X1033
LI/78
4D365
X1033
12
0863
X9C202
1840U001A
9S317
A0842
A2941
P13/R237
1779N005B
XPT9568
801
458
X9G207
1921
361
4F986
HIQC/1
0863
LI/78
L3/79
N1538
N2238
ET247
X9M111
XLT-373
H
H
H
H
H
H
E
H
H
H
B
B
E
H
H
H
E
E
H
E
A
H
H
A
B
H
B
H
H
E
E
H
H
H
H
H
B
B
H
A
H
H
H
H
E
E
S
B
H
Volume
10 
10 
10 
10 
10
10
10
10
10
5
5
10
10
10
10 dil
10
10
10
10
5
10
5
5
10 dil
5
3
10
10 dil
3
10
10
10
5
10
5
5
5
5
10
10
5
10
10
5
3
10
10
10
10
5
5
3
10
10
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179 14.04.80
180 28.04.80
181 19.05.80
7 02.06.80
182 09.06.80
183 23.06.80
184 07.07.80
185 21.07.80
186 04.08.80
187 18.08.80
188 01.09.80
189 15.09.80
8 29.09.80
190 13.10.80
191 27.10.80
192 10.11.80
9 17.11.80
193 01.12.80
194 15.12.80
195 12.01.81
196 26.01.81
197 09.02.81
198 23.02.81
199 09.03.81
200 23.03.81
10 06.04.81
201 27.04.81
202 18.05.81
203 01.06.81
204 15.06.81
205 29.06.81
206 13.07.81
207 27.07.81
208 10.08.81
209 24.08.81
11 14.09.81
210 28.09.81
211 12.10.81
212 26.10.81
213 09.11.81
214 23.11.81
215 07.12.81
12 04.01.82
216 18.01.82
217 01.02.82
218 15.02.82
219 01.03.82
220 15.03.82
221 29.03.82
222 19.04.82
223 10.05.82
224 07.06.82
225 21.06.82
226 05.07.82
227 19.07.82
228 02.08.82
229 16.08.82
230 06.09.82
231 20.09.82
Ortho 
DADE
tLiberton 
Ortho 
Liberton 
Technicon 
Puree 
Puree 
Liberton 
Puree 
Technicon
BCL
Nyegaard 
Wellcome 
^Hyland 
Liberton 
GD 
TCS
Roche
Roche
Liberton
Technicon 
BCL 
^Wellcome
DADE
Ortho
Ortho
TCS
Puree
Ortho
Nyegaard
Technicon
Wellcome 
^Nyegaard
Ortho
Ortho
Liberton
DADE
Puree
Gibco
Wellcome
Liberton
Wellcome
Roche
Roche
Wellcome
Puree
Ortho
Beckman
Wellcome
Nyegaard
Puree
Puree
Puree
Roche
Roche
Roche
Wellcome
Normal unassayed
QAP (Monitrol II)
NQCS
Abnormal unassayed
Scottish BTS Control
Alert 1
Armtrol
Armtrol abnormal
+NQCS Trial
Armtrol
Alert 2
Precipath U
Precipath U
Seronorm
NEQAS Internal QC
9S219
SPXP9601
L2/79
9S317
13
BOD363
547
488
LI/78
489
BOE364
805
805
154
HIQC/2
Q-Pak I 1840U001AA
Scottish BTS Control
QAS Level II
Equitrol
Control N
Control P
NQCS Trial
Alert 2
PreciFlo
NEQAS Internal QC
Monitrol II.X
+Abnormal
+Normal
Equitrol
+Armtrol
Abnormal
Pathonorm L
Alert 2
NEQAS Internal QC
Pathonorm H
Abnormal
Normal
+NQCS Trial
Monitrol II.X
Armtrol
Gibcotrol High
Special Services
SNBTS
Wellcomtrol II
Control N
Control P
Wellcomtrol I
Armtrol
"""Abnormal
Decision
+NEQAS Internal QC
Seronorm
Armtrol
Armtrol
NEQAS Internal QC
Control N
Control P
Control N
NEQAS Internal QC
37
4D523
1240
T0832
T1532
L4/80
BOM874
11-603
HIQC/3
XPT9581
9S317
9S219
1304
489
W24X02B
18
B1E511
HIQC/4
18
9S317
W27X02B
L4/80
SPXP9613
551
159
HIQC/5
68
K9122
T1734
T2440
K2690
650
W24X02B
C111747G
HIQC/5
158
651
465
660
E3031
E0641
E0340
HIQC/6
H
H
H
H
B
B
B
B
H
B
B
H
H
E
H
H
B
H
E
E
E
H
B
B
H
H
H
H
E
B
H
B
B
H
B
H
H
H
H
B
A
H
B
E
E
E
B
B
H
H
H
E
B
B
H
E
E
E
H
10
10
10
10
10
10
10
10
10
10
10
5
5
5
10
5
10
10 dil
10
5
5
10
10
10 dil
10
10
10
10
10
10
10
5
10
10
5
10
10
10
10
10
10
10
10
10
5
5
10
10
10
Liquid
10
5
10
10
10
5
5
5
10
421
232 
233 
234 
235 
236 
237
238
239
13
240
241
242
243
244
14
14A
245
246
247
248
249
250
251
252
253
254
255
256
257
15
151
258
259
260
261
262
263
264
265
266
267
16
161
268
269
270
271
272
273
274
275
17
17A
276
277
278
279
280
04.10.82 
18.10.82 
01.11.82 
15.11.82 
29.11.82 
13.12.82
03.01.83
17.01.83
31.01.83
14.02.83
28.02.83
14.03.83
28.03.83
18.04.83
09.05.83
09.05.83
23.05.83
13.06.83
27.06.83
11.07.83
25.07.83
08.08.83
22.08.83
12.09.83
26.09.83
10.10.83
24.10.83
07.11.83
21.11.83
05.12.83
05.12.83
19.12.83
16.01.84
30.01.84
13.02.84
27-02.84
12.03.84
26.03.84
09.04.84
30.04.84
14.05.84
04.06.84
04.06.84
18.06.84
02.07.84
16.07.84
30.07.84
13.08.84
03.09.84
17.09.84
01.10.84
15.10.84
15.10.84
29.10.84
12.11.84
26.11.84
10.12.84
31.12.84
Technicon 
Ortho 
Technicon 
Ortho 
Biotrol 
Gibco
Wellcome
^Purce
Beckman
Roche
Ortho
Puree
Ortho
Roche
^Ortho
Beckman
Wellcome
Ortho
Liberton
Wellcome
Roche
Ortho
Puree
Ortho
Technicon
Roche
Technicon
Ortho
^Purce
^Purce
Technicon
Puree
Gibco
Ortho
Technicon
Technicon
Roche
Ortho
Biotrol
Wellcome
DADE
^t^Wellcome
Wellcome
Wellcome
Roche
DADE
Roche
Nyegaard
Technicon
Nyegaard
^Technicon
Ortho
^tTechnicon
Ortho
Lome
Ortho
Lome
Wellcome
Alert 1 
Level II 
Alert 2 
Level I 
Biotrol-00 
Gibcotrol High
Special Services
+NEQAS Internal QC
Link II
Control N
Level II
+Armtrol
Level III
Control P
Level II
Link II
"""Special Services
Level I
+NEQAS
Special Services
Control N
Abnormal Assayed
Armtrol
Normal Assayed
Alert 1
Control P
Alert 2"""Normal
NEQAS Internal QC
NEQAS Internal QC
RA-100 Calibrator I
Armtrol
Gibcotrol High
Level II
Alert 1
Alert 2
Control N"""Level II
Biotrol-00
Wellcomtrol Two
QAP Level II
B2E289 
X40Y02B 
B2G290 
X39Y02B 
1929 
199
K5164/2
660
C204236
P1833
008Y01
551
009Y01
P2533
X40Y02B
C204236
K6026
007Y01
L4/80
K6025
P1039
025A01
726
020A01
B3G623
P2439
B3G624
W27X02B
HIQC/8
HIQC/8
B3A581
727
195
008X01
B3M351
B3M361
U0433
X40Y02B
1934
K8609
524.01
NEQAS Internal QC K8680/HIQC/9
Wellcomtrol Two K8609
NEQAS Internal QC K8680/HIQC/9
Control Serum N
QAP Level I
Control Serum P
Pathonorm L
TESTpoint 2
Pathonorm H
TESTpoint 1
"""Level II
"""RA-1000 Calibrator
Abnormal Assayed
Normal
Normal Assayed
Pathological
NEQAS Internal QC
U2140
523.01
U2840
20
B4F361
20
B4F351
X40Y02B
I B3A581
025B01
N41
020B01
P41
HIQC/10
B 
H 
B 
H 
B 
A
B
H
H
E
B
B
B
E
H
H
B
B
H
B
E
H
B
H
B
E
B
H
H
H
B
B
A
B
B
B
E
H
B
E
H
H
E
H
E
H
E
B
B
B
B
H
B
H
H
H
H
H
10 
10 
10 
10 
10 
10
10
10
Liquid
5
10
10
10
5
10
Liquid
10
10
10
10
5
5
10
5
10
5
10
10
10
10
3
10
10
10
10 dil
10 dil
5
10
10
10
10
10
10
10
5
10
5
5
10 dil
5
10 dil
10
3
5
5
5
5
10
422
281 21.01.85
18 04.02.85
18A 04.02.85
282 18.02.85
283 04.03.85
284 18.03.85
285 01.04.85
286 22.04.85
287 13.05.85
288 03.06.85
289 17.06.85
19 01.07.85
290 15.07.85
291 29.07.85
292 12.08.85
293 02.09.85
20 16.09.85
294 30.09.85
295 14.10.85
296 28.10.85
297 11.11.85
21 25.11.85
298 09.12.85
299 06.01.86
300 20.01.86
301 03.02.86
302 17.02.86
303 03.03.86
304 17.03.86
305 03.04.86
306 21.04.86
307 12.05.86
308 29.05.86
309 16.06.86
310 30.06.86
311 14.07.86
312 28.07.86
313 11.08.86
314 08.09.86
315 25.09.86
316 13.10.86
317 27.10.86
318 10.11.86
319 24.11.86
320 08.12.86
321 05.01.87
322 19.01.87
323 02.02.87
324 16.02.87
325 02.03.87
326 16.03.87
327 30.03.87
328 13.04.87
329 11.05.87
330 01.06.87
331 15.06.87
332 29.06.87
tRoche 
tWellcome
Ortho
Ortho
Roche
Wellcome
Roche
Ortho
Nyegaard
Gibco 
fcPurce
Wellcome
Wellcome
Roche
Roche 
^Wellcome
Nyegaard
Ortho
Wellcome
Technicon 
^Technicon
Wellcome
Gilford
Puree
Ortho
Gibco
Puree
Wellcome
Wellcome
Wellcome
Gibco
Nyegaard
Wellcome
Wellcome
Roche
Roche
DADE
Roche
Roche
Wellcome
Nycomed
Wellcome
Wellcome
Roche
Roche
Roche 
Puree 
Nycomed 
Wellcome 
Gilford 
Puree 
Ortho 
Technicon 
Technicon 
+Wellcome 
Gibco 
Gibco
Control N
NEQAS Internal QC
Level III
Level II
Control P
Abnormal
Control N
Level III
Seronorm
Gibcotrol High
Armtrol
NEQAS Internal QC
NEQAS Internal QC
Control N
Control P
"Abnormal"
Seronorm Enzyme
+Level II
BCZ6
TESTpoint 1
TESTpoint 2
"Abnormal"
Level II
Armtrol
+Level III
Gibcotrol High
Armtrol
"•""Abnormal"
Wellcomtrol 0344
Heat-treated human
Gibcotrol Abnormal
Pathonorm H
NEQAS Internal QC
WHO reference
Control N
Control P
QAP Level II
Control N
Control P
NEQAS Internal QC
Seronorm
+Heat-treated human
Abnormal
Control N
Control P
Control N
Armtrol
Pathonorm L
[BC03]
Level III
Armtrol
Level I
TESTpoint 2
TESTpoint 1
WHO reference
Gibcotrol High
Gibcotrol Abnormal
B1732
HIQC/10
009B01
008A01
B0637
K9301
B2936
009B01
166
412
815
HIQC/11
HIQC/11
B2941
B1442
K7275
802
008A01
K340110
V5J128
V5J072
K7275
008501
833
009B01
451
848
K7275
K4077
K466610
458
21
HIQC/12
K860210
L3231
L2132
524.03
L0736
L2236
HIQC/13
177
K466610
K409650
L1541
L2941
L2838
896
21
Unlabelled
009501
901
007B01
V7B011
V7B013
K860210
495
491
E
H
B
B
E
B
E
B
E
A
B
H
H
E
E
B
E
B
B
B
B
B
B
B
B
B
B
B
B
H
A
B
H
B
E
E
H
E
E
H
E
H
B
E
E
E
B
E
B
B
B
B
B
B
B
A
A
5
10
10
10
5
10
5
10
5
10
10
10
10
5
5
10
3
10
10
10 dil
10 dil
10
10
10
10
10
10
10
10
10
10
5
10
10
5
5
10
5
5
10
5
10
10
5
5
5
10
5
10
10
10
10
10 dil
10 dil
10
10
10
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was distributed twice (Table 1.2).
To minimise the effects of interlaboratory variations in the time 
between reconstitution and assay, a protocol for the handling of 
specimens was established; the criterion for a negligible effect 
was a change in activity of <5% (Bullock et al, 1979 and 1986b). 
This protocol specified addition of the appropriate volume of 
distilled water, gentle agitation at ambient temperature until 
dissolution was complete (20-30 min) and storage at 4°C until the 
time of assay. CK activity was to be assayed immediately, ALP 
activity within 4 h, and AST, ALT, LD and amylase activities 
within 48 h (preferably within 24 h).
Outlier elimination was by truncation of any results >2 SD from 
the untrimmed method mean, and no calculations were made for any 
method group with <10 results. VI scoring was introduced at 
Survey 19, the method mean being used as DV (no scoring for the 
Other method or temperature group).
The method classification systems used (Bullock et al, 1986b) 
emphasised robust methods in wide use, primarily those based on 
officially recommended procedures. Those from the Scandinavian 
Committee on Enzymes (SCE) were regarded as 'reliable' methods 
for many of the studies.
Reports showed for each enzyme the statistical data classified 
according to method, the laboratory's result and (from Survey 19) 
its VIS. A histogram of the results for the laboratory's method 
group was also given, except for the heterogeneous Other method 
or temperature group.
1.2.3 UKEQAS for Lead in Blood
The preparation of the liquid haemolysates from fresh human blood 
for use in this scheme has been described by Bullock et al 
(1986c). Truncation is at +3 SD. Reports were changed from mass 
to molar SI units in 1979, and cadmium was included from 1982 
(with scoring from 1986). The overall mean is used as DV, and 
reporting of VISs and MRVISs was introduced in 1979.
1.2.4 UKEQAS for Urinary Pregnancy Oestrogens
The operation of this scheme has been described by Bullock and 
Wilde (1985) and previously by Oakey (1980). Distribution of the 
lyophilised urine specimens was formerly three-weekly, but was
424
changed to fortnightly on transfer to WRL and later reduced to 4- 
weekly in 1984. Truncation is at +3 SD, with results expressed in 
umol/24h assuming a urine volume of 2L. Creatinine (mmol/24h) was 
included fully in 1984.
The method mean is used as DV (or overall mean for the 
Miscellaneous group), and BIS, MRVIS, MRBIS and SDBIS have been 
reported since scheme transfer.
1.2.5 UKEQAS for Specific Proteins
The initial surveys in this scheme were described by Chambers et 
al (1984). Specimens comprise clarified liquid normal human 
serum, with two pairs of dilution-related specimens being 
distributed in initial surveys. Later surveys comprised first two 
and later one unrelated specimen, with a final 4-weekly 
frequency. Initial surveys included immunoglobulins G, A and M, 
with complement components C3 and C4, alpha-^-antitrypsin (Al-AT), 
orosomucoid and C-reactive protein being added later.
Truncation is at +2 SD. VISs and MRVISs, for immunoglobulins 
only, have been reported since the CCVs were established in 
1985. The overall mean is used as DV.
1.2.6 UKEQAS for Salicylate and Paracetamol
Initial surveys included separate specimens for the two analytes, 
but 4-weekly distribution of a single specimen for both drugs was 
selected in 1985. The liquid specimens used comprise pure drugs 
in sterile equine serum (Bullock, 1987). Truncation is at ^3 SD, 
and VISs and MRVISs based on the overall mean as DV have been 
reported since 1985.
1.2.7 UKEQAS for PKU Screening
Specimens are prepared by addition of phenylalanine (PheA) 
solutions to fresh human whole blood with CPDA as anticoagulant. 
After one hour's gentle agititation, blood is spotted onto filter 
paper cards or placed into capillary tubes, as appropriate for 
each participant. Laboratories are asked to classify each 
specimen as having a normal, intermediate or high PheA content, 
giving their coded action (Table 7.1) and also a quantitative or 
semiquantitative PheA concentration if appropriate.
There is no computer processing of the results, and reports 
comprise tabulations of results, actions and scores (eg Figures
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7.1 and 7.2). The PheA concentration determined by two (formerly 
one) reference laboratories not undertaking PKU screening is used 
as a target. The evolution of this design and the details of the 
scoring system are described fully in sections 7.2.2 and 7.2.3.
1.3 Other EQASs
For the two international schemes sponsored by WHO, sets of 6 
specimens are distributed, to be assayed by participants at 
monthly intervals. Truncation is at +3 SD. DVs are derived from 
prior distribution of the same material through the UKEQAS. 
Reports include the laboratory's results, comparative data from 
the UKEQAS and scheme, and VI parameters (VISs and OMRVIS). 
Similar schemes have also been organised in China and Thailand.
1.3.1 International EQAS (IEQAS)
The scheme was established in 1975, and currently has about 150 
participants from about 65 countries. Specimens and reports are 
sent by diplomatic pouch via WHO Geneva to avoid customs delays.
UKEQAS overall consensus values were used as DVs for all analytes 
except glucose and cholesterol, for which the UKEQAS method means 
were used. Since 1986 scoring has been against the appropriate 
UKEQAS or IEQAS method mean (overall mean for the Miscellaneous 
group; no score for the Other group).
1.3.2 Middle East EQAS (MEEQAS)
The MEEQAS (Bacchus et al, 1982 and 1987) was established in 
1980, as a WHO-recognised scheme financed by the Riyadh Al-Kharj 
Programme in Saudi Arabia, who are the joint organisers with WRL. 
Specimens are sent to Riyadh via the Royal Saudi Air Force to 
avoid customs delays, for local distribution to participants. The 
scheme is a regional one including participants from 10 
neighbouring countries as well as from Saudi Arabia, and has 
about 80 participants. Grouped method means from the UKEQAS are 
used as DVs, with no scoring for the Other group.
1.3.3 Intensive EQASs
The objective of these schemes, outlined in section 3.2.3, is a 
short-term intensive interaction with a limited number of 
participants to improve performance. There is no cumulation of 
data, since the laboratories should show continuing improvement. 
Such schemes have been operated in Colombia, Italy, Mexico, 
Thailand and UK.
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Each laboratory receives three sera for assay together. 
Evaluation uses UKEQAS consensus values as DVs, and includes 
calculation of VISs. The reports include the VISs and an average 
VIS over all analytes in the distribution for the laboratory, 
in a table also showing the same information for other 
participants and average VISs for each analyte and for all 
laboratories.
An integral part of the report is a graph of the laboratory's 
results against DVs for each analyte (eg Figure 10.9), with 
helpful interpretive comments regarding the likely sources of 
error added by the scheme organiser. Participants also receive a 
further set of vials, so they can investigate the situation and 
check the effectiveness of their corrective actions before the 
next distribution.
I.4 WRL International Intercomparison Scheme (WHS)
This scheme was established to give a more objective assessment 
of whether biases did exist between established national EQASs, 
and of the magnitude of any such biases. The principles of the 
study are described in section 5.6.1.
NEQAS organisers were requested to select three or 5 suitable 
laboratories, ie those with small bias and regular return rate, 
from their scheme. Sets of 6 specimens were distributed to 
participants via their NEQAS organiser, for replicate analysis at 
monthly intervals and return of results, in either SI or 
'conventional' (mg/dL) unit sets, to WRL for processing.
Overall means were obtained after truncation at +3 SD, and the 
percentage deviation of each result from this WHS consensus then 
calculated. These percentage deviations were cumulated for all 
the WHS participants in each country over 4 distributions, to 
yield a cumulative average percentage deviation. VISs (Appendix
II.2.4) were also calculated, but not reported.
Reports to participants showed the data derived from laboratories 
in their country, with the cumulative average percentage 
deviations for all countries (identified only by a country code). 
The participant's own results were not included. Any results 
received after the deadline for the main computer run were 
assessed and the files updated before results for the following
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distribution were processed.
1.5 EQA surveys
The operating procedures for surveys are similar to those 
described above for EQASs. There is no scoring, nor any 
cumulation of data.
1.5.1 HDL cholesterol
These surveys (John, 1983) included the group of 12-20 
laboratories participating the standardisation initiative 
(Whitehead et al, 1979). The specimens in Surveys 2, 4 and 5 
comprised pooled sera from patients and freshly-drawn plasma from 
normal subjects; Survey 3 comprised 6 commercial QCMs (sera D, G, 
N, P, U and W; Table III.3).
Results for HDL were classified according to precipitation 
procedure (PhT, Hep or PEG). Results not obtained using enzymic 
methods for cholesterol assay were excluded, as were those >2 SD 
from the untrimmed mean.
1.5.2 Urinary total protein
Specimens comprised both normal and pathological urine specimens 
and aqueous solutions of salts and urea; various protein 
preparations (human and bovine sera and albumins) were added to 
some. Each distribution included one to four specimens. 
Procedures used by participants were classified according to 
method principle (Table 2.8) and calibrant. Truncation was at +2 
SD.
1.5.3 Extra-laboratory assays
These surveys (section 2.3; Browning and Bullock, 1987) used 
lyophilised bovine sera distributed previously in the UKEQAS for 
General Clinical Chemistry (as distributions 286 and 302; Table 
1.2) initially, but the third survey comprised two lots of 
"Sugar-Chex" (Alpha Laboratories), a suspension of fixed bovine 
erythrocytes in an aqueous medium.
The specimens were distributed via laboratories: those responding 
to a previous questionnaire (Browning et al, 1984) for the first 
survey, then all UKEQAS participants. The laboratories were 
requested to reconstitute the lyophilised sera and distribute the 
specimens to extra-laboratory sites for analysis. Surveys 1 and 2 
included sodium, potassium and glucose, and Survey 3 glucose
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only; bilirubin was also requested in Survey 1.
The surveys were conducted anonymously, participants returning 
only their results and details of the reagents, calibrant and 
instrument used. Truncation was at +2 SD, and the UKEQAS data 
(Surveys 1 and 2) were reprocessed similarly for comparison. VISs 
were calculated against the appropriate method mean from the 
extra-laboratory survey as DV. The method classification for 
glucose was based on instrument manufacturer (Table 2.4), with a 
sub-coding according to model. Glucose results obtained by visual 
reading were excluded from this analysis, but were specifically 
sought in Survey 3 and analysed separately.
1.5.4 Urinary aminoacids
The development and operation of these surveys is described fully 
in section 7.3. The specimens, distributed in pairs, comprised 
urine from normal subjects or patients with well-characterised 
clinical conditions. Participants were requested to characterise 
the chromatographic pattern obtained and return results from 
their usual 'spot tests' (Figure 7.3). Reports included details 
of specimen origin, a list of all laboratories' responses and 
summaries of the spot test results (Figures 7.4 and 7.5), and 
were accompanied by comments from scientific advisors.
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Appendix II:
VARIANCE INDEX SCORING SYSTEM
11.1 General aspects of Variance Index (VI) scoring
Variance Index scoring was described originally by Whitehead et 
al (1973). This was soon changed to the more reliable version 
incorporating scaling by Chosen Coefficient of Variation (CCV) 
rather than by SD (Whitehead et al, 1975; Whitehead, 1977). Later 
refinements which introduced BISs and their cumulated running 
indices were described by Bullock and Wilde (1985). As described 
in Chapters 4 and 9, the system provides a simple but reliable 
indication of laboratory performance which has proved useful over 
many years, in assessing both laboratory performance and changes 
in this over time.
11.2 VI scoring in UKEQASs
The definitions and derivation of the parameters used are as 
follows:
11.2.1 Bias Index Score (BIS)
The difference between the result obtained by the laboratory (x) 
and the designated value (DV; see below) expressed as a 
percentage of the method mean, divided by the CCV (see below) for 
the analyte and again expressed as a percentage:
(x - DV) 100BIS = —————— . 100 . ————
DV CCV
Any score greater in magnitude than 400 is set to 400. The BIS 
may therefore be in the range -400 to +400.
11.2.2 Designated Value (DV)
The DV is the 'target value' for the analyte in the specimen 
distributed. It is usually an overall or method-related mean 
(consensus value) from the scheme (see Appendix I).
11.2.3 Chosen Coefficient of Variation (CCV)
The CCV is a scaling factor for each analyte, correcting for 
differences in the state of the art and yielding VISs in a 
'common currency'; it does not represent a 'clinically acceptable 
error'. For the original 14 general clinical chemistry analytes 
(sodium to cholesterol) CCVs are the best interlaboratory CVs 
achieved in the UKEQAS in 1972, which are still representative of 
the relative performance; their values are given in Table 4.3.
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CCVs for other analytes were selected to yield similar VISs, 
using 'calibrated' data for reliable method groups (Bullock et 
al, 1986b; Chapter 13); their values are given in Tables 4.3 and 
II.1.
11.2.4 Variance Index Score (VIS)
The VIS is the absolute value of the BIS, ie ignoring its sign. 
Values may be in the range 0 to 400.
11.2.5 Mean Running VIS (MRVIS)
The MRVIS is the mean of the 10 most recent VISs for the 
individual analyte. Values may be in the range 0 to 400.
11.2.6 Mean Running BIS (MRBIS)
The MRBIS is the mean of the 10 most recent BISs for the 
individual analyte. Values may be in the range -400 to +400.
11.2.7 Standard Deviation of the BIS (SDBIS)
The SDBIS is the SD of the 10 most recent BISs for the individual 
analyte. Values may be in the range 0 to 422.
11.2.8 Overall Mean Running VIS (OMRVIS)
The OMRVIS is the mean of the 40 most recent VISs for the 
laboratory, irrespective of analyte. Values may be in the range 0 
to 400.
11.3 VI scoring in other EQASs
11.3.1 International EQAS and Middle East EQAS
The system described above is also applied in these EQASs 
operated from WRL (Appendix 1.3), with two differences:
- the DV is not derived from the scheme, but from prior 
distribution of the same material in the UKEQAS for General 
Clinical Chemistry.
- the OMRVIS is calculated from the most recent 30, rather 
than 40, VISs.
11.3.2 Intensive EQASs
In such schemes (Appendix 1.3.3), the VISs calculated are 
averaged for each laboratory over all analytes and specimens in 
the current distribution only. There is no cumulation of scores 
from distribution to distribution.
11.4 Graphical presentation of VIS data
Graphs of running scores against time are produced, covering a
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Table I I.I Chosen Coefficients of Variation for analytes not in 
UKEQAS for General Clinical Chemistry
	CCV
Salicylate 12.5
Paracetamol 15.0
IgG 11.9
IgA 14.2
IgM 15.9
Lead 15.0
Cadmium 15.0
Oestrogens 15,0
Greatinine (urine) 12.0
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period of about two and a half years for a scheme with 
fortnightly distributions. These are plotted against distribution 
number and include OMRVIS alone, MRVIS alone, or MRVIS, MRBIS and 
SDBIS together (eg Figures 10.4, 10.6 and 10.7 respectively). 
Indications of the current 5th, 50th and 95th centiles of OMRVIS 
or MRVIS are included.
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Appendix III:
STUDY DESIGNS
III.l Studies on the validity of consensus values
111.1.1 Reproducibility
The percentage differences between successive distributions of 
the same material in an EQAS were calculated. The mean and SD 
from all pairs within the period considered were then calculated 
(Tables 5.1 and 5.3). The periods covered distributions 205-330 
in the UKEQAS for General Clinical Chemistry (Table 1.2; 13 
pairs), 99-131 in the IEQAS (Table III.l; 11 pairs) and 55-83 in 
the MEEQAS (Table 111.2; 8 pairs).
111.1.2 Ad hoc comparisons between EQASs
The UKEQAS distributions (Table 1.2) considered were 185 and 187 
(Table 5.4), 197 and 224 (Table 5.5), 267, 270 and 312 (Table 
5.6) and 161, 179 and 295 (Table 5.7). The values for comparison 
were obtained from the scheme organisers in Holland and South 
Africa, from Broughton and Eldjarn (1985) for Norway, and from 
the QCM suppliers in the other cases.
111.1.3 Comparisons with values assigned by reference and 
definitive methods
The data for the WHO material (Table 5.8) were obtained from WHO 
and those for Seronorm lot 158 (Table 5.9; UKEQAS distribution 
224; Table 1.2) from Eldjarn and Broughton (1985).
The difference of the overall consensus value in the UKEQAS from 
the value assigned by DGKC (supplied by Roche) was calculated for 
all batches of Roche Control Sera N and P distributed in the 
UKEQAS from 1977 to 1986 (Table 1.2) and averaged for each year 
(Table 5.10). No DGKC values were available for distributions 
195, 196, 228, 229, 240 or 313.
111.1.4 Comparisons between EQASs
The percentage difference of the overall consensus value obtained 
in the IEQAS or MEEQAS from that in the UKEQAS was calculated. 
The mean and SD (Tables 5.11 and 5.12) were then calculated for 
20 distributions: 111-130 in the IEQAS (Table III.l) and 41-60 in 
the MEEQAS (Table III.2).
111.1.5 Comparisons among NEQASs in the WHS
Appendix 1.4 describes the calculation of cumulative average
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Table IIl.l Materials distributed in International EQAS, 1984- 
1987. For explanation see Table 1.2
Date
92 02.01.84
93 06.02.84
94 05.03.84
95 02.04.84
96 07.05.84
97 04.06.84
98 02.07.84
99 27.08.84
100 24.09.84
101 29.10.84
102 26.11.84
103 31.12.84
104 28.01.85
105 25.02.85
106 25.03.85
107 29.04.85
108 27.05.85
109 24.06.85
110 29.07.85
111 26.08.85
112 30.09.85
113 28.10.85
114 25.11.85
115 30.12.85
116 27.01.86
117 25.02.86
118 28.03.86
119 29.04.86
120 27.05.86
121 24.06.86
122 29.07.86
123 25.08.86
124 29.09.86
125 27.10.86
126 24.11.86
127 29.12.86
128 26.01.87
129 23.02.87
130 30.03.87
131 27.04.87
132 25.05.87
133 29.06.87
Supplier
Liberton
Puree
Ortho
Wellcome
Puree
Wellcome
Gibco
Ortho
Technicon
DADE
Wellcome
Ortho
Biotrol
Ortho
Puree
Technicon
Wellcome
Bade
Ortho
Ortho
Wellcome
Gibco
Wellcome
Ortho
Puree
Ortho
Wellcome
Wellcome
Technicon
Gilford
Puree 
Gibco 
Wellcome 
Gibco 
Wellcome
Wellcome
Puree
Wellcome
Gibco
Wellcome
Wellcome
Wellcome
Material
NEQAS
+Armtrol
Level II
NEQAS
Armtrol
Special Services
Gibcotrol High
Level II
Alert 2
QAP Level II
Wellcomtrol Two
+Level III
Biotrol -OO
+Level II
NEQAS
TESTpoint 2
+Wellcomtrol Two
+QAP Level II
Level II
Level III
Abnormal
Gibcotrol High
NEQAS
+Level II
Armtrol
+Level III
NEQAS
"Abnormal"
TESTpoint 2
Level II
Armtrol
Gibcotrol High
Heat-treated human
Gibcotrol Abnormal
"•""Abnormal"
+NEQAS
Armtrol
"•"Abnormal
+Gibcotrol High
+Heat- treated human
BCZ6
HIQC/13
Lot
L4/80
651
008Y01
HIQC/6
727
K6025
195
008X01
B3M361
524.01
K8609
009Y01
1934
008X01
HIQC/8
B4F361
K8609
524.01
008A01
009B01
K9301
412
HIQC/9
008A01
815
009B01
HIQC/11
K7275
V5J072
008501
833
451
K466610
458
K7275
HIQC/11
848
K930150
451
K466610
K340110
K641010
Base
H
B
B
H
B
B
A
B
B
H
E
B
B
B
H
B
E
H
B
B
B
A
H
B
B
B
H
B
B
B
B
A
H
A
H
H
B
B
A
H
B
H
Volume
(mL)
10
10
10
10
10
10
10
10
10 dil
10
10
10
10
10
10
10 dil
10
10
10
10
10
10
10
10
10
10
10
10
10 dil
10
10
10
10
10
10
10
10
10
10
10
10
10
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Table III.2 Materials distributed in Middle East EQAS, 1983-1987.
For explanation see Table 1.2
Date
33 20.01.83
34 17.02.83
35 17.03.83
36 21.04.83
37 26.05.83
38 23.06.83
39 21.07.83
40 25.08.83
41 29.09.83
42 27.10.83
43 01.12.83
44 05.01.84
45 02.02.84
46 01.03.84
47 05.04.84
48 03.05.84
49 07.06.84
50 05.07.84
51 09.08.84
52 06.09.84
53 11.10.84
54 08.11.84
55 13.12.84
56 17.01.85
57 14.02.85
58 14.03.85
59 18.04.85
60 16.05.85
61 27.06.85
62 25.07.85
63 29.08.85
64 26.09.85
65 24.10.85
66 28.11.85
67 09.01.86
68 06.02.86
69 06.03.86
70 10.04.86
71 08.05.86
72 12.06.86
73 17.07.86
74 14.08.86
75 18.09.86
76 16.10.86
77 20.11.86
78 01.01.87
79 05.02.87
80 05.03.87
81 02.04.87
82 07.05.87
83 11.06.87
Supplier
BADE
Puree
Ortho
Wellcome
Ortho
Puree
Gibco
Puree
DADE
Biotrol
Ortho
Wellcome
Ortho
Ortho
Wellcome
Puree
Liberton
Wellcome
Gibco
Ortho
Puree
Ortho
Ortho
Technicon
Wellcome
Biotrol
Wellcome
DADE
Ortho
Puree
Ortho
DADE
Gibco
Wellcome
Ortho
Puree
Technicon
Wellcome
Wellcome
Gibco
Puree
Ortho
Puree
Wellcome
Gibco
Gilford
Wellcome
Gibco
Wellcome
Gilford
Puree
Material
Monitrol II.X
Armtrol 
+Normal 
+Wellcomtrol I
Level II
Armtrol
Gibcotrol High 
+Armtrol 
+Monitrol II.X
Biotrol-00
Level II
Special Services 
+Normal
Level III
Special Services
Armtrol 
+NEQAS Trial
Special Services
Gibcotrol High
Level II
Armtrol 
+Level II 
+Level III
Alert II
Special Services 
Biotrol-00 
Wellcomtrol II 
QAP Level II 
Level II
UKEQAS Internal QC 
Level III 
+QAP Level II 
Gibcotrol High 
Abnormal
+Level III
Armtrol
TESTpoint 2
UKEQAS Internal QC
Wellcomtrol 
+Gibcotrol High
Armtrol 
+Level III
Armtrol 
+Wellcomtrol
Gibcotrol High
Level II
BCZ6 
+Gibcotrol High
Heat-treated human 
+Level II 
+Armtrol
Lot Base Volume
(mL)
SPXP9613
650
9S219
K2690
X40Y02B
651
199
551
SPXP9613
1929
008Y01
K6026
W27X02B
009Y01
K6025
726
L4/80
K6026
195
008X01
727
X40Y02B
009Y01
B3M361
K8680
1934
K8609
524.01
008A01
HIQC/8
009B01
524.01
412
K9301
009Y01
815
B4F361
HIQC/10
K7275
412
833
009B01
848
K7275
451
008501
K340110
451
K466610
008501
833
H
B
H
B
H
B
A
B
H
B
B
B
H
B
B
B
H
B
A
B
B
H
B
B
H
B
E
H
B
H
B
H
A
B
B
B
B
H
B
A
B
B
B
B
A
B
B
A
H
B
B
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10 dil
10
10
10
10
10
10
10
10
10
10
10
10
10 dil
10
10
10
10
10
10
10
10
10
10
10
10
10
10
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percentage deviations for each country. The mean of these 
parameters at distributions 104, 108 and 112 were calculated 
(Table 5.14), representing all distributions between 101 and 112. 
The specimens were the same as those in the IEQAS (Table III.l).
NEQAS organisers were asked to provide information on the average 
deviation of the laboratories participating in the WHS from 
their NEQAS over the same period (October 1984 - September 1985; 
Table 5.16). These deviations were used as described in section 
5.6.3 to estimate the net differences of each NEQAS from the WHS 
consensus (Tables 5.17 and 18).
III.2 Studies of interlaboratory agreement
Data for UKEQAS distributions 181-220 (Table 1.2) were accessed, 
including the results for the 16 analytes (sodium to magnesium; 
Table 4.3) then covered by the scheme. The conclusions were 
validated by testing them on the independent database provided by 
the 43 distributions (221-263) in the following two years.
III.2.1 Relationship with analyte level
The data were assessed initially by plotting against the 
recalculated mean (after truncation at ;+3 SD) the indicators of 
overall performance and of discrepant performance listed in Table 
6.1. These graphs suggested that the overall CV was very variable 
and hence of little utility in assessing the quality of the 
specimens distributed, as were the numerical presentations of the 
excluded results and high VISs. These indicators were not 
pursued further, and attention was concentrated on the 
recalculated CV, average VIS and the percentage presentations.
The graphs also confirmed that the data from some distributions 
were at variance with the rest of the database, largely due to 
poor between-laboratory agreement. Further examination explained 
most: 4 materials containing Tris buffer (an inhibitor of urease) 
gave high CVs for urea, a material with a Tris/caesium/carbonate 
buffer as diluent and intended primarily as a calibrant for SMA 
systems yielded poor agreement for other methods and hence poor 
overall CVs, and one material with bacterial contamination and 
another which was subsequently confirmed by the manufacturer to 
have been dispensed by a defective machine gave discernibly high 
CVs for most analytes. These three completely unsatisfactory 
materials were excluded completely from further data processing,
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and the others for the specific analytes.
Distributions 222, 235 and 238 from the validation period were 
similarly excluded; these materials had been found to be 
unsatisfactory for comparison purposes (one liquid serum 
stabilised by ethylene glycol for which incorrect handling 
instructions had been provided, one material for which vials from 
two lots had been labelled with the same lot number, and one with 
an apparently unacceptable filling precision). Three materials 
with Tris buffer were excluded from consideration for urea, as 
were materials with (unexplained) poor interlaboratory agreement 
for urate and bilirubin. Distributions 221 and 223 were excluded 
from the examination of data classified according to method, in 
order to give a uniform method classification throughout the 
period; this classification was different from that used in the 
study period.
Data classified according to method were later examined, for a 
more limited range of 11 analytes (the 16 studied apart from 
potassium, chloride, bilirubin, lithium and magnesium). The same 
indicators (Table 6.1) were again plotted, for each method, 
against the recalculated mean (for all participants), and with 
the same distributions as before excluded.
111.2.2 Relationship with species of origin
The reduced range of indicators were re-examined having 
classified the materials with respect to the species of origin of 
the base serum (Table 14.1).
111.2.3 Relationship with manufacturer
The reduced range of indicators were re-examined having 
classified the materials with respect to their manufacturer 
(Table 14.1). As only three manufacturers were represented by 5 
or more materials the 7 manufacturers represented by more than 
two were considered.
The proportions of manufacturers whose materials were distributed 
through the NEQAS differed substantially between the study and 
validation periods, and the conclusions concerning Nyegaard and 
Scottish Blood Transfusion Service materials could therefore not 
be validated. The other 5 manufacturers were represented by 
larger numbers of materials (Table 14.1).
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III.3 Studies in the UKEQAS for PKU Screening
In 1984 participants completed a questionnaire requesting details 
of their annual workload for 1983, the average number of assay 
batches per week, and their current method.
111.3.1 Relationship with workload
The average score (section 7.2.3) per survey over Surveys 15-19 
(1985-1986) was calculated for each laboratory. The average 
turnround time, estimated as the period between reported dates of 
specimen receipt and analysis (see section 8.4.2 for 
explanation), was also determined. Both performance parameters 
were plotted against the laboratory's 1983 workload (Figure
II.2).
111.3.2 Relationship with analytical method
For maximum reliability of conclusions, the average score over 
Surveys 6-19 (1983-1986) was calculated as above. Turnround time 
in 1985-1986 was similarly assessed, and both parameters related 
to the analytical method used (Figures 8.4 and 8.5). The 
'Chromatography' group included both thin-layer and paper 
procedures.
III.4 Calibration studies
On several occasions two or more specimens were distributed 
together. Participants were requested to assay the materials 
together in the same analytical batch.
Following the usual data processing and report production stages, 
a further data set was generated from the results returned. Each 
laboratory's result for the 'survey' specimen was recalculated, 
using its result for and the value assigned to the other 
'reference' or 'calibrant' specimen:
Assigned value Calibrated result = Survey result . ------------------
Reference result
The usual statistical parameters, both overall and classified 
according to method, were calculated, but no individual reports 
were generated for participants.
III.4.1 UKEQAS Enzyme Surveys
Surveys 14 to 18 each comprised two specimens (Table 1.2). 
Participants reconstituted and assayed the materials together for 
selected enzymes (Table 13.6; Bullock et al, 1986b). The assigned
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value was the mean value for the SCE optimised 37°C method group 
for all enzymes except amylase, for which the Phadebas 37°C group 
mean was used.
111.4.2 UKEQAS for Urinary Pregnancy Oestrogens
These studies (Table 13.4) have been described by Bullock and 
Wilde (1985). In study A participants received two aqueous 
solutions containing 40 and 60 umol/L oestriol with specimen 171 
(Lever method group mean 110 umol/24h); each laboratory's mean 
result for these calibrants was then used in conjunction with an 
assigned value of 100 umol/24h (urine volume 2L).
In studies B, C and D the calibrant was another lyophilised urine 
specimen. This came from the same set of linearly-related 
specimens in study B, and from a different set in studies C and 
D. The Lever group means for survey specimen and calibrant were 
44 and 82, 113 and 156, and 40 and 186 umol/24h respectively.
111.4.3 Urine protein surveys
Surveys 2 (November 1985) and 3 (May 1986) each included two 
specimens for calibration assessment (Table 13.5). The survey 
specimens comprised pooled urine from patients with nephrotic 
syndrome, and the calibrants human albumin in normal urine. In 
each case the assigned value was the weighed-in concentration of 
protein (3.4 and 5.0 g/L respectively).
111.4.4 UKEQAS for Specific Proteins
The procedure used in this scheme differed, since many methods do 
not have a linear calibration relationship between the measured 
property, eg RID immunoprecipitin ring diameter, and analyte 
concentration. Therefore some distributions included a 
calibration material with assigned values, which participants 
were requested to use as a calibrant in their assays (Chambers et 
al, 1987). This was reference preparation SPS-01, prepared and 
calibrated for general use in the UK for specific protein assays 
(Milford Ward et al, 1984).
Five distributions (Chambers et al, 1984), each of two sample 
pairs related by dilution (range of ratios 0.67 to 0.83), were 
made before this study. These yielded 20 sets of results for 
immunoglobulins and 8 for C3, C4 and Al-AT. Two distributions, 
each again comprising two dilution pairs (total 8 specimens), 
were made with SPS-01 calibrant; all assays were calibrated
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directly or indirectly against SPS-01.
Four distributions, consisting of two unrelated specimens only 
(total 8 specimens), made after the SPS-01 study were considered. 
Three specimens were of normal human serum as before. The other 5 
were pooled human sera derived from patients with inflammatory 
disease; these immune complexes and rheumatoid factor, and had 
increased concentrations of acute phase proteins.
The mean between-laboratory CV for each distribution period was 
calculated from pooled individual means and variances. Within- 
laboratory precision was estimated from the differences for each 
laboratory within each pair of specimens, after correction for 
dilution. The significance of differences in mean CVs was 
determined by the Mann-Whitney U test.
III.5 Studies on HDL cholesterol assay
These studies have been described previously (Bullock et al, 
1980b).
III.5.1 Materials and methods
The 25 sera studied are identified in Table III.3, which also 
shows the species of origin of the base serum. All but serum V (a 
frozen liquid preparation) were lyophilised materials, obtained 
commercially or commissioned by UKEQAS. Pooled and individual 
sera from patients were also studied.
The PhT precipitation procedure was modified from that of 
Burstein et al (1970). Lipoproteins other than HDL were 
precipitated from 1 mL serum by adding 100 uL of phosphotungstate 
reagent (phosphotungstic acid, 45 g/L; sodium hydroxide, 160 
mmol/L) and 25 uL of magnesium chloride (2.0 mmol/L). The Hep 
precipitation procedure was also modified from that of Burstein 
et al (1970). To 1 mL serum 50 uL of heparin (7500 kilo-USP 
units/L in 150 mmol/L saline; Grade I, cat no H3125, Sigma) and 
50 uL of manganous chloride (2.02 mmol/L) were added. For both 
procedures, after incubation at ambient temperature (22-25°C) for 
30 min the precipitate was removed by centrifugation and the 
cholesterol content of the supernatant determined using a fully 
enzymic procedure (product no 187313, BCL; Roschlau et al, 1974, 
modified). After mixing 40 uL of supernatant with 1 mL of reagent 
and incubation at ambient temperature for at least 35 min, the
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Table III.3 Identity of the QC materials assessed for HDL
cholesterol assay All materials lyophilised except serum V 
(frozen liquid presentation); * denotes material not 
available commercially
Serum Origin Supplier Material
A
B
C
D
E
F
G
H
I
J
K
L
M
N
P
Q
R
S
T
U
V
W
X
Y
Z
Human
Human
Human
Human
Human
Human
Human
Equine
Bovine
Human
Human
Human
Bovine
Bovine
Equine
Human
Human
Human
Animal
Equine
Equine
Bovine
Human
Bovine
Human
BCL
BCL
Bio-Rad
DADE
GD
GD
Hyland
Nyegaard
Nyegaard
Ortho
Ortho
Liberton
Liberton
Puree
Roche
Roche
SKI
SKI
Technicon
TCS
TCS
Wellcome
Wellcome
Wellcome
Roche
Precilip, 763 
Precinorm U, 801
ECS Lypho-Check Elevated 
Lipid, 21196
Moni-trol I.X, XLT-350
*Clinical Chemistry, 7109
Quality Assurance Serum 
Level II, 4D365
Q-Pak I, 1779N003AA 
Seronorm, 144 
Seronorm Lipid, 55 
Abnormal Unassayed, 9S317 
Elevated Lipids, 2S906
*NQCS Trial, LI/78
*Clinical Chemistry QC, 12 
Armtrol, 390 
Control Serum N, A2137 
Lipid Control Serum, A0740 
Target Normal, 626011 
Target Elevated Lipid, 593311 
Multisystem ABN, X9C202 
Equitrol Lyophilised, 0419a 
Equitrol Frozen, 0819 
Autoset H, K2847
*NQCS Special Services, K5437 
Wellcomtrol 3, K6147
*WHO Tentative Reference, 77/1
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absorbance at 500 nm was measured and multiplied by 4.37 (PhT) or 
4.27 (Hep) to obtain the serum HDL cholesterol concentration 
(mmol/L).
III.5.2 Study protocol
Within-batch precision (Table 12.1) was determined by replicate 
analysis (n=10; n=20 for the pooled sera) of each serum by both 
procedures. Between-day precision (Table 12.2) was also 
determined for 6 QCMs of varying origin and within-batch 
performance (sera D, G, N, P, U and W; Table III.3) by analysis 
on 10 successive working days. Reconstituted sera were stored (at 
4°C) for no longer than 7 days before assay.
III.6 Studies on heat-treated human serum
These studies have been described previously (Bullock et al,
1986a).
111.6.1 Preparation of materials
Lots HIQC/9 to HIQC/12 (see Appendix IV) were prepared using 
Wellcome Diagnostics' usual manufacturing procedures. In summary, 
the constituent 5 litre pools were bulked and maintained at 4°C, 
with continual mixing, during filtration, addition of inorganic, 
organic, enzyme and hormone components, and sterile filtration. 
The filled vials of serum were then lyophilised using 
conventional techniques, stoppered in an atmosphere of nitrogen, 
capped, labelled and stored at 4°C.
After pooling, the bulk serum used in preparation of the heat- 
treated batch (lot K466610) was heated to 56°C in a well-stirred 
vessel by gradual injection of steam into the vessel jacket. 
After 30 min the final temperature was attained and maintained 
for 30 min (the maximum temperature of the bulk serum was 
57.0°C), before cold water was introduced into the vessel jacket 
to cool the serum to 4°C over 5 h. The remainder of the 
processing was as described above for lots HIQC/9 to HIQC/12. Lot 
HIQC/13 was prepared similarly, except that the temperature of 
56°C was maintained for 1 h.
111.6.2 Evaluation at WRL
Measurements of pH, turbidity (absorbance at 400, 500 and 600nm 
of a 1 in 10 dilution of serum in 154 mmol/L saline) and 
microbiological contamination were each made on three vials. 
Vial-to-vial variability was assessed by determination of sodium
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on the reconstituted contents of 40 individual vials.
Stability was assessed at 25°C and 37°C for both unreconstituted 
and reconstituted material. Duplicate vials were reconstituted 
and analysed (for sodium, potassium, urea, glucose, calcium, 
urate, bilirubin, total protein, albumin and AST, on an SMA 
12/60; Technicon Instruments Corp) each week for 13 weeks. The 
reconstituted material was similarly analysed over 29 hours 
following reconstitution.
III.6.3 UKEQAS distributions
The materials constituted normal distributions in the UKEQAS for 
General Clinical Chemistry and UKEQAS Enzyme Surveys (Table 1.2). 
For lots HIQC/9 to HIQC/11 these were separate, but lots K466610, 
HIQC/12 and HIQC/13 constituted distributions 305, 308 and 315, 
following incorporation of enzymes into the UKEQAS for General 
Clinical Chemistry. Lot K466610 was redistributed as 317, 6 
months after its initial distribution. The materials were also 
distributed through the UKEQASs for Steroid Hormones and Thyroid- 
related Hormones (Groom, 1985a; DHSS, 1986b) as additional 
specimens; participants' performance was not assessed on these.
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Appendix IV:
UKEQAS HUMAN SERUM FOR INTRALABORATORY QUALITY CONTROL
IV.1 Serum processing and production procedures
This material is prepared from serum collected by the National 
Blood Transfusion Service from male and female volunteer donors 
whose blood is unsuitable for therapeutic purposes. The blood is 
collected without anticoagulant, and the serum separated after 
clotting at ambient temperature. Each donation is tested for 
HBsAg and (since October 1985) antibody to HIV, and those found 
negative are pooled and stored frozen (-20 or -30°C).
Processing is carried out by Wellcome Diagnostics (Puree 
Associates for lots HIQC/7 and HIQC/8) using their usual 
production procedures, outlined in Appendix 111.6.1 and by 
Bullock et al (1986a). Only inorganic and simple organic analytes 
were added to the initial batches, but the levels of bilirubin, 
enzymes, thyroid-related hormones and steroid hormones were 
enhanced in later batches. Analyte concentrations have not been 
increased greatly (to discourage use of this material for 
calibration), and no preservatives or stabilisers are added.
Sample vials are provided to WRL for evaluation and for 
distribution through the appropriate UKEQASs (Appendix 111.6.2 
and 111.6.3). After value assignment (see below), packs of 5 or 6 
vials of the remaining material are prepared and provided to UK 
clinical laboratories at a rate equivalent to one lOmL vial per 
week (or fortnight, if the laboratory needs less) to permit an 
occasional but regular check on the accuracy and stability of 
their analytical systems.
Each pack includes a package insert (Figures I V.I and IV.2). As 
well as giving the assigned values, this describes the purpose, 
preparation and properties of the material and the value 
assignment procedures.
IV.2 Value assignment procedures
Evidence from the evaluation and UKEQAS distributions are 
considered by a Value Assignment Committee, comprising nominees 
from the professional bodies in clinical chemistry (Figure IV.1) 
and WRL staff. Provided the material is of satisfactory quality 
and properties, values based on the UKEQAS data are assigned.
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Figure IV.l Package insert: for lot HIQC/12 - description of 
purpose, preparation and value assignment procedures
U.K. External Quality 
Assessment Scheme lor 
General Clinical Chemistry
Human Serum for 
Intralaboratory 
Quality Control
Lot: HIQC/12
UKEOAS
wolison Research laBoratones 
Queen Elizaoem Meoicai Centre 
_ Sirmmgnam 815 2TH
U.K. External Quality Assessment Scheme tor General Clinical Chemistry* 
Human Serum for Intralaboratory Quality Control, HIQC/12
INTRODUCTION In recent vears me World Health Assemoly has passed resolutions, me ooiecl ol wnicn is 
10 sumulaie couniries to oecome seit-sutticieni witn regard to numan oiood orooucis. mciuoing ouality comrol 
materials of numan origin. Tne aistnBulion ol me enclosed product reoresems our lirs! steo in this direction. Human 
serum nas oeen collected By the National Blood Translusion Service in me United Kingdom, and nas Oe«n 
orocessed lor aistnoulion witnm me UK lor internal quality control in clinical cnemistry laooratories. This proiect is 
supported oy me OHSS.
This ivoonilised preparation nas oeen orocessed with as little modilication as possiole to provide, atter 
reconstitution a product with prooerties similar to those ol normal Iresn numan serum. The ooiect is to enaoe 
laporatpnes to Check tneir assay results, occasionally Dul regularly, against me values assigned to me serum. 
Please note mat me serum is mienoed as a check on caupraiion and staOility ol the analytical system ano not as a 
calipration material in useil: any oiscreoancies Between ooserved and assigned values snouid tnereiore siimulate the 
user to investigate his assay system, not simoly to alter me values assigned to nis calioraiion material 
Human serum is scarce ano difficult to collect, and most internal Quality control orocedures in a laDoraiory should 
use ammai serum or previously assayed oooied oaliems serum. Occasionally, however a cross-cnecu against 
indeoenoeratv assaved human serum is assiraoie. and our intention is to arsmouie sufficient tyopniliseo serum to 
provide 10 mi per laooratory per weeK.
ORIGIN The case ol this oroducl is numan serum, collected &y me National Blood Translusion Service from 
volunteer maie and temaie aonors wno wouid normally oonaie lor meraoeuiic ourooses out wnose olood was 
unsuitaoie rar translusion The oiooo was allowed 10 dot at amoient temperatuie and me exuded serum pooled alter 
cerariluoaiion ano stored at - 20"C. all ooeraiions oeing penormed asepncallv Inorvioual 5 litre poois wmcn were 
shown to oe negative lor H8,Ag. were thawed and comomed. ana supoiemenieo wnere necessary, including corusoi. 
oestradiol. orogesterone. myroxme and inioootnyronine. The processing, vial filling ano freeze drying were carried 
oul oy Weilcome Diagnostics.
RECONSTITUTION ANO STORAGE The material snouid Be stored at 4'C. and reconstituted py 
aaoinq iO-0 mi of distilled water The material snouid oe gently mixed lor 30 minutes at amoient lemoeraiure and 
men stored m me dark at 4'C until used The proroct snouid Be used on lh« day of reconstilutton. The material 
nas oeen testeo careiully it lh« individual donation stage lor H8sAg and tor antiooay to HTLV HI (LAV Hivi ana
•tuna to oe negative
•UKEOAS. lormeriv UK National Oualirv Conirol Scheme
STABILITY The long term siaointv of me unreconstituteo serum nas noi vei seen estaotisneo. and i 
conservative esumaie ol 18 months at t"Z lor organic ano inorganic constituents nas oeen maoe. Tne laoei 
tnereiore dears me recommenoaiion mat me serum is used oelore 30in Npvemoer 1987 II is anticipated now*ver 
mat inese constiiuents wui oe staoie lor a lurmer year, witn me oossioie exceotion ol giucose ano eruymes. 
VALUE ASSIGNMENT The assignment of values to me material nas oeen undertaken ov me UKEOAS 
wim me aovice ol the Organisers ol me reievani UKEOASs (Or. Gv Groom lor conisa. Pro! J.G Ratciilfe lor 
tnyroxine and triioooinvroninei and an mteroroiessionai Vaiue Assignment Commmee consisting ol reoreseraairves ol 
leievam proiessionai podies. Tnese were Or H Wonn (Association ol Clinical fliocnemtsisi. Or C. Hooos 
(Association ol Clinical Patnoiogistsl. Mr M. Nicnoison llnstitute ol Medical Laooratory Sciencesi and Or. M. P.nsier 
iflovai College ol Pamoiogrstsi.
'he Commmee considered me evidence regaroing me duauiy 01 me material ano consipereo il to oe a saiislactory 
oaten, tnougn sngntly more lurpid man might Be oesiraole lor some anaivses The Commmee oecioed mat me 
values assigned to me material snouid Be me consensus values ootained cv cistnoution tnrougn me UKEOASs m 
May 1986 {participants wui nave received detailed reoorts on inese oisirioutionsi. exciuomg mose lor some memoes 
wmcn were no longer considered satisfactory, lor enzvmes. values weie assigned oniv lor wioeiv-used apparent* 
ropust memodS. generally ootimised according to recommendauons ov the Scandinavian (SCfl or German IOGKC) 
Societies. No values were assigned tor caicium ov metnvithvmol Blue, lor creatine kinase (CK). iron or tor lotal irorv 
ainoing caoacuv. due 10 excessive vanaoiinv in results: variaoilny in magnesium pv coiorimetric croceoures was 
iioterj.
These consensus values were aoooted with the assurance mat mere is no evioence ol oias. not exoiicaoie in terms 
ol me anaivtica' memoos used. Between UKEQAS results and mose of me Central fieterence Insmuiion of me 
German Society tor Clinical Chemistry, on cnecmng twice veany This cross-cnecx is. nowever. carried out on eouine 
sera ana me consensus vaiues lor mis numan material nave tnereiore also oeen cnecxeo against me results ol 
repncate anarvsis (pn i separate oaysi Pv at least 8 UK value monitoring laooratones using a varietv of calioraiion 
maienais: mese laooratones were chosen as consistent penormers over several years in me UKEOAS rather man 
me current pest oenormers.
The assigned value and SO given are mose ootameo Bv recalculation alter exclusion pi results lying more man 3 SO 
(2 SO lor eravmesi Irom me mean, tor invroxine ano irnodotnyrohine see me lootnote to me taole These vaiues 
imprv mat 2 out of 3 results trom oamcioanng. laBoraiones were wtmm one SO ol me assianeo value. The numoers 
ol signiticant ligures in me assigned values are appropriate IP me numoer oi results, and olten in excess ol mose 
neeaed m laooratory practice. Furthermore, me differences oetween meinoa means are generally smail. ano ol 
uncertain stgnilicance at oresenl.
COMMENTS AS me continued distribution of material ol mis type is slill under consideration, anv comments 
on me material and me protect would Be aoorecaied. Assigned values nave oeen provided lor 28 anaivies and 
suilaoility lor others is oeing assessed. Put you may wisn to use me material lor additional anaivtes. II vou oo so. 
aiease report me values ootamea with a oriel summary ol the memoos used: sucn vaiues ana comments will Be of 
great assistance m peveiooing materials lor tuture distrioution.
J.G. flaiclille Director 
O.G. Sullock Organiser. UKEOAS 
8th July 1986 Wolison Researcn laoorarories
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insert HIQC/12 - assigned
Human Serum for Intralaboratory Quality Control 
Assigned Values, lot HIQO12
MtlfKXJ
InnnminiH - All 
IUIU SCcootmises 37'C 
OGXC ooimisea. 37'C
Albumin icy.., Bromcmso, orMn 
3romaesoi ouroie
Alkaiiiwanosoflaiase 
- HP ,u/L. SCE.TCKCootim.sea 37'C 
-NPP.AMP 37'C
Am»iii« Uil/ '"Maoeoas. 37'C 
:3CL coiorimeiric 37"C
Asoanat* 
iranumirujse - AST 
lU/L) SCE/OGKC ootmiseo. 37'C
Silinibm lumofru DiuonsaiKxi
Calcium immol/U Atomic aDsorotionrAuiomaiic rnrator 
Gesoioninaiein
Chloride imrnouu Cokirinieinc£ouionw!iic
Choiejlerol imnxwu cnnrnic
Cortuol irmwi) GCMS reieience meinoa 
riuorimetnc 
Raoioimmunoassa w 
comoemrvt oroiein nnarq
Cninmnt lumwu Cominuous IKM Jalle 
Manuauoi$creie (including xtneiic) 
,aiit
• Glucojt immol/U Glucose ouast 
Hexoti/use
Uciin 
(WtydroqtniH - LO 
IU/U SCETOGKC oonmurt. 37'C
Ulnium immoi/U Flame onoiomeiryMiomic aosoniion
Ut^ntsium immoiAJ Atomic aosoroiion 
Counmeinc
OtttntM lomoi/U GCMS reference meinco 
Raaioimmunoassav
Osmouility
imosmoi'kgi Freezing point/Vaoour oressure
PhospruK immouu C*(itT»inc/Pnosnnomotvtx«le 
340nm
Pmiuium immol/U Fame onoiomeirv/lnairecl on- 
swecirve etecirooe
ProQMttront inmoi/lj GCMS reference meinoc 
Saoioimmunoassjy leicruoin; 
NFJRIAoHIO)
Sodium immol/U Flame onoiomeirvnnaireci ion. 
seiecirve eieciroae
Ttslo«itron« inmoi/U GCMS reference meinod 
Aaaioimmunoassav
Thyroid stimulating 
hormom TSH
imu/L' fladiwmmunoassav 
Uonocionai IRMA
Thyroxirw inmoi/l> immunoassav
Toial Protein [yi; 5ian«es Siurei 
UnciartKM orurei
Triiodothyronme
inmol/li Raanimmunoassav
Unte immol/U Uricase/Colormetnc
Urea immoi/U U'ease/Oiacetvimonoxune
AuignMnHM
So
S4
39 ' 
376
j«:
245
£60 
1232
35
544
2.90 
2.97
100.5
445
*832 
875
907
138.6 
130.8
8.22 
3.37
952
132
0.93 
0.99
SO).
8
18 
2.3
is
j!
7E
c
54
0.07 
0.08
•9
0.23
57 
113
75 
10.2
0.30 
O.u
ICl
006
0.04 
007
' Not yei jvaiiao* 
610 HE
292
1 59
5.75
U
0.10
312
+ Not vet avaiiaow 
26.0 46
1454 1 7
•>• Not vei avaiiaow
8.3 iS
:23 
ct 7
= 124
527
we
C3.0
9589
J67
COS 
03.2
** ' '
25 
22
304
0.037
0.33
NuniMr of mam
103
39
3i3
43
134
142
:3*
:i
2£5
405
S3
355
257
334
22 
i»9
168 
25<
374
99
144
276
122 
116
S3
249
333
439
104
440
59
66 
80
106
114
33
335
465
• Please note reconsniuiion ana storage instructions
* Two assays >n ouoncate
c Statistical caKuuiau oaseo on ag normal aramouiiore mm outnei reiecinn ov tne meinoa ol Hearv
iCIin Cftem. 25. 67M77 1979i 
< Pnarmicia Oujgnosfics AB 
: Soennnger Corooration lUinconi Lie
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For early batches individual method means were assigned. With 
increasing experience, the Committee's confidence in these 
materials has allowed the grouping of method-related data. For 
many analytes this policy yields a single assigned value (Figure 
IV.2), though data are not combined if there are indications of 
differences in means or SDs among the methods involved. GCMS 
reference method values for steroid hormones (Groom, 1985b) have 
also been assigned where these were available.
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Appendix V:
SUPPLIERS OF QUALITY CONTROL MATERIALS AND REAGENTS
Abbott
Alpha
Amersham
BCL
Beckman
Becton-Dickinson
Bio-Rad
Biotrol
Boots-Celltech
Corning
DADE
DPC
GD
Gibco
Gilford
Hyland
Liberton
Lome
Miles
NETRIA
Nyccmed
Nyegaard
Ortho
Puree
Roche
Serono
SKI
Sigma
Sorin
TCS
Technicon
Travenol
Wellcome
WRL
Abbott Laboratories Ltd, Wdkingham, Berks RG11 2QZ 
Alpha Laboratories Ltd, Eastleigh, Hants SOS 4NU 
Amersham International pic, Aylesbury, Bucks HP20 2TP 
Boehringer Corporation London Ltd, Lewes, E Sussex BN7 1LG 
Beckman-RIIC Ltd, High Wyoonbe, Bucks HP12 4JL 
Becton-Dickinson (UK) Ltd, Oxford 0X4 3LY 
Bio-Rad Laboratories Ltd, Watford, Herts WD1 8RP 
Scientific Hospital Supplies Ltd, Liverpool L7 3JG 
Boots-Celltech Diagnostics Ltd, Slough, Berks SL1 4ET 
Ciba-Corning Diagnostics, Halstead, Essex 009 2DX 
Travenol Laboratories Ltd, Newbury, Berks RG16 OQW 
Diagnostic Products (UK) Ltd, Wallingford, Oxen 0X10 9DA 
General Diagnostics, Chandlers Ford, Hants 
Gibco Ltd, Paisley, Scotland PAS 4EF 
Ciba-Corning Diagnostics, Halstead, Essex CO9 2DX 
Travenol Laboratories Ltd, Newbury, Berks RG16 OQW
Protein Fractionation Centre. Scottish National Blood 
Transfusion Service, Edinburgh EH17 7QT
Lome Diagnostics Ltd, Bury St Edmunds, Suffolk IP32 7DF
Miles Laboratories Ltd, Slough Sll 1YT
NE Thames Regional Immunoassay Unit, London EC1A 7BE
Nyocmed (UK) Ltd, Birmingham B26 SEA
Roomed (UK) Ltd, Birmingham B26 SEA
Ortho Diagnostics Ltd, High Wyoombe, Bucks HP10 9UF
Puree Associates Ltd, Co Antrim, N Ireland BT41 1AB
Roche Diagnostica Division, CH-4002 Basel, Switzerland
Seronon Diagnostics Ltd, Wbking, Surrey GU21 5JY
Beckman-RIIC Ltd, High Wycombe, Bucks HP12 4JL
Sigma Chemical Co, Poole, Dorset BH17 7NH
CIS (UK) Ltd, High Wyoombe, Bucks HP12 3RD
Tissue Culture Services Ltd, Slough, Berks SL1 4XX
Technicon Instruments Corp, Tarrytown, New York 10591, USA
Travenol Laboratories Ltd, Newbury, Berks RG16 OQW
Wellcome Diagnostics, Dart ford, Kent DA1 5AH
Wolf son Research Laboratories, Birmingham B15 2TH
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